0001739104-21-000017.txt : 20211105 0001739104-21-000017.hdr.sgml : 20211105 20211105085848 ACCESSION NUMBER: 0001739104-21-000017 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 80 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211105 DATE AS OF CHANGE: 20211105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elanco Animal Health Inc CENTRAL INDEX KEY: 0001739104 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 825497352 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38661 FILM NUMBER: 211382482 BUSINESS ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 BUSINESS PHONE: 877-352-6261 MAIL ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 10-Q 1 elan-20210930.htm 10-Q elan-20210930
false2021Q30001739104--12-31http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613Member1http://fasb.org/us-gaap/2021-01-31#PensionPlansDefinedBenefitMember00017391042021-01-012021-09-300001739104elan:CommonStockNoParValueMember2021-01-012021-09-300001739104elan:A500TangibleEquityUnitsMember2021-01-012021-09-30xbrli:shares00017391042021-11-01iso4217:USD00017391042021-07-012021-09-3000017391042020-07-012020-09-3000017391042020-01-012020-09-30iso4217:USDxbrli:shares00017391042021-09-3000017391042020-12-310001739104us-gaap:CommonStockMember2019-12-310001739104us-gaap:AdditionalPaidInCapitalMember2019-12-310001739104us-gaap:RetainedEarningsMember2019-12-310001739104us-gaap:AccumulatedTranslationAdjustmentMember2019-12-310001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-12-310001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-3100017391042019-12-310001739104us-gaap:RetainedEarningsMember2020-01-012020-03-3100017391042020-01-012020-03-3100017391042019-01-012019-12-310001739104srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2019-12-310001739104srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-12-310001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-01-012020-03-310001739104us-gaap:AccumulatedTranslationAdjustmentMember2020-01-012020-03-310001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-01-012020-03-310001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310001739104us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310001739104us-gaap:CommonStockMember2020-01-012020-03-310001739104us-gaap:CommonStockMember2020-03-310001739104us-gaap:AdditionalPaidInCapitalMember2020-03-310001739104us-gaap:RetainedEarningsMember2020-03-310001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-03-310001739104us-gaap:AccumulatedTranslationAdjustmentMember2020-03-310001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-03-310001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-3100017391042020-03-310001739104us-gaap:RetainedEarningsMember2020-04-012020-06-3000017391042020-04-012020-06-300001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-04-012020-06-300001739104us-gaap:AccumulatedTranslationAdjustmentMember2020-04-012020-06-300001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-04-012020-06-300001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-012020-06-300001739104us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-300001739104us-gaap:CommonStockMember2020-04-012020-06-300001739104us-gaap:CommonStockMember2020-06-300001739104us-gaap:AdditionalPaidInCapitalMember2020-06-300001739104us-gaap:RetainedEarningsMember2020-06-300001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-06-300001739104us-gaap:AccumulatedTranslationAdjustmentMember2020-06-300001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-06-300001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-3000017391042020-06-300001739104us-gaap:RetainedEarningsMember2020-07-012020-09-300001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-07-012020-09-300001739104us-gaap:AccumulatedTranslationAdjustmentMember2020-07-012020-09-300001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-07-012020-09-300001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300001739104us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300001739104us-gaap:CommonStockMember2020-07-012020-09-300001739104us-gaap:CommonStockMember2020-09-300001739104us-gaap:AdditionalPaidInCapitalMember2020-09-300001739104us-gaap:RetainedEarningsMember2020-09-300001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-09-300001739104us-gaap:AccumulatedTranslationAdjustmentMember2020-09-300001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-09-300001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-3000017391042020-09-300001739104us-gaap:CommonStockMember2020-12-310001739104us-gaap:AdditionalPaidInCapitalMember2020-12-310001739104us-gaap:RetainedEarningsMember2020-12-310001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-12-310001739104us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-12-310001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001739104us-gaap:RetainedEarningsMember2021-01-012021-03-3100017391042021-01-012021-03-310001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-01-012021-03-310001739104us-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-03-310001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-01-012021-03-310001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001739104us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001739104us-gaap:CommonStockMember2021-01-012021-03-310001739104us-gaap:CommonStockMember2021-03-310001739104us-gaap:AdditionalPaidInCapitalMember2021-03-310001739104us-gaap:RetainedEarningsMember2021-03-310001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-03-310001739104us-gaap:AccumulatedTranslationAdjustmentMember2021-03-310001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-03-310001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-3100017391042021-03-310001739104us-gaap:RetainedEarningsMember2021-04-012021-06-3000017391042021-04-012021-06-300001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-04-012021-06-300001739104us-gaap:AccumulatedTranslationAdjustmentMember2021-04-012021-06-300001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-04-012021-06-300001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001739104us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001739104us-gaap:CommonStockMember2021-06-300001739104us-gaap:AdditionalPaidInCapitalMember2021-06-300001739104us-gaap:RetainedEarningsMember2021-06-300001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-06-300001739104us-gaap:AccumulatedTranslationAdjustmentMember2021-06-300001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-06-300001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-3000017391042021-06-300001739104us-gaap:RetainedEarningsMember2021-07-012021-09-300001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-07-012021-09-300001739104us-gaap:AccumulatedTranslationAdjustmentMember2021-07-012021-09-300001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-07-012021-09-300001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300001739104us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001739104us-gaap:CommonStockMember2021-09-300001739104us-gaap:AdditionalPaidInCapitalMember2021-09-300001739104us-gaap:RetainedEarningsMember2021-09-300001739104us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-09-300001739104us-gaap:AccumulatedTranslationAdjustmentMember2021-09-300001739104us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-09-300001739104us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-30xbrli:pure0001739104country:USus-gaap:GeographicConcentrationRiskMemberelan:ContractWithCustomerLiabilityMember2021-01-012021-09-300001739104country:USus-gaap:GeographicConcentrationRiskMemberelan:ContractWithCustomerLiabilityMember2020-01-012020-09-300001739104elan:ProductReturnConcentrationRiskMemberelan:GlobalCustomersMemberus-gaap:RevenueFromContractWithCustomerMember2021-07-012021-09-300001739104elan:ProductReturnConcentrationRiskMemberelan:GlobalCustomersMemberus-gaap:RevenueFromContractWithCustomerMember2020-07-012020-09-300001739104elan:ProductReturnConcentrationRiskMemberelan:GlobalCustomersMemberus-gaap:RevenueFromContractWithCustomerMember2021-01-012021-09-300001739104elan:ProductReturnConcentrationRiskMemberelan:GlobalCustomersMemberus-gaap:RevenueFromContractWithCustomerMember2020-01-012020-09-300001739104elan:PetHealthMember2021-07-012021-09-300001739104elan:PetHealthMember2020-07-012020-09-300001739104elan:PetHealthMember2021-01-012021-09-300001739104elan:PetHealthMember2020-01-012020-09-300001739104elan:FarmAnimalMember2021-07-012021-09-300001739104elan:FarmAnimalMember2020-07-012020-09-300001739104elan:FarmAnimalMember2021-01-012021-09-300001739104elan:FarmAnimalMember2020-01-012020-09-300001739104elan:ContractManufacturingMember2021-07-012021-09-300001739104elan:ContractManufacturingMember2020-07-012020-09-300001739104elan:ContractManufacturingMember2021-01-012021-09-300001739104elan:ContractManufacturingMember2020-01-012020-09-300001739104elan:KindredBioMember2021-08-270001739104elan:KindredBioMember2021-06-300001739104elan:KindredBioMember2021-07-012021-09-300001739104elan:KindredBioMember2021-01-012021-09-300001739104elan:KindredBioMemberus-gaap:InProcessResearchAndDevelopmentMember2021-08-270001739104elan:BayerAnimalBusinessMember2020-08-012020-08-010001739104elan:BayerAnimalBusinessMember2020-08-010001739104elan:BayerAnimalBusinessMember2021-01-012021-09-300001739104elan:BayerAnimalBusinessMember2020-01-012020-09-300001739104elan:BayerAnimalBusinessMember2020-07-012020-09-300001739104elan:BayerAnimalBusinessMember2021-07-012021-09-300001739104elan:BayerAnimalBusinessMemberelan:FinishedGoodsMember2020-08-010001739104elan:InProcessMemberelan:BayerAnimalBusinessMember2020-08-010001739104elan:BayerAnimalBusinessMemberus-gaap:PublicUtilitiesInventoryRawMaterialsMember2020-08-010001739104elan:BayerAnimalBusinessMemberus-gaap:InProcessResearchAndDevelopmentMember2020-08-010001739104us-gaap:MarketingRelatedIntangibleAssetsMemberelan:BayerAnimalBusinessMember2020-08-010001739104elan:RightsToTheProfenderAndDrontalProductFamiliesMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberus-gaap:MarketingRelatedIntangibleAssetsMember2020-08-010001739104elan:RightsToTheProfenderAndDrontalProductFamiliesMemberus-gaap:InventoriesMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2020-08-01elan:employee0001739104us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2021-06-300001739104us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2021-01-012021-09-300001739104us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberelan:ShawneeMember2021-08-012021-08-010001739104elan:RightsToTheProfenderAndDrontalProductFamiliesMemberus-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMemberus-gaap:InProcessResearchAndDevelopmentMember2020-07-012020-09-300001739104us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2020-07-012020-09-300001739104us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember2020-01-012020-09-300001739104elan:WorldwideRightsToOsurniaAndUSRightsToCapstarMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2021-09-300001739104elan:WorldwideRightsToOsurniaAndUSRightsToCapstarMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2020-12-31elan:position0001739104elan:A2021RestructuringPlanMember2021-01-012021-09-300001739104elan:BayerAnimalBusinessMember2021-01-012021-09-30elan:country0001739104us-gaap:FacilityClosingMember2019-12-310001739104us-gaap:EmployeeSeveranceMember2019-12-310001739104us-gaap:FacilityClosingMember2020-01-012020-09-300001739104us-gaap:EmployeeSeveranceMember2020-01-012020-09-300001739104us-gaap:FacilityClosingMember2020-09-300001739104us-gaap:EmployeeSeveranceMember2020-09-300001739104us-gaap:FacilityClosingMember2020-12-310001739104us-gaap:EmployeeSeveranceMember2020-12-310001739104us-gaap:FacilityClosingMember2021-01-012021-09-300001739104us-gaap:EmployeeSeveranceMember2021-01-012021-09-300001739104us-gaap:FacilityClosingMember2021-09-300001739104us-gaap:EmployeeSeveranceMember2021-09-300001739104elan:CommonStockOfferingMember2020-01-222020-01-220001739104elan:CommonStockOfferingMember2020-01-220001739104us-gaap:OverAllotmentOptionMember2020-01-222020-01-2200017391042020-01-232020-01-230001739104elan:TangibleEquityUnitMember2020-01-222020-01-220001739104elan:A500TangibleEquityUnitsMemberus-gaap:SeniorNotesMember2020-01-220001739104elan:TangibleEquityUnitMember2020-01-220001739104elan:TangibleEquityUnitEquityComponentMember2020-01-220001739104elan:TangibleEquityUnitDebtComponentMember2020-01-220001739104elan:TangibleEquityUnitEquityComponentMember2020-01-222020-01-220001739104elan:TangibleEquityUnitDebtComponentMember2020-01-222020-01-220001739104elan:A275SeniorAmortizingNotesMemberus-gaap:SeniorNotesMember2020-01-220001739104elan:A275SeniorAmortizingNotesMemberus-gaap:SeniorNotesMember2020-01-222020-01-220001739104elan:TangibleEquityUnitMember2020-01-22elan:tradingDay0001739104elan:A500TangibleEquityUnitsMemberus-gaap:SeniorNotesMember2020-01-222020-01-220001739104srt:MaximumMemberelan:TangibleEquityUnitMember2020-01-220001739104srt:MinimumMemberelan:TangibleEquityUnitMember2020-01-220001739104elan:IncrementalTermFacilityMemberus-gaap:LineOfCreditMember2021-09-300001739104elan:IncrementalTermFacilityMemberus-gaap:LineOfCreditMember2020-09-300001739104elan:TermBLoanFacilityMemberus-gaap:LineOfCreditMember2021-09-300001739104elan:TermBLoanFacilityMemberus-gaap:LineOfCreditMember2020-09-300001739104us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2021-09-300001739104us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2020-09-300001739104us-gaap:SeniorNotesMemberelan:A3.912SeniorNotesDue2021Member2021-09-300001739104us-gaap:SeniorNotesMemberelan:A3.912SeniorNotesDue2021Member2020-09-300001739104us-gaap:SeniorNotesMemberelan:A4.272SeniorNotesDue2023Member2021-09-300001739104us-gaap:SeniorNotesMemberelan:A4.272SeniorNotesDue2023Member2020-09-300001739104us-gaap:SeniorNotesMemberelan:A4.9SeniorNotesDue2028Member2021-09-300001739104us-gaap:SeniorNotesMemberelan:A4.9SeniorNotesDue2028Member2020-09-300001739104elan:A500TangibleEquityUnitsMemberus-gaap:SeniorNotesMember2021-09-300001739104elan:A500TangibleEquityUnitsMemberus-gaap:SeniorNotesMember2020-09-300001739104us-gaap:NotesPayableOtherPayablesMember2021-09-300001739104us-gaap:NotesPayableOtherPayablesMember2020-09-300001739104elan:FarmCreditTermLoanFacilityMemberus-gaap:LineOfCreditMember2021-08-122021-08-120001739104elan:TermBLoanFacilityMemberelan:BayerAnimalBusinessMemberus-gaap:LineOfCreditMember2020-08-010001739104elan:TermBLoanFacilityMemberelan:BayerAnimalBusinessMemberus-gaap:LineOfCreditMember2020-08-012020-08-010001739104us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2020-08-010001739104us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2020-08-012020-08-010001739104us-gaap:LondonInterbankOfferedRateLIBORMembersrt:MinimumMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2020-08-012020-08-010001739104us-gaap:LondonInterbankOfferedRateLIBORMembersrt:MaximumMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2020-08-012020-08-010001739104us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2021-03-012021-03-310001739104us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2021-04-012021-04-300001739104us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2021-08-312021-08-31elan:covenant0001739104us-gaap:SeniorNotesMember2018-08-310001739104us-gaap:SeniorNotesMemberelan:A3.912SeniorNotesDue2021Member2018-08-310001739104us-gaap:SeniorNotesMemberelan:A4.272SeniorNotesDue2023Member2018-08-310001739104us-gaap:SeniorNotesMemberelan:A4900SeniorNotesDue2028Member2018-08-310001739104elan:A500TangibleEquityUnitsMemberus-gaap:SeniorNotesMember2021-07-012021-09-300001739104elan:A500TangibleEquityUnitsMemberus-gaap:SeniorNotesMember2021-01-012021-09-300001739104elan:TermCreditFacilityMemberus-gaap:LineOfCreditMember2020-01-312020-01-310001739104elan:TermCreditFacilityMemberus-gaap:LineOfCreditMember2020-09-250001739104elan:TermCreditFacilityMemberus-gaap:LineOfCreditMember2020-09-252020-09-250001739104us-gaap:ForeignExchangeContractMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2021-09-300001739104us-gaap:ForeignExchangeContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-09-300001739104us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel2Memberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2021-09-300001739104us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2021-09-300001739104us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ForeignExchangeContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2021-09-300001739104us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentAssetsMember2021-09-300001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueInputsLevel1Member2021-09-300001739104us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentAssetsMember2021-09-300001739104us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentAssetsMember2021-09-300001739104us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentAssetsMember2021-09-300001739104us-gaap:ForeignExchangeContractMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentLiabilitiesMember2021-09-300001739104us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueInputsLevel1Member2021-09-300001739104us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentLiabilitiesMember2021-09-300001739104us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentLiabilitiesMember2021-09-300001739104us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentLiabilitiesMember2021-09-300001739104us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentLiabilitiesMember2021-09-300001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueInputsLevel1Member2021-09-300001739104us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentLiabilitiesMember2021-09-300001739104us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentLiabilitiesMember2021-09-300001739104us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentLiabilitiesMember2021-09-300001739104us-gaap:InterestRateContractMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentAssetsMember2021-09-300001739104us-gaap:InterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueInputsLevel1Member2021-09-300001739104us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentAssetsMember2021-09-300001739104us-gaap:FairValueInputsLevel3Memberus-gaap:InterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentAssetsMember2021-09-300001739104us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:InterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentAssetsMember2021-09-300001739104us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2021-09-300001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-09-300001739104us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-09-300001739104us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-09-300001739104us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2021-09-300001739104us-gaap:ForeignExchangeContractMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001739104us-gaap:ForeignExchangeContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-12-310001739104us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel2Memberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001739104us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001739104us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ForeignExchangeContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001739104us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentAssetsMember2020-12-310001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueInputsLevel1Member2020-12-310001739104us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentAssetsMember2020-12-310001739104us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentAssetsMember2020-12-310001739104us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentAssetsMember2020-12-310001739104us-gaap:ForeignExchangeContractMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentLiabilitiesMember2020-12-310001739104us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:FairValueInputsLevel1Member2020-12-310001739104us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentLiabilitiesMember2020-12-310001739104us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentLiabilitiesMember2020-12-310001739104us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherCurrentLiabilitiesMember2020-12-310001739104us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMember2020-12-310001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel1Member2020-12-310001739104us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMember2020-12-310001739104us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMember2020-12-310001739104us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentLiabilitiesMember2020-12-310001739104us-gaap:InterestRateContractMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentAssetsMember2020-12-310001739104us-gaap:InterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueInputsLevel1Member2020-12-310001739104us-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentAssetsMember2020-12-310001739104us-gaap:FairValueInputsLevel3Memberus-gaap:InterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentAssetsMember2020-12-310001739104us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:InterestRateContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:OtherNoncurrentAssetsMember2020-12-310001739104us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001739104us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-12-310001739104us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001739104us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001739104us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001739104elan:AratanaTherapeuticsInc.Member2021-09-300001739104elan:PrevtecMicrobiaInc.Member2021-09-300001739104us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2021-09-300001739104us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2020-12-310001739104us-gaap:OtherOperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2021-07-012021-09-300001739104us-gaap:OtherOperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2020-07-012020-09-300001739104us-gaap:OtherOperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2021-01-012021-09-300001739104us-gaap:OtherOperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2020-01-012020-09-300001739104us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember2018-10-012018-10-31iso4217:CHF0001739104us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember2018-10-310001739104us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember2020-01-012020-09-300001739104us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:InterestExpenseMember2021-07-012021-09-300001739104us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:InterestExpenseMember2020-07-012020-09-300001739104us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:InterestExpenseMember2021-01-012021-09-300001739104us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:InterestExpenseMember2020-01-012020-09-300001739104us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember2021-07-012021-09-300001739104us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember2020-07-012020-09-300001739104us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMember2021-01-012021-09-300001739104us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2020-03-310001739104us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2021-07-012021-09-300001739104us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2020-07-012020-09-300001739104us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2021-01-012021-09-300001739104us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMemberus-gaap:CashFlowHedgingMember2020-01-012020-09-3000017391042020-10-160001739104elan:CustomerAMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-07-012021-09-300001739104elan:CustomerAMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-07-012020-09-300001739104elan:CustomerAMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-09-300001739104elan:CustomerAMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-09-300001739104us-gaap:ProductMember2021-09-300001739104us-gaap:ProductMember2020-12-310001739104country:US2021-07-012021-09-300001739104country:US2020-07-012020-09-300001739104country:US2021-01-012021-09-300001739104country:US2020-01-012020-09-300001739104us-gaap:NonUsMember2021-07-012021-09-300001739104us-gaap:NonUsMember2020-07-012020-09-300001739104us-gaap:NonUsMember2021-01-012021-09-300001739104us-gaap:NonUsMember2020-01-012020-09-30elan:segment0001739104us-gaap:PensionPlansDefinedBenefitMember2021-07-012021-09-300001739104us-gaap:PensionPlansDefinedBenefitMember2020-07-012020-09-300001739104us-gaap:PensionPlansDefinedBenefitMember2021-01-012021-09-300001739104us-gaap:PensionPlansDefinedBenefitMember2020-01-012020-09-300001739104elan:BayerMember2021-01-012021-09-30

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
☒ Quarterly Report Under Section 13 or 15(d) of the
Securities Exchange Act of 1934
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2021
OR
☐ Transition Report Pursuant To Section 13 or 15(d) of the
Securities Exchange Act of 1934
COMMISSION FILE NUMBER 001-38661
elan-20210930_g1.jpg
Elanco Animal Health Incorporated
(Exact name of Registrant as specified in its charter)
INDIANA
 82-5497352
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
2500 INNOVATION WAY, GREENFIELD, INDIANA 46140
(Address of principal executive offices)
Registrant’s telephone number, including area code (877) 352-6261
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, no par valueELANNew York Stock Exchange
5.00% Tangible Equity UnitsELATNew York Stock Exchange
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of a “large accelerated filer,” “accelerated filer,” “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☒
Accelerated filer
☐
Non-accelerated filer
☐
Smaller reporting company
☐
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No ☒
The number of shares of common stock outstanding as of November 1, 2021 were 473,098,643



ELANCO ANIMAL HEALTH INCORPORATED
FORM 10-Q
FOR THE QUARTER ENDED SEPTEMBER 30, 2021
TABLE OF CONTENTS
Item 1.
Item 2.
Item 3.
Item 4.
Item 1.
Item 1A.
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.

2021 Q3 Form 10-Q | 2
elan-20210930_g1.jpg

FORWARD-LOOKING STATEMENTS AND RISK FACTOR SUMMARY

This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of the federal securities laws. These forward-looking statements, include, without limitation, statements concerning the impact on Elanco Animal Health Incorporated and its subsidiaries (collectively, Elanco, the Company, we, us or our) caused by the integration of Kindred Biosciences, Inc. (KindredBio) and the animal health business of Bayer Aktiengesellschaft (Bayer), expected synergies and cost savings, expectations relating to the potential carve-out of the microbiome research and development (R&D) platform, the sales of manufacturing facilities, product launches, independent company stand-up costs and timing, the coronavirus (COVID-19) global pandemic, reduction of debt, expectations relating to liquidity and sources of capital, our expected compliance with debt covenants, cost savings, expenses, and reserves relating to restructuring actions, our industry and our operations, performance and financial condition, and including, in particular, statements relating to our business, growth strategies, distribution strategies, product development efforts and future expenses.

Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national, or global political, economic, business, competitive, market, and regulatory conditions, including but not limited to the following:
•heightened competition, including from generics;
•the impact of disruptive innovations and advances in veterinary medical practices, animal health technologies and alternatives to animal-derived protein;
•changes in regulatory restrictions on the use of antibiotics in farm animals;
•our ability to implement our business strategies or achieve targeted cost efficiencies and gross margin improvements;
•consolidation of our customers and distributors;
•an outbreak of infectious disease carried by farm animals;
•the impact on our operations, the supply chain, customer demand, and our liquidity as a result of the COVID-19 global health pandemic;
•the success of our R&D and licensing efforts;
•misuse, off-label or counterfeiting use of our products;
•unanticipated safety, quality or efficacy concerns and the impact of identified concerns associated with our products;
•the impact of weather conditions and the availability of natural resources;
•use of alternative distribution channels and the impact of increased or decreased sales to our channel distributors resulting in fluctuation in our revenues;
•manufacturing problems and capacity imbalances;
•challenges to our intellectual property rights or our alleged violation of rights of others;
•risks related to our presence in foreign markets;
•breaches of our information technology systems;
•our ability to complete acquisitions and successfully integrate the businesses we acquire, including KindredBio and the animal health business of Bayer (Bayer Animal Health);
•the terms, timing or structure of any separation of the microbiome R&D platform, including whether it will be consummated at all, and whether the operational and strategic benefits of such transaction can be achieved, including whether the uncertainty of announcing the separation initiative will have adverse impacts on the employees, customers and suppliers related to the platform;
•the effect of our substantial indebtedness on our business;
2021 Q3 Form 10-Q | 3
elan-20210930_g1.jpg

•the uncertainties inherent in research relating to product safety and additional analyses of existing safety data;
•actions by regulatory bodies, including as a result of their interpretation of studies on product safety;
•unfavorable publicity resulting from media reports on our products;
•public acceptance of our products;
•fluctuations in our business results due to seasonality and other factors; and
•the impact of litigation, regulatory investigations, and other legal matters.
See Item 1A, “Risk Factors,” of Part I of our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission (SEC), and Item 1A, "Risk Factors," of Part II of our Quarterly Reports on Form 10-Q for the periods ended June 30, 2021 and March 31, 2021 and Part II of this Quarterly Report on Form 10-Q, for a further description of these and other factors. Although we have attempted to identify important risk factors, there may be other risk factors not presently known to us or that we presently believe are not material that could cause actual results and developments to differ materially from those made in or suggested by the forward-looking statements contained in this quarterly report. If any of these risks materialize, or if any of the assumptions underlying forward-looking statements prove incorrect, actual results and developments may differ materially from those made in or suggested by the forward-looking statements contained in this quarterly report. We caution you against relying on any forward-looking statements, which should also be read in conjunction with the other cautionary statements that are included elsewhere in this quarterly report. Any forward-looking statement made by us in this quarterly report speaks only as of the date hereof. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update or to revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.


2021 Q3 Form 10-Q | 4
elan-20210930_g1.jpg

PART I
ITEM 1. FINANCIAL STATEMENTS

Elanco Animal Health Incorporated
Condensed Consolidated Statements of Operations (Unaudited)
(in millions, except per-share data)
 Three Months Ended September 30,Nine Months Ended September 30,
 2021202020212020
Revenue$1,131 $890 $3,652 $2,134 
Costs, expenses and other:
Cost of sales502 442 1,622 1,071 
Research and development94 88 277 214 
Marketing, selling and administrative342 278 1,075 623 
Amortization of intangible assets
141 96 417 197 
Asset impairment, restructuring and other special charges
111 262 518 456 
Interest expense, net of capitalized interest60 48 181 89 
Other (income) expense, net11 (115)8 (162)
1,261 1,099 4,098 2,488 
Loss before income taxes(130)(209)(446)(354)
Income tax benefit(26)(74)(71)(117)
Net loss$(104)$(135)$(375)$(237)
Loss per share:
Basic $(0.21)$(0.29)$(0.77)$(0.56)
Diluted$(0.21)$(0.29)$(0.77)$(0.56)
Weighted average shares outstanding:
Basic487.3 462.4 487.1 426.5 
Diluted487.3 462.4 487.1 426.5 
See notes to condensed consolidated financial statements.
2021 Q3 Form 10-Q | 5
elan-20210930_g1.jpg

Elanco Animal Health Incorporated
Condensed Consolidated Statements of Comprehensive Loss (Unaudited)
(in millions)
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Net loss$(104)$(135)$(375)$(237)
Other comprehensive income (loss):
Unrealized gain (loss) on derivatives for cash flow hedges, net of taxes4 (7)52 (67)
Foreign currency translation(209)101 (506)121 
Defined benefit pension and retiree health benefit plans, net of taxes(6)(1)5 (2)
Other comprehensive income (loss), net of taxes(211)93 (449)52 
Comprehensive loss$(315)$(42)$(824)$(185)
See notes to condensed consolidated financial statements.

2021 Q3 Form 10-Q | 6
elan-20210930_g1.jpg

Elanco Animal Health Incorporated
Condensed Consolidated Balance Sheets
(in millions, except share data)
September 30, 2021December 31, 2020
(Unaudited)
Assets 
Current Assets
Cash and cash equivalents$453 $495 
Accounts receivable, net of allowances of $11 (2021) and $9 (2020)
924 872 
Other receivables158 205 
Inventories1,383 1,578 
Prepaid expenses and other242 256 
Restricted cash— 11 
Total current assets3,160 3,417 
Noncurrent Assets
Goodwill6,191 6,225 
Other intangibles, net5,816 6,387 
Other noncurrent assets357 348 
Property and equipment, net of accumulated depreciation of $1,050 (2021) and $1,038 (2020)
1,041 1,316 
Total assets$16,565 $17,693 
Liabilities and Equity
Current Liabilities
Accounts payable$436 $501 
Employee compensation159 144 
Sales rebates and discounts316 295 
Current portion of long-term debt61 555 
Other current liabilities390 582 
Total current liabilities1,362 2,077 
Noncurrent Liabilities
Long-term debt6,273 5,572 
Accrued retirement benefits 302 346 
Deferred taxes726 900 
Other noncurrent liabilities220 322 
Total liabilities8,883 9,217 
Commitments and Contingencies— — 
Equity
Preferred stock, no par value, 1,000,000,000 shares authorized; none issued
— — 
Common stock, no par value, 5,000,000,000 shares authorized, 473,033,625 and 471,921,116 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively
— — 
Additional paid-in capital8,680 8,650 
Accumulated deficit(852)(477)
Accumulated other comprehensive income (loss)(146)303 
Total equity7,682 8,476 
Total liabilities and equity$16,565 $17,693 
See notes to condensed consolidated financial statements.
2021 Q3 Form 10-Q | 7
elan-20210930_g1.jpg

Elanco Animal Health Incorporated
Condensed Consolidated Statements of Equity (Unaudited)
(Dollars and shares in millions)
Common StockAccumulated Other Comprehensive Income (Loss)
SharesAmountAdditional Paid-in CapitalRetained Earnings (Accumulated Deficit)Cash Flow Hedge Gain (Loss)Foreign Currency TranslationDefined Benefit Pension and Retiree Health Benefit PlansTotalTotal Equity
December 31, 2019373.0 $— $5,636 $84 $— $(199)$25 $(174)$5,546 
Net loss— — — (49)— — — — (49)
Adoption of Accounting Standards Update 2016-13
— — — (1)— — — — (1)
Other comprehensive loss, net of tax— — — — (39)(29)(1)(69)(69)
Separation activities (1)
— — 16 — — — — — 16 
Stock compensation — — 11 — — — — — 11 
Issuance of stock under employee stock plans, net0.8 — (13)— — — — — (13)
Issuance of common stock, net of issuance costs25.0 — 768 — — — — — 768 
Issuance of tangible equity units, net of issuance costs— — 452 — — — — — 452 
March 31, 2020398.8 — 6,870 34 (39)(228)24 (243)6,661 
Net loss— — — (53)— — — — (53)
Other comprehensive income (loss), net of tax— — — — (21)50 (1)28 28 
Separation activities (1)
— — 9 — — — — — 9 
Stock compensation— — 8 — — — — — 8 
Issuance of stock under employee stock plans, net0.1 — (1)— — — — — (1)
June 30, 2020398.9 — 6,886 (19)(60)(178)23 (215)6,652 
Net loss— — — (135)— — — — (135)
Other comprehensive income (loss), net of tax— — — — (7)101 (1)93 93 
Stock compensation— — 11 — — — — — 11 
Issuance of stock under employee stock plans, net0.1 — 0 — — — — — 0 
Issuance of stock to Bayer for acquisition, net of issuance costs72.9 — 1,723 — — — — — 1,723 
September 30, 2020471.9 $— $8,620 $(154)$(67)$(77)$22 $(122)$8,344 
(1)Represent amounts associated with transactions between us and Eli Lilly and Company (Lilly), related primarily to the completion of the local country asset purchases, the finalization of assets and liabilities associated with the legal separation from Lilly, centralized cash management, and resulting impacts on deferred tax assets, that occurred subsequent to our initial public offering.

2021 Q3 Form 10-Q | 8
elan-20210930_g1.jpg

Elanco Animal Health Incorporated
Condensed Consolidated Statements of Equity (Unaudited), Continued
(Dollars and shares in millions)
Common StockAccumulated Other Comprehensive Income (Loss)
SharesAmountAdditional Paid-in CapitalRetained Earnings (Accumulated Deficit)Cash Flow Hedge Gain (Loss)Foreign Currency TranslationDefined Benefit Pension and Retiree Health Benefit PlansTotalTotal Equity
December 31, 2020471.9 $— $8,650 $(477)$(61)$360 $4 $303 $8,476 
Net loss— — — (61)— — — — (61)
Other comprehensive income (loss), net of tax— — — — 53 (466)8 (405)(405)
Stock compensation— — 15 — — — — — 15 
Issuance of stock under employee stock plans, net1.1 — (18)— — — — — (18)
March 31, 2021473.0 — 8,647 (538)(8)(106)12 (102)8,007 
Net loss— — — (210)— — — — (210)
Other comprehensive income (loss), net of tax— — — — (5)169 3 167 167 
Stock compensation— — 16 — — — — — 16 
June 30, 2021473.0 — 8,663 (748)(13)63 15 65 7,980 
Net loss— — — (104)— — — — (104)
Other comprehensive income (loss), net of tax— — — — 4 (209)(6)(211)(211)
Stock compensation— — 17 — — — — — 17 
September 30, 2021473.0 $— $8,680 $(852)$(9)$(146)$9 $(146)$7,682 

See notes to condensed consolidated financial statements.
2021 Q3 Form 10-Q | 9
elan-20210930_g1.jpg

Elanco Animal Health Incorporated
Condensed Consolidated Statements of Cash Flows (Unaudited)
(Dollars in millions)
Nine Months Ended September 30,
 20212020
Cash Flows from Operating Activities
Net loss$(375)$(237)
Adjustments to reconcile net loss to cash flows from operating activities:
Depreciation and amortization542 295 
Change in deferred income taxes(119)(160)
Stock-based compensation expense48 31 
Asset impairment and write-down charges334 5 
Gain on sale of assets— (51)
Loss (gain) on divestitures2 (170)
Inventory fair value step-up amortization64 33 
Changes in operating assets and liabilities, net of acquisitions
(243)291 
Other non-cash operating activities, net7 15 
Net Cash Provided by Operating Activities260 52 
Cash Flows from Investing Activities
Net purchases of property and equipment(60)(16)
Cash paid for acquisitions, net of cash acquired(342)(5,001)
Proceeds from settlement of net investment hedges— 33 
Proceeds from product divestitures— 435 
Purchases of intangible assets(35)— 
Purchases of software(11)(148)
Other investing activities, net(8)(8)
Net Cash Used for Investing Activities(456)(4,705)
Cash Flows from Financing Activities
Repayments of borrowings(555)(684)
Net proceeds from revolving credit facility250 — 
Proceeds from issuance of long-term debt500 4,554 
Proceeds from issuance of common stock and tangible equity units— 1,220 
Debt issuance costs(1)(103)
Other net financing transactions with Lilly (11)— 
Other financing activities, net(17)(15)
Net Cash Provided by Financing Activities166 4,972 
Effect of exchange rate changes on cash and cash equivalents(23)7 
Net increase (decrease) in cash, cash equivalents and restricted cash(53)326 
Cash, cash equivalents and restricted cash at January 1506 345 
Cash, cash equivalents and restricted cash at September 30$453 $671 
September 30,
20212020
Cash and cash equivalents$453 $660 
Restricted cash— 11 
Cash, cash equivalents and restricted cash at September 30$453 $671 
See notes to condensed consolidated financial statements.
2021 Q3 Form 10-Q | 10
elan-20210930_g1.jpg

Elanco Animal Health Incorporated
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Tables present dollars and shares in millions, except per-share and per-unit data)

Note 1. Basis of Presentation and Summary of Significant Accounting Policies

Elanco Animal Health Incorporated (Elanco Parent) and its subsidiaries (collectively, Elanco, the Company, we, us, or our) is a premier animal health company that innovates, develops, manufactures and markets products for pets and farm animals.

Elanco was originally a wholly owned subsidiary of Eli Lilly and Company (Lilly). Elanco Parent, formed as the ultimate parent company of substantially all of the animal health businesses of Lilly, completed an initial public offering (IPO) in September 2018 and Lilly completed the disposition of all of its ownership interest in Elanco in March 2019.

We have prepared the accompanying unaudited condensed consolidated financial statements in accordance with the United States (U.S.) Securities and Exchange Commission (SEC) requirements for interim reporting. As permitted under those rules, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the U.S. (GAAP) have been condensed or omitted. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated and combined financial statements and accompanying notes for the year ended December 31, 2020 included in our Annual Report on Form 10-K filed with the SEC on March 1, 2021. In addition, results for interim periods should not be considered indicative of results for any other interim period or for the full year ending December 31, 2021 or any other future period.

In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates.

The significant accounting policies set forth in Note 4 to the consolidated and combined financial statements in our Annual Report on Form 10-K for the year ended December 31, 2020 appropriately represent, in all material respects, the current status of our accounting policies, except as it relates to the adoption of the standard that was effective January 1, 2021 as described in Note 2: Implementation of New Financial Accounting Pronouncements.

On August 1, 2020 and August 27, 2021 we completed the acquisitions of Bayer Animal Health and KindredBio, respectively. See Note 4: Acquisitions and Divestitures for additional information.

Note 2. Implementation of New Financial Accounting Pronouncements

The following table provides a brief description of an accounting standard that was effective January 1, 2021 and was adopted on that date:
StandardDescriptionEffect on the financial statements or other significant matters
Accounting Standards Update (ASU) 2019-12, Simplifying the Accounting for Income Taxes
The amendments in this update include simplifications related to accounting for income taxes including removing certain exceptions related to the approach for intraperiod tax allocation and the recognition of deferred tax liabilities for outside basis differences. The standard also clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The adoption of this guidance did not have a material impact on our consolidated financial statements.

2021 Q3 Form 10-Q | 11
elan-20210930_g1.jpg

The following table provides a brief description of an accounting standard that is applicable to us but has not yet been adopted:
StandardDescriptionEffective DateEffect on the financial statements or other significant matters
ASU 2020-04, Reference rate reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting; ASU 2021-01, Reference Rate Reform (Topic 848): Scope
ASU 2020-04 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. ASU 2021-01 clarifies the scope of Topic 848 so that derivatives affected by the discounting transition are explicitly eligible for certain optional expedients and exceptions.These standards were effective as of March 12, 2020 through December 31, 2022 and adoption is permitted at any time during the period on a prospective basis.We are currently in the process of evaluating the impact of the London Interbank Offered Rate (LIBOR) on our existing contracts and may elect optional expedients in future periods as reference rate reform activities occur. We do not expect that these updates will have a material impact on our consolidated financial statements.

Note 3. Revenue

Our sales rebates are based on specific agreements. The most significant of our sales rebate programs in terms of accrual and payment amounts, percentage of our products that are sold via these programs, and level of judgment required in estimating the appropriate transaction price, relate to our programs in the U.S., France and the United Kingdom (U.K.). As of September 30, 2021 and 2020, the aggregate liability for sales rebates for these countries represented approximately 72% and 74%, respectively, of our total liability.

The following table summarizes the activity in our global sales rebates liability:
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Beginning balance$303 $164 $295 $211 
Bayer Animal Health at acquisition— 78 — 78 
Reduction of revenue163 145 516 316 
Payments(150)(108)(495)(326)
Ending balance$316 $279 $316 $279 

Adjustments to revenue recognized as a result of changes in estimates for the judgments described above during the three and nine months ended September 30, 2021 and 2020 for product shipped in previous periods were not material.

Actual global product returns were approximately 2% and less than 1% of net revenue for the three months ended September 30, 2021 and 2020, respectively. Actual global product returns were approximately 1% of net revenue for the nine months ended September 30, 2021 and 2020.

2021 Q3 Form 10-Q | 12
elan-20210930_g1.jpg

Disaggregation of Revenue

In the first quarter of 2021, management revisited how it analyzes revenue, both internally and externally, and determined that disaggregation by major product line provides a more meaningful view of our results. Accordingly, we updated our disaggregated revenue presentation from the previous five categories (i.e., pet health disease prevention, pet health therapeutics, farm animal future protein & health, farm animal ruminants & swine, and contract manufacturing) to the following:
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Pet Health$527 $401 $1,857 $861 
Farm Animal583 473 1,728 1,222 
Contract Manufacturing (1)
21 16 67 51 
Revenue$1,131 $890 $3,652 $2,134 
(1)Represents revenue from arrangements in which we act as a contract manufacturer, including supply agreements associated with divestitures of products related to the acquisition of Bayer Animal Health.

Note 4. Acquisitions and Divestitures

During 2021 and 2020, we completed the acquisitions of KindredBio and Bayer Animal Health, respectively. These transactions were accounted for as business combinations under the acquisition method of accounting. The acquisition method requires, among other things, that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date. The determination of estimated fair value requires management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions are included in our condensed consolidated financial statements from the dates of acquisition.

KindredBio Acquisition

On August 27, 2021, we acquired KindredBio, a publicly traded biopharmaceutical company that develops innovative biologics focused on saving and improving the lives of pets. The acquisition further accelerates our pet health expansion, particularly by expanding our presence in dermatology. In connection with the merger agreement, we acquired all outstanding stock of KindredBio for $9.25 per share, or an aggregate cash purchase consideration of $444 million. We utilized our revolving credit facility and cash on hand to finance the acquisition. Refer to Note 8: Debt for further details.

During the three months ended June 30, 2021, we signed an agreement with KindredBio to acquire exclusive global rights to KIND-030, a monoclonal antibody that is being developed for the treatment and prevention of canine parvovirus. We calculated the fair value of the liability associated with that agreement using an income approach leveraging the estimated sales royalty, sales milestone and technical milestone payments avoided, and the $26 million liability was settled upon the closing of our acquisition of KindredBio. Refer to Note 5: Asset Impairment, Restructuring and Other Special Charges for further discussion.

We incurred transaction costs in connection with the KindredBio acquisition of $4 million and $6 million during the three and nine months ended September 30, 2021, respectively. Transaction costs were primarily associated with legal and other professional services related to the acquisition and are reflected within asset impairment, restructuring and other special charges in our condensed consolidated statements of operations.

Revenue and loss from KindredBio included in our condensed consolidated statements of operations since the date of acquisition for the three and nine months ended September 30, 2021 were immaterial.

The valuation of assets acquired and liabilities assumed has not yet been finalized as of September 30, 2021. The purchase price allocation is preliminary and subject to change, including the valuation of property and equipment, intangible assets, income taxes and goodwill. The amounts recognized will be finalized as the information necessary to complete the analysis is obtained, but no later than one year after the acquisition date.

2021 Q3 Form 10-Q | 13
elan-20210930_g1.jpg

The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:

Estimated Fair Value at August 27, 2021
Cash and cash equivalents$31 
Other net working capital1 
Property and equipment26 
Intangible assets, primarily acquired in-process research and development352 
Deferred income taxes(22)
Total identifiable net assets388 
Goodwill30 
Settlement of liability related to previous license agreement26 
Total consideration transferred$444 

Property and equipment is mostly composed of land, buildings, equipment (including laboratory equipment, furniture and fixtures, and computer equipment), and construction in progress. The fair value of property and equipment is currently equal to its net book value at the time of the acquisition, as we are in the process of gathering information to complete our fair value assessment.

The preliminary estimated fair values of acquired in-process research and development (IPR&D) were determined using the income approach, which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. Some of the significant assumptions inherent in the development of these asset valuations include the estimated net cash flows for each year for each asset (including revenues, cost of sales, R&D expenses, marketing, selling and administrative expenses, and contributory asset charges), the appropriate discount rate necessary to measure the risk inherent in each future cash flow stream, the life cycle of each asset, the potential regulatory and commercial success risk, and competitive trends impacting the asset and each cash flow stream, as well as other factors. The fair value of acquired IPR&D as of September 30, 2021 is based on preliminary assumptions which are subject to change as we complete our valuation procedures.

The goodwill recognized from this acquisition is attributable primarily to KindredBio's assembled workforce. The majority of goodwill associated with this acquisition is not deductible for tax purposes.

Bayer Animal Health Acquisition

On August 1, 2020, we completed the acquisition of Bayer Animal Health. The acquisition has expanded our pet health product category, advancing our planned portfolio mix transformation and creating a better balance between our farm animal and pet health product categories. Our product portfolio and pipeline have been enhanced by the addition of Bayer Animal Health, which complements our commercial operations and international infrastructure while expanding our direct to retailer/e-commerce presence.

Total consideration transferred to Bayer and its subsidiaries for the acquisition is summarized as follows:

Cash consideration (1)
$5,054 
Fair value of Elanco common stock (2)
1,724 
Fair value of total consideration transferred$6,778 
(1)Includes initial cash consideration of $5,170 million less working capital and tax adjustments of $116 million.
(2)Represents the acquisition date fair value of 73 million shares of Elanco common stock at $23.64 per share. Per the terms of the stock and asset purchase agreement, the number of shares was based on approximately $2.3 billion divided by the 20-day volume-weighted average stock price as of the last day of trading before the closing of the acquisition (but subject to a 7.5% symmetrical collar centered on the baseline share number of approximately $2.3 billion divided by an initial share price of $33.60).

2021 Q3 Form 10-Q | 14
elan-20210930_g1.jpg

We recognized transaction costs related to the acquisition of Bayer Animal Health of $3 million and $93 million during the nine months ended September 30, 2021 and 2020, respectively. Transaction costs for the three months ended September 30, 2020 were $35 million. Transaction costs were primarily associated with financial advisory, legal and other professional services related to the acquisition and are reflected within asset impairment, restructuring and other special charges in our condensed consolidated statements of operations.

The amount of revenue attributable to Bayer Animal Health included in our condensed consolidated statements of operations for the three and nine months ended September 30, 2021 is $421 million and $1,509 million, respectively. Bayer Animal Health revenues were $196 million for both the three and nine months ended September 30, 2020. Based on our current operational structure, we have not recorded standalone costs for Bayer Animal Health after the date of the acquisition. As a result, we are unable to accurately determine earnings or loss attributable to Bayer Animal Health since the date of acquisition.

The following table summarizes the fair value of assets acquired and liabilities assumed as of the acquisition date:

Estimated Fair Value at August 1, 2020
Cash and cash equivalents$169 
Accounts receivable10 
Inventories487 
Prepaid expenses and other current assets60 
Property and equipment315 
Intangible assets:
Acquired in-process research and development 65 
Marketed products3,740 
Assets held for sale138 
Accounts payable and accrued liabilities(237)
Accrued retirement benefits(220)
Other noncurrent assets and liabilities, net (878)
Total identifiable net assets3,649 
Goodwill3,129 
Total consideration transferred$6,778 

The valuation of assets acquired and liabilities assumed was finalized during the second quarter of 2021. The measurement period adjustments recorded during 2021, which were made to reflect the facts and circumstances in existence as of the acquisition date, primarily related to the finalization of our fair value assessment of property and equipment located at the Shawnee, Kansas site (Shawnee), revised cash flow assumptions for marketed products, adjustments related to changes in inventory balances and gross margin assumptions, tax adjustments, and minor working capital adjustments. These adjustments resulted in a decrease to marketed products intangible assets of $210 million, a decrease to property and equipment of $32 million, a net decrease to working capital accounts and other non-current assets and liabilities of $14 million, and an increase to goodwill of $207 million.

Inventories comprised of $311 million, $81 million, $95 million in finished products, work in process, and raw materials, respectively. The estimate of fair value of finished products was determined based on net realizable value adjusted for the costs to complete the sales process, a reasonable profit allowance from the sales process, and estimated holding costs. The estimate of fair value of work in process was determined based on net realizable value adjusted for costs to complete the manufacturing process, costs of the sales process, a reasonable profit allowance for the remaining manufacturing and sales process effort, and an estimate of holding costs. The fair value of raw materials was determined to approximate book value. The net fair value step-up adjustment to inventories of $152 million has been amortized to cost of sales as the inventory is sold to customers. As of September 30, 2021, the fair value step-up adjustment has been fully amortized.

Property and equipment is mostly composed of land, buildings, equipment (including machinery, furniture and fixtures, and computer equipment), and construction in progress. The estimated fair value of real property was
2021 Q3 Form 10-Q | 15
elan-20210930_g1.jpg

determined using the sales comparison data valuation technique and personal property was determined using the direct replacement cost method. The estimated fair value of property and equipment located at the Shawnee, Kansas site was determined using the income approach.

Intangible assets relate to $65 million of IPR&D and $3,740 million of marketed products. The acquired definite-lived intangible assets are being amortized over a weighted-average estimated useful life of approximately 10 years on a straight-line basis. The estimated fair values of identifiable intangible assets were determined using the income approach. Some of the significant assumptions inherent in the development of these asset valuations include the estimated net cash flows for each year for each asset or product (including revenues, cost of sales, R&D expenses, marketing, selling and administrative expenses, and contributory asset charges), the appropriate discount rate necessary to measure the risk inherent in each future cash flow stream, the life cycle of each asset, the potential regulatory and commercial success risk, and competitive trends impacting the asset and each cash flow stream, as well as other factors.
    
Assets held for sale include $133 million of intangible assets, consisting of marketed products and IPR&D, and $5 million of inventory related to the divestitures of Drontal™, Profender™ and other products. See the Divestitures section below for further details.

Accrued retirement benefits primarily relate to certain Bayer Animal Health international subsidiaries that have underfunded defined benefit pension plans. We have recorded the fair value of these plans using assumptions and accounting policies similar to those disclosed in Note 19: Retirement Benefits to the consolidated and combined financial statements in our Annual Report on Form 10-K for the year ended December 31, 2020. Upon acquisition, the excess of projected benefit obligation over the fair value of plan assets was recognized as a liability and previously existing deferred actuarial gains and losses and unrecognized service costs or benefits were eliminated.

The goodwill recognized from this acquisition represents the value of additional growth platforms and an expanded revenue base as well as anticipated operational synergies and cost savings from the creation of a single combined global organization. The majority of goodwill associated with this acquisition is not deductible for tax purposes.

Pro forma financial information (unaudited)

The following table presents the estimated unaudited pro forma combined results of Elanco and Bayer Animal Health as if the acquisition of Bayer Animal Health had occurred on January 1, 2020:
Three Months Ended September 30, 2020Nine Months Ended September 30, 2020
Revenue$1,069 $3,308 
Loss before income taxes
(227)(392)

The supplemental pro forma financial information has been prepared using the acquisition method of accounting and is based on the historical financial information of Elanco and Bayer Animal Health. The supplemental pro forma financial information does not necessarily represent what the combined companies' revenue or results of operations would have been had the acquisition been completed on January 1, 2020, nor is it intended to be a projection of future operating results of the combined company. It also does not reflect any operating efficiencies or potential cost savings that might be achieved from synergies of combining Elanco and Bayer Animal Health.

The unaudited supplemental pro forma financial information reflects primarily pro forma adjustments related to divestitures; fair value estimates for property and equipment, intangibles and inventory; interest expense and amortization of debt issuance costs for the debt issuance to finance the acquisition of Bayer Animal Health. The unaudited supplemental pro forma financial information includes transaction charges associated with the acquisition. There are no material, nonrecurring pro forma adjustments directly attributable to the acquisition included in the reported pro forma revenue and loss before income taxes.


2021 Q3 Form 10-Q | 16
elan-20210930_g1.jpg

Divestitures

Shawnee and Speke divestitures

In the second quarter of 2021, as part of our strategy to optimize our manufacturing footprint, we announced an agreement with TriRx Pharmaceuticals (TriRx) to sell our manufacturing sites in Shawnee and Speke, U.K. (Speke), including the planned transfer of approximately 600 employees. In connection with these arrangements, we also entered into long-term manufacturing and supply agreements, under which TriRx will manufacture existing Elanco products at both sites upon the closing of the transactions. During the nine months ended September 30, 2021, we recorded a $271 million pre-tax charge to reduce the carrying value of the disposal groups to an amount equal to fair value less costs to sell in asset impairment, restructuring, and other special charges in our condensed consolidated statements of operations. Our fair value less costs to sell assessment includes the fair value of the favorable manufacturing and supply agreements, estimated using a combined income and market approach which incorporated Level 3 inputs. On August 1, 2021, we completed the sale of our Shawnee site and expect to receive gross cash proceeds of $51 million over a period of three years based on the terms of the agreement. This activity is considered non-cash investing activity within our condensed consolidated statements of cash flows for the nine months ended September 30, 2021. We expect to close the Speke transaction in the first quarter of 2022; therefore, the related assets are classified as held for sale as of September 30, 2021. See Note 5: Asset Impairment, Restructuring and Other Special Charges for further information.

Elanco and Bayer Animal Health product divestitures

In connection with advancing our efforts to secure the necessary regulatory clearances for our acquisition of Bayer Animal Health, we signed agreements in 2020 to divest the rights to manufacture and commercialize certain legacy Elanco products. In 2020, we signed agreements to divest the worldwide rights to Osurnia™ and Vecoxan™ and the U.S. rights to Capstar. In July 2020, we completed these sales, along with certain other immaterial divestitures. The transactions were accounted for as asset divestitures.

In 2020, we also signed an agreement to divest the worldwide rights to the legacy Elanco products Itrafungol™ and Clomicalm™ in connection with the required disposal of an early-stage IPR&D asset. We also made a payment during the nine months ended September 30, 2021 and accrued for future amounts we are required to pay to the buyer of the IPR&D asset to help fund their development costs for a set period of time. The divestiture closed during the nine months ended September 30, 2021. There were no proceeds received from the disposition of these assets and the resulting immaterial impact was recorded in other (income) expense, net in our condensed consolidated statements of operations. The related assets met the assets held for sale criteria as of December 31, 2020.

To allow the Bayer Animal Health acquisition to close on a timely basis, we signed agreements to divest the rights to the legacy Bayer Animal Health products Drontal and Profender within the U.K. and European Economic Area as well as other IPR&D. We completed the transactions, which were accounted for as asset divestitures, in August 2020. Drontal, Profender, and the IPR&D rights were acquired as part of the Bayer Animal Health acquisition. The related assets were classified as held for sale on the balance sheet as of the acquisition date and measured at fair value at the time of the acquisition; therefore, no gains were recognized on the sales. During the three months ended September 2020, a loss of $7 million was recorded on the sale of IPR&D as recognition of the potential income from the divestiture was constrained by revenue accounting standards.

There were additional marketed and pipeline products that we were required to dispose of in order to comply with regulatory requirements. These divestitures did not have a material effect on our operations, cash flows or financial position.

During the three and nine months ended September 30, 2020, we received gross cash proceeds of $435 million and recognized pre-tax gains of $156 million (net of transaction costs of $13 million) relating to the product divestitures described above. Pre-tax gains were included in other (income) expense, net in our condensed consolidated statements of operations.

2021 Q3 Form 10-Q | 17
elan-20210930_g1.jpg

Assets Held For Sale

Assets and liabilities considered held for sale in connection with the above divestitures were included in the respective line items on our condensed consolidated balance sheets as follows:
September 30, 2021December 31, 2020
Inventories$38 $2 
Other intangibles, net— 4 
Property and equipment, net55 — 
Deferred tax asset— 1 
Total assets held for sale$93 $7 

Other intangibles, net classified as held for sale primarily consisted of marketed products.

Microbiome R&D platform carve-out

On October 5, 2021, we announced our intention to carve out our microbiome R&D platform, aiming to create a privately funded, independent, biopharmaceutical company focused on developing solutions for animal and human health. We are exploring structures with both strategic and financial sponsors, and may retain a minority stake in this new entity. The potential carve-out is expected to be completed by the end of the first quarter of 2022 and assets transferred are not expected to be material. We determined that the disposal of the related net assets does not qualify for reporting as a discontinued operation because it does not represent a strategic shift that has or will have a major effect on our operations and financial results.

Note 5. Asset Impairment, Restructuring and Other Special Charges

In recent years, we have incurred substantial costs associated with restructuring programs and cost-reduction initiatives designed to achieve a flexible and competitive cost structure. Restructuring activities primarily include charges associated with facility rationalization and workforce reductions. In connection with our recent acquisitions, including the acquisitions of Bayer Animal Health and KindredBio, we have also incurred costs associated with executing transactions and integrating acquired operations, which may include expenditures for banking, legal, accounting, and other similar services. In addition, we have incurred costs to stand up our organization as an independent company. All operating functions can be impacted by these actions; therefore, non-cash expenses associated with our tangible and intangible assets can be incurred as a result of revised fair value projections and/or determinations to no longer utilize certain assets in the business on an ongoing basis.

For finite-lived intangible asset and other long-lived assets, whenever impairment indicators are present, we calculate the undiscounted value of projected cash flows associated with the asset, or group of assets, and compare it to the carrying amount. If the carrying amount is greater, we record an impairment loss for the excess of book value over fair value. Determinations of fair value can result from a complex series of judgments and rely on estimates and assumptions. See Note 1: Basis of Presentation and Summary of Significant Accounting Policies for discussion regarding estimates and assumptions.

2021 Q3 Form 10-Q | 18
elan-20210930_g1.jpg

Components of asset impairment, restructuring and other special charges are as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Restructuring charges:
Severance and other costs (1)
$(2)$130 $26 $131 
Facility exit costs (1)
— — — 1 
Acquisition related charges:
Transaction and integration costs (2)
30 131 141 318 
Non-cash and other items:
Asset impairment (3)
50 — 63 4 
Asset write-down (4)
6 1 275 3 
Gain on sale of fixed assets (5)
— — — (4)
Settlements and other (6)
27 — 13 3 
Total expense$111 $262 $518 $456 
(1)For the nine months ended September 30, 2021, these charges primarily related to a restructuring program announced and initiated in January 2021. These costs were partially offset by the reversal of severance accruals associated with the January 2021 and September 2020 programs during the period. See below for further details.
For the three and nine months ended September 30, 2020, these charges primarily related to a restructuring program announced and initiated in September 2020. See below for further details.
(2)Transaction costs represent external costs directly related to acquiring businesses and primarily include expenditures for banking, legal, accounting and other similar services. Integration costs represent internal and external incremental costs directly related to integrating acquired businesses, including the acquisitions of KindredBio and Bayer Animal Health (e.g., expenditures for consulting, system and process integration, and product transfers), as well as independent company stand-up costs related to the implementation of new systems, programs, and processes.
(3)Asset impairment charges for the three and nine months ended September 30, 2021 related to adjustments to the fair value of IPR&D assets that were subject to product rationalization. The asset impairment charge during the three months ended September 30, 2021 reflects a decision by management to terminate an IPR&D project and fully impair the related asset, which is associated with a farm animal parasiticide. The decision was prompted by unfavorable efficacy results observed during the quarter.
Asset impairment charges for the nine months ended September 30, 2020 related to the impairment of an IPR&D asset resulting from product rationalization and a reassessment of geographic viability.
(4)Asset write-down expenses for the nine months ended September 30, 2021 include the initial adjustments recorded to write down the Shawnee and Speke assets classified as held for sale as of June 30, 2021 to an amount equal to estimated fair value less costs to sell, as well as adjustments to values of assets sold in relation to the Shawnee manufacturing site sold on August 1, 2021 and assets classified as held for sale in relation to the future sale of the Speke manufacturing site during the three months ended September 30, 2021. See Note 4: Acquisitions and Divestitures for further discussion. Other charges for the nine months ended September 30, 2021 include adjustments recorded to write down assets in Belford Roxo, Brazil; Basel, Switzerland; Cuxhaven, Germany; and Manukau, New Zealand that were classified as held and used to their current fair value. These charges were recorded in connection with the January 2021 and September 2020 restructuring programs.
Asset write-down expenses for the three and nine months ended September 30, 2020 resulted from adjustments recorded to write down assets classified as held and used to their current fair value. These charges primarily related to fixed assets in Wusi, China in connection with the announced 2019 program to streamline operations.
(5)Represents a gain on the disposal from the sale of an R&D facility in Prince Edward Island, Canada.
(6)Settlements and other expenses for the three and nine months ended September 30, 2021 include a charge associated with the settlement of a liability for future royalty and milestone payments triggered in connection with our acquisition of KindredBio as discussed further in Note 4: Acquisitions and Divestitures, accounting and advisory fees related to the sale of our manufacturing site in Shawnee, and an $8 million charge related to a litigation settlement for a matter that originated prior to our acquisition of Bayer Animal Health, partially offset by net curtailment and settlement gains from the remeasurement of our pension benefit obligation as a result of workforce reductions in connection with our September 2020 and January 2021 restructuring programs. See Note 13: Retirement Benefits for further information. The amount for the nine months ended September 30, 2021 also includes the gain recorded on the divestiture of an early-stage IPR&D asset acquired as part of the Bayer Animal Health acquisition.
Settlements and other expenses for the three and nine months ended September 30, 2020 relate to a non-recurring litigation settlement for a matter that originated prior to our separation from Lilly.

2021 Q3 Form 10-Q | 19
elan-20210930_g1.jpg

In January 2021, we announced a restructuring aligned with our ongoing efforts to improve operating efficiencies. The proposed actions focused on streamlining processes and delivering increased efficiency in functional areas, while improving the productivity of our investments in innovation. As part of the restructuring plan, we closed our R&D sites in Manukau, New Zealand and Cuxhaven, Germany. We have also reduced duplication and optimized structures in U.S. operations, marketing, manufacturing and quality central functions, and administrative areas. The restructuring resulted in the elimination of approximately 330 positions around the world. Activities related to this initiative resulted in favorable adjustments of $1 million and charges of $44 million during the three and nine months ended September 30, 2021, respectively. The favorable adjustments reflect a change in estimate resulting from ongoing negotiations. Initiatives under this program are expected to be substantially completed by the end of 2021.

In September 2020, following the closing of the Bayer Animal Health acquisition, we implemented a restructuring program designed to reduce duplication, drive efficiency and optimize our footprint in key geographies. As part of the restructuring plan, we have eliminated approximately 900 positions across 40 countries, primarily in the commercial and marketing functions, but also in R&D, manufacturing and quality, and back office support functions. During the three and nine months ended September 30, 2021 we recorded favorable adjustments of $1 million and $15 million, respectively, as a change in estimate related to this initiative, which reflects adjustments to severance accruals resulting from favorable negotiations and certain restructured employees filling open positions. Initiatives under this program are expected to be substantially completed by the end of 2021.

The following table summarizes the activity in our reserves established in connection with restructuring activities:
Facility exit costs SeveranceTotal
Balance at December 31, 2019$5 $16 $21 
Charges1 132 133 
Reserve adjustments— (1)(1)
Cash paid(1)(15)(16)
Balance at September 30, 2020$5 $132 $137 
Balance at December 31, 2020$— $130 $130 
Charges— 41 41 
Reserve adjustments— (15)(15)
Cash paid— (95)(95)
Balance at September 30, 2021$— $61 $61 

These reserves are included in other current and noncurrent liabilities on our condensed consolidated balance sheets. Substantially all of the reserves are expected to be paid in the next 15 months primarily due to certain country negotiations and regulations. We believe that the reserves are adequate.

Note 6. Inventories

We state all inventories at the lower of cost or net realizable value. We use the last-in, first-out (LIFO) method for a portion of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method or the weighted average cost method.

Inventories consisted of the following:
September 30, 2021December 31, 2020
Finished products$595 $772 
Work in process576 625 
Raw materials and supplies255 210 
Total1,426 1,607 
Decrease to LIFO cost(43)(29)
Inventories$1,383 $1,578 
2021 Q3 Form 10-Q | 20
elan-20210930_g1.jpg

Note 7. Equity

Common Stock Offering

On January 22, 2020, we entered into an underwriting agreement in which we agreed to sell approximately 23 million shares of our common stock at a public offering price of $32.00 per share. In connection with the offering, we granted the underwriters an option to purchase up to an additional 2 million shares, which was exercised in full on January 23, 2020. As a result, we issued and sold a total of approximately 25 million shares of our common stock for $768 million, after issuance costs.

Tangible Equity Unit (TEU) Offering

On January 22, 2020, we also completed our offering of 11 million, 5.00% TEUs. Total proceeds, net of issuance costs, were $528 million. Each TEU, which has a stated amount of $50, is comprised of a prepaid stock purchase contract (prepaid stock) and a senior amortizing note due February 1, 2023. Subsequent to issuance, each TEU may be legally separated into the two components. The prepaid stock is considered a freestanding financial instrument, indexed to Elanco common stock, and meets the conditions for equity classification.

The value allocated to the prepaid stock is reflected net of issuance costs in additional paid-in capital. The value allocated to the senior amortizing notes is reflected in long-term debt on the condensed consolidated balance sheets, with payments expected in the next twelve months reflected in current portion of long-term debt. Issuance costs related to the amortizing notes are reflected as a reduction of the carrying amount and will be amortized through the maturity date using the effective interest rate method.

The proceeds from the issuance were allocated to equity and debt based on the relative fair value of the respective components of each TEU as follows:
Equity ComponentDebt ComponentTotal
Fair value per unit$42.80 $7.20 $50.00 
Gross proceeds$471 $79 $550 
Less: Issuance costs19 3 22 
Net proceeds$452 $76 $528 

The senior amortizing notes have an aggregate principal amount of $79 million and bear interest at 2.75% per year. On each February 1, May 1, August 1, and November 1 until the maturity date, we will pay equal quarterly cash installments of $0.6250 per each amortizing note with an initial principal amount of $7.2007 (except for the first installment payment of $0.6528 per amortizing note paid on May 1, 2020). Each installment constitutes a payment of interest and partial payment of principal, and in the aggregate will be equivalent to 5.00% per year with respect to the $50 stated amount per TEU.

Unless settled early at the holder’s or our election, each prepaid stock purchase contract will automatically settle on February 1, 2023 (the mandatory settlement date) for a number of shares of common stock per contract based on the average of the volume-weighted average trading prices during the 20 consecutive trading day period beginning on, and including the 21st scheduled trading day immediately preceding February 1, 2023 (applicable market value) with reference to the following settlement rates:
Applicable Market ValueCommon Stock Issued
Equal to or greater than $38.40
1.3021 shares (minimum settlement rate)
Less than $38.40, but greater than $32.00
$50 divided by applicable market value
Less than or equal to $32.00
1.5625 (maximum settlement rate)

2021 Q3 Form 10-Q | 21
elan-20210930_g1.jpg

The prepaid stock purchase contracts are mandatorily convertible into a minimum of 14 million shares or a maximum of 17 million shares of our common stock on the mandatory settlement date (unless redeemed by us or settled earlier at the unit holder's option). The 14 million minimum shares are included in the calculation of basic weighted average shares outstanding. The difference between the minimum and maximum shares represents potentially dilutive securities, which are included in the calculation of diluted weighted average shares outstanding on a pro rata basis to the extent that the average applicable market value is higher than $32.00 but is less than $38.40 during the period.

Note 8. Debt

Long-term debt consisted of the following:
September 30, 2021December 31, 2020
Incremental Term Facility$500 $— 
Term Loan B4,129 4,164 
Revolving Credit Facility250 — 
3.912% Senior Notes due 2021
— 500 
4.272% Senior Notes due 2023
750 750 
4.900% Senior Notes due 2028
750 750 
TEU Amortizing Notes40 60 
Other obligations— 1 
Unamortized debt issuance costs(85)(98)
6,334 6,127 
Less current portion of long-term debt61 555 
Total long-term debt$6,273 $5,572 
Farm Credit Agreement

On August 12, 2021, we entered into a new debt financing arrangement with Farm Credit Mid-America, PCA (Farm Credit) for a $500 million credit facility, consisting of a senior secured term loan (Incremental Term Facility) to retire our existing Senior Notes due August 27, 2021. The Incremental Term Facility bears interest at a floating rate of LIBOR plus 175 basis points and is payable in quarterly installments with a final balloon payment due on August 12, 2028. The terms of the Incremental Term Facility, including pledged collateral and financial maintenance covenants, are generally consistent with the terms of our existing term loan B credit facility (Term Loan B) and revolving credit facility.

Bayer Animal Health Related Financing

In connection with the acquisition of Bayer Animal Health, on August 1, 2020, we borrowed $4,275 million under a Term Loan B facility. The Term Loan B bears interest at a floating rate of LIBOR plus 175 basis points and is payable in quarterly installments through August 1, 2027.
Simultaneously, we entered into a revolving credit facility providing up to $750 million (with incremental capacity available if certain conditions are met) and maturing over a five-year term. The revolving credit facility bears interest at LIBOR plus an applicable margin ranging between 1.50% and 2.25% per annum based on our corporate family rating or corporate credit rating. In February 2021, we drew down $150 million on the revolving credit facility for working capital needs. We subsequently repaid $100 million in March 2021 and the remaining $50 million in April 2021. In August 2021, we drew down $350 million on the revolving credit facility to partially fund the acquisition of KindredBio. We subsequently repaid $100 million in September 2021.
These senior secured first lien credit facilities are secured by a significant portion of our assets. They include two financial maintenance covenants which are solely for the benefit of lenders under the revolving credit facility. There are no financial maintenance covenants for the benefit of the Term Loan B facility. The lenders under the Term Loan B facility have no enforcement rights with respect to the financial maintenance covenants for the revolving credit facility.
2021 Q3 Form 10-Q | 22
elan-20210930_g1.jpg


The first financial maintenance covenant for the revolving credit facility requires us to maintain a net total leverage ratio level (which is not subject to step-downs) as of the end of each quarter. The required level of this covenant is based on closing date pro forma net leverage and pro forma adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) not exceeding 7.71 to 1.00 of our pro forma adjusted EBITDA for the four fiscal quarters ended September 30, 2021.

The second financial maintenance covenant for the revolving credit facility requires us to maintain a ratio of pro forma adjusted EBITDA to cash interest expense of no less than 2.00 to 1.00, tested as of the end of each fiscal quarter. We were in compliance with all covenants under the credit facility as of September 30, 2021.

Senior Notes

In August 2018, we issued $2 billion of senior notes (Senior Notes). The Senior Notes comprised of $500 million of 3.912% Senior Notes due August 27, 2021, which were fully repaid as part of the Farm Credit refinancing, $750 million of 4.272% Senior Notes due August 28, 2023, and $750 million of 4.900% Senior Notes due August 28, 2028. The interest rate payable on each series of Senior Notes is subject to adjustment if Moody's Investor Services, Inc. or Standard & Poor's Financial Services LLC downgrades, or subsequently upgrades, its ratings on the respective series of Senior Notes.
The indenture that governs the Senior Notes contains covenants that limit our, and certain of our subsidiaries' ability, to incur liens or engage in sale-leaseback transactions. The indenture also contains restrictions on our ability to consolidate, merge or sell substantially all of our assets, in addition, to other customary terms. We were in compliance with all such covenants under the indenture governing the Senior Notes as of September 30, 2021.
TEU Amortizing Notes

On January 22, 2020, we issued $550 million in TEUs. We offered 11 million, 5.00% TEUs at the stated amount of $50 per unit, comprised of prepaid stock purchase contracts and a senior amortizing note due February 1, 2023 (the mandatory settlement date). Total cash of $528 million was received, comprised of $452 million of prepaid stock purchase contracts and $76 million of senior amortizing notes, net of issuance costs. During the three and nine months ended September 30, 2021, we paid $7 million and $21 million, respectively, representing partial payment of principal and interest on the TEU amortizing notes. See Note 7: Equity for further information.

Debt Extinguishment

On January 31, 2020, we repaid indebtedness outstanding under our previous term loan facility. We paid $372 million in cash, composed of $371 million of principal and $1 million of accrued interest, resulting in a debt extinguishment loss of $1 million (recognized in interest expense, net of capitalized interest in our condensed consolidated statements of operations for the nine months ended September 30, 2020), primarily related to the write-off of deferred debt issuance costs.

On September 25, 2020, we made a repayment of principal of $100 million on the indebtedness outstanding under our Term Loan B. The repayment was accounted for as a partial debt extinguishment and resulted in a debt extinguishment loss of $2 million (recognized in interest expense, net of capitalized interest in the condensed consolidated statements of operations for the three and nine months ended September 30, 2020), primarily related to the write-off of deferred debt issuance costs.

Note 9. Financial Instruments and Fair Value

Financial instruments that are potentially subject to credit risk consist principally of trade receivables. We evaluate the creditworthiness of our customers on a regular basis, monitor economic conditions, and calculate allowances for estimated credit losses on our trade receivables on a quarterly basis using an expected credit loss model. We assess whether collectability is probable at the time of sale and on an ongoing basis. Collateral is generally not required. The risk associated with this concentration is mitigated by our ongoing credit-review procedures.

2021 Q3 Form 10-Q | 23
elan-20210930_g1.jpg

A large portion of our cash is held by a few major financial institutions. We monitor the exposure with these institutions and do not expect any of these institutions to fail to meet their obligations. All highly liquid investments with a maturity of three months or less from the date of purchase are considered to be cash equivalents. The cost of these investments approximates fair value. We also consider the carrying value of restricted cash balances to be representative of its fair value.

We had investments without readily determinable fair values and equity method investments included in other noncurrent assets on our condensed consolidated balance sheets totaling $21 million and $24 million as of September 30, 2021 and December 31, 2020, respectively. Unrealized net gains and losses on our investments for the three and nine months ended September 30, 2021 and 2020 were immaterial.

The following table summarizes the fair value information at September 30, 2021 and December 31, 2020 for foreign exchange contract assets (liabilities), investments, contingent consideration liabilities, and cash flow hedge assets (liabilities) measured at fair value on a recurring basis in the respective balance sheet line items, as well as long-term debt (including TEU amortizing notes) for which fair value is disclosed on a recurring basis:
  Fair Value Measurements Using 
Financial statement line itemCarrying
Amount		Quoted Prices in Active Markets for Identical Assets
(Level 1)		Significant
Other Observable Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Fair
Value
September 30, 2021
Prepaid expenses and other - foreign exchange contracts not designated as hedging instruments$30 $— $30 $— $30 
Other noncurrent assets - investments15 15 — — 15 
Other current liabilities - foreign exchange contracts not designated as hedging instruments(30)— (30)— (30)
Other current liabilities - contingent consideration(1)— — (1)(1)
Other noncurrent liabilities - forward-starting interest rate contracts designated as cash flow hedges(24)— (24)— (24)
Long-term debt, including current portion(6,419)— (6,551)— (6,551)
December 31, 2020
Prepaid expenses and other - foreign exchange contracts not designated as hedging instruments$36 $— $36 $— $36 
Other noncurrent assets - investments9 9 — — 9 
Other current liabilities - foreign exchange contracts not designated as hedging instruments(36)— (36)— (36)
Other noncurrent liabilities - contingent consideration(1)— — (1)(1)
Other noncurrent liabilities - forward-starting interest rate contracts designated as cash flow hedges(76)— (76)— (76)
Long-term debt, including current portion(6,225)— (6,420)— (6,420)
We determine our Level 2 fair value measurements based on a market approach using quoted market values or significant other observable inputs for identical or comparable assets or liabilities.

2021 Q3 Form 10-Q | 24
elan-20210930_g1.jpg

Contingent consideration liabilities as of September 30, 2021 and December 31, 2020 related to contingent consideration associated with the acquisitions of Aratana Therapeutics, Inc. (Aratana) and Prevtec Microbia Inc. (Prevtec) during 2019. For Aratana, we will pay up to $12 million in contingent value rights that are dependent on the achievement of a specified milestone by December 31, 2021 as outlined in the merger agreement. For Prevtec, based on the terms of the purchase agreement, we will pay up to $16 million contingent upon the achievement of specific Coliprotec sales milestones by December 31, 2021. The fair value of both contingent consideration liabilities was estimated using the Monte Carlo simulation model and Level 3 inputs including historical revenue, discount rate, asset volatility, and revenue volatility.

Derivative Instruments and Hedging Activities

We are exposed to market risks, such as changes in foreign currency exchange rates and interest rates. To manage the volatility related to these exposures, we have entered into various derivative transactions. We formally assess, designate and document, as a hedge of an underlying exposure, each qualifying derivative instrument that will be accounted for as an accounting hedge at inception. Additionally, we assess, both at inception and at least quarterly thereafter, whether the financial instruments used in the hedging transaction are effective at offsetting changes in either the fair values or cash flows of the underlying exposures.

Derivatives Not Designated as Hedges

We may enter into foreign exchange forward or option contracts to reduce the effect of fluctuating currency exchange rates. These derivative financial instruments primarily offset exposures in the British pound, Canadian dollar, Euro, Japanese yen, Swiss franc (CHF), and Chinese yuan. Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures and are recorded at fair value with the gain or loss recognized in other (income) expense, net in the condensed consolidated statements of operations. Forward contracts generally have maturities not exceeding 12 months. At September 30, 2021 and December 31, 2020, we had outstanding foreign exchange contracts with aggregate notional amounts of $1,417 million and $1,391 million, respectively.

The amounts of net gain (loss) on derivative instruments not designated as hedging instruments, recorded in other (income) expense, net are as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Foreign exchange forward contracts (1)
$(2)$(2)$(29)$19 

(1)These amounts were substantially offset in other (income) expense, net by the effect of changing exchange rates on the underlying foreign currency exposures.

Derivatives Designated as Hedges

In October 2018, as a means of mitigating the impact of currency fluctuations on our operations in Switzerland, we entered into a five-year cross-currency fixed interest rate swap with a 750 million CHF notional amount, which was designated as a net investment hedge (NIH) against CHF denominated assets (the fair value of which was estimated based on quoted market values of similar hedges and was classified as Level 2). During the nine months ended September 30, 2020 we fully liquidated our cross currency interest rate swaps for a cash benefit of $35 million (including $2 million in interest). Notwithstanding settlement, gains and losses within accumulated other comprehensive income (loss) will remain in accumulated other comprehensive income (loss) until either the sale or substantial liquidation of the hedged subsidiary.

Gains on the NIH, recognized within interest expense, net of capitalized interest, are as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Cross-currency interest rate swap contracts$— $— $— $6 

2021 Q3 Form 10-Q | 25
elan-20210930_g1.jpg

Over the life of the derivative, gains or losses due to spot rate fluctuations were recorded in cumulative translation adjustment in other comprehensive income (loss). The amounts of net gains on interest rate swap contracts, recorded, net of tax, in accumulated other comprehensive income (loss), are as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Cross-currency interest rate swap contracts$— $— $— $24 

Separately, in March 2020, as a means of mitigating variability in cash flows associated with the anticipated Term Loan B issuance, we executed forward-starting interest rate swaps with a $4.1 billion notional amount, which are designated as cash flow hedges and have maturity dates ranging between 2022 and 2025. These instruments effectively convert floating-rate debt to fixed-rate debt. The cash flow hedges are recorded at fair value on our condensed consolidated balance sheets, while changes in the fair value of the hedge are recognized in other comprehensive income (loss). Fair value is estimated based on quoted market values of similar hedges and is classified as Level 2. Amounts recorded in accumulated other comprehensive income (loss) are recognized in earnings in interest expense, net of capitalized interest when the hedged transaction affects earnings (i.e., as interest payments are accrued on the Term Loan B).

The amounts of net gains (losses) on cash flow hedges, recorded, net of tax, in accumulated other comprehensive income (loss), are as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Forward-starting interest rate swaps, net of tax benefit of $0, $2, $0 and $20, respectively
$4 $(7)$52 $(67)

There was no tax effect for the three and nine months ended September 30, 2021 after the application of the U.S. valuation allowance. See Note 10: Income Taxes for further discussion. Over the next 12 months we expect to reclassify $26 million from accumulated other comprehensive income (loss) to interest expense, net of capitalized interest due to the amortization of net losses on the interest rate swaps. During the three and nine months ended September 30, 2021, we reclassified $8 million and $22 million, respectively, of net losses into interest expense.

Note 10. Income Taxes

Income Tax BenefitThree Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Income tax benefit$(26)$(74)$(71)$(117)
Effective tax rate20.0 %35.4 %15.9 %32.9 %

We were included in Lilly's U.S. tax examinations by the Internal Revenue Service through the full separation date of March 11, 2019. Pursuant to the tax matters agreement we executed with Lilly in connection with the IPO, the potential liabilities or potential refunds attributable to pre-IPO periods in which Elanco was included in a Lilly consolidated or combined tax return remain with Lilly. The U.S. examination of tax years 2016 - 2018 began in the fourth quarter of 2019 and remains ongoing; therefore, the resolution of this audit period will likely extend beyond the next 12 months.

For the three and nine months ended September 30, 2021, we recognized an income tax benefit of $26 million and $71 million, respectively. For the three months ended September 30, 2021, our effective tax rate of 20.0% differs from the statutory income tax rate primarily due to preliminary accounting for the acquisition of KindredBio, which caused a partial release of the U.S. federal valuation allowance, as well as profits being located in jurisdictions with higher statutory tax rates. For the nine months ended September 30, 2021, our effective tax rate of 15.9% differs from the statutory income tax rate primarily because the U.S. federal and state jurisdictions are currently generating losses that are subject to valuation allowances.

2021 Q3 Form 10-Q | 26
elan-20210930_g1.jpg

For the three and nine months ended September 30, 2020, we recognized an income tax benefit of $74 million and $117 million, respectively. For the three and nine months ended September 30, 2020, our effective tax rate of 35.4% and 32.9%, respectively, differs from the statutory income tax rate primarily due to the release of foreign valuation allowances as a result of gains on divestitures. Additionally, the state tax benefit is a result of U.S. pre-tax losses and the foreign tax benefit is due to losses in jurisdictions with tax rates higher than U.S. statutory rates.

Note 11. Commitments and Contingencies

Legal Matters

On May 20, 2020, a shareholder class action lawsuit captioned Hunter v. Elanco Animal Health Inc., et al. was filed in the United States District Court for the Southern District of Indiana (the Court) against Elanco, Jeffrey Simmons and Todd Young. On September 3, 2020, the Court appointed a lead plaintiff, and on November 9, 2020, the lead plaintiff filed an amended complaint. The lawsuit alleges, in part, that Elanco and certain of its executives made materially false and/or misleading statements and/or failed to disclose certain facts about Elanco’s supply chain, inventory, revenue and projections. The lawsuit seeks unspecified monetary damages and purports to represent purchasers of Elanco securities between September 30, 2018 and May 6, 2020, and purchasers of Elanco common stock issued in connection with Elanco's acquisition of Aratana. We filed a motion to dismiss on January 13, 2021. The timing of the Court's decision is uncertain. We believe the claims made in the case are meritless, and we intend to vigorously defend our position. The process of resolving these matters is inherently uncertain and may develop over an extended period of time; therefore, at this time, the ultimate resolution cannot be predicted.

On October 16, 2020, a shareholder class action lawsuit captioned Safron Capital Corporation v. Elanco Animal Health Inc., et al. was filed in the Marion Superior Court of Indiana against Elanco, certain executives, and other individuals. On December 23, 2020, the plaintiffs filed an amended complaint adding an additional plaintiff. The lawsuit alleges, in part, that Elanco and certain of its executives made materially false and/or misleading statements and/or failed to disclose certain facts about Elanco’s relationships with third party distributors and revenue attributable to those distributors within the registration statement on Form S-3 dated January 21, 2020 and accompanying prospectus filed in connection with Elanco’s public offering which closed on or about January 27, 2020. The lawsuit seeks unspecified monetary damages and purports to represent purchasers of Elanco common stock or 5.00% TEUs issued in connection with the public offering. This case is currently stayed in deference to Hunter v. Elanco Animal Health Inc.

Claims seeking actual damages, injunctive relief, and/or restitution for allegedly deceptive marketing have been made against Elanco Animal Health Inc. and Bayer HealthCare LLC, along with other Elanco and Bayer entities, arising out of the use of Seresto™, a non-prescription flea and tick collar for cats and dogs. During the nine months ended September 30, 2021, putative class action lawsuits were filed in state and federal courts in the U.S. alleging that the Seresto collars contain pesticides and other ingredients that can cause serious injury and death to cats and/or dogs wearing the product. The cases mention the existence of incident reports involving humans, but no plaintiff has claimed personal harm from the product. One plaintiff filed a petition before the Judicial Panel on Multidistrict Litigation (JPML). The hearing on the JPML petition took place on July 29, 2021, and a decision was reached to consolidate and transfer all pending lawsuits to the federal court in the Northern District of Illinois. We continue to receive information with respect to potential litigation costs, and we will be taking appropriate steps to defend these class action lawsuits.

Further, a U.S. House of Representative subcommittee chair requested that Elanco produce certain documents and information related to the Seresto collar and further made a request to temporarily recall Seresto collars from the market. We are continuing to cooperate with the subcommittee and have produced information pursuant to the request.

Seresto is a pesticide registered with the Environmental Protection Agency (EPA). A non-profit organization submitted a petition to the EPA requesting that the agency take action to cancel Seresto’s pesticide registration and suspend the registration pending cancellation. The EPA is considering this petition and asked for public comment. We submitted a comment to the EPA supporting the safety profile of Seresto. All data and scientific evaluation used during the product registration process and through pharmacovigilance review supports the product’s positive safety profile and efficacy. Therefore, we believe no removal, recall, or cancellation of the pesticide registration is warranted, nor has it been suggested by any regulatory agency. We continue to stand behind the safety profile for Seresto, and it remains available to consumers globally.
2021 Q3 Form 10-Q | 27
elan-20210930_g1.jpg


We are party to various other legal actions in the normal course of business. In determining whether a pending matter is significant for financial reporting and disclosure purposes, we consider both quantitative and qualitative factors in order to assess materiality. We accrue for liability claims to the extent that it is probable we will incur a loss and we can formulate a reasonable estimate of the costs. As of September 30, 2021 and December 31, 2020, we had no material liabilities established related to litigation as there were no significant claims which were probable and estimable. We are not currently subject to a significant claim other than the lawsuits noted above.

Regulatory Matters

On July 1, 2021, we received a subpoena from the SEC relating to our channel inventory and sales practices prior to mid-2020. We have cooperated in providing documents and information to the SEC and will continue to do so. Management believes that its actions were appropriate.

Note 12. Geographic Information

We operate as a single operating segment engaged in the development, manufacturing, marketing and sales of animal health products worldwide for both farm animals and pets. Consistent with our operational structure, our President and Chief Executive Officer (CEO), as the chief operating decision maker, makes resource allocation and business process decisions globally across our consolidated business. Strategic decisions are managed globally with global functional leaders responsible for determining significant costs/investments and with regional leaders responsible for overseeing the execution of the global strategy. Our global research and development organization is responsible for development of new products. Our manufacturing organization is responsible for the manufacturing and supply of products and for the optimization of our supply chain. Regional leaders are responsible for the distribution and sale of our products and for local direct costs. The business is also supported by global corporate staff functions. Managing and allocating resources at the global corporate level enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, product types, regional commercial organizations and research and development projects in line with our overarching long-term corporate-wide strategic goals, rather than on a product or geographic basis. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, allocating resources, setting incentive compensation targets, as well as forecasting future period financial results.

Our products include Baycox™, Cydectin™, Denagard™, Maxiban™, Optaflexx™, Rumensin™, Tylan™, and other products for livestock and poultry, as well as Advantage™, Advantix™, Advocate™ (collectively referred to as the Advantage Family), Credelio™, Duramune™, Galliprant™, Interceptor™ Plus, Seresto, Trifexis™, and other products for pets.

We have a single customer that accounted for 11% and 12% of revenue for the three months ended September 30, 2021 and 2020, respectively, and 9% and 12% of revenue for the nine months ended September 30, 2021 and 2020, respectively. Product sales with this customer resulted in accounts receivable of $80 million and $87 million as of September 30, 2021 and December 31, 2020, respectively.

We are exposed to the risk of changes in social, political and economic conditions inherent in foreign operations and our results of operations and the value of our foreign assets are affected by fluctuations in foreign currency exchange rates.

Selected geographic area information was as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Revenue
United States$507 $422 $1,621 $970 
International624 468 2,031 1,164 
Revenue$1,131 $890 $3,652 $2,134 

2021 Q3 Form 10-Q | 28
elan-20210930_g1.jpg

Note 13. Retirement Benefits

The following table summarizes net periodic benefit cost (income) relating to our defined benefit pension plans:
Three Months Ended September 30,
Nine Months Ended September 30,
2021202020212020
Service cost$4 $3 $14 $8 
Interest cost1 — 2 1 
Expected return on plan assets(2)(2)(5)(4)
Amortization of prior service cost(1)(2)(5)(6)
Amortization of net actuarial loss— 1 1 2 
Net curtailments and settlements (Note 5)(9)— (26)— 
Net periodic benefit cost (income)$(7)$— $(19)$1 

The components of net periodic benefit cost other than service cost and net curtailments and settlements are included in other (income) expense, net in our condensed consolidated statements of operations. Net curtailments and settlements are included in asset impairment, restructuring and other special charges, in our condensed consolidated statements of operations.

Note 14. Loss Per Share

We compute basic loss per share by dividing net loss available to common shareholders by the actual weighted average number of common shares outstanding for the reporting period. Elanco has variable common stock equivalents relating to certain equity awards in stock-based compensation arrangements and the TEU prepaid stock purchase contracts (see Note 7: Equity for further discussion). Diluted earnings per share reflects the potential dilution that could occur if holders of the unvested equity awards and unsettled TEUs converted their holdings into common stock. The weighted average number of potentially dilutive shares outstanding is calculated using the treasury stock method. Potential common shares that would have the effect of increasing diluted earnings per share (or reducing loss per share) are considered to be anti-dilutive and as such, these shares are not included in the calculation of diluted loss per share.

Basic and diluted loss per share are calculated as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Net loss available to common shareholders$(104)$(135)$(375)$(237)
Determination of shares:
Weighted average common shares outstanding487.3 462.4487.1 426.5
Assumed conversion of dilutive common stock equivalents (1)
— — — — 
Diluted weighted average shares outstanding487.3 462.4487.1 426.5
Loss per share (2)
Basic$(0.21)$(0.29)$(0.77)$(0.56)
Diluted$(0.21)$(0.29)$(0.77)$(0.56)
(1)During the three and nine months ended September 30, 2021 and 2020, we reported a net loss. Therefore, dilutive common stock equivalents are not assumed to have been issued since their effect is anti-dilutive. As a result, basic and diluted weighted average shares are the same, causing diluted net loss per share to be equivalent to basic net loss per share. For the three months ended September 30, 2021 and 2020, approximately 1.7 million and 1.6 million, respectively, of potential common shares were excluded from the calculation of diluted earnings per share because their effect was anti-dilutive. For the nine months ended September 30, 2021 and 2020, approximately 1.6 million and 1.9 million, respectively, of potential common shares were excluded from the calculation of diluted earnings per share because their effect was anti-dilutive.
(2)Due to rounding conventions, loss per share may not recalculate precisely based on the amounts presented within this table.

2021 Q3 Form 10-Q | 29
elan-20210930_g1.jpg

Note 15. Transactions and Agreements with Bayer

While Bayer is no longer considered a related party, we have transacted with Bayer during the period after the acquisition of Bayer Animal Health, including the period in which Bayer was considered a principal owner of Elanco. These transactions primarily related to local country asset purchases and various transitional services agreements (TSAs), contract manufacturing arrangements, and certain lease agreements to ensure business continuity after the acquisition.

For regulatory purposes in certain jurisdictions, consideration was required to be paid locally at closing in addition to amounts paid globally for the acquisition. Pursuant to the stock and asset purchase agreement, Bayer has provided a refund for payment amounts duplicated in these regions. The total amount paid to and received from Bayer during the nine months ended September 30, 2021 for these local country asset purchases was approximately $16 million. All local country asset purchases have been completed as of September 30, 2021.


2021 Q3 Form 10-Q | 30
elan-20210930_g1.jpg

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Management’s discussion and analysis of financial condition and results of operations (MD&A) is intended to assist the reader in understanding and assessing significant changes and trends related to our results of operations and financial position. This discussion and analysis should be read in conjunction with the condensed consolidated financial statements and accompanying footnotes in Item 1 of Part I of this Quarterly Report on Form 10-Q. Certain statements in this Item 2 of Part I of this Quarterly Report on Form 10-Q constitute forward-looking statements. Various risks and uncertainties, including those discussed in "Forward-Looking Statements" of this Quarterly Report on Form 10-Q, in Item 1A, "Risk Factors" of Part II of this Quarterly Report on Form 10-Q, and in Item 1A, “Risk Factors” of Part I of our Annual Report on Form 10-K for the year ended December 31, 2020, may cause our actual results, financial position, and cash generated from operations to differ materially from these forward-looking statements. Further, due to the seasonality of our pet health sales, interim results are not necessarily an appropriate base from which to project annual results.

Overview

Founded in 1954, Elanco is a premier animal health company that innovates, develops, manufactures and markets products for pets and farm animals. Headquartered in Greenfield, Indiana, we are one of the largest animal health companies in the world, with pro forma combined revenue of Elanco and Bayer Animal Health of approximately $4.4 billion for the year ended December 31, 2020.

On August 1, 2020, we completed the acquisition of Bayer Animal Health. The acquisition expanded our pet health product category, advancing our planned portfolio mix transformation and creating a better balance between our farm animal and pet health product categories. Our product portfolio and pipeline have been enhanced by the addition of Bayer Animal Health, which complements our commercial operations and international infrastructure. See Note 4: Acquisitions and Divestitures to the condensed consolidated financial statements for additional information on the acquisition. Subsequent to the acquisition date, our consolidated financial statements include the assets, liabilities, operating results and cash flows of Bayer Animal Health.

On August 27, 2021, we acquired KindredBio, a biopharmaceutical company that develops innovative biologics focused on saving and improving the lives of pets. We had previously signed an agreement with KindredBio in the second quarter of 2021 to acquire exclusive global rights to KIND-030, a monoclonal antibody that is being developed for the treatment and prevention of canine parvovirus. The acquisition of KindredBio further accelerates our pet health expansion, particularly by expanding our presence in dermatology. See Note 4: Acquisitions and Divestitures to the condensed consolidated financial statements for additional information on the acquisition. Subsequent to the acquisition date, our consolidated financial statements include the assets, liabilities, operating results and cash flows of KindredBio.

On October 5, 2021, we announced our intention to carve out our microbiome R&D platform, aiming to create a privately funded, independent, biopharmaceutical company focused on developing solutions for animal and human health. We are exploring structures with both strategic and financial sponsors, and may retain a minority stake in this new entity. The potential carve-out is expected to be completed by the end of the first quarter of 2022.

We offer a diverse portfolio of approximately 190 brands that make us a trusted partner to veterinarians and farm animal producers in more than 90 countries. Our products are generally sold worldwide to third-party distributors, retailers, and directly to farm animal producers and veterinarians. With the acquisition of Bayer Animal Health, we have expanded our presence in retail and e-commerce channels in order to meet pet owners where they want to purchase.

We operate our business in a single segment directed at fulfilling our vision of enriching the lives of people through food, making protein more accessible and affordable, and through pet companionship, helping pets live longer, healthier lives. In 2020, we renamed our four primary product categories by replacing "food animal" and "companion animal" with "farm animal" and "pet health," respectively, to better reflect the terminology used by our customers. We advance our vision with the following offering of portfolio solutions:

2021 Q3 Form 10-Q | 31
elan-20210930_g1.jpg

Pet Health: Our portfolio is focused on parasiticides, vaccines and therapeutics. We have one of the broadest parasiticide portfolios in the pet health sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. Our Seresto and Advantage, Advantix, Advocate (collectively referred to as the Advantage Family) products are over-the-counter treatments for the elimination and prevention, respectively, of fleas and ticks, and complement our prescription parasiticide products, Credelio, Interceptor Plus, and Trifexis. Our vaccines portfolio provides differentiated prevention coverage for a number of important pet health risks and is available in the U.S. only. In therapeutics, we have a broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. Pet owners are increasingly treating osteoarthritis in their pets, and our Galliprant™ product is one of the fastest growing osteoarthritis treatments in the U.S. Additionally, we have products that offer treatment for otitis (ear infections) with Claro™, as well as treatments for certain cardiovascular and dermatology indications.
Farm Animal: Our farm animal portfolio consists of products to prevent, control and treat health challenges primarily focused on cattle (beef and dairy), swine, poultry, and aquaculture (cold and warm water) production. Our products include medicated feed additives, injectable antibiotics, vaccines, insecticides, and enzymes, among others. We have a wide range of farm animal products, including Rumensin and Baytril™, both of which are used extensively in ruminants (e.g., cattle, sheep and goats) and swine production. In poultry, our Maxiban product, is a valuable offering for the control and prevention of intestinal disease.
A summary of our 2021 revenue and net loss compared with the same period in 2020 is as follows:
Three Months Ended September 30,Nine Months Ended September 30,
(Dollars in millions)2021202020212020
Revenue$1,131 $890 $3,652 $2,134 
Net loss(104)(135)(375)(237)
Increases or decreases in inventory levels at our channel distributors can positively or negatively impact our quarterly and annual revenue results, leading to variations in quarterly revenues. This can be a result of various factors, such as end customer demand, new customer contracts, heightened and generic competition, the need for certain inventory levels, our ability to renew distribution contracts with expected terms, our ability to implement commercial strategies, regulatory restrictions, unexpected customer behavior, proactive measures taken by us in response to shifting market dynamics, payment terms we extend, which are subject to internal policies, and procedures and environmental factors beyond our control, including weather conditions and the COVID-19 global pandemic.

Key Trends and Conditions Affecting Our Results of Operations

Industry Trends

The animal health industry, which includes both farm animals and pets, is a growing industry that benefits billions of people worldwide.

As demand for animal protein grows, farm animal health is becoming increasingly important. We believe that factors influencing growth in demand for farm animal medicines and vaccines include:

•two in three people needing improved nutrition;
•increased global demand for protein, particularly poultry and aquaculture;
•natural resource constraints, such as scarcity of arable land, fresh water and increased competition for cultivated land, driving the need for more efficient food production;
•loss of productivity due to farm animal disease and death;
•increased focus on food safety and food security; and
•human population growth, increased standards of living, particularly in many emerging markets, and increased urbanization.
2021 Q3 Form 10-Q | 32
elan-20210930_g1.jpg


Growth in farm animal nutritional health products (enzymes, probiotics and prebiotics) is influenced, among other factors, by demand for antibiotic alternatives that can promote animal health and increase productivity.
We believe that factors influencing growth in demand for pet medicines and vaccines include:

•increased pet ownership globally;
•pets living longer; and
•increased pet spending as pets are viewed as members of the family by owners.

Factors Affecting Our Results of Operations

COVID-19 Pandemic

Our business has been impacted by the COVID-19 pandemic. We continue to monitor the global outbreak of COVID-19 and have worked with our customers, employees, suppliers and other stakeholders to mitigate the risks posed by its spread. The COVID-19 pandemic continues to impact the economy in the U.S. and globally, and has affected the operations of our company, vendors and suppliers, and supply of and demand for our products as follows:

Operations

As a result of the COVID-19 pandemic, governmental authorities implemented measures to try to contain the virus, such as travel bans and restrictions, limits on gatherings, quarantines, shelter-in-place orders, site closures and business shutdowns. These measures have affected the ability of our employees, vendors, and suppliers to perform their respective responsibilities and obligations relative to the conduct of our business. We have important manufacturing operations worldwide that have been impacted by the outbreak. Measures requiring business shutdowns generally exclude certain essential services, and those essential services commonly include critical infrastructure and the businesses that support that critical infrastructure. Because the animal health industry has been designated an essential business, our manufacturing and research facilities remain operational, while our employees in other company functions continue to primarily work remotely. These measures have impacted and may further impact our workforce and operations, as well as those of our customers, vendors and suppliers.

In late 2020 and early 2021, vaccines effective in combating COVID-19 were authorized for use by health agencies in certain countries and regions in which we operate (including the U.S., U.K., European Union, Canada and Mexico) and began to be administered. As a result, certain countries and regions in which we operate lifted travel bans and eased restrictions put in place to contain the virus. However, some countries and regions reinstated travel bans and restrictions in connection with the resurgence of COVID-19 cases due to the Delta variant. In addition, the availability of COVID-19 vaccines, their continued effectiveness and the need for and availability of boosters are difficult to predict, and vaccination levels vary across jurisdictions. The pace and shape of the COVID-19 recovery as well as the impact and extent of COVID-19 variants or potential resurgences is not presently known. As a result, it is possible the COVID-19 pandemic, particularly in light of variant strains of the virus, could further impact our operations and the operations of our customers, suppliers and vendors as a result of quarantines, facility closures, illnesses, and travel and logistics restrictions.

Supply

The COVID-19 pandemic and related economic effects have disrupted the global supply chain across all modes of transportation, which in turn has resulted in less reliable transportation schedules and increased freight costs. This disruption, combined with increased demand for key raw materials (including those used in COVID-19 vaccine manufacturing), has also impacted our suppliers, resulting in shortages of raw materials or components required to manufacture our products. We continue to work closely with suppliers and freight partners to mitigate impacts to customers, including the addition of new transportation routes and targeted increases of certain safety stocks. Although we regularly monitor the financial health of companies in our supply chain, prolonged financial hardship on our suppliers and labor shortages caused by the COVID-19 pandemic could continue to disrupt our ability to obtain key raw materials, adversely affecting our operations. The global industry freight environment has experienced, and could continue to experience, lead time disruptions and increases in shipping costs, negatively impacting our profitability.
2021 Q3 Form 10-Q | 33
elan-20210930_g1.jpg


Demand

The COVID-19 pandemic has adversely impacted global economic conditions. In particular, the COVID-19 pandemic created significant uncertainty for our channel distribution partners with respect to end customer demand and working capital. Our third party distributors may face difficulties maintaining operations and normal liquidity in light of government-mandated restrictions. Due to liquidity and working capital pressure caused by the COVID-19 pandemic, our distributors continue to manage inventory more tightly. In response to this along with a shift in tactics for demand generation with our distributors, we reduced channel inventory levels during the first half of 2020 as we tightened our approach across all facets of our distributor relationships. We estimate that this decreased our revenue by approximately $160 million in the first half of 2020. These actions have allowed us to improve working capital management, increase gross margin, implement new compensation structures with our distributors and enable greater control of overall stock levels. For our pet health business, demand in our direct to retailer and e-commerce channels could be negatively impacted by economic conditions as they fluctuate.

In our farm animal business, demand was negatively impacted by processing plant closures in 2020, resulting in a backlog of animals ready for processing, and weakened food service demand, which collectively put pressure on producer economics. Processing plants have adjusted operations and have cleared most of the backlog, and demand for certain protein categories continues to recover. While the impact was most significant for the U.S. livestock industry, particularly in the second and third quarters of 2020, the pressure has occurred globally and across species. As the pandemic has continued throughout 2021, our business has been affected by lower levels of demand in certain markets due to unfavorable macroeconomic conditions and reduced food service consumption as well as an overall reduction in the bird and animal populations due to herd reduction and disease. As a result, the industry has seen lowered prices and producer profitability across species, most notably in international poultry and aqua. While we anticipate that recovery of end consumer demand will continue to occur, particularly in the food service business, this recovery may be negatively impacted by ongoing labor shortages in the swine, poultry, dairy and beef industries or the effect of inflation on customer profitability. We also expect this recovery to be volatile and uncertain. In addition, demand may be impacted by potential future mitigation measures such as shutdowns if prolonged resurgences in COVID-19 and its variants occur globally.

We continue to monitor the impacts on our customers' liquidity and therefore our ability to collect on our accounts receivable. While our allowance on these receivables factors in expected credit losses, disruption and declines in the global economy could result in difficulties in our ability to collect, which we have not experienced on a material basis at this time. If significant issues with collections occur, material increases in our allowance for doubtful accounts may be required.

Our Acquisition of Bayer Animal Health and KindredBio

We have incurred and expect to continue to incur expenses in connection with our acquisitions of Bayer Animal Health and KindredBio including fees for professional services such as legal, accounting, consulting, and other advisory fees and expenses. Expenses incurred in 2021 primarily relate to integration activities. In addition, we have incurred and expect to continue to incur costs related to the build out of processes and systems to support finance and global supply and logistics and to expand administrative functions, including, but not limited to, information technology, facilities management, distribution, human resources, and manufacturing, to replace services previously provided by the former parent company of Bayer Animal Health. We anticipate that these additional costs will be partially offset by expected synergies.

Product Development and New Product Launches

A key element of our targeted value creation strategy is to drive growth through portfolio development and product innovation. We continue to pursue the development of new chemical and biological molecules through our approach to innovation. Our future growth and success depend on both our pipeline of new products, including new products that we may develop through joint ventures and products that we are able to obtain through license or acquisition, and the expansion of the use of our existing products. We believe we are an industry leader in animal health R&D, with a track record of product innovation, business development and commercialization.

2021 Q3 Form 10-Q | 34
elan-20210930_g1.jpg

Competition

We face intense competition. Principal methods of competition vary depending on the particular region, species, product category, or individual product. Some of these methods include new product development, including generic alternatives to our products, quality, price, service and promotion.

Our primary competitors include animal health medicines and vaccines companies such as Zoetis Inc.; Boehringer Ingelheim Vetmedica, Inc., the animal health division of Boehringer Ingelheim GmbH; and Merck Animal Health, the animal health division of Merck & Co., Inc. We also face competition globally from manufacturers of generic drugs, as well as from producers of nutritional health products, such as DSM Nutritional Products AG and Danisco Animal Nutrition, the animal health division of E.I. du Pont de Nemours and Company, a subsidiary of DowDuPont, Inc. There are also several new start-up companies working in the animal health area. In addition, we compete with numerous other producers of animal health products throughout the world.

Productivity

Our results during the periods presented have benefited from operational and productivity initiatives implemented following recent acquisitions and in response to changing market demand for antibiotics and other headwinds.

Prior to the acquisition of Bayer Animal Health, our acquisitions within the last six years added in the aggregate $1.4 billion in revenue, 4,600 full-time employees, 12 manufacturing and eight R&D sites. The acquisitions of Bayer Animal Health on August 1, 2020 and KindredBio on August 27, 2021 added 3,950 full-time employees, 10 manufacturing sites, and five R&D sites. In addition, from 2015 to 2020, changing market demand for antibiotics and other headwinds, such as competition with generics and competitor innovation, affected some of our highest gross margin products, resulting in a change to our product mix and driving operating margin lower. In response, we implemented a number of initiatives across the manufacturing, R&D and selling, general and administrative (SG&A) functions. Our manufacturing cost savings strategies included improving manufacturing processes and headcount through lean manufacturing (minimizing waste while maintaining productivity), closing and selling manufacturing sites, consolidating our CMO network, strategically insourcing certain projects, and pursuing cost savings opportunities with respect to raw materials via a new procurement process. Additional cost savings have resulted from reducing the number of R&D sites, SG&A savings from sales force consolidation, and reducing discretionary and other general and administrative (G&A) operating expense.

Seasonality

The results of our pet health business may fluctuate due to seasonality. For example, based upon historical results, approximately 70% and 60% of total annual revenue contributed by our higher-margin parasiticide products Seresto and Advantage Family, respectively, has occurred during the first half of the year, which is reflective of the flea and tick season in the Northern Hemisphere. Therefore, a period-to-period comparison of our historical results may not be meaningful and fluctuations in total revenue for our pet health products are not necessarily an indication of future performance.

Foreign Exchange Rates

Significant portions of our revenue and costs are exposed to changes in foreign exchange rates. Our products are sold in more than 90 countries and, as a result, our revenue is influenced by changes in foreign exchange rates. During the nine months ended September 30, 2021 and 2020, approximately 51% and 52%, respectively, of our revenue was denominated in foreign currencies. As we operate in multiple foreign currencies, including the Euro, British pound, Swiss franc, Brazilian real, Australian dollar, Japanese yen, Canadian dollar, Chinese yuan, and other currencies, changes in those currencies relative to the U.S. dollar impact our revenue, cost of sales and expenses, and consequently, net income. These fluctuations may also affect the ability to buy and sell our products between markets impacted by significant exchange rate variances. Currency movements increased revenue by 2% during the nine months ended September 30, 2021 and decreased revenue by 1% during the nine months ended September 30, 2020.

Our Relationship with Lilly and Additional Standalone Costs

All operations-focused TSAs that went into effect after our 2018 separation from Lilly were exited as planned during the first half of 2021. We are nearly complete with investments in expanding our own administrative
2021 Q3 Form 10-Q | 35
elan-20210930_g1.jpg

functions, including, but not limited to, information technology, facilities management, distribution, human resources, and manufacturing, to replace services previously provided by Lilly. Because of initial stand-up costs and overlaps with services previously provided by Lilly, we have incurred and expect to continue to incur certain temporary, duplicative expenses in connection with the separation. We have also incurred costs related to the build out of processes and systems to support finance and global supply and logistics, among others. At the present time, we expect minimal additional costs to be incurred and we anticipate that total costs incurred will be between $325 million and $335 million, net of completed and planned real estate dispositions and employee benefit changes, of which a portion will be capitalized and the remainder will be expensed.

Asset Impairment, Restructuring and Other Special Charges

During the nine months ended September 30, 2021 and 2020 we incurred charges related to asset impairment, restructuring and other special charges, including in connection with the productivity initiatives described above under "Factors Affecting Our Results of Operations - Productivity," and integration of acquired businesses. These charges include: severance costs resulting from actions taken to reduce our costs; asset impairment charges and write-downs primarily related to competitive pressures for certain pet health products; product rationalizations; site closures; the sale of manufacturing sites; transaction and integration costs from acquired businesses and other related expenses, primarily Bayer Animal Health; costs associated with the acquisition of KindredBio; and costs related to the build out of processes and systems to support finance and global supply and logistics, among others, as we stand our organization up as an independent company.

For more information on these charges, see Note 5: Asset Impairment, Restructuring and Other Special Charges to the condensed consolidated financial statements.

Results of Operations

The following discussion and analysis of our results of operations should be read along with our condensed consolidated financial statements and the notes thereto.
Three Months Ended September 30,Nine Months Ended September 30,
(Dollars in millions)20212020% Change20212020% Change
Revenue $1,131 $890 27 %$3,652 $2,134 71 %
Costs, expenses and other:
Cost of sales502 442 14 %1,622 1,071 51 %
% of revenue44 %50 %(6)%44 %50 %(6)%
Research and development94 88 7 %277 214 29 %
% of revenue8 %10 %(2)%8 %10 %(2)%
Marketing, selling and administrative342 278 23 %1,075 623 73 %
% of revenue30 %31 %(1)%29 %29 %— %
Amortization of intangible assets141 96 47 %417 197 112 %
% of revenue12 %11 %2 %11 %9 %2 %
Asset impairment, restructuring and other special charges111 262 (58)%518 456 14 %
Interest expense, net of capitalized interest60 48 25 %181 89 103 %
Other (income) expense, net11 (115)NM8 (162)NM
Loss before income taxes(130)(209)38 %(446)(354)(26)%
% of revenue(11)%(23)%12 %(12)%(17)%5 %
Income tax benefit(26)(74)(65)%(71)(117)(39)%
Net loss$(104)$(135)23 %$(375)$(237)(58)%
Certain amounts and percentages may reflect rounding adjustments.
NM - Not meaningful

2021 Q3 Form 10-Q | 36
elan-20210930_g1.jpg

Disaggregated Revenue

On a global basis, our revenue by product category for the three months ended September 30 is summarized as follows:
Revenue% of Total RevenueIncrease (Decrease)
(Dollars in millions)2021202020212020$ Change% Change
CER (1)
Pet Health$527 $401 47 %45 %$12631 %30 %
Farm Animal583 473 52 %53 %11023 %22 %
Subtotal1,110 874 98 %98 %23627 %26 %
Contract Manufacturing(2)
21 16 2 %2 %531 %31 %
Total$1,131 $890 100 %100 %24127 %26 %
(1)Constant exchange rate (CER), a non-GAAP measure, is defined as revenue growth excluding the impact of foreign exchange. The calculation assumes the same foreign currency exchange rates that were in effect for the comparable prior-year period were used in translation of the current period results. We believe this metric provides a useful comparison to previous periods.
(2)Represents revenue from arrangements in which we act as a contract manufacturer, including supply agreements associated with divestitures of products related to the acquisition of Bayer Animal Health.
Total revenue increased $241 million to $1,131 million, comprised of $710 million from the legacy Elanco portfolio and $421 million from the legacy Bayer Animal Health portfolio. This 27% increase reflects a 24% increase in volume, a 2% increase in price, and a 1% favorable impact from foreign exchange rates.

The detailed change in revenue by product category was as follows:

•Pet Health revenue increased by $126 million, or 31%, for the quarter, driven by an increase in revenue as a result of the addition of Bayer Animal Health product revenue of $247 million in the quarter as compared to $113 million in the prior year. The decrease in the legacy Elanco business was driven by declines in older generation parasiticides and the impact of divestitures, partially offset by volume increases for newer generation parasiticide and pain products, as well as price growth. Current period growth in the Bayer Animal Health business was mostly attributable to the inclusion of a full quarter of revenue in comparison to a partial quarter in the prior year, as well as price growth.
•Farm Animal revenue increased by $110 million, or 23%, for the quarter, driven by an increase in revenue as a result of the addition of Bayer Animal Health product revenue of $157 million in the quarter as compared to $77 million in the prior year. Legacy Elanco revenue increased as a result of a favorable comparison to the prior year, which included lower levels of demand due to the impact of the COVID-19 pandemic on global protein markets, as well as volume growth in global cattle and U.S. swine, improvement in international poultry and aqua, and revenue from new products launched in 2021. Current period revenue was negatively impacted by generic competition and lower levels of producer demand in China's swine market due to herd liquidation. Current period growth in the Bayer Animal Health business was mostly attributable to the inclusion of a full quarter of revenue in comparison to a partial quarter in the prior year, as well as price growth.
•Contract Manufacturing revenue was $21 million, and represented 2% of total revenue. Contract manufacturing revenue for the period includes $17 million resulting from the acquisition of Bayer Animal Health.
2021 Q3 Form 10-Q | 37
elan-20210930_g1.jpg

On a global basis, our revenue by product category for the nine months ended September 30 is summarized as follows:
Revenue% of Total RevenueIncrease (Decrease)
(Dollars in millions)2021202020212020$ Change% Change
CER (1)
Pet Health$1,857 $861 51 %40 %$996116 %114 %
Farm Animal1,728 1,222 47 %57 %50641 %39 %
Subtotal3,585 2,083 98 %98 %1,50272 %70 %
Contract Manufacturing(2)
67 51 2 %2 %1631 %31 %
Total$3,652 $2,134 100 %100 %1,51871 %69 %
(1)Constant exchange rate (CER), a non-GAAP measure, is defined as revenue growth excluding the impact of foreign exchange. The calculation assumes the same foreign currency exchange rates that were in effect for the comparable prior-year period were used in translation of the current period results. We believe this metric provides a useful comparison to previous periods.
(2)Represents revenue from arrangements in which we act as a contract manufacturer, including supply agreements associated with divestitures of products related to the acquisition of Bayer Animal Health.

Total revenue increased $1,518 million to $3,652 million, comprised of $2,143 million from the legacy Elanco portfolio and $1,509 million from the legacy Bayer Animal Health portfolio. This 71% increase reflects a 67% increase in volume, a 2% increase in price, and a 2% favorable impact from foreign exchange rates.

The detailed change in revenue by product category was as follows:

•Pet Health revenue increased by $996 million, or 116%, for the period, driven by an increase in revenue as a result of the addition of Bayer Animal Health product revenue of $964 million in the period as compared to $113 million in the prior year. The increase in the legacy Elanco business was driven by a favorable comparison to the prior year, during which we reduced channel inventory levels with our distributors during the first half of the year and experienced reduced demand for veterinary products, primarily in U.S. vaccines and international markets, due to the COVID-19 pandemic. Current period growth in the legacy Elanco business was attributable to higher volume in newer generation parasiticide and pain products and price growth led by U.S. vaccines, partially offset by declines in older generation parasiticides and the impact of divestitures.
•Farm Animal revenue increased by $506 million, or 41%, for the period, driven by an increase in revenue as a result of the addition of Bayer Animal Health product revenue of $488 million in the period as compared to $77 million in the prior year. Legacy Elanco revenue increased as a result of a favorable comparison to the prior year, which included lower levels of demand due to the impact of the COVID-19 pandemic on global protein markets and actions taken across brands to reduce channel inventory levels in the first half of the year due to the pandemic. In the current period, revenue increases due to price growth, volume growth in global cattle and U.S. swine, improvement in international poultry and aqua, and revenue from new products launched in 2021 were partially offset by lower levels of demand in certain markets due to the negative impact of the COVID-19 pandemic on poultry and aqua consumption, production, and profitability, generic competition, and lower levels of producer demand in China's swine market due to herd liquidation.
•Contract Manufacturing revenue was $67 million, and represented 2% of total revenue. Contract manufacturing revenue for the period includes $57 million resulting from the acquisition of Bayer Animal Health.
Cost of Sales
Three Months Ended September 30,Nine Months Ended September 30,
(Dollars in millions)20212020% Change20212020% Change
Cost of sales$502 $442 14 %$1,622 $1,071 51 %
% of revenue44 %50 %44 %50 %

2021 Q3 Form 10-Q | 38
elan-20210930_g1.jpg

Cost of sales increased 14% for the three months ended September 30, 2021, primarily due to increased sales. Cost of sales during the three months ended September 30, 2021 was approximately 44% of revenue, compared to 50% in the prior year. This decrease is due to the inclusion of a full quarter of Bayer Animal Health products, which have higher margins, as well as lower amortization of the inventory fair value adjustment associated with the Bayer Animal Health acquisition, continued improvements in manufacturing productivity and increases in price, partially offset by product mix.

Cost of sales increased 51% for the nine months ended September 30, 2021, primarily due to increased sales and higher amortization of the inventory fair value adjustment associated with the Bayer Animal Health acquisition. Cost of sales during the nine months ended September 30, 2021 was approximately 44% of revenue, compared to 50% in the prior year. This decrease is due to the inclusion of Bayer Animal Health products, which have higher margins, as well as continued improvements in manufacturing productivity and increases in price, partially offset by higher amortization of the inventory fair value adjustment.

Research and development
Three Months Ended September 30,Nine Months Ended September 30,
(Dollars in millions)20212020% Change20212020% Change
Research and development$94 $88 7 %$277 $214 29 %
% of revenue8 %10 %8 %10 %

R&D expenses increased 7% for the three months ended September 30, 2021 and 29% for the nine months ended September 30, 2021, primarily due to the inclusion of the Bayer Animal Health and KindredBio businesses. As a percent of revenue, research and development was 8% compared to 10% in the prior year for both periods, primarily due to the rationalization of R&D projects, personnel and site operations in the current year following the acquisition of Bayer Animal Health.

Marketing, selling and administrative
Three Months Ended September 30,Nine Months Ended September 30,
(Dollars in millions)20212020% Change20212020% Change
Marketing, selling and administrative$342 $278 23 %$1,075 $623 73 %
% of revenue30 %31 %29 %29 %

Marketing, selling and administrative expenses for the three months ended September 30, 2021 were 30% of revenue, as compared to 31% in the prior year. Expenses increased 23% over prior year, primarily as a result of the acquisition of Bayer Animal Health, increased market research costs and promotional spend for direct-to-consumer and digital advertising, increased information technology spending, increased legal costs, and increases in legacy Elanco compensation and benefits due to the addition of employees to perform activities that were previously covered by the TSAs with Lilly that were exited during the first half of 2021. These increases were partially offset by disciplined cost management across the business.

Marketing, selling and administrative expenses as a percentage of revenue were 29% of revenue for the nine months ended September 30, 2021, and 2020. Expenses increased 73% over prior year, primarily as a result of the acquisition of Bayer Animal Health, increased promotional spend for direct-to-consumer and digital advertising, increased information technology spending, increases in legal and administrative costs, and increases in legacy Elanco compensation and benefits due to the addition of employees to perform activities that were previously covered by the TSAs with Lilly that were exited during the first half of 2021. These increases were partially offset by disciplined cost management across the business.

2021 Q3 Form 10-Q | 39
elan-20210930_g1.jpg

Amortization of intangible assets
Three Months Ended September 30,Nine Months Ended September 30,
(Dollars in millions)20212020% Change20212020% Change
Amortization of intangible assets$141 $96 47 %$417 $197112 %

Amortization of intangible assets increased for the three and nine months ended September 30, 2021, primarily due to the addition of amortization of intangible assets recorded from the acquisition of Bayer Animal Health.

Asset impairment, restructuring and other special charges
Three Months Ended September 30,Nine Months Ended September 30,
(Dollars in millions)20212020% Change20212020% Change
Asset impairment, restructuring and other special charges$111 $262 (58)%$518 $45614 %

Asset impairment, restructuring and other special charges decreased $151 million for the three months ended September 30, 2021 as compared to the prior year. During the three months ended September 30, 2021, we recorded a $26 million charge to establish a liability for future royalty and milestone payments relating to our canine parvovirus license agreement with KindredBio, $4 million of costs in relation to the acquisition of KindredBio, $16 million of costs associated with the implementation of new systems, programs, and processes in connection with the acquisition of the animal health business of Bayer, adjustments of $6 million to previous write-downs of assets at our Shawnee and Speke sites that were classified as held for sale in the second quarter, an $8 million charge related to a litigation settlement for a matter that originated prior to our acquisition of Bayer Animal Health, and a $50 million impairment charge for an IPR&D asset that was subject to product rationalization due to observed efficacy results. These costs were partially offset by $9 million of pension curtailment gains recorded during the period. During the three months ended September 30, 2020, we recorded $130 million of charges for severance associated with a restructuring program announced during the period, $91 million of transaction and integration costs directly related to business acquisitions, including the acquisition of the animal health business of Bayer, and $40 million of costs associated with the implementation of new systems, programs, and processes due to our separation from Lilly.

Asset impairment, restructuring and other special charges increased $62 million for the nine months ended September 30, 2021 as compared to the prior year. During the nine months ended September 30, 2021, we recorded a $271 million charge to write down assets at our Shawnee and Speke sites that were classified as held for sale to an amount equal to estimated fair value less costs to sell, $41 million of severance associated with a restructuring program announced during the period, $63 million of impairment charges for intangible assets that were subject to product rationalization, $50 million of integration costs for the Bayer Animal Health acquisition, $59 million of costs associated with the implementation of new systems, programs, and processes due to our separation from Lilly, a $26 million charge to establish a liability for future royalty and milestone payments relating to our canine parvovirus license agreement with KindredBio, $7 million of costs incurred in relation to the acquisition of KindredBio, $24 million of costs associated with the implementation of new systems, programs, and processes in connection with the acquisition of the animal health business of Bayer, and an $8 million charge related to a litigation settlement for a matter that originated prior to our acquisition of Bayer Animal Health. These costs were partially offset by $26 million of pension curtailment gains as well as a $16 million reversal of severance accruals during the period due primarily to favorable negotiations. During the nine months ended September 30, 2020, charges primarily consisted of $130 million of severance associated with a restructuring program announced in September 2020, $4 million of impairment charges for intangible assets that were subject to product rationalization, $219 million of transaction and integration costs directly related to business acquisitions, including the acquisition of the animal health business of Bayer, and $100 million of costs associated with the implementation of new systems, programs, and processes due to our separation from Lilly.

For additional information regarding our asset impairment, restructuring and other special charges, see Note 5: Asset Impairment, Restructuring and Other Special Charges to the condensed consolidated financial statements.

2021 Q3 Form 10-Q | 40
elan-20210930_g1.jpg

Interest expense, net of capitalized interest
Three Months Ended September 30,Nine Months Ended September 30,
(Dollars in millions)20212020% Change20212020% Change
Interest expense, net of capitalized interest$60 $48 25 %$181 $89103 %

Interest expense, net of capitalized interest, increased for the three and nine months ended September 30, 2021, primarily due to interest associated with the Term Loan B entered into August 1, 2020 and used to finance the Bayer Animal Health acquisition and additional debt used to finance the KindredBio acquisition.

Other (income) expense, net
Three Months Ended September 30,Nine Months Ended September 30,
(Dollars in millions)20212020% Change20212020% Change
Other (income) expense, net$11 $(115)NM$8 $(162)NM

Other expense recorded during the three months ended September 30, 2021 primarily consisted of mark-to-market adjustments on equity investments and foreign exchange losses, partially offset by certain components of net periodic benefit income. See Note 13: Retirement Benefits to the condensed consolidated financial statements for further discussion related to net periodic benefit income recorded during the period. Other income recorded during the three months ended September 30, 2020 was primarily composed of gains recorded on the divestitures of certain products.

Other expense recorded during the nine months ended September 30, 2021 primarily consisted of mark-to-market adjustments on equity investments, losses recorded in relation to divestitures, and foreign exchange losses, partially offset by certain components of net periodic benefit income, an up-front payment received in relation to an asset assignment agreement, and up-front payments received, milestones earned, and equity issued to us in relation to a license agreement. Other income recorded during the nine months ended September 30, 2020 was primarily composed of gains recorded on the divestitures of certain products and a $46 million gain on the sale of land and buildings in New South Wales, Australia.

Income tax benefit
Three Months Ended September 30,Nine Months Ended September 30,
(Dollars in millions)20212020% Change20212020% Change
Income tax benefit$(26)$(74)(65)%$(71)$(117)(39)%
Effective tax rate20.0 %35.4 %15.9 %32.9 %

Income tax benefit decreased for the three months ended September 30, 2021, primarily due to a decrease in pre-tax loss. The effective tax rate decreased for the three months ended September 30, 2021, primarily as a result of the preliminary accounting for KindredBio, which caused a partial release of the U.S. federal valuation allowance, and the impact of profits located in jurisdictions with higher statutory tax rates. The income tax benefit and effective tax rate decreased for the nine months ended September 30, 2021 primarily due to the fact that U.S. federal and state jurisdictions are currently generating losses that are subject to valuation allowances. See Note 10: Income Taxes to the condensed consolidated financial statements.

Liquidity and Capital Resources

Our primary sources of liquidity are cash on hand, cash flows from operations and funds available under our credit facilities. As a significant portion of our business is conducted internationally, we hold a significant portion of cash outside of the U.S. We monitor and adjust the amount of foreign cash based on projected cash flow requirements. Our ability to use foreign cash to fund cash flow requirements in the U.S. may be impacted by local regulations and, to a lesser extent, following U.S. tax reforms, the income taxes associated with transferring cash to the U.S. We currently intend to indefinitely reinvest foreign earnings for continued use in our foreign operations. As our structure evolves as a standalone company, we may change that strategy, particularly to the extent we identify tax efficient reinvestment alternatives for our foreign earnings or change our cash management strategy.
2021 Q3 Form 10-Q | 41
elan-20210930_g1.jpg


We believe our primary sources of liquidity are sufficient to fund our short-term and long-term existing and planned capital requirements, which include working capital obligations, funding existing marketed and pipeline products, capital expenditures, business development in our targeted areas, short-term and long-term debt obligations which include principal and interest payments as well as interest rate swaps, operating lease payments, purchase obligations, and costs associated with the integration of Bayer Animal Health and KindredBio. In addition, we have the ability to access capital markets to obtain debt refinancing for longer-term funding, if required, to service our long-term debt obligations. Further, we believe we have sufficient cash flow and liquidity to remain in compliance with our debt covenants.

Our ability to meet future funding requirements may be impacted by macroeconomic, business and financial volatility. As markets change, we will continue to monitor our liquidity position. However, a challenging economic environment or an economic downturn may impact our liquidity or ability to obtain future financing. See "Item 1A. Risk Factors - We may not be able to generate sufficient cash to service all of our indebtedness and may be forced to take other actions to satisfy our obligations under our indebtedness, which may not be successful" in Part I of our Annual Report on Form 10-K for the year ended December 31, 2020.

Cash Flows

The following table provides a summary of cash flows from operating, investing and financing activities for the periods presented:

(Dollars in millions)Nine Months Ended September 30,
Net cash provided by (used for):20212020$ Change
Operating activities$260 $52 $208 
Investing activities(456)(4,705)4,249 
Financing activities166 4,972 (4,806)
Effect of exchange-rate changes on cash and cash equivalents(23)7 (30)
Net increase (decrease) in cash, cash equivalents and restricted cash$(53)$326 $(379)

Operating activities

Our cash provided by operating activities increased by $208 million, to $260 million for the nine months ended September 30, 2021 from $52 million for the nine months ended September 30, 2020. While we incurred a higher net loss year over year, the exclusion of non-cash items during the nine months ended September 30, 2021 more than offset the impact of this higher net loss and the decrease in cash due to changes in operating assets and liabilities, particularly accounts payable and other liabilities, as compared to the nine months ended September 30, 2020. Cash provided by operating activities during the nine months ended September 30, 2021 as compared to September 30, 2020 reflects the impact of the acquisition of Bayer Animal Health on our results, a favorable comparison to the prior year due to the channel inventory reduction in the first half of 2020, and the overall recovery observed in the current year after the COVID-19 global health pandemic impacted the global economy for much of 2020. In the past, we have extended our payment terms for distributors on occasion. Although we presently have no plans to do so in the future, it is possible that we will need to extend payment terms in certain situations as a result of the COVID-19 global health pandemic, competitive pressures and the need for certain inventory levels at our channel distributors to avoid supply disruptions. If so, such extensions of customer payment terms could result in additional uses of our cash flow.

Investing activities

Our cash used for investing activities decreased $4,249 million, to $456 million for the nine months ended September 30, 2021 from $4,705 million for the nine months ended September 30, 2020. The decrease was primarily driven by lower cash paid for acquisitions. During the nine months ended September 30, 2021, cash paid for acquisitions was comprised of $444 million of cash consideration paid to acquire KindredBio, partially offset by cash acquired from KindredBio and the impact of the finalization of the working capital adjustment related to the acquisition of Bayer Animal Health. Cash used for investing activities during the nine months ended September 30, 2020 was composed of $5,170 million of cash consideration paid to acquire Bayer Animal Health, partially offset by
2021 Q3 Form 10-Q | 42
elan-20210930_g1.jpg

cash acquired from Bayer Animal Health and proceeds from product divestitures and the settlement of net investment hedges.

Financing activities

Our cash provided by financing activities decreased $4,806 million, to $166 million for the nine months ended September 30, 2021 from $4,972 million for the nine months ended September 30, 2020. Cash provided by financing activities during the nine months ended September 30, 2021 primarily reflected the repayment of indebtedness outstanding under our Senior Notes, proceeds from our borrowings under our new debt financing arrangement with Farm Credit, and net proceeds from our revolving credit facility. Cash provided by financing activities during the nine months ended September 30, 2020, reflected proceeds from our borrowings under the term loan B and revolving credit facility and issuances of common stock and TEUs to finance the acquisition of Bayer Animal Health during the period, partially offset by the repayment of indebtedness outstanding under our credit facilities.

Description of Indebtedness

For a complete description of our description of our debt and available credit facilities as of September 30, 2021 and December 31, 2020, see Note 8: Debt to the condensed consolidated financial statements.

Off Balance-Sheet Arrangements

Other than the commitments and contingencies disclosed in Note 11: Commitments and Contingencies, we had no off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on our financial condition, results of operations, or liquidity.

Contractual Obligations

Our contractual obligations and commitments as of September 30, 2021 are primarily comprised of long-term debt obligations, including principal repayments and interest payments, operating leases, and purchase obligations. Our long-term debt obligations are comprised of our expected principal and interest obligations and our interest rate swaps. Purchase obligations consist of open purchase orders as of September 30, 2021 and contractual payment obligations with significant vendors which are noncancelable and are not contingent. These obligations are primarily short-term in nature.

Critical Accounting Policies

The preparation of financial statements in accordance with GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. Certain of our accounting policies are considered critical because these policies are the most important to the depiction of our financial statements and require significant, difficult or complex judgments by us, often requiring the use of estimates about the effects of matters that are inherently uncertain. Actual results that differ from our estimates could have an unfavorable effect on our financial position and results of operations. We apply estimation methodologies consistently from year to year. Such policies are summarized in Item 7, "Management's Discussion & Analysis of Results of Financial Condition and Results of Operations," of our Annual Report on Form 10-K for the year ended December 31, 2020. There have been no significant changes in the application of our critical accounting policies during the nine months ended September 30, 2021.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Foreign Exchange Risk

We operate on a global basis and are exposed to the risk that our earnings, cash flows and equity could be adversely impacted by fluctuations in foreign exchange rates. We are primarily exposed to foreign exchange risk with respect to net assets denominated in the Euro, British pound, Swiss franc, Brazilian real, Australian dollar, Japanese yen, Canadian dollar, and Chinese yuan.
2021 Q3 Form 10-Q | 43
elan-20210930_g1.jpg


We face foreign currency exchange exposures when we enter into transactions arising from subsidiary trade and loan payables and receivables denominated in foreign currencies. We also face currency exposure that arises from translating the results of our global operations to the U.S. dollar at exchange rates that have fluctuated from the beginning of the period. We may enter into foreign currency forward or option derivative contracts to reduce the effect of fluctuating currency exchange rates in future periods.

We estimate that a hypothetical 10% adverse movement in all foreign currency exchange rates related to the translation of the results of our foreign operations would decrease our net income by approximately $18 million for the nine months ended September 30, 2021.

We generally identify hyperinflationary markets as those markets whose cumulative inflation rate over a three-year period exceeds 100%. We have concluded that our Argentina subsidiary is operating in a hyperinflationary market. As a result, beginning in the second quarter of 2018, the functional currency of our Argentina subsidiary changed from the local currency to the U.S. dollar. During the nine months ended September 30, 2021, sales in Argentina represented less than 1% of our consolidated sales. Assets held in Argentina as of September 30, 2021 represented less than 1% of our consolidated assets. While the hyperinflationary conditions did not have a material impact on our business during the nine months ended September 30, 2021, in the future, we may incur larger currency devaluations, which could have a material adverse impact on our results of operations.

Interest Risk

Borrowings under our Incremental Term Facility, Term Loan B, and revolving credit facility are exposed to interest rate fluctuations based on LIBOR. As of September 30, 2021, we held certain interest rate swap agreements with a notional value of approximately $4.1 billion that have the economic effect of modifying the variable-interest obligations associated with the Term Loan B, so that a portion of the variable-rate interest payable becomes fixed. During the nine months ended September 30, 2021, we recorded a gain of $52 million, net of taxes on these interest rate swaps in other comprehensive income (loss). The gain is primarily attributable to an increase in the U.S. Treasury yield curve during the first half of 2021. See Note 9: Financial Instruments and Fair Value to the condensed consolidated financial statements for further information.

Recently Issued Accounting Pronouncements

For discussion of our new accounting standards, see Note 2: Implementation of New Financial Accounting Pronouncements to the condensed consolidated financial statements.

ITEM 4. CONTROLS AND PROCEDURES

(a)Evaluation of Disclosure Controls and Procedures. Under applicable SEC regulations, management of a reporting company, with the participation of the principal executive officer and principal financial officer, must periodically evaluate the company’s “disclosure controls and procedures,” which are defined generally as controls and other procedures of a reporting company designed to ensure that information required to be disclosed by the reporting company in its periodic reports filed with the SEC (such as this Form 10-Q) is recorded, processed, summarized, and reported on a timely basis.

Our management, with the participation of Jeffrey N. Simmons, president and chief executive officer, and Todd S. Young, executive vice president and chief financial officer, evaluated our disclosure controls and procedures as of September 30, 2021. Based on this evaluation, the chief executive officer and the chief financial officer concluded that the disclosure controls and procedures are effective.

(b)Changes in Internal Controls. As of September 30, 2021, management is in the process of integrating the internal controls of the acquired Bayer Animal Health business into our existing operations as part of planned integration activities. In addition, we have transitioned from a Lilly solutions center to a newly established Elanco solutions center and substantially completed the implementation of our new Enterprise Resource Planning (ERP) system during the first quarter of 2021. Other than the controls enhanced or implemented to integrate the Bayer Animal Health business and certain control processes that were updated to reflect our ERP implementation, there has been no change in our internal control over financial reporting during the quarter ended September 30, 2021,
2021 Q3 Form 10-Q | 44
elan-20210930_g1.jpg

that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. As additional transformation activities occur, we will continue to monitor and evaluate our internal control over financial reporting. Further, we have not experienced any material impact to our internal controls over financial reporting despite our accounting, finance, and legal employees working remotely due to the COVID-19 pandemic. We are continually monitoring and assessing COVID-19 on our internal controls to minimize the impact on their design and operating effectiveness.

PART II
ITEM 1. LEGAL PROCEEDINGS

See Note 11: Commitments and Contingencies to the condensed consolidated financial statements for a summary of our legal proceedings, which is incorporated herein by reference.

ITEM 1A. RISK FACTORS

Other than the revisions set forth below, there have been no material changes from the risk factors disclosed in Part I of our Annual Report on Form 10-K for the year ended December 31, 2020.

The following risk factors have been changed from the risk factors that were previously disclosed:

Unanticipated safety, quality or efficacy concerns or identified concerns associated with our products may harm our reputation and have an adverse impact on our performance.

Unanticipated safety, quality or efficacy concerns arise from time to time with respect to animal health products, whether or not scientifically or clinically supported, potentially leading to product recalls, withdrawals or suspended or declining sales, as well as product liability and other claims. Regulatory actions based on these types of safety, quality or efficacy concerns could impact all, or a significant portion, of a product’s sales.

For example, lawsuits seeking actual damages, injunctive relief, and/or restitution for allegedly deceptive marketing have been filed against us arising out of the use of Seresto, a non-prescription flea and tick collar for cats and dogs, based on reports alleging that the collar has caused injury and death to pets. Further, a U.S. House of Representatives' subcommittee chair requested that we produce certain documents and information related to the Seresto collar and further made a request to temporarily remove Seresto collars from the market. Similar actions relating to Seresto could be taken by regulatory agencies. If any such claims with respect to Seresto or our other products are resolved adversely to us, or if a regulatory agency determines that a recall of any of our products, including Seresto, is necessary, such action could cause harm to our reputation, reduce our product sales, result in monetary penalties and other costly remedies against us, and could therefore have a material adverse effect on our business, financial condition and results of operations.

In addition, we depend on positive perceptions of the safety, quality and efficacy of our products, and animal health products in general, by food producers, veterinarians and pet owners. Any concern as to the safety, quality or efficacy of our products, whether actual or perceived, may harm our reputation. These concerns, including those relating to Seresto, and the related harm to our reputation could materially adversely affect our business, financial condition and results of operations, regardless of whether such reports are accurate.

We may incur substantial costs and receive adverse outcomes in litigation, regulatory investigations, and other legal matters.

Our business, financial condition and results of operations could be materially adversely affected by unfavorable results in pending or future litigation, regulatory investigation, and other legal matters. These matters may include, among other things, allegations of violation of U.S. and foreign competition law, labor laws, securities laws and regulations, consumer protection laws and environmental laws and regulations, as well as claims or litigation relating to product liability, intellectual property, securities, breach of contract and tort. For example, shareholder class action lawsuits that were recently filed against us allege, in part, that we and certain of our executives made materially false and/or misleading statements and/or failed to disclose certain facts about our supply chain,
2021 Q3 Form 10-Q | 45
elan-20210930_g1.jpg

inventory, revenue, projections and our relationships with third party distributors and revenue attributable to those distributors. We intend to vigorously defend the claims made in these lawsuits, however, the ultimate resolution cannot be predicted and the claims raised in these lawsuits may result in further legal matters or actions against us, including, but not limited to, government enforcement actions or additional private litigation. In addition, changes in the interpretations of laws and regulations to which we are subject, or in legal standards in one or more of the jurisdictions in which we operate, could increase our exposure to liability. For example, in the U.S., attempts have been made to allow damages for emotional distress and pain and suffering in connection with the loss of, or injury to, a pet. If such attempts were successful, our exposure with respect to product liability claims could increase materially.

Also, on July 1, 2021, we received a subpoena from the U.S. Securities and Exchange Commission (the SEC) relating to our channel inventory and sales practices prior to mid-2020. We have been responding to requests for documents and information from the SEC and will continue to do so. We believe that our actions were appropriate. However, we cannot predict the outcome of any particular proceeding, or whether the SEC investigation will be resolved favorably or ultimately result in charges or material damages, fines or other penalties, enforcement actions, or civil or criminal proceedings against us or members of our senior management.

Litigation matters and regulatory investigations, regardless of their merits or their ultimate outcomes, are costly, divert management’s attention and may materially adversely affect our reputation and demand for our products. We cannot predict with certainty the eventual outcome of pending or future legal matters. An adverse outcome of litigation or legal matters could result in us being responsible for significant damages. Any of these negative effects resulting from litigation, regulatory investigations and other legal matters could materially adversely affect our business, financial condition and results of operations.

We have identified the following additional risk factors:

We may not be able to successfully complete favorable transactions or successfully integrate acquired businesses when we pursue acquisitions, divestitures, joint ventures or other significant transactions, such as the acquisition of KindredBio and proposed carve-out of our microbiome R&D platform.

From time to time, we evaluate potential acquisitions, divestitures or joint ventures, such as the acquisition of KindredBio and the proposed carve-out of our microbiome R&D platform, that would further our strategic objectives. The completion of such transactions is often subject to conditions that may be outside our control, including obtaining the requisite approval of the stockholders of the target company and/or government approval pursuant to the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. Accordingly, we may not be able to complete announced and signed transactions and therefore not realize the anticipated benefits therefrom.

After the closing of an acquisition, including the transaction with KindredBio, we will be required to devote significant management attention and resources to integrating the portfolio and operations of the target company. Potential difficulties that we may encounter in the integration process, including as a result of distraction of our management, include the following:
•the inability to realize the anticipated value from various assets of the target company;
•the inability to combine the businesses of the acquired company with ours in a manner that permits us to achieve the cost savings or other synergies anticipated as a result of the transaction or to achieve such cost savings or other anticipated synergies in a timely manner, which could result in us not realizing some anticipated benefits of the transaction in the time frame anticipated, or at all;
•loss of key employees;
•potential unknown liabilities and unforeseen increased expenses, delays or unfavorable conditions in connection with the closing of the transaction and the subsequent integration; and
•performance shortfalls at our or the target company as a result of the diversion of management’s attention from ongoing business activities as a result of completing the transaction and integrating the companies’ operations.
In the case of our recent announcement regarding our intention to carve-out our microbiome R&D platform, the terms, timing and structure of any such separation of this platform, or whether the separation can be completed at all, remain uncertain, as is our ability to achieve any operational and strategic benefits from the separation. In the
2021 Q3 Form 10-Q | 46
elan-20210930_g1.jpg

meantime, the uncertainty of announcing the separation initiative may adversely impact employees, customers and suppliers related to the microbiome R&D platform.

Future acquisitions could also result in potentially dilutive issuances of equity securities, the incurrence of debt, contingent liabilities or amortization expenses related to intangible assets, and increased operating expenses, which could adversely affect our results of operations and financial condition. Furthermore, if we issue equity or debt securities to raise additional funds, our existing shareholders may experience significant dilution, and the new equity or debt securities may have rights, preferences and privileges senior to those of our existing stockholders. Furthermore, if we sell a substantial number of shares of common stock in the public markets, the availability of those shares for sale could adversely affect the market price of our common stock. Such sales, or the perception in the market that holders of a large number of shares intend to sell shares, could depress the market price of our common stock and impair our ability to raise capital through the sale of additional equity securities.

Our business results fluctuate due to seasonality and other factors and the extent of such fluctuations may be unpredictable.

Historically, our operating results have fluctuated during the year, and we expect these fluctuations to continue. For example, on average, approximately 70% and 60% of total annual revenue contribution from our higher-margin parasiticide products Seresto and Advantage Family, respectively, occurs in the first half of the year. This dynamic is reflective of the flea and tick season in the Northern Hemisphere and our growing pet health portfolio.

Other factors that may cause our operating results to fluctuate are:

•weather conditions and the availability of natural resources;

•increased or decreased inventory levels at our channel distributors;
•timing of customer orders and deliveries;
•competitive changes, such as price changes or new product introductions that we or our competitors may make;
•timing of marketing programs and events; and
•availability of veterinarians to use our products, as there are seasonal impacts, due to veterinarian vacations or training events that limit their ability to serve their customers that result in the use of our products.

For more detailed information on some of the above-listed factors that can cause fluctuations in our operating results, see "Our business may be negatively affected by weather conditions and the availability of natural resources" and "Increased or decreased inventory levels at our channel distributors can lead to fluctuations in our revenues and variations in our payment terms extended to our distributors can impact our cash flows" in Part I - Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2020.

Accordingly, the fluctuations in our revenues due to seasonality and other factors, many of which are beyond our control, mean period-to-period comparisons of our historical results are not necessarily meaningful. Investors should not rely on such fluctuations as an indication of our future performance. To the extent that we experience the factors described above, our future operating results may not meet the expectations of securities analysts or investors, which may cause the market price of our common stock to decline.


2021 Q3 Form 10-Q | 47
elan-20210930_g1.jpg

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

(none)

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

(none)

ITEM 4. MINE SAFETY DISCLOSURES

(none)

ITEM 5. OTHER INFORMATION

(none)
2021 Q3 Form 10-Q | 48
elan-20210930_g1.jpg

ITEM 6. EXHIBITS

The following exhibits are either filed or furnished herewith (as applicable) or, if so indicated, incorporated by reference to the documents indicated in parentheses, which have previously been filed or furnished with the Securities and Exchange Commission.

Exhibit NumberDescription
10.1 
31.1 
31.2 
32 
101 Interactive Data Files
104 Cover Page Interactive Data File (formatted as Inline XBRL document and included in Exhibit 101)

2021 Q3 Form 10-Q | 49
elan-20210930_g1.jpg

Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
ELANCO ANIMAL HEALTH INCORPORATED
(Registrant)
Date:November 5, 2021/s/ Jeffrey N. Simmons
Jeffrey N. Simmons
President and Chief Executive Officer
Date:November 5, 2021/s/ Todd S. Young
Todd S. Young
Executive Vice President, Chief Financial Officer

2021 Q3 Form 10-Q | 50
elan-20210930_g1.jpg
 EX-31.1 2 ex311elanco-20210930xceoce.htm EX-31.1 Document

EXHIBIT 31.1
CERTIFICATIONS
I, Jeffrey N. Simmons, certify that:
1.    I have reviewed this report on Form 10-Q of Elanco Animal Health Incorporated;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):
a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and
b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 
Date:November 5, 2021
By:/s/Jeffrey N. Simmons
 Jeffrey N. Simmons
 President and Chief Executive Officer


 EX-31.2 3 ex312elanco-20210930xcfoce.htm EX-31.2 Document

EXHIBIT 31.2
CERTIFICATIONS
I, Todd S. Young, certify that:
1.    I have reviewed this report on Form 10-Q of Elanco Animal Health Incorporated;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):
a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and
b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 
Date:November 5, 2021
By:/s/Todd S. Young
 Todd S. Young
 Executive Vice President and Chief Financial Officer


 EX-32 4 ex32elanco-20210930xsectio.htm EX-32 Document

EXHIBIT 32
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Elanco Animal Health Incorporated, an Indiana corporation (the “Company”), does hereby certify that, to the best of their knowledge:
The Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 (the “Form 10-Q”) of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date:November 5, 2021/s/Jeffrey N. Simmons
 Jeffrey N. Simmons
 President and Chief Executive Officer
 
Date:November 5, 2021/s/Todd S. Young
 Todd S. Young
 Executive Vice President and Chief Financial Officer


 EX-101.SCH 5 elan-20210930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Condensed Consolidated Statements of Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - Implementation of New Financial Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Implementation of New Financial Accounting Pronouncements (Tables) link:presentationLink link:calculationLink link:definitionLink 2105103 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 2306302 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 2407401 - Disclosure - Revenue - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Revenue - Summary of Activity in Sales Rebates and Discounts Liability (Details) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Revenue - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2110104 - Disclosure - Acquisitions and Divestitures link:presentationLink link:calculationLink link:definitionLink 2311303 - Disclosure - Acquisitions and Divestitures (Tables) link:presentationLink link:calculationLink link:definitionLink 2412404 - Disclosure - Acquisitions and Divestitures - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2413405 - Disclosure - Acquisitions and Divestitures - Summary of Amounts Recognized for Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 2414406 - Disclosure - Acquisitions and Divestitures - Purchase Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 2415407 - Disclosure - Acquisitions and Divestitures - Pro Forma Information (Details) link:presentationLink link:calculationLink link:definitionLink 2416408 - Disclosure - Acquisitions and Divestitures - Assets and Liabilities Held for Sale (Details) link:presentationLink link:calculationLink link:definitionLink 2117105 - Disclosure - Asset Impairment, Restructuring and Other Special Charges link:presentationLink link:calculationLink link:definitionLink 2318304 - Disclosure - Asset Impairment, Restructuring and Other Special Charges (Tables) link:presentationLink link:calculationLink link:definitionLink 2419409 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Total Charges Related to Asset Impairment, Restructuring and Other Special Charges (Details) link:presentationLink link:calculationLink link:definitionLink 2420410 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2421411 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Summary of Activity in Reserves (Details) link:presentationLink link:calculationLink link:definitionLink 2122106 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2323305 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2424412 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2125107 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 2326306 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2427413 - Disclosure - Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2428414 - Disclosure - Equity - Schedule of Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 2129108 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 2330307 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2431415 - Disclosure - Debt - Schedule of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2431415 - Disclosure - Debt - Schedule of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2432416 - Disclosure - Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2133109 - Disclosure - Financial Instruments and Fair Value link:presentationLink link:calculationLink link:definitionLink 2334308 - Disclosure - Financial Instruments and Fair Value (Tables) link:presentationLink link:calculationLink link:definitionLink 2435417 - Disclosure - Financial Instruments and Fair Value - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2436418 - Disclosure - Financial Instruments and Fair Value - Summary of Fair Value Information (Details) link:presentationLink link:calculationLink link:definitionLink 2437419 - Disclosure - Financial Instruments and Fair Value - Net Gain/Loss on Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2138110 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2339309 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2440420 - Disclosure - Income Taxes - Provision for Taxes on Income (Details) link:presentationLink link:calculationLink link:definitionLink 2441421 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2142111 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2443422 - Disclosure - Commitments and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2144112 - Disclosure - Geographic Information link:presentationLink link:calculationLink link:definitionLink 2345310 - Disclosure - Geographic Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2446423 - Disclosure - Geographic Information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2447424 - Disclosure - Geographic Information - Revenue by Selected Geographic Area Information (Details) link:presentationLink link:calculationLink link:definitionLink 2148113 - Disclosure - Retirement Benefits link:presentationLink link:calculationLink link:definitionLink 2349311 - Disclosure - Retirement Benefits (Tables) link:presentationLink link:calculationLink link:definitionLink 2450425 - Disclosure - Retirement Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 2151114 - Disclosure - Loss Per Share link:presentationLink link:calculationLink link:definitionLink 2352312 - Disclosure - Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2453426 - Disclosure - Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2154115 - Disclosure - Transactions and Agreements with Bayer link:presentationLink link:calculationLink link:definitionLink 2455427 - Disclosure - Transactions and Agreements with Bayer - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 elan-20210930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 elan-20210930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 elan-20210930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Hedging Designation [Domain] Hedging Designation [Domain] Customer [Domain] Customer [Domain] Commitments and Contingencies Legal Matters and Contingencies [Text Block] Work in process Inventory, Work in Process, Gross Transaction and integration costs Business Combination, Integration Related Costs Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Net loss Net loss Net loss available to common shareholders Net Income (Loss) Attributable to Parent Entity Emerging Growth Company Entity Emerging Growth Company Purchase Consideration Schedule of Business Acquisitions, by Acquisition [Table Text Block] Interest cost Defined Benefit Plan, Interest Cost Employee compensation Employee-related Liabilities, Current Other net financing transactions with Lilly Proceeds From (Payments To) Transactions With Parent Proceeds From (Payments To) Transactions With Parent Income Statement Location [Axis] Income Statement Location [Axis] Forward-starting interest rate contracts designated as cash flow hedges Interest Rate Contract [Member] Range [Domain] Statistical Measurement [Domain] Transaction costs incurred Business Combination, Acquisition Related Costs Entity Address, Address Line One Entity Address, Address Line One Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Summary of Activity in Sales Rebates and Discounts Liability Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Entity Filer Category Entity Filer Category Restructuring Type [Axis] Restructuring Type [Axis] Other noncurrent assets Other Assets, Noncurrent Proceeds from settlement of net investment hedges Proceeds from Hedge, Investing Activities Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Term Loan B Term B Loan Facility [Member] Term B Loan Facility Retirement Benefits [Abstract] Intangible assets, primarily acquired in-process research and development In Process Research and Development [Member] Net increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Inventories Inventories [Member] Stock compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Facility exit costs Business Exit Costs Goodwill adjustment Goodwill, Purchase Accounting Adjustments Asset write-down Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down Document Fiscal Year Focus Document Fiscal Year Focus Litigation settlement charges Litigation Settlement, Expense Deferred income taxes Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Amortization of intangible assets Amortization of Intangible Assets Summary of Activity in Reserves Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Weighted average useful life Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Asset impairment Impairment of Long-Lived Assets to be Disposed of Proceeds from issuance of common stock and tangible equity units Gross proceeds Proceeds from Issuance or Sale of Equity Proceeds from issuance of long-term debt Proceeds from Issuance of Senior Long-term Debt Antidilutive shares not included in calculating diluted earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Schedule of Inventories Schedule of Inventory, Current [Table Text Block] Reduction of revenue Contract with Customer, Liability, Revenue Recognized Sale of Stock [Axis] Sale of Stock [Axis] Property, plant, and equipment, adjustments Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Property, Plant, and Equipment Business Combination and Asset Acquisition [Abstract] Business Acquisition [Axis] Business Acquisition [Axis] Cash Flow Hedging Cash Flow Hedging [Member] Summary of Fair Value Information Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Disposal Group Name [Axis] Disposal Group Name [Axis] Accrued retirement benefits Liability, Defined Benefit Plan, Noncurrent Fair value used in estimate Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Used In Estimate Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Used In Estimate Credit Facility [Domain] Credit Facility [Domain] Assets Assets [Abstract] Related Party Transactions [Abstract] Related Party Transactions [Abstract] Product Return Concentration Risk Product Return Concentration Risk [Member] Product Return Concentration Risk [Member] Amortization of net actuarial loss Defined Benefit Plan, Amortization of Gain (Loss) Percent of TEUs issued involved in lawsuit Loss Contingency, Percent of TEUs Issued Involved in Lawsuit Loss Contingency, Percent of TEUs Issued Involved in Lawsuit Restructuring costs Restructuring Costs Concentration risk (less than 0.1%) Concentration risk (as a percent) Concentration Risk, Percentage Preferred stock, no par value, 1,000,000,000 shares authorized; none issued Preferred Stock, Value, Issued Entity Address, City or Town Entity Address, City or Town Number of consecutive trading days Debt Instrument, Convertible, Threshold Consecutive Trading Days Derivative assets (liabilities) Derivative Assets (Liabilities), at Fair Value, Net Proceeds from product divestitures Proceeds from Divestiture of Businesses and Interests in Affiliates Retained Earnings (Accumulated Deficit) Retained Earnings [Member] Debt Instrument [Axis] Debt Instrument [Axis] Noncurrent Liabilities Liabilities, Noncurrent [Abstract] Worldwide rights to Osurnia and U.S. rights to Capstar Worldwide Rights To Osurnia And U.S. Rights To Capstar [Member] Worldwide Rights To Osurnia And U.S. Rights To Capstar Deferred tax asset Disposal Group, Including Discontinued Operation, Deferred Tax Assets Related Party [Axis] Related Party [Axis] Amortization of prior service cost Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Repayment of principal on indebtedness outstanding Debt Instrument, Repurchased Face Amount Restructuring charges: Restructuring, Settlement and Impairment Provisions [Abstract] Inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Marketed products Marketing-Related Intangible Assets [Member] Pro Forma Information Business Acquisition, Pro Forma Information [Table Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Property and equipment, net Disposal Group, Including Discontinued Operation, Property, Plant and Equipment Entity Interactive Data Current Entity Interactive Data Current Expected reclassification from accumulated other comprehensive loss Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Number of operating segments Number of Operating Segments Loss (gain) on divestitures Sale of IPR&D Gain (Loss) on Disposition of Business Basic (usd per share) Earnings Per Share, Basic Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Defined benefit pension and retiree health benefit plans, net of taxes Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Payments Contract With Customer, Liability, Increase From Cash Receipts Contract With Customer, Liability, Increase From Cash Receipts Revenue Revenue from Contract with Customer [Text Block] Bayer Animal Business Bayer Animal Business [Member] Bayer Animal Business Number of countries expected to eliminate positions Restructuring And Related Cost, Number Of Countries Expected to Eliminate Positions Restructuring And Related Cost, Number Of Countries Expected to Eliminate Positions Document Type Document Type Total identifiable net assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Geographic Concentration Risk Geographic Concentration Risk [Member] Non-cash and other items: Disposal Group, Including Discontinued Operation, Additional Disclosures [Abstract] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Marketed products Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Entity Current Reporting Status Entity Current Reporting Status Cumulative Effect, Period of Adoption, Adjustment Cumulative Effect, Period of Adoption, Adjustment [Member] Contingent consideration Nonfinancial Liabilities Fair Value Disclosure Issuance of stock under employee stock plans, net Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 4.900% Senior Notes due 2028 4.9% Senior Notes Due 2028 [Member] 4.9% Senior Notes Due 2028 [Member] Other Operating Income (Expense) Other Operating Income (Expense) [Member] Consideration paid for acquisition Fair value of total consideration transferred Business Combination, Consideration Transferred Long Lived Assets Held-for-sale, Name [Domain] Long Lived Assets Held-for-sale, Name [Domain] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Long-term debt, gross Long-term Debt, Gross Restructuring adjustments Reserve adjustments Restructuring Reserve, Accrual Adjustment Net proceeds Total debt Long-term Debt Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Cash Flows from Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Other non-cash operating activities, net Other Operating Activities, Cash Flow Statement Document Transition Report Document Transition Report Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Total liabilities and equity Liabilities and Equity Unrealized gain (loss) on derivatives for cash flow hedges, net of taxes Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Sales rebates and discounts Contract with Customer, Liability, Current Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations [Member] Farm Animal Farm Animal [Member] Farm Animal Additional paid-in capital Additional Paid in Capital Concentration Risk [Line Items] Concentration Risk [Line Items] Liabilities and Equity Liabilities and Equity [Abstract] Hedging Relationship [Domain] Hedging Relationship [Domain] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Other intangibles, net Disposal Group, Including Discontinued Operation, Intangible Assets Loss Per Share Earnings Per Share [Text Block] Total assets held for sale Disposal Group, Including Discontinued Operation, Assets Accounting Changes and Error Corrections [Abstract] Accounting Changes and Error Corrections [Abstract] Minimum Minimum [Member] Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Marketing, selling and administrative Selling, General and Administrative Expense Unamortized debt issuance costs Debt Issuance Costs, Net Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Accounts payable and accrued liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable And Other Current Assets Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable And Other Current Assets Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Shawnee Shawnee [Member] Shawnee Required ratio of pro forma adjusted EBITDA to cash interest expense (no less than) Required Ratio Of Pro Forma Adjusted EBITDA To Cash Interest Expense Required Ratio Of Pro Forma Adjusted EBITDA To Cash Interest Expense Balance at beginning of period Balance at end of period Restructuring Reserve Trading Symbol Trading Symbol Issuance of stock to Bayer for acquisition, net of issuance costs Stock Issued During Period, Value, Acquisitions Decrease to LIFO cost Inventory, LIFO Reserve Current Liabilities Liabilities, Current [Abstract] Issuance of common stock, net of issuance costs Stock Issued During Period, Value, New Issues Cash paid for acquisitions, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Debt Debt Disclosure [Text Block] Restructuring Plan [Domain] Restructuring Plan [Domain] Foreign Currency Translation Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Balance at beginning of period (in shares) Balance at end of period (in shares) Shares, Outstanding Provision for Taxes on Income Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Credit facility Credit Facility Line of Credit [Member] Senior Notes Senior Notes [Member] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Inventories Inventory Disclosure [Text Block] Derivative Instrument [Axis] Derivative Instrument [Axis] Asset purchase refund Related Party Transaction, Asset Purchase Refund Related Party Transaction, Asset Purchase Refund Interest included in cash benefit Derivative Instruments, Liquidated For Cash Benefit, Interest, Amount Derivative Instruments, Liquidated For Cash Benefit, Interest, Amount Common stock, no par value, 5,000,000,000 shares authorized, 473,033,625 and 471,921,116 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively Common Stock, Value, Issued Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Other (income) expense, net Nonoperating Income (Expense) Separation activities Stockholders' Equity, Separation Adjustments Stockholders' Equity, Separation Adjustments Customer Concentration Risk Customer Concentration Risk [Member] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Commitments and Contingencies Commitments and Contingencies Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Accounts receivable, net of allowances Accounts Receivable, Allowance for Credit Loss, Current Debt issuance costs Payments of Debt Issuance Costs Disposal Group Classification [Axis] Disposal Group Classification [Axis] Document Period End Date Document Period End Date Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Costs, expenses and other Costs and Expenses Revenue by Selected Geographic Area Information Revenue from External Customers by Geographic Areas [Table Text Block] Quarterly cash installment per amortizing note Debt Instrument, Periodic Payment Per Amortizing Note Debt Instrument, Periodic Payment Per Amortizing Note Class of Stock [Axis] Class of Stock [Axis] Net curtailments and settlements (Note 5) Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment Loss before income taxes Business Acquisition, Pro Forma Net Income (Loss) Entity Registrant Name Entity Registrant Name Proceeds after underwriting discounts and commissions Net proceeds Sale of Stock, Consideration Received on Transaction Prepaid expenses and other Prepaid Expense and Other Assets, Current Aratana Aratana Therapeutics, Inc. [Member] Aratana Therapeutics, Inc. [Member] Shares issued to previous shareholders upon closing (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Revenue Revenue Revenue Revenue from Contract with Customer, Excluding Assessed Tax Inventory fair value step-up amortization Business Combination, Inventories, Step-Up Fair Value Adjustment Business Combination, Inventories, Step-Up Fair Value Adjustment Prevtec Prevtec Microbia, Inc. [Member] Prevtec Microbia, Inc. [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Carrying Amount Reported Value Measurement [Member] Equity [Abstract] Equity [Abstract] Cash paid Payments for Restructuring Other obligations Notes Payable, Other Payables [Member] Common Stock Common Stock [Member] Variable Rate [Axis] Variable Rate [Axis] Inventories Disposal Group, Including Discontinued Operation, Inventory Geographic Information Segment Reporting Disclosure [Text Block] 2.75% Senior Amortizing Notes 2.75% Senior Amortizing Notes [Member] 2.75% Senior Amortizing Notes Long Lived Assets Held-for-sale by Asset Type [Axis] Long Lived Assets Held-for-sale by Asset Type [Axis] Assets held for sale Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Assets Held For Sale Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Assets Held For Sale First installment payment per amortizing note Debt Instrument, First Periodic Payment Per Amortizing Note Debt Instrument, First Periodic Payment Per Amortizing Note Hedging Designation [Axis] Hedging Designation [Axis] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Issuance of common stock, net of issuance costs (in shares) Shares Issued, Shares, Share-based Payment Arrangement, Forfeited Stock-based compensation expense Share-based Payment Arrangement, Noncash Expense Variable Rate [Domain] Variable Rate [Domain] Inventory [Axis] Inventory [Axis] Additional Paid-in Capital Additional Paid-in Capital [Member] Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Debt repaid Repayments of Debt Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Rights To The Profender And Drontal Rights To The Profender And Drontal Product Families [Member] Rights To The Profender And Drontal Product Families Debt repaid, interest Repayments Of Long Term Debt, Accrued Interest Repayments Of Long Term Debt, Accrued Interest Description of Accounting Standards Adopted and Not Yet Adopted Accounting Standards Update and Change in Accounting Principle [Table Text Block] Net proceeds from revolving credit facility Proceeds from Lines of Credit Notional amount (USD, CHF) Derivative, Notional Amount Other investing activities, net Payments for (Proceeds from) Other Investing Activities Net purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Other current liabilities Other Liabilities, Current Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Facility exit costs Facility Closing [Member] Maximum Maximum [Member] 4.272% Senior Notes due 2023 4.272% Senior Notes Due 2023 [Member] 4.272% Senior Notes Due 2023 [Member] Total liabilities Liabilities Cash Flows from Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Total equity Balance at beginning of period Balance at end of period Stockholders' Equity Attributable to Parent Common stock, shares issued (in shares) Common Stock, Shares, Issued Volume weighted average stock price as of the last day of trading before the closing of the acquisition duration Business Combination, Volume Weighted Average Stock Price As Of Last Day Of Trading Before Closing Acquisition Duration Business Combination, Volume Weighted Average Stock Price As Of Last Day Of Trading Before Closing Acquisition Duration Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Prepaid expenses and other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Intangible assets, primarily acquired in-process research and development Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Common Stock Offering Common Stock Offering [Member] Common Stock Offering Designated as Hedging Instrument Designated as Hedging Instrument [Member] Debt extinguishment loss Gain (Loss) on Extinguishment of Debt Changes in operating assets and liabilities, net of acquisitions Increase (Decrease) in Operating Capital Other noncurrent assets and liabilities, net Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Noncurrent Assets And Other Liabilities, Net Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Noncurrent Assets And Other Liabilities, Net Common stock price (in dollars per share) Business Acquisition, Share Price Equity Stockholders' Equity Attributable to Parent [Abstract] Retirement Plan Type [Axis] Retirement Plan Type [Axis] Settlement rate Tangible Equity Unit, Settlement Rate Tangible Equity Unit, Settlement Rate Settlements and other Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal Other net working capital Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Net Working Capital Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Net Working Capital in Process in Process [Member] in Process Balance Sheet Location [Axis] Balance Sheet Location [Axis] Partial payment on principal and interest Debt Instrument, Payment, Principal And Interest Debt Instrument, Payment, Principal And Interest Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] Debt instrument, face amount Debt Instrument, Face Amount Noncurrent Assets Assets, Noncurrent [Abstract] Interest expense, net of capitalized interest Interest Expense Net periodic benefit cost (income) Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Total consideration transferred Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net City Area Code City Area Code Accumulated deficit Retained Earnings (Accumulated Deficit) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Issuance of stock under employee stock plans, net (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Gain (loss), net of tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Net Of Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Net Of Tax Business Acquisition [Line Items] Business Acquisition [Line Items] Equity method investments Equity Method Investments Income Statement [Abstract] Income Statement [Abstract] Amendment Flag Amendment Flag Concentration Risk [Table] Concentration Risk [Table] Fair Value Estimate of Fair Value Measurement [Member] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Repayments of lines of credit Repayments of Lines of Credit Accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Implementation of New Financial Accounting Pronouncements Accounting Standards Update and Change in Accounting Principle [Text Block] Other noncurrent assets Other Noncurrent Assets [Member] Long-term debt - senior notes Notes Payable, Fair Value Disclosure Term of contract Derivative, Term of Contract Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Income tax benefit Income tax benefit Income tax benefit Income Tax Expense (Benefit) Accounts receivable, net of allowances of $11 (2021) and $9 (2020) Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Equity Components [Axis] Equity Components [Axis] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Finished Products Finished Goods [Member] Finished Goods Total current assets Assets, Current Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Sale of Stock [Domain] Sale of Stock [Domain] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Debt Component Tangible Equity Unit, Debt Component [Member] Tangible Equity Unit, Debt Component Average applicable market value necessary to be included in calculation of diluted shares outstanding (usd per share) Applicable Market Value (usd per share) Tangible Equity Unit, Average Applicable Market Value Triggering Inclusion In Calculation Of Diluted Shares Outstanding, Per Share Tangible Equity Unit, Average Applicable Market Value Triggering Inclusion In Calculation Of Diluted Shares Outstanding, Per Share Inventories Inventories Inventory, Net Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Schedule of Stockholders Equity Schedule of Stockholders Equity [Table Text Block] Entity File Number Entity File Number Pet Health Pet Health [Member] Pet Health Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Symmetrical collar (as a percent) Business Combination, Consideration Transferred, Symmetrical Collar Business Combination, Consideration Transferred, Symmetrical Collar Current portion of long-term debt Less current portion of long-term debt Long-term Debt, Current Maturities Expected payment term Restructuring, Expected Payment Term Restructuring, Expected Payment Term Product and Service [Axis] Product and Service [Axis] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Small Business Entity Small Business Restructuring Plan [Axis] Restructuring Plan [Axis] Basis of Presentation and Summary of Significant Accounting Policies Basis of Accounting [Text Block] Revenue Revenue Benchmark [Member] Equity Component [Domain] Equity Component [Domain] Foreign currency translation Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Disposal Group Name [Domain] Disposal Group Name [Domain] Fair value of Elanco common stock Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Statement [Line Items] Statement [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Issuance of stock to Bayer for acquisition, net of issuance costs (in shares) Stock Issued During Period, Shares, Acquisitions Gain on sale of fixed assets Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Working capital and other adjustment Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Working Capital and Other Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Working Capital and Other Retirement Plan Type [Domain] Retirement Plan Type [Domain] Maximum aggregate contingent payment Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Divestiture transaction costs Disposal Group, Including Discontinued Operation, Transaction Costs Disposal Group, Including Discontinued Operation, Transaction Costs Debt Disclosure [Abstract] Debt Disclosure [Abstract] Entity Address, State or Province Entity Address, State or Province Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Document Information [Table] Document Information [Table] Net gain (loss) on derivative instruments Derivative, Gain (Loss) on Derivative, Net Segment Reporting [Abstract] Segment Reporting [Abstract] Type of Restructuring [Domain] Type of Restructuring [Domain] Issuance of tangible equity units, net of issuance costs Tangible Equity Units Issued During Period, Value Tangible Equity Units Issued During Period, Value Customer [Axis] Customer [Axis] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Retirement Benefits Retirement Benefits [Text Block] Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Entity Shell Company Entity Shell Company Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Local Phone Number Local Phone Number Asset impairment, restructuring and other special charges Total expense Restructuring, Settlement and Impairment Provisions Number of financial covenants Debt Instrument, Number Of Financial Covenants Debt Instrument, Number Of Financial Covenants Total assets Assets Common stock, shares authorized (in shares) Common Stock, Shares Authorized Geographical [Domain] Geographical [Domain] Required ratio of pro forma net leverage and pro forma adjusted EBITDA Required Ratio Of Pro Forma Net Leverage And Pro Forma Adjusted EBITDA Required Ratio Of Pro Forma Net Leverage And Pro Forma Adjusted EBITDA Product and Service [Domain] Product and Service [Domain] Research and development Research and Development Expense Interest rate on debt component Interest rate Debt Instrument, Interest Rate, Stated Percentage Derivative Contract [Domain] Derivative Contract [Domain] 3.912% Senior Notes due 2021 3.912% Senior Notes Due 2021 [Member] 3.912% Senior Notes Due 2021 [Member] Revolving Credit Facility Revolving Credit Facility [Member] Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Measurement Frequency [Axis] Measurement Frequency [Axis] Net Cash Provided by Operating Activities Net Cash Provided by (Used in) Operating Activities Volume weighted average price for thirty trading days (usd per share) Business Combination, Volume Weighted Average Price For 30 Trading Days Business Combination, Volume Weighted Average Price For 30 Trading Days Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Entity Tax Identification Number Entity Tax Identification Number Other receivables Other Receivables, Net, Current Geographical [Axis] Geographical [Axis] Amount offsetting interest expense Derivative, Excluded Component, Gain (Loss), Recognized in Earnings Basic (in shares) Weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted (usd per share) Earnings Per Share, Diluted Repayments of borrowings Repayments of Long-term Lines of Credit Offering price (usd per share) Fair value per unit (usd per share) Sale of Stock, Price Per Share Assumed conversion of dilutive common stock equivalents (in shares) Weighted Average Number Diluted Shares Outstanding Adjustment Product Sales Product [Member] Service cost Defined Benefit Plan, Service Cost Net Investment Hedging Net Investment Hedging [Member] Hedging Relationship [Axis] Hedging Relationship [Axis] Acquisitions and Divestitures Mergers, Acquisitions and Dispositions Disclosures [Text Block] Interest Expense Interest Expense [Member] Accounting Standards Update [Extensible List] Accounting Standards Update [Extensible Enumeration] Next Largest Country International Non-US [Member] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Other intangibles, net Intangible Assets, Net (Excluding Goodwill) Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Severance Employee Severance [Member] Beginning balance Ending balance Contract with Customer, Liability Expected number of positions eliminated Restructuring and Related Cost, Expected Number of Positions Eliminated Net Cash Provided by Financing Activities Net Cash Provided by (Used in) Financing Activities Weighted average shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Deferred taxes Deferred Income Tax Liabilities, Net Related Party Transaction [Line Items] Related Party Transaction [Line Items] Other noncurrent liabilities Other Noncurrent Liabilities [Member] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Property and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Gain on sale of assets Gain (Loss) on Disposition of Other Assets Financial Instruments and Fair Value Fair Value Disclosures [Text Block] Charges Restructuring Charges Accounts payable Accounts Payable, Current Concentration Risk Type [Axis] Concentration Risk Type [Axis] Depreciation and amortization Depreciation, Depletion and Amortization Intangible asset adjustment Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles Payments to acquire businesses, before working capital adjustment Payments to Acquire Businesses, Before Working Capital Adjustment Payments to Acquire Businesses, Before Working Capital Adjustment Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Number of employees transferred Disposal Group, Including Discontinued Operation, Number of Employees Transferred Disposal Group, Including Discontinued Operation, Number of Employees Transferred Total Charges Related to Asset Impairment, Restructuring and Other Special Charges Restructuring and Related Costs [Table Text Block] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Raw materials and supplies Inventory, Raw Materials and Supplies, Gross Cost of sales Cost of Goods and Services Sold Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Purchases of intangible assets Payments to Acquire Intangible Assets Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Shares issued upon conversion of prepaid stock purchase contracts (in shares) Tangible Equity Unit, Prepaid Stock Purchase Contract, Shares Issued Upon Conversion Tangible Equity Unit, Prepaid Stock Purchase Contract, Shares Issued Upon Conversion Inventory [Domain] Inventory [Domain] 5.00% Tangible Equity Units TEU Amortizing Notes TEUs 5.00% Tangible Equity Units [Member] 5.00% Tangible Equity Units Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement Location [Domain] Income Statement Location [Domain] Debt maturity term Debt Instrument, Term Raw Materials Raw Materials [Member] Held for Sale Disposal Group, Held-for-sale, Not Discontinued Operations [Member] Property and equipment, net of accumulated depreciation of $1,050 (2021) and $1,038 (2020) Property, Plant and Equipment, Net Other noncurrent liabilities Other Liabilities, Noncurrent Schedule of Long-term Debt Schedule of Long-term Debt Instruments [Table Text Block] Debt repaid, principal Repayments of Long-term Debt Debt Instrument [Line Items] Debt Instrument [Line Items] Loss per share: Earnings Per Share [Abstract] Earnings Per Share [Abstract] Revenue Business Acquisition, Pro Forma Revenue Total Inventory, Gross Net Revenue Revenue from Contract with Customer Benchmark [Member] Document Quarterly Report Document Quarterly Report Reclassification from AOCI Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Other current liabilities Other Current Liabilities [Member] Severance and other costs Severance Costs Cross-currency fixed interest rate swap Foreign exchange contracts not designated as hedging instruments Foreign Exchange Contract [Member] Finished products Inventory, Finished Goods, Gross Defined Benefit Plan, Type [Extensible Enumeration] Defined Benefit Plan, Type [Extensible Enumeration] Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Costs, expenses and other: Costs and Expenses [Abstract] Accrued retirement benefits Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Employee-Related Liabilities, Current Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Employee-Related Liabilities, Current Long-term debt Total long-term debt Long-term Debt, Excluding Current Maturities Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Change In Contract With Customer, Liability [Roll Forward] Change In Contract With Customer, Liability [Roll Forward] Change In Contract With Customer, Liability [Roll Forward] Term Loan Facility Term Credit Facility [Member] Term Credit Facility [Member] Document Fiscal Period Focus Document Fiscal Period Focus Effective tax rate Effective Income Tax Rate Reconciliation, Percent Restricted cash Restricted cash Restricted Cash, Current Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Number of shares sold in public offering (in shares) Number of shares issued (in shares) Sale of Stock, Number of Shares Issued in Transaction United States UNITED STATES Cash benefit for liquidation Derivative Instruments, Liquidated For Cash Benefit, Amount Derivative Instruments, Liquidated For Cash Benefit, Amount Current Assets Assets, Current [Abstract] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] 2021 Restructuring Plan 2021 Restructuring Plan [Member] 2021 Restructuring Plan Other financing activities, net Proceeds from (Payments for) Other Financing Activities Entity Central Index Key Entity Central Index Key LIBOR London Interbank Offered Rate (LIBOR) [Member] Security Exchange Name Security Exchange Name Disposal Group Classification [Domain] Disposal Group Classification [Domain] Contract Manufacturing Contract Manufacturing [Member] Contract Manufacturing [Member] Diluted (in shares) Diluted weighted average shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Other comprehensive income (loss), net of taxes Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax Recurring Fair Value, Recurring [Member] Common stock, no par value Common Stock, No Par Value [Member] Common Stock, No Par Value Liabilities related to litigation Estimated Litigation Liability Income Taxes Income Tax Disclosure [Text Block] Over-Allotment Option Over-Allotment Option [Member] Related Party [Domain] Related Party [Domain] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Global Customers Global Customers [Member] Global Customers Current Fiscal Year End Date Current Fiscal Year End Date Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Equity Stockholders' Equity Note Disclosure [Text Block] Schedule of Net Benefit Costs Schedule of Net Benefit Costs [Table Text Block] Divestitures Activities Disposal Groups, Including Discontinued Operations [Table Text Block] Measurement Basis [Axis] Measurement Basis [Axis] Cash Flow Hedge Gain (Loss) Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Class of Stock [Line Items] Class of Stock [Line Items] Not Designated as Hedging Instrument Not Designated as Hedging Instrument [Member] Credit Facility [Axis] Credit Facility [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Net Cash Used for Investing Activities Net Cash Provided by (Used in) Investing Activities Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Property and equipment, net of accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Single Customer Customer A [Member] Customer A [Member] KindredBio KindredBio [Member] KindredBio Cash Flows from Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Asset impairment and write-down charges Asset Impairment Charges, Including Inventory Write-Down Asset Impairment Charges, Including Inventory Write-Down Tangible Equity Unit (TEU) Tangible Equity Unit [Member] Tangible Equity Unit Total current liabilities Liabilities, Current Class of Stock [Domain] Class of Stock [Domain] Cash consideration Payments to Acquire Businesses, Gross Less: Issuance costs Payment of Financing and Stock Issuance Costs Interest rate swaps, net of tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Tax Credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Entity Address, Postal Zip Code Entity Address, Postal Zip Code Working capital adjustments Business Combination, Consideration Transferred, Working Capital Adjustments Business Combination, Consideration Transferred, Working Capital Adjustments Incremental Term Facility Incremental Term Facility [Member] Incremental Term Facility Equity Component Tangible Equity Unit, Equity Component [Member] Tangible Equity Unit, Equity Component Document Information [Line Items] Document Information [Line Items] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Title of 12(b) Security Title of 12(b) Security Statement [Table] Statement [Table] Bayer Bayer [Member] Bayer Implementation of New Financial Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Prepaid expenses and other Prepaid Expenses and Other Current Assets [Member] Gain (loss), net of tax Offsetting Liabilities [Table Text Block] Range [Axis] Statistical Measurement [Axis] Purchases of software Payments for Software Initial principal amount Debt Instrument, Initial Principal Amount Debt Instrument, Initial Principal Amount Asset Impairment, Restructuring and Other Special Charges Restructuring, Impairment, and Other Activities Disclosure [Text Block] Cover [Abstract] Goodwill Goodwill Goodwill Acquisition related charges: Asset Impairment Charges [Abstract] Farm Credit Term Loan Facility Farm Credit Term Loan Facility [Member] Farm Credit Term Loan Facility Adjustments to reconcile net loss to cash flows from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Pension Plan Pension Plan [Member] Contract With Customer Liability Contract With Customer, Liability [Member] Contract With Customer, Liability [Member] Transactions and Agreements with Bayer Related Party Transactions Disclosure [Text Block] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] 4.900% Senior Notes Due 2028 4.900% Senior Notes Due 2028 [Member] 4.900% Senior Notes Due 2028 Defined Benefit Pension and Retiree Health Benefit Plans Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Settlement of liability related to previous license agreement Business Acquisition, Preacquisition Contingency, Amount of Settlement Bayer Animal Health at acquisition Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination Change in deferred income taxes Deferred Income Tax Expense (Benefit) Accounting Standards Update 2016-13 [Member] EX-101.PRE 9 elan-20210930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 10 elan-20210930_g1.jpg begin 644 elan-20210930_g1.jpg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end XML 11 elan-20210930_htm.xml IDEA: XBRL DOCUMENT 0001739104 2021-01-01 2021-09-30 0001739104 elan:CommonStockNoParValueMember 2021-01-01 2021-09-30 0001739104 elan:A500TangibleEquityUnitsMember 2021-01-01 2021-09-30 0001739104 2021-11-01 0001739104 2021-07-01 2021-09-30 0001739104 2020-07-01 2020-09-30 0001739104 2020-01-01 2020-09-30 0001739104 2021-09-30 0001739104 2020-12-31 0001739104 us-gaap:CommonStockMember 2019-12-31 0001739104 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001739104 us-gaap:RetainedEarningsMember 2019-12-31 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-31 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001739104 2019-12-31 0001739104 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001739104 2020-01-01 2020-03-31 0001739104 2019-01-01 2019-12-31 0001739104 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2019-12-31 0001739104 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-12-31 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-03-31 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-03-31 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-01-01 2020-03-31 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001739104 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001739104 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001739104 us-gaap:CommonStockMember 2020-03-31 0001739104 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001739104 us-gaap:RetainedEarningsMember 2020-03-31 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-03-31 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2020-03-31 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-03-31 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001739104 2020-03-31 0001739104 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001739104 2020-04-01 2020-06-30 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-04-01 2020-06-30 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2020-04-01 2020-06-30 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-04-01 2020-06-30 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001739104 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001739104 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001739104 us-gaap:CommonStockMember 2020-06-30 0001739104 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001739104 us-gaap:RetainedEarningsMember 2020-06-30 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-06-30 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2020-06-30 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-06-30 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001739104 2020-06-30 0001739104 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-07-01 2020-09-30 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2020-07-01 2020-09-30 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-07-01 2020-09-30 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0001739104 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001739104 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001739104 us-gaap:CommonStockMember 2020-09-30 0001739104 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001739104 us-gaap:RetainedEarningsMember 2020-09-30 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-09-30 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2020-09-30 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-09-30 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001739104 2020-09-30 0001739104 us-gaap:CommonStockMember 2020-12-31 0001739104 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001739104 us-gaap:RetainedEarningsMember 2020-12-31 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-12-31 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-31 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-12-31 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001739104 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001739104 2021-01-01 2021-03-31 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-01-01 2021-03-31 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-03-31 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-01-01 2021-03-31 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001739104 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001739104 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001739104 us-gaap:CommonStockMember 2021-03-31 0001739104 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001739104 us-gaap:RetainedEarningsMember 2021-03-31 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-03-31 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2021-03-31 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-03-31 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001739104 2021-03-31 0001739104 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001739104 2021-04-01 2021-06-30 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-04-01 2021-06-30 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2021-04-01 2021-06-30 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-04-01 2021-06-30 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001739104 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001739104 us-gaap:CommonStockMember 2021-06-30 0001739104 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001739104 us-gaap:RetainedEarningsMember 2021-06-30 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-06-30 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2021-06-30 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-06-30 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001739104 2021-06-30 0001739104 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-07-01 2021-09-30 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2021-07-01 2021-09-30 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-07-01 2021-09-30 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0001739104 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001739104 us-gaap:CommonStockMember 2021-09-30 0001739104 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001739104 us-gaap:RetainedEarningsMember 2021-09-30 0001739104 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-09-30 0001739104 us-gaap:AccumulatedTranslationAdjustmentMember 2021-09-30 0001739104 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-09-30 0001739104 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001739104 country:US elan:ContractWithCustomerLiabilityMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-09-30 0001739104 country:US elan:ContractWithCustomerLiabilityMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-09-30 0001739104 elan:GlobalCustomersMember us-gaap:RevenueFromContractWithCustomerMember elan:ProductReturnConcentrationRiskMember 2021-07-01 2021-09-30 0001739104 elan:GlobalCustomersMember us-gaap:RevenueFromContractWithCustomerMember elan:ProductReturnConcentrationRiskMember 2020-07-01 2020-09-30 0001739104 elan:GlobalCustomersMember us-gaap:RevenueFromContractWithCustomerMember elan:ProductReturnConcentrationRiskMember 2021-01-01 2021-09-30 0001739104 elan:GlobalCustomersMember us-gaap:RevenueFromContractWithCustomerMember elan:ProductReturnConcentrationRiskMember 2020-01-01 2020-09-30 0001739104 elan:PetHealthMember 2021-07-01 2021-09-30 0001739104 elan:PetHealthMember 2020-07-01 2020-09-30 0001739104 elan:PetHealthMember 2021-01-01 2021-09-30 0001739104 elan:PetHealthMember 2020-01-01 2020-09-30 0001739104 elan:FarmAnimalMember 2021-07-01 2021-09-30 0001739104 elan:FarmAnimalMember 2020-07-01 2020-09-30 0001739104 elan:FarmAnimalMember 2021-01-01 2021-09-30 0001739104 elan:FarmAnimalMember 2020-01-01 2020-09-30 0001739104 elan:ContractManufacturingMember 2021-07-01 2021-09-30 0001739104 elan:ContractManufacturingMember 2020-07-01 2020-09-30 0001739104 elan:ContractManufacturingMember 2021-01-01 2021-09-30 0001739104 elan:ContractManufacturingMember 2020-01-01 2020-09-30 0001739104 elan:KindredBioMember 2021-08-27 0001739104 elan:KindredBioMember 2021-06-30 0001739104 elan:KindredBioMember 2021-07-01 2021-09-30 0001739104 elan:KindredBioMember 2021-01-01 2021-09-30 0001739104 elan:KindredBioMember us-gaap:InProcessResearchAndDevelopmentMember 2021-08-27 0001739104 elan:BayerAnimalBusinessMember 2020-08-01 2020-08-01 0001739104 elan:BayerAnimalBusinessMember 2020-08-01 0001739104 elan:BayerAnimalBusinessMember 2021-01-01 2021-09-30 0001739104 elan:BayerAnimalBusinessMember 2020-01-01 2020-09-30 0001739104 elan:BayerAnimalBusinessMember 2020-07-01 2020-09-30 0001739104 elan:BayerAnimalBusinessMember 2021-07-01 2021-09-30 0001739104 elan:BayerAnimalBusinessMember elan:FinishedGoodsMember 2020-08-01 0001739104 elan:BayerAnimalBusinessMember elan:InProcessMember 2020-08-01 0001739104 elan:BayerAnimalBusinessMember us-gaap:PublicUtilitiesInventoryRawMaterialsMember 2020-08-01 0001739104 elan:BayerAnimalBusinessMember us-gaap:InProcessResearchAndDevelopmentMember 2020-08-01 0001739104 elan:BayerAnimalBusinessMember us-gaap:MarketingRelatedIntangibleAssetsMember 2020-08-01 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:RightsToTheProfenderAndDrontalProductFamiliesMember us-gaap:MarketingRelatedIntangibleAssetsMember 2020-08-01 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:RightsToTheProfenderAndDrontalProductFamiliesMember us-gaap:InventoriesMember 2020-08-01 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember 2021-06-30 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember 2021-01-01 2021-09-30 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:ShawneeMember 2021-08-01 2021-08-01 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember elan:RightsToTheProfenderAndDrontalProductFamiliesMember us-gaap:InProcessResearchAndDevelopmentMember 2020-07-01 2020-09-30 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember 2020-07-01 2020-09-30 0001739104 us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember 2020-01-01 2020-09-30 0001739104 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember elan:WorldwideRightsToOsurniaAndUSRightsToCapstarMember 2021-09-30 0001739104 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember elan:WorldwideRightsToOsurniaAndUSRightsToCapstarMember 2020-12-31 0001739104 elan:A2021RestructuringPlanMember 2021-01-01 2021-09-30 0001739104 elan:BayerAnimalBusinessMember 2021-01-01 2021-09-30 0001739104 us-gaap:FacilityClosingMember 2019-12-31 0001739104 us-gaap:EmployeeSeveranceMember 2019-12-31 0001739104 us-gaap:FacilityClosingMember 2020-01-01 2020-09-30 0001739104 us-gaap:EmployeeSeveranceMember 2020-01-01 2020-09-30 0001739104 us-gaap:FacilityClosingMember 2020-09-30 0001739104 us-gaap:EmployeeSeveranceMember 2020-09-30 0001739104 us-gaap:FacilityClosingMember 2020-12-31 0001739104 us-gaap:EmployeeSeveranceMember 2020-12-31 0001739104 us-gaap:FacilityClosingMember 2021-01-01 2021-09-30 0001739104 us-gaap:EmployeeSeveranceMember 2021-01-01 2021-09-30 0001739104 us-gaap:FacilityClosingMember 2021-09-30 0001739104 us-gaap:EmployeeSeveranceMember 2021-09-30 0001739104 elan:CommonStockOfferingMember 2020-01-22 2020-01-22 0001739104 elan:CommonStockOfferingMember 2020-01-22 0001739104 us-gaap:OverAllotmentOptionMember 2020-01-22 2020-01-22 0001739104 2020-01-23 2020-01-23 0001739104 elan:TangibleEquityUnitMember 2020-01-22 2020-01-22 0001739104 elan:A500TangibleEquityUnitsMember us-gaap:SeniorNotesMember 2020-01-22 0001739104 elan:TangibleEquityUnitMember 2020-01-22 0001739104 elan:TangibleEquityUnitEquityComponentMember 2020-01-22 0001739104 elan:TangibleEquityUnitDebtComponentMember 2020-01-22 0001739104 elan:TangibleEquityUnitEquityComponentMember 2020-01-22 2020-01-22 0001739104 elan:TangibleEquityUnitDebtComponentMember 2020-01-22 2020-01-22 0001739104 elan:A275SeniorAmortizingNotesMember us-gaap:SeniorNotesMember 2020-01-22 0001739104 elan:A275SeniorAmortizingNotesMember us-gaap:SeniorNotesMember 2020-01-22 2020-01-22 0001739104 elan:TangibleEquityUnitMember 2020-01-22 0001739104 elan:A500TangibleEquityUnitsMember us-gaap:SeniorNotesMember 2020-01-22 2020-01-22 0001739104 srt:MaximumMember elan:TangibleEquityUnitMember 2020-01-22 0001739104 srt:MinimumMember elan:TangibleEquityUnitMember 2020-01-22 0001739104 elan:IncrementalTermFacilityMember us-gaap:LineOfCreditMember 2021-09-30 0001739104 elan:IncrementalTermFacilityMember us-gaap:LineOfCreditMember 2020-09-30 0001739104 elan:TermBLoanFacilityMember us-gaap:LineOfCreditMember 2021-09-30 0001739104 elan:TermBLoanFacilityMember us-gaap:LineOfCreditMember 2020-09-30 0001739104 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2021-09-30 0001739104 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2020-09-30 0001739104 elan:A3.912SeniorNotesDue2021Member us-gaap:SeniorNotesMember 2021-09-30 0001739104 elan:A3.912SeniorNotesDue2021Member us-gaap:SeniorNotesMember 2020-09-30 0001739104 elan:A4.272SeniorNotesDue2023Member us-gaap:SeniorNotesMember 2021-09-30 0001739104 elan:A4.272SeniorNotesDue2023Member us-gaap:SeniorNotesMember 2020-09-30 0001739104 elan:A4.9SeniorNotesDue2028Member us-gaap:SeniorNotesMember 2021-09-30 0001739104 elan:A4.9SeniorNotesDue2028Member us-gaap:SeniorNotesMember 2020-09-30 0001739104 elan:A500TangibleEquityUnitsMember us-gaap:SeniorNotesMember 2021-09-30 0001739104 elan:A500TangibleEquityUnitsMember us-gaap:SeniorNotesMember 2020-09-30 0001739104 us-gaap:NotesPayableOtherPayablesMember 2021-09-30 0001739104 us-gaap:NotesPayableOtherPayablesMember 2020-09-30 0001739104 elan:FarmCreditTermLoanFacilityMember us-gaap:LineOfCreditMember 2021-08-12 2021-08-12 0001739104 elan:BayerAnimalBusinessMember elan:TermBLoanFacilityMember us-gaap:LineOfCreditMember 2020-08-01 0001739104 elan:BayerAnimalBusinessMember elan:TermBLoanFacilityMember us-gaap:LineOfCreditMember 2020-08-01 2020-08-01 0001739104 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2020-08-01 0001739104 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2020-08-01 2020-08-01 0001739104 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-08-01 2020-08-01 0001739104 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-08-01 2020-08-01 0001739104 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2021-03-01 2021-03-31 0001739104 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2021-04-01 2021-04-30 0001739104 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2021-08-31 2021-08-31 0001739104 us-gaap:SeniorNotesMember 2018-08-31 0001739104 elan:A3.912SeniorNotesDue2021Member us-gaap:SeniorNotesMember 2018-08-31 0001739104 elan:A4.272SeniorNotesDue2023Member us-gaap:SeniorNotesMember 2018-08-31 0001739104 elan:A4900SeniorNotesDue2028Member us-gaap:SeniorNotesMember 2018-08-31 0001739104 elan:A500TangibleEquityUnitsMember us-gaap:SeniorNotesMember 2021-07-01 2021-09-30 0001739104 elan:A500TangibleEquityUnitsMember us-gaap:SeniorNotesMember 2021-01-01 2021-09-30 0001739104 elan:TermCreditFacilityMember us-gaap:LineOfCreditMember 2020-01-31 2020-01-31 0001739104 elan:TermCreditFacilityMember us-gaap:LineOfCreditMember 2020-09-25 0001739104 elan:TermCreditFacilityMember us-gaap:LineOfCreditMember 2020-09-25 2020-09-25 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001739104 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001739104 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001739104 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001739104 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001739104 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001739104 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001739104 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001739104 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001739104 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001739104 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001739104 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001739104 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001739104 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001739104 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001739104 elan:AratanaTherapeuticsInc.Member 2021-09-30 0001739104 elan:PrevtecMicrobiaInc.Member 2021-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2021-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2020-12-31 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:OtherOperatingIncomeExpenseMember 2021-07-01 2021-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:OtherOperatingIncomeExpenseMember 2020-07-01 2020-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:OtherOperatingIncomeExpenseMember 2021-01-01 2021-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember us-gaap:OtherOperatingIncomeExpenseMember 2020-01-01 2020-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-10-01 2018-10-31 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-10-31 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2021-07-01 2021-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2020-07-01 2020-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2021-01-01 2021-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2020-01-01 2020-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-07-01 2021-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-07-01 2020-09-30 0001739104 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-01-01 2021-09-30 0001739104 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0001739104 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-07-01 2021-09-30 0001739104 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-07-01 2020-09-30 0001739104 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-01-01 2021-09-30 0001739104 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-09-30 0001739104 2020-10-16 0001739104 elan:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0001739104 elan:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0001739104 elan:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0001739104 elan:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0001739104 us-gaap:ProductMember 2021-09-30 0001739104 us-gaap:ProductMember 2020-12-31 0001739104 country:US 2021-07-01 2021-09-30 0001739104 country:US 2020-07-01 2020-09-30 0001739104 country:US 2021-01-01 2021-09-30 0001739104 country:US 2020-01-01 2020-09-30 0001739104 us-gaap:NonUsMember 2021-07-01 2021-09-30 0001739104 us-gaap:NonUsMember 2020-07-01 2020-09-30 0001739104 us-gaap:NonUsMember 2021-01-01 2021-09-30 0001739104 us-gaap:NonUsMember 2020-01-01 2020-09-30 0001739104 us-gaap:PensionPlansDefinedBenefitMember 2021-07-01 2021-09-30 0001739104 us-gaap:PensionPlansDefinedBenefitMember 2020-07-01 2020-09-30 0001739104 us-gaap:PensionPlansDefinedBenefitMember 2021-01-01 2021-09-30 0001739104 us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-09-30 0001739104 elan:BayerMember 2021-01-01 2021-09-30 shares iso4217:USD iso4217:USD shares pure elan:employee elan:position elan:country elan:tradingDay elan:covenant iso4217:CHF elan:segment false 2021 Q3 0001739104 --12-31 http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613Member 1 http://fasb.org/us-gaap/2021-01-31#PensionPlansDefinedBenefitMember 10-Q true 2021-09-30 false 001-38661 Elanco Animal Health Inc IN 82-5497352 2500 INNOVATION WAY GREENFIELD IN 46140 877 352-6261 Common stock, no par value ELAN NYSE 5.00% Tangible Equity Units ELAT NYSE Yes Yes Large Accelerated Filer false false false 473098643 1131000000 890000000 3652000000 2134000000 502000000 442000000 1622000000 1071000000 94000000 88000000 277000000 214000000 342000000 278000000 1075000000 623000000 141000000 96000000 417000000 197000000 111000000 262000000 518000000 456000000 60000000 48000000 181000000 89000000 -11000000 115000000 -8000000 162000000 1261000000 1099000000 4098000000 2488000000 -130000000 -209000000 -446000000 -354000000 -26000000 -74000000 -71000000 -117000000 -104000000 -135000000 -375000000 -237000000 -0.21 -0.29 -0.77 -0.56 -0.21 -0.29 -0.77 -0.56 487300000 462400000 487100000 426500000 487300000 462400000 487100000 426500000 -104000000 -135000000 -375000000 -237000000 4000000 -7000000 52000000 -67000000 -209000000 101000000 -506000000 121000000 6000000 1000000 -5000000 2000000 -211000000 93000000 -449000000 52000000 -315000000 -42000000 -824000000 -185000000 453000000 495000000 11000000 9000000 924000000 872000000 158000000 205000000 1383000000 1578000000 242000000 256000000 0 11000000 3160000000 3417000000 6191000000 6225000000 5816000000 6387000000 357000000 348000000 1050000000 1038000000 1041000000 1316000000 16565000000 17693000000 436000000 501000000 159000000 144000000 316000000 295000000 61000000 555000000 390000000 582000000 1362000000 2077000000 6273000000 5572000000 302000000 346000000 726000000 900000000 220000000 322000000 8883000000 9217000000 0 0 1000000000 1000000000 0 0 0 0 5000000000 5000000000 473033625 473033625 471921116 471921116 0 0 8680000000 8650000000 -852000000 -477000000 -146000000 303000000 7682000000 8476000000 16565000000 17693000000 373000000.0 0 5636000000 84000000 -199000000 25000000 -174000000 5546000000 -49000000 -49000000 -1000000 -1000000 -39000000 -29000000 -1000000 -69000000 -69000000 16000000 16000000 11000000 11000000 800000 13000000 13000000 25000000.0 768000000 768000000 452000000 452000000 398800000 0 6870000000 34000000 -39000000 -228000000 24000000 -243000000 6661000000 -53000000 -53000000 -21000000 50000000 -1000000 28000000 28000000 9000000 9000000 8000000 8000000 100000 1000000 1000000 398900000 0 6886000000 -19000000 -60000000 -178000000 23000000 -215000000 6652000000 -135000000 -135000000 -7000000 101000000 -1000000 93000000 93000000 11000000 11000000 100000 0 0 72900000 1723000000 1723000000 471900000 0 8620000000 -154000000 -67000000 -77000000 22000000 -122000000 8344000000 471900000 0 8650000000 -477000000 -61000000 360000000 4000000 303000000 8476000000 -61000000 -61000000 53000000 -466000000 8000000 -405000000 -405000000 15000000 15000000 1100000 18000000 18000000 473000000.0 0 8647000000 -538000000 -8000000 -106000000 12000000 -102000000 8007000000 -210000000 -210000000 -5000000 169000000 3000000 167000000 167000000 16000000 16000000 473000000.0 0 8663000000 -748000000 -13000000 63000000 15000000 65000000 7980000000 -104000000 -104000000 4000000 -209000000 -6000000 -211000000 -211000000 17000000 17000000 473000000.0 0 8680000000 -852000000 -9000000 -146000000 9000000 -146000000 7682000000 -375000000 -237000000 542000000 295000000 -119000000 -160000000 48000000 31000000 334000000 5000000 51000000 -2000000 170000000 64000000 33000000 243000000 -291000000 7000000 15000000 260000000 52000000 60000000 16000000 342000000 5001000000 0 33000000 0 435000000 35000000 0 11000000 148000000 8000000 8000000 -456000000 -4705000000 555000000 684000000 250000000 0 500000000 4554000000 0 1220000000 1000000 103000000 -11000000 0 -17000000 -15000000 166000000 4972000000 -23000000 7000000 -53000000 326000000 506000000 345000000 453000000 671000000 453000000 660000000 0 11000000 453000000 671000000 <div><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1. Basis of Presentation and Summary of Significant Accounting Policies</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elanco Animal Health Incorporated (Elanco Parent) and its subsidiaries (collectively, Elanco, the Company, we, us, or our) is a premier animal health company that innovates, develops, manufactures and markets products for pets and farm animals. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elanco was originally a wholly owned subsidiary of Eli Lilly and Company (Lilly). Elanco Parent, formed as the ultimate parent company of substantially all of the animal health businesses of Lilly, completed an initial public offering (IPO) in September 2018 and Lilly completed the disposition of all of its ownership interest in Elanco in March 2019.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have prepared the accompanying unaudited condensed consolidated financial statements in accordance with the United States (U.S.) Securities and Exchange Commission (SEC) requirements for interim reporting. As permitted under those rules, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the U.S. (GAAP) have been condensed or omitted. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated and combined financial statements and accompanying notes for the year ended December 31, 2020 included in our Annual Report on Form 10-K filed with the SEC on March 1, 2021. In addition, results for interim periods should not be considered indicative of results for any other interim period or for the full year ending December 31, 2021 or any other future period. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant accounting policies set forth in Note 4 to the consolidated and combined financial statements in our Annual Report on Form 10-K for the year ended December 31, 2020 appropriately represent, in all material respects, the current status of our accounting policies, except as it relates to the adoption of the standard that was effective January 1, 2021 as described in Note 2: Implementation of New Financial Accounting Pronouncements.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2020 and August 27, 2021 we completed the acquisitions of Bayer Animal Health and KindredBio, respectively. See Note 4: Acquisitions and Divestitures for additional information.</span></div> We have prepared the accompanying unaudited condensed consolidated financial statements in accordance with the United States (U.S.) Securities and Exchange Commission (SEC) requirements for interim reporting. As permitted under those rules, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the U.S. (GAAP) have been condensed or omitted. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated and combined financial statements and accompanying notes for the year ended December 31, 2020 included in our Annual Report on Form 10-K filed with the SEC on March 1, 2021. In addition, results for interim periods should not be considered indicative of results for any other interim period or for the full year ending December 31, 2021 or any other future period. In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates. <div style="text-align:justify"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2. Implementation of New Financial Accounting Pronouncements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a brief description of an accounting standard that was effective January 1, 2021 and was adopted on that date:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.382%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the financial statements or other significant matters</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update (ASU) 2019-12, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendments in this update include simplifications related to accounting for income taxes including removing certain exceptions related to the approach for intraperiod tax allocation and the recognition of deferred tax liabilities for outside basis differences. The standard also clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. </span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adoption of this guidance did not have a material impact on our consolidated financial statements.</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a brief description of an accounting standard that is applicable to us but has not yet been adopted:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.319%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the financial statements or other significant matters</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-04, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference rate reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2021-01, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Scope</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-04 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. ASU 2021-01 clarifies the scope of Topic 848 so that derivatives affected by the discounting transition are explicitly eligible for certain optional expedients and exceptions.</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These standards were effective as of March 12, 2020 through December 31, 2022 and adoption is permitted at any time during the period on a prospective basis.</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently in the process of evaluating the impact of the London Interbank Offered Rate (LIBOR) on our existing contracts and may elect optional expedients in future periods as reference rate reform activities occur. We do not expect that these updates will have a material impact on our consolidated financial statements.</span></td></tr></table></div> <div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a brief description of an accounting standard that was effective January 1, 2021 and was adopted on that date:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.382%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the financial statements or other significant matters</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update (ASU) 2019-12, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendments in this update include simplifications related to accounting for income taxes including removing certain exceptions related to the approach for intraperiod tax allocation and the recognition of deferred tax liabilities for outside basis differences. The standard also clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. </span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adoption of this guidance did not have a material impact on our consolidated financial statements.</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a brief description of an accounting standard that is applicable to us but has not yet been adopted:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.319%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the financial statements or other significant matters</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-04, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference rate reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2021-01, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Scope</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-04 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. ASU 2021-01 clarifies the scope of Topic 848 so that derivatives affected by the discounting transition are explicitly eligible for certain optional expedients and exceptions.</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These standards were effective as of March 12, 2020 through December 31, 2022 and adoption is permitted at any time during the period on a prospective basis.</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently in the process of evaluating the impact of the London Interbank Offered Rate (LIBOR) on our existing contracts and may elect optional expedients in future periods as reference rate reform activities occur. We do not expect that these updates will have a material impact on our consolidated financial statements.</span></td></tr></table></div> <div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a brief description of an accounting standard that was effective January 1, 2021 and was adopted on that date:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.382%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the financial statements or other significant matters</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Update (ASU) 2019-12, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendments in this update include simplifications related to accounting for income taxes including removing certain exceptions related to the approach for intraperiod tax allocation and the recognition of deferred tax liabilities for outside basis differences. The standard also clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. </span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adoption of this guidance did not have a material impact on our consolidated financial statements.</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a brief description of an accounting standard that is applicable to us but has not yet been adopted:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.319%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect on the financial statements or other significant matters</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-04, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference rate reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2021-01, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Scope</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-04 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. ASU 2021-01 clarifies the scope of Topic 848 so that derivatives affected by the discounting transition are explicitly eligible for certain optional expedients and exceptions.</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These standards were effective as of March 12, 2020 through December 31, 2022 and adoption is permitted at any time during the period on a prospective basis.</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently in the process of evaluating the impact of the London Interbank Offered Rate (LIBOR) on our existing contracts and may elect optional expedients in future periods as reference rate reform activities occur. We do not expect that these updates will have a material impact on our consolidated financial statements.</span></td></tr></table></div> <div><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3. Revenue </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales rebates are based on specific agreements. The most significant of our sales rebate programs in terms of accrual and payment amounts, percentage of our products that are sold via these programs, and level of judgment required in estimating the appropriate transaction price, relate to our programs in the U.S., France and the United Kingdom (U.K.). As of September 30, 2021 and 2020, the aggregate liability for sales rebates for these countries represented approximately 72% and 74%, respectively, of our total liability. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity in our global sales rebates liability:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bayer Animal Health at acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of revenue</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(495)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(326)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to revenue recognized as a result of changes in estimates for the judgments described above during the three and nine months ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2021 and 2020 for product shipped in previous periods were not material.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual global product returns were approximately 2% and less than 1% of net revenue for the three months ended September 30, 2021 and 2020, respectively. Actual global product returns were approximately 1% of net revenue for the nine months ended September 30, 2021 and 2020.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2021, management revisited how it analyzes revenue, both internally and externally, and determined that disaggregation by major product line provides a more meaningful view of our results. Accordingly, we updated our disaggregated revenue presentation from the previous five categories (i.e., pet health disease prevention, pet health therapeutics, farm animal future protein &amp; health, farm animal ruminants &amp; swine, and contract manufacturing) to the following:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pet Health</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,857 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Farm Animal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,728 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Manufacturing </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,131 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,652 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,134 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)Represents revenue from arrangements in which we act as a contract manufacturer, including supply agreements associated with divestitures of products related to the acquisition of Bayer Animal Health. 0.72 0.74 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity in our global sales rebates liability:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bayer Animal Health at acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of revenue</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(495)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(326)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 303000000 164000000 295000000 211000000 0 78000000 0 78000000 163000000 145000000 516000000 316000000 150000000 108000000 495000000 326000000 316000000 279000000 316000000 279000000 0.02 0.01 0.01 0.01 <div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2021, management revisited how it analyzes revenue, both internally and externally, and determined that disaggregation by major product line provides a more meaningful view of our results. Accordingly, we updated our disaggregated revenue presentation from the previous five categories (i.e., pet health disease prevention, pet health therapeutics, farm animal future protein &amp; health, farm animal ruminants &amp; swine, and contract manufacturing) to the following:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pet Health</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,857 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Farm Animal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,728 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract Manufacturing </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,131 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,652 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,134 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)Represents revenue from arrangements in which we act as a contract manufacturer, including supply agreements associated with divestitures of products related to the acquisition of Bayer Animal Health. 527000000 401000000 1857000000 861000000 583000000 473000000 1728000000 1222000000 21000000 16000000 67000000 51000000 1131000000 890000000 3652000000 2134000000 <div><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4. Acquisitions and Divestitures</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021 and 2020, we completed the acquisitions of KindredBio and Bayer Animal Health, respectively. These transactions were accounted for as business combinations under the acquisition method of accounting. The acquisition method requires, among other things, that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date. The determination of estimated fair value requires management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions are included in our condensed consolidated financial statements from the dates of acquisition.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">KindredBio Acquisition</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 27, 2021, we acquired KindredBio, a publicly traded biopharmaceutical company that develops innovative biologics focused on saving and improving the lives of pets. The acquisition further accelerates our pet health expansion, particularly by expanding our presence in dermatology. In connection with the merger agreement, we acquired all outstanding stock of KindredBio for $9.25 per share, or an aggregate cash purchase consideration of $444 million. We utilized our revolving credit facility and cash on hand to finance the acquisition. Refer to Note 8: Debt for further details. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2021, we signed an agreement with KindredBio to acquire exclusive global rights to KIND-030, a monoclonal antibody that is being developed for the treatment and prevention of canine parvovirus. We calculated the fair value of the liability associated with that agreement using an income approach leveraging the estimated sales royalty, sales milestone and technical milestone payments avoided, and the $26 million liability was settled upon the closing of our acquisition of KindredBio. Refer to Note 5: Asset Impairment, Restructuring and Other Special Charges for further discussion.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred transaction costs in connection with the KindredBio acquisition of $4 million and $6 million during the three and nine months ended September 30, 2021, respectively. Transaction costs were primarily associated with legal and other professional services related to the acquisition and are reflected within asset impairment, restructuring and other special charges in our condensed consolidated statements of operations.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue and loss from KindredBio included in our condensed consolidated statements of operations since the date of acquisition for the three and nine months ended September 30, 2021 were immaterial.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation of assets acquired and liabilities assumed has not yet been finalized as of September 30, 2021. The purchase price allocation is preliminary and subject to change, including the valuation of property and equipment, intangible assets, income taxes and goodwill. The amounts recognized will be finalized as the information necessary to complete the analysis is obtained, but no later than one year after the acquisition date. </span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at August 27, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other net working capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, primarily acquired in-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement of liability related to previous license agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is mostly composed of land, buildings, equipment (including laboratory equipment, furniture and fixtures, and computer equipment), and construction in progress. The fair value of property and equipment is currently equal to its net book value at the time of the acquisition, as we are in the process of gathering information to complete our fair value assessment.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preliminary estimated fair values of acquired in-process research and development (IPR&amp;D) were determined using the income approach, which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. Some of the significant assumptions inherent in the development of these asset valuations include the estimated net cash flows for each year for each asset (including revenues, cost of sales, R&amp;D expenses, marketing, selling and administrative expenses, and contributory asset charges), the appropriate discount rate necessary to measure the risk inherent in each future cash flow stream, the life cycle of each asset, the potential regulatory and commercial success risk, and competitive trends impacting the asset and each cash flow stream, as well as other factors. The fair value of acquired IPR&amp;D as of September 30, 2021 is based on preliminary assumptions which are subject to change as we complete our valuation procedures.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The goodwill recognized from this acquisition is attributable primarily to KindredBio's assembled workforce. The majority of goodwill associated with this acquisition is not deductible for tax purposes.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bayer Animal Health Acquisition</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2020, we completed the acquisition of Bayer Animal Health. The acquisition has expanded our pet health product category, advancing our planned portfolio mix transformation and creating a better balance between our farm animal and pet health product categories. Our product portfolio and pipeline have been enhanced by the addition of Bayer Animal Health, which complements our commercial operations and international infrastructure while expanding our direct to retailer/e-commerce presence.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total consideration transferred to Bayer and its subsidiaries for the acquisition is summarized as follows: </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash consideration </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,054 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Elanco common stock </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of total consideration transferred</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,778 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Includes initial cash consideration of $5,170 million less working capital and tax adjustments of $116 million. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Represents the acquisition date fair value of 73 million shares of Elanco common stock at $23.64 per share. Per the terms of the stock and asset purchase agreement, the number of shares was based on approximately $2.3 billion divided by the 20-day volume-weighted average stock price as of the last day of trading before the closing of the acquisition (but subject to a 7.5% symmetrical collar centered on the baseline share number of approximately $2.3 billion divided by an initial share price of $33.60).</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized transaction costs related to the acquisition of Bayer Animal Health of $3 million and $93 million during the nine months ended September 30, 2021 and 2020, respectively. Transaction costs for the three months ended September 30, 2020 were $35 million. Transaction costs were primarily associated with financial advisory, legal and other professional services related to the acquisition and are reflected within asset impairment, restructuring and other special charges in our condensed consolidated statements of operations.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of revenue attributable to Bayer Animal Health included in our condensed consolidated statements of operations for the three and nine months ended September 30, 2021 is $421 million and $1,509 million, respectively. Bayer Animal Health revenues were $196 million for both the three and nine months ended September 30, 2020. Based on our current operational structure, we have not recorded standalone costs for Bayer Animal Health after the date of the acquisition. As a result, we are unable to accurately determine earnings or loss attributable to Bayer Animal Health since the date of acquisition.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at August 1, 2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development </span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,740 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets held for sale</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued retirement benefits</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets and liabilities, net </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(878)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,649 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,778 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation of assets acquired and liabilities assumed was finalized during the second quarter of 2021. The measurement period adjustments recorded during 2021, which were made to reflect the facts and circumstances in existence as of the acquisition date, primarily related to the finalization of our fair value assessment of property and equipment located at the Shawnee, Kansas site (Shawnee), revised cash flow assumptions for marketed products, adjustments related to changes in inventory balances and gross margin assumptions, tax adjustments, and minor working capital adjustments. These adjustments resulted in a decrease to marketed products intangible assets of $210 million, a decrease to property and equipment of $32 million, a net decrease to working capital accounts and other non-current assets and liabilities of $14 million, and an increase to goodwill of $207 million. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories comprised of $311 million, $81 million, $95 million in finished products, work in process, and raw materials, respectively. The estimate of fair value of finished products was determined based on net realizable value adjusted for the costs to complete the sales process, a reasonable profit allowance from the sales process, and estimated holding costs. The estimate of fair value of work in process was determined based on net realizable value adjusted for costs to complete the manufacturing process, costs of the sales process, a reasonable profit allowance for the remaining manufacturing and sales process effort, and an estimate of holding costs. The fair value of raw materials was determined to approximate book value. The net fair value step-up adjustment to inventories of $152 million has been amortized to cost of sales as the inventory is sold to customers. As of September 30, 2021, the fair value step-up adjustment has been fully amortized.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is mostly composed of land, buildings, equipment (including machinery, furniture and fixtures, and computer equipment), and construction in progress. The estimated fair value of real property was </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determined using the sales comparison data valuation technique and personal property was determined using the direct replacement cost method. The estimated fair value of property and equipment located at the Shawnee, Kansas site was determined using the income approach.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets relate to $65 million of IPR&amp;D and $3,740 million of marketed products. The acquired definite-lived intangible assets are being amortized over a weighted-average estimated useful life of approximately 10 years on a straight-line basis. The estimated fair values of identifiable intangible assets were determined using the income approach. Some of the significant assumptions inherent in the development of these asset valuations include the estimated net cash flows for each year for each asset or product (including revenues, cost of sales, R&amp;D expenses, marketing, selling and administrative expenses, and contributory asset charges), the appropriate discount rate necessary to measure the risk inherent in each future cash flow stream, the life cycle of each asset, the potential regulatory and commercial success risk, and competitive trends impacting the asset and each cash flow stream, as well as other factors. </span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Assets held for sale include $133 million of intangible assets, consisting of marketed products and IPR&amp;D, and $5 million of inventory related to the divestitures of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Drontal</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">™, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Profender</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">™ and other products. See the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Divestitures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> section below for further details.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued retirement benefits primarily relate to certain Bayer Animal Health international subsidiaries that have underfunded defined benefit pension plans. We have recorded the fair value of these plans using assumptions and accounting policies similar to those disclosed in Note 19: Retirement Benefits to the consolidated and combined financial statements in our Annual Report on Form 10-K for the year ended December 31, 2020. Upon acquisition, the excess of projected benefit obligation over the fair value of plan assets was recognized as a liability and previously existing deferred actuarial gains and losses and unrecognized service costs or benefits were eliminated. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The goodwill recognized from this acquisition represents the value of additional growth platforms and an expanded revenue base as well as anticipated operational synergies and cost savings from the creation of a single combined global organization. The majority of goodwill associated with this acquisition is not deductible for tax purposes.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pro forma financial information (unaudited)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the estimated unaudited pro forma combined results of Elanco and Bayer Animal Health as if the acquisition of Bayer Animal Health had occurred on January 1, 2020:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.560%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,069 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,308 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loss before income taxes</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(227)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(392)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The supplemental pro forma financial information has been prepared using the acquisition method of accounting and is based on the historical financial information of Elanco and Bayer Animal Health. The supplemental pro forma financial information does not necessarily represent what the combined companies' revenue or results of operations would have been had the acquisition been completed on January 1, 2020, nor is it intended to be a projection of future operating results of the combined company. It also does not reflect any operating efficiencies or potential cost savings that might be achieved from synergies of combining Elanco and Bayer Animal Health.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited supplemental pro forma financial information reflects primarily pro forma adjustments related to divestitures; fair value estimates for property and equipment, intangibles and inventory; interest expense and amortization of debt issuance costs for the debt issuance to finance the acquisition of Bayer Animal Health. The unaudited supplemental pro forma financial information includes transaction charges associated with the acquisition. There are no material, nonrecurring pro forma adjustments directly attributable to the acquisition included in the reported pro forma revenue and loss before income taxes.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestitures</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shawnee and Speke divestitures</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2021, as part of our strategy to optimize our manufacturing footprint, we announced an agreement with TriRx Pharmaceuticals (TriRx) to sell our manufacturing sites in Shawnee and Speke, U.K. (Speke), including the planned transfer of approximately 600 employees. In connection with these arrangements, we also entered into long-term manufacturing and supply agreements, under which TriRx will manufacture existing Elanco products at both sites upon the closing of the transactions. During the nine months ended September 30, 2021, we recorded a $271 million pre-tax charge to reduce the carrying value of the disposal groups to an amount equal to fair value less costs to sell in asset impairment, restructuring, and other special charges in our condensed consolidated statements of operations. Our fair value less costs to sell assessment includes the fair value of the favorable manufacturing and supply agreements, estimated using a combined income and market approach which incorporated Level 3 inputs. On August 1, 2021, we completed the sale of our Shawnee site and expect to receive gross cash proceeds of $51 million over a period of three years based on the terms of the agreement. This activity is considered non-cash investing activity within our condensed consolidated statements of cash flows for the nine months ended September 30, 2021. We expect to close the Speke transaction in the first quarter of 2022; therefore, the related assets are classified as held for sale as of September 30, 2021. See Note 5: Asset Impairment, Restructuring and Other Special Charges for further information. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Elanco and Bayer Animal Health product divestitures</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with advancing our efforts to secure the necessary regulatory clearances for our acquisition of Bayer Animal Health, we signed agreements in 2020 to divest the rights to manufacture and commercialize certain legacy Elanco products. In 2020, we signed agreements to divest the worldwide rights to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Osurnia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vecoxan</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">™</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the U.S. rights to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capstar.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In July 2020, we completed these sales, along with certain other immaterial divestitures. The transactions were accounted for as asset divestitures.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we also signed an agreement to divest the worldwide rights to the legacy Elanco products </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Itrafungol</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">™ and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clomicalm</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">™ in connection with the required disposal of an early-stage IPR&amp;D asset. We also made a payment during the nine months ended September 30, 2021 and accrued for future amounts we are required to pay to the buyer of the IPR&amp;D asset to help fund their development costs for a set period of time. The divestiture closed during the nine months ended September 30, 2021. There were no proceeds received from the disposition of these assets and the resulting immaterial impact was recorded in other (income) expense, net in our condensed consolidated statements of operations. The related assets met the assets held for sale criteria as of December 31, 2020.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To allow the Bayer Animal Health acquisition to close on a timely basis, we signed agreements to divest the rights to the legacy Bayer Animal Health products </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drontal</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Profender</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within the U.K. and European Economic Area as well as other IPR&amp;D. We completed the transactions, which were accounted for as asset divestitures, in August 2020. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drontal</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Profender</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and the IPR&amp;D rights were acquired as part of the Bayer Animal Health acquisition. The related assets were classified as held for sale on the balance sheet as of the acquisition date and measured at fair value at the time of the acquisition; therefore, no gains were recognized on the sales. During the three months ended September 2020, a loss of $7 million was recorded on the sale of IPR&amp;D as recognition of the potential income from the divestiture was constrained by revenue accounting standards. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were additional marketed and pipeline products that we were required to dispose of in order to comply with regulatory requirements. These divestitures did not have a material effect on our operations, cash flows or financial position.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2020, we received gross cash proceeds of $435 million and recognized pre-tax gains of $156 million (net of transaction costs of $13 million) relating to the product divestitures described above. Pre-tax gains were included in other (income) expense, net in our condensed consolidated statements of operations. </span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets Held For Sale</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities considered held for sale in connection with the above divestitures were included in the respective line items on our condensed consolidated balance sheets as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangibles, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets held for sale</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangibles, net classified as held for sale primarily consisted of marketed products.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Microbiome R&amp;D platform carve-out</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 5, 2021, we announced our intention to carve out our microbiome R&amp;D platform, aiming to create a privately funded, independent, biopharmaceutical company focused on developing solutions for animal and human health. We are exploring structures with both strategic and financial sponsors, and may retain a minority stake in this new entity. The potential carve-out is expected to be completed by the end of the first quarter of 2022 and assets transferred are not expected to be material. We determined that the disposal of the related net assets does not qualify for reporting as a discontinued operation because it does not represent a strategic shift that has or will have a major effect on our operations and financial results.</span></div> 9.25 444000000 -26000000 4000000 6000000 The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at August 27, 2021</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other net working capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, primarily acquired in-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement of liability related to previous license agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of assets acquired and liabilities assumed as of the acquisition date:</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value at August 1, 2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development </span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,740 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets held for sale</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued retirement benefits</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets and liabilities, net </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(878)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,649 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration transferred</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,778 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 31000000 1000000 26000000 352000000 22000000 388000000 30000000 -26000000 444000000 <div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total consideration transferred to Bayer and its subsidiaries for the acquisition is summarized as follows: </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash consideration </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,054 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Elanco common stock </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of total consideration transferred</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,778 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Includes initial cash consideration of $5,170 million less working capital and tax adjustments of $116 million. </span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Represents the acquisition date fair value of 73 million shares of Elanco common stock at $23.64 per share. Per the terms of the stock and asset purchase agreement, the number of shares was based on approximately $2.3 billion divided by the 20-day volume-weighted average stock price as of the last day of trading before the closing of the acquisition (but subject to a 7.5% symmetrical collar centered on the baseline share number of approximately $2.3 billion divided by an initial share price of $33.60).</span> 5054000000 1724000000 6778000000 5170000000 116000000 73000000 23.64 2300000000 P20D 0.075 2300000000 33.60 3000000 93000000 35000000 421000000 1509000000 196000000 196000000 169000000 10000000 487000000 60000000 315000000 65000000 3740000000 138000000 237000000 220000000 878000000 3649000000 3129000000 6778000000 210000000 32000000 14000000 207000000 311000000 81000000 95000000 152000000 65000000 3740000000 P10Y 133000000 5000000 <div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the estimated unaudited pro forma combined results of Elanco and Bayer Animal Health as if the acquisition of Bayer Animal Health had occurred on January 1, 2020:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.560%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,069 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,308 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loss before income taxes</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(227)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(392)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1069000000 3308000000 -227000000 -392000000 600 271000000 51000000 7000000 435000000 435000000 156000000 156000000 13000000 13000000 <div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities considered held for sale in connection with the above divestitures were included in the respective line items on our condensed consolidated balance sheets as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangibles, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets held for sale</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 38000000 2000000 0 4000000 55000000 0 0 1000000 93000000 7000000 <div style="text-align:justify"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5. Asset Impairment, Restructuring and Other Special Charges </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, we have incurred substantial costs associated with restructuring programs and cost-reduction initiatives designed to achieve a flexible and competitive cost structure. Restructuring activities primarily include charges associated with facility rationalization and workforce reductions. In connection with our recent acquisitions, including the acquisitions of Bayer Animal Health and KindredBio, we have also incurred costs associated with executing transactions and integrating acquired operations, which may include expenditures for banking, legal, accounting, and other similar services. In addition, we have incurred costs to stand up our organization as an independent company. All operating functions can be impacted by these actions; therefore, non-cash expenses associated with our tangible and intangible assets can be incurred as a result of revised fair value projections and/or determinations to no longer utilize certain assets in the business on an ongoing basis.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For finite-lived intangible asset and other long-lived assets, whenever impairment indicators are present, we calculate the undiscounted value of projected cash flows associated with the asset, or group of assets, and compare it to the carrying amount. If the carrying amount is greater, we record an impairment loss for the excess of book value over fair value. Determinations of fair value can result from a complex series of judgments and rely on estimates and assumptions. See Note 1: Basis of Presentation and Summary of Significant Accounting Policies for discussion regarding estimates and assumptions.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Components of asset impairment, restructuring and other special charges are as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restructuring charges: </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and other costs </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility exit costs </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Acquisition related charges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction and integration costs </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-cash and other items:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset write-down</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (4)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of fixed assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements and other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total expense</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">For the nine months ended September 30, 2021, these charges primarily related to a restructuring program announced and initiated in January 2021. These costs were partially offset by the reversal of severance accruals associated with the January 2021 and September 2020 programs during the period. See below for further details.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2020, these charges primarily related to a restructuring program announced and initiated in September 2020. See below for further details.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Transaction costs represent external costs directly related to acquiring businesses and primarily include expenditures for banking, legal, accounting and other similar services. Integration costs represent internal and external incremental costs directly related to integrating acquired businesses, including the acquisitions of KindredBio and Bayer Animal Health (e.g., expenditures for consulting, system and process integration, and product transfers), as well as independent company stand-up costs related to the implementation of new systems, programs, and processes.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Asset impairment charges for the three and nine months ended September 30, 2021 related to adjustments to the fair value of IPR&amp;D assets that were subject to product rationalization. The asset impairment charge during the three months ended September 30, 2021 reflects a decision by management to terminate an IPR&amp;D project and fully impair the related asset, which is associated with a farm animal parasiticide. The decision was prompted by unfavorable efficacy results observed during the quarter. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Asset impairment charges for the nine months ended September 30, 2020 related to the impairment of an IPR&amp;D asset resulting from product rationalization and a reassessment of geographic viability.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Asset write-down expenses for the nine months ended September 30, 2021 include the initial adjustments recorded to write down the Shawnee and Speke assets classified as held for sale as of June 30, 2021 to an amount equal to estimated fair value less costs to sell, as well as adjustments to values of assets sold in relation to the Shawnee manufacturing site sold on August 1, 2021 and assets classified as held for sale in relation to the future sale of the Speke manufacturing site during the three months ended September 30, 2021. See Note 4: Acquisitions and Divestitures for further discussion. Other charges for the nine months ended September 30, 2021 include adjustments recorded to write down assets in Belford Roxo, Brazil; Basel, Switzerland; Cuxhaven, Germany; and Manukau, New Zealand that were classified as held and used to their current fair value. These charges were recorded in connection with the January 2021 and September 2020 restructuring programs.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Asset write-down expenses for the three and nine months ended September 30, 2020 resulted from adjustments recorded to write down assets classified as held and used to their current fair value. These charges primarily related to fixed assets in Wusi, China in connection with the announced 2019 program to streamline operations.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Represents a gain on the disposal from the sale of an R&amp;D facility in Prince Edward Island, Canada.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Settlements and other expenses for the three and nine months ended September 30, 2021 include a charge associated with the settlement of a liability for future royalty and milestone payments triggered in connection with our acquisition of KindredBio as discussed further in Note 4: Acquisitions and Divestitures, accounting and advisory fees related to the sale of our manufacturing site in Shawnee, and an $8 million charge related to a litigation settlement for a matter that originated prior to our acquisition of Bayer Animal Health, partially offset by net curtailment and settlement gains from the remeasurement of our pension benefit obligation as a result of workforce reductions in connection with our September 2020 and January 2021 restructuring programs. See Note 13: Retirement Benefits for further information. The amount for the nine months ended September 30, 2021 also includes the gain recorded on the divestiture of an early-stage IPR&amp;D asset acquired as part of the Bayer Animal Health acquisition. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Settlements and other expenses for the three and nine months ended September 30, 2020 relate to a non-recurring litigation settlement for a matter that originated prior to our separation from Lilly.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we announced a restructuring aligned with our ongoing efforts to improve operating efficiencies. The proposed actions focused on streamlining processes and delivering increased efficiency in functional areas, while improving the productivity of our investments in innovation. As part of the restructuring plan, we closed our R&amp;D sites in Manukau, New Zealand and Cuxhaven, Germany. We have also reduced duplication and optimized structures in U.S. operations, marketing, manufacturing and quality central functions, and administrative areas. The restructuring resulted in the elimination of approximately 330 positions around the world. Activities related to this initiative resulted in favorable adjustments of $1 million and charges of $44 million during the three and nine months ended September 30, 2021, respectively. The favorable adjustments reflect a change in estimate resulting from ongoing negotiations. Initiatives under this program are expected to be substantially completed by the end of 2021.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, following the closing of the Bayer Animal Health acquisition, we implemented a restructuring program designed to reduce duplication, drive efficiency and optimize our footprint in key geographies. As part of the restructuring plan, we have eliminated approximately 900 positions across 40 countries, primarily in the commercial and marketing functions, but also in R&amp;D, manufacturing and quality, and back office support functions. During the three and nine months ended September 30, 2021 we recorded favorable adjustments of $1 million and $15 million, respectively, as a change in estimate related to this initiative, which reflects adjustments to severance accruals resulting from favorable negotiations and certain restructured employees filling open positions. Initiatives under this program are expected to be substantially completed by the end of 2021.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity in our reserves established in connection with restructuring activities:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.207%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Facility exit costs </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve adjustments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve adjustments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These reserves are included in other current and noncurrent liabilities on our condensed consolidated balance sheets. Substantially all of the reserves are expected to be paid in the next 15 months primarily due to certain country negotiations and regulations. We believe that the reserves are adequate.</span></div> <div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Components of asset impairment, restructuring and other special charges are as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restructuring charges: </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and other costs </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility exit costs </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Acquisition related charges:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction and integration costs </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-cash and other items:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairment </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset write-down</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (4)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of fixed assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements and other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total expense</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">For the nine months ended September 30, 2021, these charges primarily related to a restructuring program announced and initiated in January 2021. These costs were partially offset by the reversal of severance accruals associated with the January 2021 and September 2020 programs during the period. See below for further details.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2020, these charges primarily related to a restructuring program announced and initiated in September 2020. See below for further details.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Transaction costs represent external costs directly related to acquiring businesses and primarily include expenditures for banking, legal, accounting and other similar services. Integration costs represent internal and external incremental costs directly related to integrating acquired businesses, including the acquisitions of KindredBio and Bayer Animal Health (e.g., expenditures for consulting, system and process integration, and product transfers), as well as independent company stand-up costs related to the implementation of new systems, programs, and processes.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Asset impairment charges for the three and nine months ended September 30, 2021 related to adjustments to the fair value of IPR&amp;D assets that were subject to product rationalization. The asset impairment charge during the three months ended September 30, 2021 reflects a decision by management to terminate an IPR&amp;D project and fully impair the related asset, which is associated with a farm animal parasiticide. The decision was prompted by unfavorable efficacy results observed during the quarter. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Asset impairment charges for the nine months ended September 30, 2020 related to the impairment of an IPR&amp;D asset resulting from product rationalization and a reassessment of geographic viability.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Asset write-down expenses for the nine months ended September 30, 2021 include the initial adjustments recorded to write down the Shawnee and Speke assets classified as held for sale as of June 30, 2021 to an amount equal to estimated fair value less costs to sell, as well as adjustments to values of assets sold in relation to the Shawnee manufacturing site sold on August 1, 2021 and assets classified as held for sale in relation to the future sale of the Speke manufacturing site during the three months ended September 30, 2021. See Note 4: Acquisitions and Divestitures for further discussion. Other charges for the nine months ended September 30, 2021 include adjustments recorded to write down assets in Belford Roxo, Brazil; Basel, Switzerland; Cuxhaven, Germany; and Manukau, New Zealand that were classified as held and used to their current fair value. These charges were recorded in connection with the January 2021 and September 2020 restructuring programs.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Asset write-down expenses for the three and nine months ended September 30, 2020 resulted from adjustments recorded to write down assets classified as held and used to their current fair value. These charges primarily related to fixed assets in Wusi, China in connection with the announced 2019 program to streamline operations.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Represents a gain on the disposal from the sale of an R&amp;D facility in Prince Edward Island, Canada.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Settlements and other expenses for the three and nine months ended September 30, 2021 include a charge associated with the settlement of a liability for future royalty and milestone payments triggered in connection with our acquisition of KindredBio as discussed further in Note 4: Acquisitions and Divestitures, accounting and advisory fees related to the sale of our manufacturing site in Shawnee, and an $8 million charge related to a litigation settlement for a matter that originated prior to our acquisition of Bayer Animal Health, partially offset by net curtailment and settlement gains from the remeasurement of our pension benefit obligation as a result of workforce reductions in connection with our September 2020 and January 2021 restructuring programs. See Note 13: Retirement Benefits for further information. The amount for the nine months ended September 30, 2021 also includes the gain recorded on the divestiture of an early-stage IPR&amp;D asset acquired as part of the Bayer Animal Health acquisition. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Settlements and other expenses for the three and nine months ended September 30, 2020 relate to a non-recurring litigation settlement for a matter that originated prior to our separation from Lilly.</span></div> -2000000 130000000 26000000 131000000 0 0 0 1000000 30000000 131000000 141000000 318000000 50000000 0 63000000 4000000 6000000 1000000 275000000 3000000 0 0 0 4000000 -27000000 0 -13000000 -3000000 111000000 262000000 518000000 456000000 8000000 8000000 330 -1000000 44000000 900 40 -1000000 -15000000 <div style="margin-bottom:6pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity in our reserves established in connection with restructuring activities:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.207%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Facility exit costs </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve adjustments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve adjustments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5000000 16000000 21000000 1000000 132000000 133000000 0 -1000000 -1000000 1000000 15000000 16000000 5000000 132000000 137000000 0 130000000 130000000 0 41000000 41000000 0 -15000000 -15000000 0 95000000 95000000 0 61000000 61000000 P15M <div><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6. Inventories </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We state all inventories at the lower of cost or net realizable value. We use the last-in, first-out (LIFO) method for a portion of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method or the weighted average cost method.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished products</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,426 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,607 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,578 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished products</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">772 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,426 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,607 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,578 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 595000000 772000000 576000000 625000000 255000000 210000000 1426000000 1607000000 43000000 29000000 1383000000 1578000000 <div style="text-align:justify"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7. Equity</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Offering</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 22, 2020, we entered into an underwriting agreement in which we agreed to sell approximately 23 million shares of our common stock at a public offering price of $32.00 per share. In connection with the offering, we granted the underwriters an option to purchase up to an additional 2 million shares, which was exercised in full on January 23, 2020. As a result, we issued and sold a total of approximately 25 million shares of our common stock for $768 million, after issuance costs.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tangible Equity Unit (TEU) Offering</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 22, 2020, we also completed our offering of 11 million, 5.00% TEUs. Total proceeds, net of issuance costs, were $528 million. Each TEU, which has a stated amount of $50, is comprised of a prepaid stock purchase contract (prepaid stock) and a senior amortizing note due February 1, 2023. Subsequent to issuance, each TEU may be legally separated into the two components. The prepaid stock is considered a freestanding financial instrument, indexed to Elanco common stock, and meets the conditions for equity classification. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The value allocated to the prepaid stock is reflected net of issuance costs in additional paid-in capital. The value allocated to the senior amortizing notes is reflected in long-term debt on the condensed consolidated balance sheets, with payments expected in the next twelve months reflected in current portion of long-term debt. Issuance costs related to the amortizing notes are reflected as a reduction of the carrying amount and will be amortized through the maturity date using the effective interest rate method.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from the issuance were allocated to equity and debt based on the relative fair value of the respective components of each TEU as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.207%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity Component</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Component</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per unit</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.80 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.20 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.00 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross proceeds</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The senior amortizing notes have an aggregate principal amount of $79 million and bear interest at 2.75% per year. On each February 1, May 1, August 1, and November 1 until the maturity date, we will pay equal quarterly cash installments of $0.6250 per each amortizing note with an initial principal amount of $7.2007 (except for the first installment payment of $0.6528 per amortizing note paid on May 1, 2020). Each installment constitutes a payment of interest and partial payment of principal, and in the aggregate will be equivalent to 5.00% per year with respect to the $50 stated amount per TEU.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless settled early at the holder’s or our election, each prepaid stock purchase contract will automatically settle on February 1, 2023 (the mandatory settlement date) for a number of shares of common stock per contract based on the average of the volume-weighted average trading prices during the 20 consecutive trading day period beginning on, and including the 21st scheduled trading day immediately preceding February 1, 2023 (applicable market value) with reference to the following settlement rates:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.607%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Applicable Market Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Issued</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equal to or greater than $38.40</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3021 shares (minimum settlement rate)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than $38.40, but greater than $32.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$50 divided by applicable market value</span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than or equal to $32.00</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5625 (maximum settlement rate)</span></div></td></tr></table></div>The prepaid stock purchase contracts are mandatorily convertible into a minimum of 14 million shares or a maximum of 17 million shares of our common stock on the mandatory settlement date (unless redeemed by us or settled earlier at the unit holder's option). The 14 million minimum shares are included in the calculation of basic weighted average shares outstanding. The difference between the minimum and maximum shares represents potentially dilutive securities, which are included in the calculation of diluted weighted average shares outstanding on a pro rata basis to the extent that the average applicable market value is higher than $32.00 but is less than $38.40 during the period. 23000000 32.00 2000000 25000000 768000000 11000000 0.0500 528000000 50 <div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from the issuance were allocated to equity and debt based on the relative fair value of the respective components of each TEU as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.207%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity Component</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Component</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per unit</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.80 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.20 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.00 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross proceeds</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net proceeds</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless settled early at the holder’s or our election, each prepaid stock purchase contract will automatically settle on February 1, 2023 (the mandatory settlement date) for a number of shares of common stock per contract based on the average of the volume-weighted average trading prices during the 20 consecutive trading day period beginning on, and including the 21st scheduled trading day immediately preceding February 1, 2023 (applicable market value) with reference to the following settlement rates:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.607%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Applicable Market Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Issued</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equal to or greater than $38.40</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3021 shares (minimum settlement rate)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than $38.40, but greater than $32.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$50 divided by applicable market value</span></div></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than or equal to $32.00</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5625 (maximum settlement rate)</span></div></td></tr></table></div> 42.80 7.20 50.00 471000000 79000000 550000000 19000000 3000000 22000000 452000000 76000000 528000000 79000000 0.0275 0.6250 7.2007 0.6528 0.0500 50 20 38.40 1.3021 38.40 32.00 50 32.00 1.5625 14000000 17000000 14000000 32.00 38.40 <div><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8. Debt </span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incremental Term Facility</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving Credit Facility</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.912% Senior Notes due 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.272% Senior Notes due 2023</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.900% Senior Notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TEU Amortizing Notes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,334 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,127 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion of long-term debt</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,273 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,572 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Farm Credit Agreement</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 12, 2021, we entered into a new debt financing arrangement with Farm Credit Mid-America, PCA (Farm Credit) for a $500 million credit facility, consisting of a senior secured term loan (Incremental Term Facility) to retire our existing Senior Notes due August 27, 2021. The Incremental Term Facility bears interest at a floating rate of LIBOR plus 175 basis points and is payable in quarterly installments with a final balloon payment due on August 12, 2028. The terms of the Incremental Term Facility, including pledged collateral and financial maintenance covenants, are generally consistent with the terms of our existing term loan B credit facility (Term Loan B) and revolving credit facility. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bayer Animal Health Related Financing</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Bayer Animal Health, on August 1, 2020, we borrowed $4,275 million under a Term Loan B facility. The Term Loan B bears interest at a floating rate of LIBOR plus 175 basis points and is payable in quarterly installments through August 1, 2027. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simultaneously, we entered into a revolving credit facility providing up to $750 million (with incremental capacity available if certain conditions are met) and maturing over a five-year term. The revolving credit facility bears interest at LIBOR plus an applicable margin ranging between 1.50% and 2.25% per annum based on our corporate family rating or corporate credit rating. In February 2021, we drew down $150 million on the revolving credit facility for working capital needs. We subsequently repaid $100 million in March 2021 and the remaining $50 million in April 2021. In August 2021, we drew down $350 million on the revolving credit facility to partially fund the acquisition of KindredBio. We subsequently repaid $100 million in September 2021. </span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These senior secured first lien credit facilities are secured by a significant portion of our assets. They include two financial maintenance covenants which are solely for the benefit of lenders under the revolving credit facility. There are no financial maintenance covenants for the benefit of the Term Loan B facility. The lenders under the Term Loan B facility have no enforcement rights with respect to the financial maintenance covenants for the revolving credit facility.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first financial maintenance covenant for the revolving credit facility requires us to maintain a net total leverage ratio level (which is not subject to step-downs) as of the end of each quarter. The required level of this covenant is based on closing date pro forma net leverage and pro forma adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) not exceeding 7.71 to 1.00 of our pro forma adjusted EBITDA for the four fiscal quarters ended September 30, 2021.</span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The second financial maintenance covenant for the revolving credit facility requires us to maintain a ratio of pro forma adjusted EBITDA to cash interest expense of no less than 2.00 to 1.00, tested as of the end of each fiscal quarter. We were in compliance with all covenants under the credit facility as of September 30, 2021.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Notes</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, we issued $2 billion of senior notes (Senior Notes). The Senior Notes comprised of $500 million of 3.912% Senior Notes due August 27, 2021, which were fully repaid as part of the Farm Credit refinancing, $750 million of 4.272% Senior Notes due August 28, 2023, and $750 million of 4.900% Senior Notes due August 28, 2028. The interest rate payable on each series of Senior Notes is subject to adjustment if Moody's Investor Services, Inc. or Standard &amp; Poor's Financial Services LLC downgrades, or subsequently upgrades, its ratings on the respective series of Senior Notes.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indenture that governs the Senior Notes contains covenants that limit our, and certain of our subsidiaries' ability, to incur liens or engage in sale-leaseback transactions. The indenture also contains restrictions on our ability to consolidate, merge or sell substantially all of our assets, in addition, to other customary terms. We were in compliance with all such covenants under the indenture governing the Senior Notes as of September 30, 2021.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TEU Amortizing Notes</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 22, 2020, we issued $550 million in TEUs. We offered 11 million, 5.00% TEUs at the stated amount of $50 per unit, comprised of prepaid stock purchase contracts and a senior amortizing note due February 1, 2023 (the mandatory settlement date). Total cash of $528 million was received, comprised of $452 million of prepaid stock purchase contracts and $76 million of senior amortizing notes, net of issuance costs. During the three and nine months ended September 30, 2021, we paid $7 million and $21 million, respectively, representing partial payment of principal and interest on the TEU amortizing notes. See Note 7: Equity for further information.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Extinguishment</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2020, we repaid indebtedness outstanding under our previous term loan facility. We paid $372 million in cash, composed of $371 million of principal and $1 million of accrued interest, resulting in a debt extinguishment loss of $1 million (recognized in interest expense, net of capitalized interest in our condensed consolidated statements of operations for the nine months ended September 30, 2020), primarily related to the write-off of deferred debt issuance costs. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 25, 2020, we made a repayment of principal of $100 million on the indebtedness outstanding under our Term Loan B. The repayment was accounted for as a partial debt extinguishment and resulted in a debt extinguishment loss of $2 million (recognized in interest expense, net of capitalized interest in the condensed consolidated statements of operations for the three and nine months ended September 30, 2020), primarily related to the write-off of deferred debt issuance costs.</span></div> <div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incremental Term Facility</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving Credit Facility</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.912% Senior Notes due 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.272% Senior Notes due 2023</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.900% Senior Notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TEU Amortizing Notes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,334 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,127 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion of long-term debt</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,273 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,572 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 500000000 0 4129000000 4164000000 250000000 0 0.03912 0 500000000 0.04272 750000000 750000000 0.04900 750000000 750000000 40000000 60000000 0 1000000 85000000 98000000 6334000000 6127000000 61000000 555000000 6273000000 5572000000 500000000 0.0175 4275000000 0.0175 750000000 P5Y 0.0150 0.0225 150000000 100000000 50000000 350000000 100000000 2 0 7.71 2.00 2000000000 500000000 0.03912 750000000 0.04272 750000000 0.04900 550000000 11000000 0.0500 50 528000000 452000000 76000000 7000000 21000000 372000000 371000000 1000000 -1000000 100000000 -2000000 <div><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9. Financial Instruments and Fair Value </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that are potentially subject to credit risk consist principally of trade receivables. We evaluate the creditworthiness of our customers on a regular basis, monitor economic conditions, and calculate allowances for estimated credit losses on our trade receivables on a quarterly basis using an expected credit loss model. We assess whether collectability is probable at the time of sale and on an ongoing basis. Collateral is generally not required. The risk associated with this concentration is mitigated by our ongoing credit-review procedures.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A large portion of our cash is held by a few major financial institutions. We monitor the exposure with these institutions and do not expect any of these institutions to fail to meet their obligations. All highly liquid investments with a maturity of three months or less from the date of purchase are considered to be cash equivalents. The cost of these investments approximates fair value. We also consider the carrying value of restricted cash balances to be representative of its fair value.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had investments without readily determinable fair values and equity method investments included in other noncurrent assets on our condensed consolidated balance sheets totaling $21 million and $24 million as of September 30, 2021 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively. Unrealized net gains and losses on our investments for the three and nine months ended September 30, 2021 and 2020 were immaterial.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value information at September 30, 2021 and December 31, 2020 for foreign exchange contract assets (liabilities), investments, contingent consideration liabilities, and cash flow hedge assets (liabilities) measured at fair value on a recurring basis in the respective balance sheet line items, as well as long-term debt (including TEU amortizing notes) for which fair value is disclosed on a recurring basis: </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.656%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial statement line item</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other - foreign exchange contracts not designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets - investments</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities - foreign exchange contracts not designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities - contingent consideration</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities - forward-starting interest rate contracts designated as cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including current portion</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,419)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,551)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,551)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other - foreign exchange contracts not designated as hedging instruments</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets - investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities - foreign exchange contracts not designated as hedging instruments</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities - contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities - forward-starting interest rate contracts designated as cash flow hedges</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,225)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,420)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,420)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine our Level 2 fair value measurements based on a market approach using quoted market values or significant other observable inputs for identical or comparable assets or liabilities. </span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration liabilities as of September 30, 2021 and December 31, 2020 related to contingent consideration associated with the acquisitions of Aratana Therapeutics, Inc. (Aratana) and Prevtec Microbia Inc. (Prevtec) during 2019. For Aratana, we will pay up to $12 million in contingent value rights that are dependent on the achievement of a specified milestone by December 31, 2021 as outlined in the merger agreement. For Prevtec, based on the terms of the purchase agreement, we will pay up to $16 million contingent upon the achievement of specific </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coliprotec</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales milestones by December 31, 2021. The fair value of both contingent consideration liabilities was estimated using the Monte Carlo simulation model and Level 3 inputs including historical revenue, discount rate, asset volatility, and revenue volatility. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks, such as changes in foreign currency exchange rates and interest rates. To manage the volatility related to these exposures, we have entered into various derivative transactions. We formally assess, designate and document, as a hedge of an underlying exposure, each qualifying derivative instrument that will be accounted for as an accounting hedge at inception. Additionally, we assess, both at inception and at least quarterly thereafter, whether the financial instruments used in the hedging transaction are effective at offsetting changes in either the fair values or cash flows of the underlying exposures.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives Not Designated as Hedges</span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may enter into foreign exchange forward or option contracts to reduce the effect of fluctuating currency exchange rates. These derivative financial instruments primarily offset exposures in the British pound, Canadian dollar, Euro, Japanese yen, Swiss franc (CHF), and Chinese yuan. Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures and are recorded at fair value with the gain or loss recognized in other (income) expense, net in the condensed consolidated statements of operations. Forward contracts generally have maturities not exceeding 12 months. At September 30, 2021 and December 31, 2020, we had outstanding foreign exchange contracts with aggregate notional amounts of $1,417 million and $1,391 million, respectively. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts of net gain (loss) on derivative instruments not designated as hedging instruments, recorded in other (income) expense, net are as follows:</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">These amounts were substantially offset in other (income) expense, net by the effect of changing exchange rates on the underlying foreign currency exposures.</span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives Designated as Hedges</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, as a means of mitigating the impact of currency fluctuations on our operations in Switzerland, we entered into a five-year cross-currency fixed interest rate swap with a 750 million CHF notional amount, which was designated as a net investment hedge (NIH) against CHF denominated assets (the fair value of which was estimated based on quoted market values of similar hedges and was classified as Level 2). During the nine months ended September 30, 2020 we fully liquidated our cross currency interest rate swaps for a cash benefit of $35 million (including $2 million in interest). Notwithstanding settlement, gains and losses within accumulated other comprehensive income (loss) will remain in accumulated other comprehensive income (loss) until either the sale or substantial liquidation of the hedged subsidiary.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains on the NIH, recognized within interest expense, net of capitalized interest, are as follows:</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swap contracts</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the life of the derivative, gains or losses due to spot rate fluctuations were recorded in cumulative translation adjustment in other comprehensive income (loss). The amounts of net gains on interest rate swap contracts, recorded, net of tax, in accumulated other comprehensive income (loss), are as follows:</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swap contracts</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, in March 2020, as a means of mitigating variability in cash flows associated with the anticipated Term Loan B issuance, we executed forward-starting interest rate swaps with a $4.1 billion notional amount, which are designated as cash flow hedges and have maturity dates ranging between 2022 and 2025. These instruments effectively convert floating-rate debt to fixed-rate debt. The cash flow hedges are recorded at fair value on our condensed consolidated balance sheets, while changes in the fair value of the hedge are recognized in other comprehensive income (loss). Fair value is estimated based on quoted market values of similar hedges and is classified as Level 2. Amounts recorded in accumulated other comprehensive income (loss) are recognized in earnings in interest expense, net of capitalized interest when the hedged transaction affects earnings (i.e., as interest payments are accrued on the Term Loan B). </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts of net gains (losses) on cash flow hedges, recorded, net of tax, in accumulated other comprehensive income (loss), are as follows:</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward-starting interest rate swaps, net of tax benefit of $0, $2, $0 and $20, respectively</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> There was no tax effect for the three and nine months ended September 30, 2021 after the application of the U.S. valuation allowance. See Note 10: Income Taxes for further discussion. Over the next 12 months we expect to reclassify $26 million from accumulated other comprehensive income (loss) to interest expense, net of capitalized interest due to the amortization of net losses on the interest rate swaps. During the three and nine months ended September 30, 2021, we reclassified $8 million and $22 million, respectively, of net losses into interest expense.</span></div> 21000000 24000000 <div style="margin-bottom:6pt;text-align:justify;text-indent:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value information at September 30, 2021 and December 31, 2020 for foreign exchange contract assets (liabilities), investments, contingent consideration liabilities, and cash flow hedge assets (liabilities) measured at fair value on a recurring basis in the respective balance sheet line items, as well as long-term debt (including TEU amortizing notes) for which fair value is disclosed on a recurring basis: </span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.656%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial statement line item</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other - foreign exchange contracts not designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets - investments</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities - foreign exchange contracts not designated as hedging instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities - contingent consideration</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities - forward-starting interest rate contracts designated as cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including current portion</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,419)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,551)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,551)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other - foreign exchange contracts not designated as hedging instruments</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets - investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities - foreign exchange contracts not designated as hedging instruments</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities - contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities - forward-starting interest rate contracts designated as cash flow hedges</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,225)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,420)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,420)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 30000000 0 30000000 0 30000000 15000000 15000000 0 0 15000000 -30000000 0 -30000000 0 -30000000 1000000 0 0 1000000 1000000 -24000000 0 -24000000 0 -24000000 6419000000 0 6551000000 0 6551000000 36000000 0 36000000 0 36000000 9000000 9000000 0 0 9000000 -36000000 0 -36000000 0 -36000000 1000000 0 0 1000000 1000000 -76000000 0 -76000000 0 -76000000 6225000000 0 6420000000 0 6420000000 12000000 16000000 1417000000 1391000000 <div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts of net gain (loss) on derivative instruments not designated as hedging instruments, recorded in other (income) expense, net are as follows:</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.613%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">These amounts were substantially offset in other (income) expense, net by the effect of changing exchange rates on the underlying foreign currency exposures.</span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains on the NIH, recognized within interest expense, net of capitalized interest, are as follows:</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swap contracts</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The amounts of net gains on interest rate swap contracts, recorded, net of tax, in accumulated other comprehensive income (loss), are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency interest rate swap contracts</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts of net gains (losses) on cash flow hedges, recorded, net of tax, in accumulated other comprehensive income (loss), are as follows:</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward-starting interest rate swaps, net of tax benefit of $0, $2, $0 and $20, respectively</span></div></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> -2000000 -2000000 -29000000 19000000 P5Y 750000000 35000000 2000000 0 0 0 6000000 0 0 0 24000000 4100000000 0 2000000 0 20000000 4000000 -7000000 52000000 -67000000 0 0 -26000000 -8000000 22000000 <div style="text-align:justify"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10. Income Taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Income Tax Benefit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:63pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were included in Lilly's U.S. tax examinations by the Internal Revenue Service through the full separation date of March 11, 2019. Pursuant to the tax matters agreement we executed with Lilly in connection with the IPO, the potential liabilities or potential refunds attributable to pre-IPO periods in which Elanco was included in a Lilly consolidated or combined tax return remain with Lilly. The U.S. examination of tax years 2016 - 2018 began in the fourth quarter of 2019 and remains ongoing; therefore, the resolution of this audit period will likely extend beyond the next 12 months.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, we recognized an income tax benefit of $26 million and $71 million, respectively. For the three months ended September 30, 2021, our effective tax rate of 20.0% differs from the statutory income tax rate primarily due to preliminary accounting for the acquisition of KindredBio, which caused a partial release of the U.S. federal valuation allowance, as well as profits being located in jurisdictions with higher statutory tax rates. For the nine months ended September 30, 2021, our effective tax rate of 15.9% differs from the statutory income tax rate primarily because the U.S. federal and state jurisdictions are currently generating losses that are subject to valuation allowances.</span></div>For the three and nine months ended September 30, 2020, we recognized an income tax benefit of $74 million and $117 million, respectively. For the three and nine months ended September 30, 2020, our effective tax rate of 35.4% and 32.9%, respectively, differs from the statutory income tax rate primarily due to the release of foreign valuation allowances as a result of gains on divestitures. Additionally, the state tax benefit is a result of U.S. pre-tax losses and the foreign tax benefit is due to losses in jurisdictions with tax rates higher than U.S. statutory rates. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Income Tax Benefit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> -26000000 -74000000 -71000000 -117000000 0.200 0.354 0.159 0.329 -26000000 -71000000 0.200 0.159 -74000000 -117000000 0.354 0.329 <div style="text-align:justify"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11. Commitments and Contingencies </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 20, 2020, a shareholder class action lawsuit captioned </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hunter v. Elanco Animal Health Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was filed in the United States District Court for the Southern District of Indiana (the Court) against Elanco, Jeffrey Simmons and Todd Young. On September 3, 2020, the Court appointed a lead plaintiff, and on November 9, 2020, the lead plaintiff filed an amended complaint. The lawsuit alleges, in part, that Elanco and certain of its executives made materially false and/or misleading statements and/or failed to disclose certain facts about Elanco’s supply chain, inventory, revenue and projections. The lawsuit seeks unspecified monetary damages and purports to represent purchasers of Elanco securities between September 30, 2018 and May 6, 2020, and purchasers of Elanco common stock issued in connection with Elanco's acquisition of Aratana. We filed a motion to dismiss on January 13, 2021. The timing of the Court's decision is uncertain. We believe the claims made in the case are meritless, and we intend to vigorously defend our position. The process of resolving these matters is inherently uncertain and may develop over an extended period of time; therefore, at this time, the ultimate resolution cannot be predicted. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 16, 2020, a shareholder class action lawsuit captioned </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Safron Capital Corporation v. Elanco Animal Health Inc., et al.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was filed in the Marion Superior Court of Indiana against Elanco, certain executives, and other individuals. On December 23, 2020, the plaintiffs filed an amended complaint adding an additional plaintiff. The lawsuit alleges, in part, that Elanco and certain of its executives made materially false and/or misleading statements and/or failed to disclose certain facts about Elanco’s relationships with third party distributors and revenue attributable to those distributors within the registration statement on Form S-3 dated January 21, 2020 and accompanying prospectus filed in connection with Elanco’s public offering which closed on or about January 27, 2020. The lawsuit seeks unspecified monetary damages and purports to represent purchasers of Elanco common stock or 5.00% TEUs issued in connection with the public offering. This case is currently stayed in deference to Hunter v. Elanco Animal Health Inc. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims seeking actual damages, injunctive relief, and/or restitution for allegedly deceptive marketing have been made against Elanco Animal Health Inc. and Bayer HealthCare LLC, along with other Elanco and Bayer entities, arising out of the use of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Seresto™</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a non-prescription flea and tick collar for cats and dogs. During the nine months ended September 30, 2021, putative class action lawsuits were filed in state and federal courts in the U.S. alleging that the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Seresto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> collars contain pesticides and other ingredients that can cause serious injury and death to cats and/or dogs wearing the product. The cases mention the existence of incident reports involving humans, but no plaintiff has claimed personal harm from the product. One plaintiff filed a petition before the Judicial Panel on Multidistrict Litigation (JPML). The hearing on the JPML petition took place on July 29, 2021, and a decision was reached to consolidate and transfer all pending lawsuits to the federal court in the Northern District of Illinois. We continue to receive information with respect to potential litigation costs, and we will be taking appropriate steps to defend these class action lawsuits.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, a U.S. House of Representative subcommittee chair requested that Elanco produce certain documents and information related to the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Seresto </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collar and further made a request to temporarily recall </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Seresto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> collars from the market. We are continuing to cooperate with the subcommittee and have produced information pursuant to the request. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Seresto </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is a pesticide registered with the Environmental Protection Agency (EPA). A non-profit organization submitted a petition to the EPA requesting that the agency take action to cancel </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Seresto’s </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pesticide registration and suspend the registration pending cancellation. The EPA is considering this petition and asked for public comment. We submitted a comment to the EPA supporting the safety profile of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Seresto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All data and scientific evaluation used during the product registration process and through pharmacovigilance review supports the product’s positive safety profile and efficacy. Therefore, we believe no removal, recall, or cancellation of the pesticide registration is warranted, nor has it been suggested by any regulatory agency. We continue to stand behind the safety profile for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Seresto, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and it remains available to consumers globally. </span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to various other legal actions in the normal course of business. In determining whether a pending matter is significant for financial reporting and disclosure purposes, we consider both quantitative and qualitative factors in order to assess materiality. We accrue for liability claims to the extent that it is probable we will incur a loss and we can formulate a reasonable estimate of the costs. As of September 30, 2021 and December 31, 2020, we had no material liabilities established related to litigation as there were no significant claims which were probable and estimable. We are not currently subject to a significant claim other than the lawsuits noted above.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Matters</span></div>On July 1, 2021, we received a subpoena from the SEC relating to our channel inventory and sales practices prior to mid-2020. We have cooperated in providing documents and information to the SEC and will continue to do so. Management believes that its actions were appropriate. 0.0500 0 0 <div style="text-align:justify"><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12. Geographic Information </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We operate as a single operating segment engaged in the development, manufacturing, marketing and sales of animal health products worldwide for both farm animals and pets. Consistent with our operational structure, our President and Chief Executive Officer (CEO), as the chief operating decision maker, makes resource allocation and business process decisions globally across our consolidated business. Strategic decisions are managed globally with global functional leaders responsible for determining significant costs/investments and with regional leaders responsible for overseeing the execution of the global strategy. Our global research and development organization is responsible for development of new products. Our manufacturing organization is responsible for the manufacturing and supply of products and for the optimization of our supply chain. Regional leaders are responsible for the distribution and sale of our products and for local direct costs. The business is also supported by global corporate staff functions. Managing and allocating resources at the global corporate level enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, product types, regional commercial organizations and research and development projects in line with our overarching long-term corporate-wide strategic goals, rather than on a product or geographic basis. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, allocating resources, setting incentive compensation targets, as well as forecasting future period financial results. </span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products include </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Baycox™, Cydectin™, Denagard™, Maxiban™, Optaflexx™, Rumensin™</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tylan™</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and other products for livestock and poultry, as well as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advantage™, Advantix™, Advocate™ </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(collectively referred to as the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advantage Family), Credelio™, Duramune™</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Galliprant™, Interceptor™ Plus,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Seresto, Trifexis™</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and other products for pets.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a single customer that accounted for 11% and 12% of revenue for the three months ended September 30, 2021 and 2020, respectively, and 9% and 12% of revenue for the nine months ended September 30, 2021 and 2020, respectively. Product sales with this customer resulted in accounts receivable of $80 million and $87 million as of September 30, 2021 and December 31, 2020, respectively.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of changes in social, political and economic conditions inherent in foreign operations and our results of operations and the value of our foreign assets are affected by fluctuations in foreign currency exchange rates.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected geographic area information was as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,621 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,031 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,131 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,652 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,134 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0.11 0.12 0.09 0.12 80000000 87000000 <div style="margin-bottom:6pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selected geographic area information was as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,621 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,031 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,131 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,652 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,134 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 507000000 422000000 1621000000 970000000 624000000 468000000 2031000000 1164000000 1131000000 890000000 3652000000 2134000000 <div><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13. Retirement Benefits</span></div><div><span><br/></span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes net periodic benefit cost (income) relating to our defined benefit <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNzMwMGRmZTU3YTQyMmRhNzYzODgyMmI4MDlmZjNjL3NlYzphYjczMDBkZmU1N2E0MjJkYTc2Mzg4MjJiODA5ZmYzY185MS9mcmFnOmZlOWNhNDc4MWM5NjQyZTZiMTNiZDgzYjgzNjVkMjg3L3RleHRyZWdpb246ZmU5Y2E0NzgxYzk2NDJlNmIxM2JkODNiODM2NWQyODdfNDg3_4f8e5ed4-02e7-483e-9888-697e10769684">pension plans</span>:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial loss</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net curtailments and settlements (Note 5)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost (income)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost other than service cost and net curtailments and settlements are included in other (income) expense, net in our condensed consolidated statements of operations. Net curtailments and settlements are included in asset impairment, restructuring and other special charges, in our condensed consolidated statements of operations.</span></div> <div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes net periodic benefit cost (income) relating to our defined benefit <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNzMwMGRmZTU3YTQyMmRhNzYzODgyMmI4MDlmZjNjL3NlYzphYjczMDBkZmU1N2E0MjJkYTc2Mzg4MjJiODA5ZmYzY185MS9mcmFnOmZlOWNhNDc4MWM5NjQyZTZiMTNiZDgzYjgzNjVkMjg3L3RleHRyZWdpb246ZmU5Y2E0NzgxYzk2NDJlNmIxM2JkODNiODM2NWQyODdfNDg3_4f8e5ed4-02e7-483e-9888-697e10769684">pension plans</span>:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial loss</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net curtailments and settlements (Note 5)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost (income)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:3pt double #000;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 4000000 3000000 14000000 8000000 1000000 0 2000000 1000000 2000000 2000000 5000000 4000000 -1000000 -2000000 -5000000 -6000000 0 -1000000 -1000000 -2000000 9000000 0 26000000 0 -7000000 0 -19000000 1000000 <div><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 14. Loss Per Share</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We compute basic loss per share by dividing net loss available to common shareholders by the actual weighted average number of common shares outstanding for the reporting period. Elanco has variable common stock equivalents relating to certain equity awards in stock-based compensation arrangements and the TEU prepaid stock purchase contracts (see Note 7: Equity for further discussion). Diluted earnings per share reflects the potential dilution that could occur if holders of the unvested equity awards and unsettled TEUs converted their holdings into common stock. The weighted average number of potentially dilutive shares outstanding is calculated using the treasury stock method. Potential common shares that would have the effect of increasing diluted earnings per share (or reducing loss per share) are considered to be anti-dilutive and as such, these shares are not included in the calculation of diluted loss per share. </span></div><div style="padding-left:9pt;text-align:justify"><span><br/></span></div><div style="padding-left:9pt;text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted loss per share are calculated as follows:</span></div><div style="padding-left:9pt;text-align:justify;text-indent:4.5pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss available to common shareholders</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(375)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Determination of shares:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487.3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462.4</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487.1 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed conversion of dilutive common stock equivalents </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average shares outstanding</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487.3 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462.4</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487.1 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.29)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.77)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.56)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">During the three and nine months ended September 30, 2021 and 2020, we reported a net loss. Therefore, dilutive common stock equivalents are not assumed to have been issued since their effect is anti-dilutive. As a result, basic and diluted weighted average shares are the same, causing diluted net loss per share to be equivalent to basic net loss per share. For the three months ended September 30, 2021 and 2020, approximately 1.7 million and 1.6 million, respectively, of potential common shares were excluded from the calculation of diluted earnings per share because their effect was anti-dilutive. For the nine months ended September 30, 2021 and 2020, approximately 1.6 million and 1.9 million, respectively, of potential common shares were excluded from the calculation of diluted earnings per share because their effect was anti-dilutive.</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Due to rounding conventions, loss per share may not recalculate precisely based on the amounts presented within this table.</span></div> <div style="padding-left:9pt;text-align:justify;text-indent:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted loss per share are calculated as follows:</span></div><div style="padding-left:9pt;text-align:justify;text-indent:4.5pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss available to common shareholders</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(375)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Determination of shares:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487.3 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462.4</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487.1 </span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assumed conversion of dilutive common stock equivalents </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average shares outstanding</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487.3 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462.4</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487.1 </span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.29)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.77)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.56)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">During the three and nine months ended September 30, 2021 and 2020, we reported a net loss. Therefore, dilutive common stock equivalents are not assumed to have been issued since their effect is anti-dilutive. As a result, basic and diluted weighted average shares are the same, causing diluted net loss per share to be equivalent to basic net loss per share. For the three months ended September 30, 2021 and 2020, approximately 1.7 million and 1.6 million, respectively, of potential common shares were excluded from the calculation of diluted earnings per share because their effect was anti-dilutive. For the nine months ended September 30, 2021 and 2020, approximately 1.6 million and 1.9 million, respectively, of potential common shares were excluded from the calculation of diluted earnings per share because their effect was anti-dilutive.</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.65pt">Due to rounding conventions, loss per share may not recalculate precisely based on the amounts presented within this table.</span></div> -104000000 -135000000 -375000000 -237000000 487300000 462400000 487100000 426500000 0 0 0 0 487300000 462400000 487100000 426500000 -0.21 -0.29 -0.77 -0.56 -0.21 -0.29 -0.77 -0.56 1700000 1600000 1600000 1900000 <div><span style="color:#0071cd;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 15. Transactions and Agreements with Bayer </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> While Bayer is no longer considered a related party, we have transacted with Bayer during the period after the acquisition of Bayer Animal Health, including the period in which Bayer was considered a principal owner of Elanco. These transactions primarily related to local country asset purchases and various transitional services agreements (TSAs), contract manufacturing arrangements, and certain lease agreements to ensure business continuity after the acquisition.</span></div><div style="text-align:justify;text-indent:9pt"><span><br/></span></div><div style="text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For regulatory purposes in certain jurisdictions, consideration was required to be paid locally at closing in addition to amounts paid globally for the acquisition. Pursuant to the stock and asset purchase agreement, Bayer has provided a refund for payment amounts duplicated in these regions. The total amount paid to and received from Bayer during the nine months ended September 30, 2021 for these local country asset purchases was approximately $16 million. All local country asset purchases have been completed as of September 30, 2021.</span></div> 16000000 Represent amounts associated with transactions between us and Eli Lilly and Company (Lilly), related primarily to the completion of the local country asset purchases, the finalization of assets and liabilities associated with the legal separation from Lilly, centralized cash management, and resulting impacts on deferred tax assets, that occurred subsequent to our initial public offering XML 12 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover Page - shares
 9 Months Ended
Sep. 30, 2021
Nov. 01, 2021
Document Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2021  
Document Transition Report false  
Entity File Number 001-38661  
Entity Registrant Name Elanco Animal Health Inc  
Entity Incorporation, State or Country Code IN  
Entity Tax Identification Number 82-5497352  
Entity Address, Address Line One 2500 INNOVATION WAY  
Entity Address, City or Town GREENFIELD  
Entity Address, State or Province IN  
Entity Address, Postal Zip Code 46140  
City Area Code 877  
Local Phone Number 352-6261  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding (in shares)   473,098,643
Amendment Flag false  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q3  
Entity Central Index Key 0001739104  
Current Fiscal Year End Date --12-31  
Common stock, no par value    
Document Information [Line Items]    
Title of 12(b) Security Common stock, no par value  
Trading Symbol ELAN  
Security Exchange Name NYSE  
5.00% Tangible Equity Units    
Document Information [Line Items]    
Title of 12(b) Security 5.00% Tangible Equity Units  
Trading Symbol ELAT  
Security Exchange Name NYSE  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Income Statement [Abstract]        
Revenue $ 1,131 $ 890 $ 3,652 $ 2,134
Costs, expenses and other:        
Cost of sales 502 442 1,622 1,071
Research and development 94 88 277 214
Marketing, selling and administrative 342 278 1,075 623
Amortization of intangible assets 141 96 417 197
Asset impairment, restructuring and other special charges 111 262 518 456
Interest expense, net of capitalized interest 60 48 181 89
Other (income) expense, net 11 (115) 8 (162)
Costs, expenses and other 1,261 1,099 4,098 2,488
Loss before income taxes (130) (209) (446) (354)
Income tax benefit (26) (74) (71) (117)
Net loss $ (104) $ (135) $ (375) $ (237)
Loss per share:        
Basic (usd per share) $ (0.21) $ (0.29) $ (0.77) $ (0.56)
Diluted (usd per share) $ (0.21) $ (0.29) $ (0.77) $ (0.56)
Weighted average shares outstanding:        
Basic (in shares) 487.3 462.4 487.1 426.5
Diluted (in shares) 487.3 462.4 487.1 426.5
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Statement of Comprehensive Income [Abstract]        
Net loss $ (104) $ (135) $ (375) $ (237)
Other comprehensive income (loss):        
Unrealized gain (loss) on derivatives for cash flow hedges, net of taxes 4 (7) 52 (67)
Foreign currency translation (209) 101 (506) 121
Defined benefit pension and retiree health benefit plans, net of taxes (6) (1) 5 (2)
Other comprehensive income (loss), net of taxes (211) 93 (449) 52
Comprehensive loss $ (315) $ (42) $ (824) $ (185)
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Current Assets    
Cash and cash equivalents $ 453 $ 495
Accounts receivable, net of allowances of $11 (2021) and $9 (2020) 924 872
Other receivables 158 205
Inventories 1,383 1,578
Prepaid expenses and other 242 256
Restricted cash 0 11
Total current assets 3,160 3,417
Noncurrent Assets    
Goodwill 6,191 6,225
Other intangibles, net 5,816 6,387
Other noncurrent assets 357 348
Property and equipment, net of accumulated depreciation of $1,050 (2021) and $1,038 (2020) 1,041 1,316
Total assets 16,565 17,693
Current Liabilities    
Accounts payable 436 501
Employee compensation 159 144
Sales rebates and discounts 316 295
Current portion of long-term debt 61 555
Other current liabilities 390 582
Total current liabilities 1,362 2,077
Noncurrent Liabilities    
Long-term debt 6,273 5,572
Accrued retirement benefits 302 346
Deferred taxes 726 900
Other noncurrent liabilities 220 322
Total liabilities 8,883 9,217
Commitments and Contingencies 0 0
Equity    
Preferred stock, no par value, 1,000,000,000 shares authorized; none issued 0 0
Common stock, no par value, 5,000,000,000 shares authorized, 473,033,625 and 471,921,116 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively 0 0
Additional paid-in capital 8,680 8,650
Accumulated deficit (852) (477)
Accumulated other comprehensive income (loss) (146) 303
Total equity 7,682 8,476
Total liabilities and equity $ 16,565 $ 17,693
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Accounts receivable, net of allowances $ 11 $ 9
Property and equipment, net of accumulated depreciation $ 1,050 $ 1,038
Preferred stock, shares authorized (in shares) 1,000,000,000 1,000,000,000
Preferred stock, shares issued (in shares) 0 0
Common stock, shares authorized (in shares) 5,000,000,000 5,000,000,000
Common stock, shares issued (in shares) 473,033,625 471,921,116
Common stock, shares outstanding (in shares) 473,033,625 471,921,116
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Equity (Unaudited) - USD ($)
shares in Millions, $ in Millions
Total
Cumulative Effect, Period of Adoption, Adjustment
Common Stock
Additional Paid-in Capital
Retained Earnings (Accumulated Deficit)
Retained Earnings (Accumulated Deficit)
Cumulative Effect, Period of Adoption, Adjustment
Accumulated Other Comprehensive Income (Loss)
Cash Flow Hedge Gain (Loss)
Foreign Currency Translation
Defined Benefit Pension and Retiree Health Benefit Plans
Balance at beginning of period (in shares) at Dec. 31, 2019     373.0              
Balance at beginning of period at Dec. 31, 2019 $ 5,546 $ (1) $ 0 $ 5,636 $ 84 $ (1) $ (174)   $ (199) $ 25
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net loss (49)       (49)          
Other comprehensive income (loss), net of tax (69)           (69) $ (39) (29) (1)
Separation activities [1] 16     16            
Stock compensation 11     11            
Issuance of stock under employee stock plans, net (in shares)     0.8              
Issuance of stock under employee stock plans, net (13)     (13)            
Issuance of common stock, net of issuance costs (in shares)     25.0              
Issuance of common stock, net of issuance costs 768     768            
Issuance of tangible equity units, net of issuance costs 452     452            
Balance at end of period (in shares) at Mar. 31, 2020     398.8              
Balance at end of period at Mar. 31, 2020 6,661   $ 0 6,870 34   (243) (39) (228) 24
Balance at beginning of period (in shares) at Dec. 31, 2019     373.0              
Balance at beginning of period at Dec. 31, 2019 5,546 $ (1) $ 0 5,636 84 $ (1) (174)   (199) 25
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net loss (237)                  
Other comprehensive income (loss), net of tax 52                  
Balance at end of period (in shares) at Sep. 30, 2020     471.9              
Balance at end of period at Sep. 30, 2020 8,344   $ 0 8,620 (154)   (122) (67) (77) 22
Balance at beginning of period (in shares) at Mar. 31, 2020     398.8              
Balance at beginning of period at Mar. 31, 2020 6,661   $ 0 6,870 34   (243) (39) (228) 24
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net loss (53)       (53)          
Other comprehensive income (loss), net of tax 28           28 (21) 50 (1)
Separation activities [1] 9     9            
Stock compensation 8     8            
Issuance of stock under employee stock plans, net (in shares)     0.1              
Issuance of stock under employee stock plans, net (1)     (1)            
Balance at end of period (in shares) at Jun. 30, 2020     398.9              
Balance at end of period at Jun. 30, 2020 6,652   $ 0 6,886 (19)   (215) (60) (178) 23
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net loss (135)       (135)          
Other comprehensive income (loss), net of tax 93           93 (7) 101 (1)
Stock compensation 11     11            
Issuance of stock under employee stock plans, net (in shares)     0.1              
Issuance of stock under employee stock plans, net 0     0            
Issuance of stock to Bayer for acquisition, net of issuance costs (in shares)     72.9              
Issuance of stock to Bayer for acquisition, net of issuance costs 1,723     1,723            
Balance at end of period (in shares) at Sep. 30, 2020     471.9              
Balance at end of period at Sep. 30, 2020 8,344   $ 0 8,620 (154)   (122) (67) (77) 22
Balance at beginning of period (in shares) at Dec. 31, 2020     471.9              
Balance at beginning of period at Dec. 31, 2020 8,476   $ 0 8,650 (477)   303 (61) 360 4
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net loss (61)       (61)          
Other comprehensive income (loss), net of tax (405)           (405) 53 (466) 8
Stock compensation 15     15            
Issuance of stock under employee stock plans, net (in shares)     1.1              
Issuance of stock under employee stock plans, net (18)     (18)            
Balance at end of period (in shares) at Mar. 31, 2021     473.0              
Balance at end of period at Mar. 31, 2021 8,007   $ 0 8,647 (538)   (102) (8) (106) 12
Balance at beginning of period (in shares) at Dec. 31, 2020     471.9              
Balance at beginning of period at Dec. 31, 2020 8,476   $ 0 8,650 (477)   303 (61) 360 4
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net loss (375)                  
Other comprehensive income (loss), net of tax (449)                  
Balance at end of period (in shares) at Sep. 30, 2021     473.0              
Balance at end of period at Sep. 30, 2021 7,682   $ 0 8,680 (852)   (146) (9) (146) 9
Balance at beginning of period (in shares) at Mar. 31, 2021     473.0              
Balance at beginning of period at Mar. 31, 2021 8,007   $ 0 8,647 (538)   (102) (8) (106) 12
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net loss (210)       (210)          
Other comprehensive income (loss), net of tax 167           167 (5) 169 3
Stock compensation 16     16            
Balance at end of period (in shares) at Jun. 30, 2021     473.0              
Balance at end of period at Jun. 30, 2021 7,980   $ 0 8,663 (748)   65 (13) 63 15
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Net loss (104)       (104)          
Other comprehensive income (loss), net of tax (211)           (211) 4 (209) (6)
Stock compensation 17     17            
Balance at end of period (in shares) at Sep. 30, 2021     473.0              
Balance at end of period at Sep. 30, 2021 $ 7,682   $ 0 $ 8,680 $ (852)   $ (146) $ (9) $ (146) $ 9
[1] Represent amounts associated with transactions between us and Eli Lilly and Company (Lilly), related primarily to the completion of the local country asset purchases, the finalization of assets and liabilities associated with the legal separation from Lilly, centralized cash management, and resulting impacts on deferred tax assets, that occurred subsequent to our initial public offering
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Cash Flows from Operating Activities    
Net loss $ (375) $ (237)
Adjustments to reconcile net loss to cash flows from operating activities:    
Depreciation and amortization 542 295
Change in deferred income taxes (119) (160)
Stock-based compensation expense 48 31
Asset impairment and write-down charges 334 5
Gain on sale of assets   (51)
Loss (gain) on divestitures 2 (170)
Inventory fair value step-up amortization 64 33
Changes in operating assets and liabilities, net of acquisitions (243) 291
Other non-cash operating activities, net 7 15
Net Cash Provided by Operating Activities 260 52
Cash Flows from Investing Activities    
Net purchases of property and equipment (60) (16)
Cash paid for acquisitions, net of cash acquired (342) (5,001)
Proceeds from settlement of net investment hedges 0 33
Proceeds from product divestitures 0 435
Purchases of intangible assets (35) 0
Purchases of software (11) (148)
Other investing activities, net (8) (8)
Net Cash Used for Investing Activities (456) (4,705)
Cash Flows from Financing Activities    
Repayments of borrowings (555) (684)
Net proceeds from revolving credit facility 250 0
Proceeds from issuance of long-term debt 500 4,554
Proceeds from issuance of common stock and tangible equity units 0 1,220
Debt issuance costs (1) (103)
Other net financing transactions with Lilly (11) 0
Other financing activities, net (17) (15)
Net Cash Provided by Financing Activities 166 4,972
Effect of exchange rate changes on cash and cash equivalents (23) 7
Net increase (decrease) in cash, cash equivalents and restricted cash (53) 326
Cash, cash equivalents and restricted cash at beginning of period 506 345
Cash, cash equivalents and restricted cash at end of period 453 671
Cash and cash equivalents 453 660
Restricted cash 0 11
Cash, cash equivalents and restricted cash $ 453 $ 671
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Basis of Presentation and Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation and Summary of Significant Accounting Policies
Note 1. Basis of Presentation and Summary of Significant Accounting Policies

Elanco Animal Health Incorporated (Elanco Parent) and its subsidiaries (collectively, Elanco, the Company, we, us, or our) is a premier animal health company that innovates, develops, manufactures and markets products for pets and farm animals.

Elanco was originally a wholly owned subsidiary of Eli Lilly and Company (Lilly). Elanco Parent, formed as the ultimate parent company of substantially all of the animal health businesses of Lilly, completed an initial public offering (IPO) in September 2018 and Lilly completed the disposition of all of its ownership interest in Elanco in March 2019.

We have prepared the accompanying unaudited condensed consolidated financial statements in accordance with the United States (U.S.) Securities and Exchange Commission (SEC) requirements for interim reporting. As permitted under those rules, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the U.S. (GAAP) have been condensed or omitted. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated and combined financial statements and accompanying notes for the year ended December 31, 2020 included in our Annual Report on Form 10-K filed with the SEC on March 1, 2021. In addition, results for interim periods should not be considered indicative of results for any other interim period or for the full year ending December 31, 2021 or any other future period.

In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates.

The significant accounting policies set forth in Note 4 to the consolidated and combined financial statements in our Annual Report on Form 10-K for the year ended December 31, 2020 appropriately represent, in all material respects, the current status of our accounting policies, except as it relates to the adoption of the standard that was effective January 1, 2021 as described in Note 2: Implementation of New Financial Accounting Pronouncements.

On August 1, 2020 and August 27, 2021 we completed the acquisitions of Bayer Animal Health and KindredBio, respectively. See Note 4: Acquisitions and Divestitures for additional information.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.21.2
Implementation of New Financial Accounting Pronouncements
 9 Months Ended
Sep. 30, 2021
Accounting Changes and Error Corrections [Abstract]  
Implementation of New Financial Accounting Pronouncements
Note 2. Implementation of New Financial Accounting Pronouncements

The following table provides a brief description of an accounting standard that was effective January 1, 2021 and was adopted on that date:
StandardDescriptionEffect on the financial statements or other significant matters
Accounting Standards Update (ASU) 2019-12, Simplifying the Accounting for Income Taxes
The amendments in this update include simplifications related to accounting for income taxes including removing certain exceptions related to the approach for intraperiod tax allocation and the recognition of deferred tax liabilities for outside basis differences. The standard also clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The adoption of this guidance did not have a material impact on our consolidated financial statements.
The following table provides a brief description of an accounting standard that is applicable to us but has not yet been adopted:
StandardDescriptionEffective DateEffect on the financial statements or other significant matters
ASU 2020-04, Reference rate reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting; ASU 2021-01, Reference Rate Reform (Topic 848): Scope
ASU 2020-04 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. ASU 2021-01 clarifies the scope of Topic 848 so that derivatives affected by the discounting transition are explicitly eligible for certain optional expedients and exceptions.These standards were effective as of March 12, 2020 through December 31, 2022 and adoption is permitted at any time during the period on a prospective basis.We are currently in the process of evaluating the impact of the London Interbank Offered Rate (LIBOR) on our existing contracts and may elect optional expedients in future periods as reference rate reform activities occur. We do not expect that these updates will have a material impact on our consolidated financial statements.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue
 9 Months Ended
Sep. 30, 2021
Revenue from Contract with Customer [Abstract]  
Revenue
Note 3. Revenue

Our sales rebates are based on specific agreements. The most significant of our sales rebate programs in terms of accrual and payment amounts, percentage of our products that are sold via these programs, and level of judgment required in estimating the appropriate transaction price, relate to our programs in the U.S., France and the United Kingdom (U.K.). As of September 30, 2021 and 2020, the aggregate liability for sales rebates for these countries represented approximately 72% and 74%, respectively, of our total liability.

The following table summarizes the activity in our global sales rebates liability:
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Beginning balance$303 $164 $295 $211 
Bayer Animal Health at acquisition— 78 — 78 
Reduction of revenue163 145 516 316 
Payments(150)(108)(495)(326)
Ending balance$316 $279 $316 $279 

Adjustments to revenue recognized as a result of changes in estimates for the judgments described above during the three and nine months ended September 30, 2021 and 2020 for product shipped in previous periods were not material.

Actual global product returns were approximately 2% and less than 1% of net revenue for the three months ended September 30, 2021 and 2020, respectively. Actual global product returns were approximately 1% of net revenue for the nine months ended September 30, 2021 and 2020.
Disaggregation of Revenue

In the first quarter of 2021, management revisited how it analyzes revenue, both internally and externally, and determined that disaggregation by major product line provides a more meaningful view of our results. Accordingly, we updated our disaggregated revenue presentation from the previous five categories (i.e., pet health disease prevention, pet health therapeutics, farm animal future protein & health, farm animal ruminants & swine, and contract manufacturing) to the following:
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Pet Health$527 $401 $1,857 $861 
Farm Animal583 473 1,728 1,222 
Contract Manufacturing (1)
21 16 67 51 
Revenue$1,131 $890 $3,652 $2,134 
(1)Represents revenue from arrangements in which we act as a contract manufacturer, including supply agreements associated with divestitures of products related to the acquisition of Bayer Animal Health.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.21.2
Acquisitions and Divestitures
 9 Months Ended
Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]  
Acquisitions and Divestitures
Note 4. Acquisitions and Divestitures

During 2021 and 2020, we completed the acquisitions of KindredBio and Bayer Animal Health, respectively. These transactions were accounted for as business combinations under the acquisition method of accounting. The acquisition method requires, among other things, that assets acquired and liabilities assumed in a business combination be recognized at their fair values as of the acquisition date. The determination of estimated fair value requires management to make significant estimates and assumptions. The excess of the purchase price over the fair value of the acquired net assets, where applicable, has been recorded as goodwill. The results of operations of these acquisitions are included in our condensed consolidated financial statements from the dates of acquisition.

KindredBio Acquisition

On August 27, 2021, we acquired KindredBio, a publicly traded biopharmaceutical company that develops innovative biologics focused on saving and improving the lives of pets. The acquisition further accelerates our pet health expansion, particularly by expanding our presence in dermatology. In connection with the merger agreement, we acquired all outstanding stock of KindredBio for $9.25 per share, or an aggregate cash purchase consideration of $444 million. We utilized our revolving credit facility and cash on hand to finance the acquisition. Refer to Note 8: Debt for further details.

During the three months ended June 30, 2021, we signed an agreement with KindredBio to acquire exclusive global rights to KIND-030, a monoclonal antibody that is being developed for the treatment and prevention of canine parvovirus. We calculated the fair value of the liability associated with that agreement using an income approach leveraging the estimated sales royalty, sales milestone and technical milestone payments avoided, and the $26 million liability was settled upon the closing of our acquisition of KindredBio. Refer to Note 5: Asset Impairment, Restructuring and Other Special Charges for further discussion.

We incurred transaction costs in connection with the KindredBio acquisition of $4 million and $6 million during the three and nine months ended September 30, 2021, respectively. Transaction costs were primarily associated with legal and other professional services related to the acquisition and are reflected within asset impairment, restructuring and other special charges in our condensed consolidated statements of operations.

Revenue and loss from KindredBio included in our condensed consolidated statements of operations since the date of acquisition for the three and nine months ended September 30, 2021 were immaterial.

The valuation of assets acquired and liabilities assumed has not yet been finalized as of September 30, 2021. The purchase price allocation is preliminary and subject to change, including the valuation of property and equipment, intangible assets, income taxes and goodwill. The amounts recognized will be finalized as the information necessary to complete the analysis is obtained, but no later than one year after the acquisition date.
The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:

Estimated Fair Value at August 27, 2021
Cash and cash equivalents$31 
Other net working capital1 
Property and equipment26 
Intangible assets, primarily acquired in-process research and development352 
Deferred income taxes(22)
Total identifiable net assets388 
Goodwill30 
Settlement of liability related to previous license agreement26 
Total consideration transferred$444 

Property and equipment is mostly composed of land, buildings, equipment (including laboratory equipment, furniture and fixtures, and computer equipment), and construction in progress. The fair value of property and equipment is currently equal to its net book value at the time of the acquisition, as we are in the process of gathering information to complete our fair value assessment.

The preliminary estimated fair values of acquired in-process research and development (IPR&D) were determined using the income approach, which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the cash flows an asset would generate over its remaining useful life. Some of the significant assumptions inherent in the development of these asset valuations include the estimated net cash flows for each year for each asset (including revenues, cost of sales, R&D expenses, marketing, selling and administrative expenses, and contributory asset charges), the appropriate discount rate necessary to measure the risk inherent in each future cash flow stream, the life cycle of each asset, the potential regulatory and commercial success risk, and competitive trends impacting the asset and each cash flow stream, as well as other factors. The fair value of acquired IPR&D as of September 30, 2021 is based on preliminary assumptions which are subject to change as we complete our valuation procedures.

The goodwill recognized from this acquisition is attributable primarily to KindredBio's assembled workforce. The majority of goodwill associated with this acquisition is not deductible for tax purposes.

Bayer Animal Health Acquisition

On August 1, 2020, we completed the acquisition of Bayer Animal Health. The acquisition has expanded our pet health product category, advancing our planned portfolio mix transformation and creating a better balance between our farm animal and pet health product categories. Our product portfolio and pipeline have been enhanced by the addition of Bayer Animal Health, which complements our commercial operations and international infrastructure while expanding our direct to retailer/e-commerce presence.

Total consideration transferred to Bayer and its subsidiaries for the acquisition is summarized as follows:

Cash consideration (1)
$5,054 
Fair value of Elanco common stock (2)
1,724 
Fair value of total consideration transferred$6,778 
(1)Includes initial cash consideration of $5,170 million less working capital and tax adjustments of $116 million.
(2)Represents the acquisition date fair value of 73 million shares of Elanco common stock at $23.64 per share. Per the terms of the stock and asset purchase agreement, the number of shares was based on approximately $2.3 billion divided by the 20-day volume-weighted average stock price as of the last day of trading before the closing of the acquisition (but subject to a 7.5% symmetrical collar centered on the baseline share number of approximately $2.3 billion divided by an initial share price of $33.60).
We recognized transaction costs related to the acquisition of Bayer Animal Health of $3 million and $93 million during the nine months ended September 30, 2021 and 2020, respectively. Transaction costs for the three months ended September 30, 2020 were $35 million. Transaction costs were primarily associated with financial advisory, legal and other professional services related to the acquisition and are reflected within asset impairment, restructuring and other special charges in our condensed consolidated statements of operations.

The amount of revenue attributable to Bayer Animal Health included in our condensed consolidated statements of operations for the three and nine months ended September 30, 2021 is $421 million and $1,509 million, respectively. Bayer Animal Health revenues were $196 million for both the three and nine months ended September 30, 2020. Based on our current operational structure, we have not recorded standalone costs for Bayer Animal Health after the date of the acquisition. As a result, we are unable to accurately determine earnings or loss attributable to Bayer Animal Health since the date of acquisition.

The following table summarizes the fair value of assets acquired and liabilities assumed as of the acquisition date:

Estimated Fair Value at August 1, 2020
Cash and cash equivalents$169 
Accounts receivable10 
Inventories487 
Prepaid expenses and other current assets60 
Property and equipment315 
Intangible assets:
Acquired in-process research and development 65 
Marketed products3,740 
Assets held for sale138 
Accounts payable and accrued liabilities(237)
Accrued retirement benefits(220)
Other noncurrent assets and liabilities, net (878)
Total identifiable net assets3,649 
Goodwill3,129 
Total consideration transferred$6,778 

The valuation of assets acquired and liabilities assumed was finalized during the second quarter of 2021. The measurement period adjustments recorded during 2021, which were made to reflect the facts and circumstances in existence as of the acquisition date, primarily related to the finalization of our fair value assessment of property and equipment located at the Shawnee, Kansas site (Shawnee), revised cash flow assumptions for marketed products, adjustments related to changes in inventory balances and gross margin assumptions, tax adjustments, and minor working capital adjustments. These adjustments resulted in a decrease to marketed products intangible assets of $210 million, a decrease to property and equipment of $32 million, a net decrease to working capital accounts and other non-current assets and liabilities of $14 million, and an increase to goodwill of $207 million.

Inventories comprised of $311 million, $81 million, $95 million in finished products, work in process, and raw materials, respectively. The estimate of fair value of finished products was determined based on net realizable value adjusted for the costs to complete the sales process, a reasonable profit allowance from the sales process, and estimated holding costs. The estimate of fair value of work in process was determined based on net realizable value adjusted for costs to complete the manufacturing process, costs of the sales process, a reasonable profit allowance for the remaining manufacturing and sales process effort, and an estimate of holding costs. The fair value of raw materials was determined to approximate book value. The net fair value step-up adjustment to inventories of $152 million has been amortized to cost of sales as the inventory is sold to customers. As of September 30, 2021, the fair value step-up adjustment has been fully amortized.

Property and equipment is mostly composed of land, buildings, equipment (including machinery, furniture and fixtures, and computer equipment), and construction in progress. The estimated fair value of real property was
determined using the sales comparison data valuation technique and personal property was determined using the direct replacement cost method. The estimated fair value of property and equipment located at the Shawnee, Kansas site was determined using the income approach.

Intangible assets relate to $65 million of IPR&D and $3,740 million of marketed products. The acquired definite-lived intangible assets are being amortized over a weighted-average estimated useful life of approximately 10 years on a straight-line basis. The estimated fair values of identifiable intangible assets were determined using the income approach. Some of the significant assumptions inherent in the development of these asset valuations include the estimated net cash flows for each year for each asset or product (including revenues, cost of sales, R&D expenses, marketing, selling and administrative expenses, and contributory asset charges), the appropriate discount rate necessary to measure the risk inherent in each future cash flow stream, the life cycle of each asset, the potential regulatory and commercial success risk, and competitive trends impacting the asset and each cash flow stream, as well as other factors.
    
Assets held for sale include $133 million of intangible assets, consisting of marketed products and IPR&D, and $5 million of inventory related to the divestitures of Drontal™, Profender™ and other products. See the Divestitures section below for further details.

Accrued retirement benefits primarily relate to certain Bayer Animal Health international subsidiaries that have underfunded defined benefit pension plans. We have recorded the fair value of these plans using assumptions and accounting policies similar to those disclosed in Note 19: Retirement Benefits to the consolidated and combined financial statements in our Annual Report on Form 10-K for the year ended December 31, 2020. Upon acquisition, the excess of projected benefit obligation over the fair value of plan assets was recognized as a liability and previously existing deferred actuarial gains and losses and unrecognized service costs or benefits were eliminated.

The goodwill recognized from this acquisition represents the value of additional growth platforms and an expanded revenue base as well as anticipated operational synergies and cost savings from the creation of a single combined global organization. The majority of goodwill associated with this acquisition is not deductible for tax purposes.

Pro forma financial information (unaudited)

The following table presents the estimated unaudited pro forma combined results of Elanco and Bayer Animal Health as if the acquisition of Bayer Animal Health had occurred on January 1, 2020:
Three Months Ended September 30, 2020Nine Months Ended September 30, 2020
Revenue$1,069 $3,308 
Loss before income taxes
(227)(392)

The supplemental pro forma financial information has been prepared using the acquisition method of accounting and is based on the historical financial information of Elanco and Bayer Animal Health. The supplemental pro forma financial information does not necessarily represent what the combined companies' revenue or results of operations would have been had the acquisition been completed on January 1, 2020, nor is it intended to be a projection of future operating results of the combined company. It also does not reflect any operating efficiencies or potential cost savings that might be achieved from synergies of combining Elanco and Bayer Animal Health.

The unaudited supplemental pro forma financial information reflects primarily pro forma adjustments related to divestitures; fair value estimates for property and equipment, intangibles and inventory; interest expense and amortization of debt issuance costs for the debt issuance to finance the acquisition of Bayer Animal Health. The unaudited supplemental pro forma financial information includes transaction charges associated with the acquisition. There are no material, nonrecurring pro forma adjustments directly attributable to the acquisition included in the reported pro forma revenue and loss before income taxes.
Divestitures

Shawnee and Speke divestitures

In the second quarter of 2021, as part of our strategy to optimize our manufacturing footprint, we announced an agreement with TriRx Pharmaceuticals (TriRx) to sell our manufacturing sites in Shawnee and Speke, U.K. (Speke), including the planned transfer of approximately 600 employees. In connection with these arrangements, we also entered into long-term manufacturing and supply agreements, under which TriRx will manufacture existing Elanco products at both sites upon the closing of the transactions. During the nine months ended September 30, 2021, we recorded a $271 million pre-tax charge to reduce the carrying value of the disposal groups to an amount equal to fair value less costs to sell in asset impairment, restructuring, and other special charges in our condensed consolidated statements of operations. Our fair value less costs to sell assessment includes the fair value of the favorable manufacturing and supply agreements, estimated using a combined income and market approach which incorporated Level 3 inputs. On August 1, 2021, we completed the sale of our Shawnee site and expect to receive gross cash proceeds of $51 million over a period of three years based on the terms of the agreement. This activity is considered non-cash investing activity within our condensed consolidated statements of cash flows for the nine months ended September 30, 2021. We expect to close the Speke transaction in the first quarter of 2022; therefore, the related assets are classified as held for sale as of September 30, 2021. See Note 5: Asset Impairment, Restructuring and Other Special Charges for further information.

Elanco and Bayer Animal Health product divestitures

In connection with advancing our efforts to secure the necessary regulatory clearances for our acquisition of Bayer Animal Health, we signed agreements in 2020 to divest the rights to manufacture and commercialize certain legacy Elanco products. In 2020, we signed agreements to divest the worldwide rights to Osurnia™ and Vecoxan™ and the U.S. rights to Capstar. In July 2020, we completed these sales, along with certain other immaterial divestitures. The transactions were accounted for as asset divestitures.

In 2020, we also signed an agreement to divest the worldwide rights to the legacy Elanco products Itrafungol™ and Clomicalm™ in connection with the required disposal of an early-stage IPR&D asset. We also made a payment during the nine months ended September 30, 2021 and accrued for future amounts we are required to pay to the buyer of the IPR&D asset to help fund their development costs for a set period of time. The divestiture closed during the nine months ended September 30, 2021. There were no proceeds received from the disposition of these assets and the resulting immaterial impact was recorded in other (income) expense, net in our condensed consolidated statements of operations. The related assets met the assets held for sale criteria as of December 31, 2020.

To allow the Bayer Animal Health acquisition to close on a timely basis, we signed agreements to divest the rights to the legacy Bayer Animal Health products Drontal and Profender within the U.K. and European Economic Area as well as other IPR&D. We completed the transactions, which were accounted for as asset divestitures, in August 2020. Drontal, Profender, and the IPR&D rights were acquired as part of the Bayer Animal Health acquisition. The related assets were classified as held for sale on the balance sheet as of the acquisition date and measured at fair value at the time of the acquisition; therefore, no gains were recognized on the sales. During the three months ended September 2020, a loss of $7 million was recorded on the sale of IPR&D as recognition of the potential income from the divestiture was constrained by revenue accounting standards.

There were additional marketed and pipeline products that we were required to dispose of in order to comply with regulatory requirements. These divestitures did not have a material effect on our operations, cash flows or financial position.

During the three and nine months ended September 30, 2020, we received gross cash proceeds of $435 million and recognized pre-tax gains of $156 million (net of transaction costs of $13 million) relating to the product divestitures described above. Pre-tax gains were included in other (income) expense, net in our condensed consolidated statements of operations.
Assets Held For Sale

Assets and liabilities considered held for sale in connection with the above divestitures were included in the respective line items on our condensed consolidated balance sheets as follows:
September 30, 2021December 31, 2020
Inventories$38 $2 
Other intangibles, net— 4 
Property and equipment, net55 — 
Deferred tax asset— 1 
Total assets held for sale$93 $7 

Other intangibles, net classified as held for sale primarily consisted of marketed products.

Microbiome R&D platform carve-out

On October 5, 2021, we announced our intention to carve out our microbiome R&D platform, aiming to create a privately funded, independent, biopharmaceutical company focused on developing solutions for animal and human health. We are exploring structures with both strategic and financial sponsors, and may retain a minority stake in this new entity. The potential carve-out is expected to be completed by the end of the first quarter of 2022 and assets transferred are not expected to be material. We determined that the disposal of the related net assets does not qualify for reporting as a discontinued operation because it does not represent a strategic shift that has or will have a major effect on our operations and financial results.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Asset Impairment, Restructuring and Other Special Charges
 9 Months Ended
Sep. 30, 2021
Restructuring and Related Activities [Abstract]  
Asset Impairment, Restructuring and Other Special Charges
Note 5. Asset Impairment, Restructuring and Other Special Charges

In recent years, we have incurred substantial costs associated with restructuring programs and cost-reduction initiatives designed to achieve a flexible and competitive cost structure. Restructuring activities primarily include charges associated with facility rationalization and workforce reductions. In connection with our recent acquisitions, including the acquisitions of Bayer Animal Health and KindredBio, we have also incurred costs associated with executing transactions and integrating acquired operations, which may include expenditures for banking, legal, accounting, and other similar services. In addition, we have incurred costs to stand up our organization as an independent company. All operating functions can be impacted by these actions; therefore, non-cash expenses associated with our tangible and intangible assets can be incurred as a result of revised fair value projections and/or determinations to no longer utilize certain assets in the business on an ongoing basis.

For finite-lived intangible asset and other long-lived assets, whenever impairment indicators are present, we calculate the undiscounted value of projected cash flows associated with the asset, or group of assets, and compare it to the carrying amount. If the carrying amount is greater, we record an impairment loss for the excess of book value over fair value. Determinations of fair value can result from a complex series of judgments and rely on estimates and assumptions. See Note 1: Basis of Presentation and Summary of Significant Accounting Policies for discussion regarding estimates and assumptions.
Components of asset impairment, restructuring and other special charges are as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Restructuring charges:
Severance and other costs (1)
$(2)$130 $26 $131 
Facility exit costs (1)
— — — 1 
Acquisition related charges:
Transaction and integration costs (2)
30 131 141 318 
Non-cash and other items:
Asset impairment (3)
50 — 63 4 
Asset write-down (4)
6 1 275 3 
Gain on sale of fixed assets (5)
— — — (4)
Settlements and other (6)
27 — 13 3 
Total expense$111 $262 $518 $456 
(1)For the nine months ended September 30, 2021, these charges primarily related to a restructuring program announced and initiated in January 2021. These costs were partially offset by the reversal of severance accruals associated with the January 2021 and September 2020 programs during the period. See below for further details.
For the three and nine months ended September 30, 2020, these charges primarily related to a restructuring program announced and initiated in September 2020. See below for further details.
(2)Transaction costs represent external costs directly related to acquiring businesses and primarily include expenditures for banking, legal, accounting and other similar services. Integration costs represent internal and external incremental costs directly related to integrating acquired businesses, including the acquisitions of KindredBio and Bayer Animal Health (e.g., expenditures for consulting, system and process integration, and product transfers), as well as independent company stand-up costs related to the implementation of new systems, programs, and processes.
(3)Asset impairment charges for the three and nine months ended September 30, 2021 related to adjustments to the fair value of IPR&D assets that were subject to product rationalization. The asset impairment charge during the three months ended September 30, 2021 reflects a decision by management to terminate an IPR&D project and fully impair the related asset, which is associated with a farm animal parasiticide. The decision was prompted by unfavorable efficacy results observed during the quarter.
Asset impairment charges for the nine months ended September 30, 2020 related to the impairment of an IPR&D asset resulting from product rationalization and a reassessment of geographic viability.
(4)Asset write-down expenses for the nine months ended September 30, 2021 include the initial adjustments recorded to write down the Shawnee and Speke assets classified as held for sale as of June 30, 2021 to an amount equal to estimated fair value less costs to sell, as well as adjustments to values of assets sold in relation to the Shawnee manufacturing site sold on August 1, 2021 and assets classified as held for sale in relation to the future sale of the Speke manufacturing site during the three months ended September 30, 2021. See Note 4: Acquisitions and Divestitures for further discussion. Other charges for the nine months ended September 30, 2021 include adjustments recorded to write down assets in Belford Roxo, Brazil; Basel, Switzerland; Cuxhaven, Germany; and Manukau, New Zealand that were classified as held and used to their current fair value. These charges were recorded in connection with the January 2021 and September 2020 restructuring programs.
Asset write-down expenses for the three and nine months ended September 30, 2020 resulted from adjustments recorded to write down assets classified as held and used to their current fair value. These charges primarily related to fixed assets in Wusi, China in connection with the announced 2019 program to streamline operations.
(5)Represents a gain on the disposal from the sale of an R&D facility in Prince Edward Island, Canada.
(6)Settlements and other expenses for the three and nine months ended September 30, 2021 include a charge associated with the settlement of a liability for future royalty and milestone payments triggered in connection with our acquisition of KindredBio as discussed further in Note 4: Acquisitions and Divestitures, accounting and advisory fees related to the sale of our manufacturing site in Shawnee, and an $8 million charge related to a litigation settlement for a matter that originated prior to our acquisition of Bayer Animal Health, partially offset by net curtailment and settlement gains from the remeasurement of our pension benefit obligation as a result of workforce reductions in connection with our September 2020 and January 2021 restructuring programs. See Note 13: Retirement Benefits for further information. The amount for the nine months ended September 30, 2021 also includes the gain recorded on the divestiture of an early-stage IPR&D asset acquired as part of the Bayer Animal Health acquisition.
Settlements and other expenses for the three and nine months ended September 30, 2020 relate to a non-recurring litigation settlement for a matter that originated prior to our separation from Lilly.
In January 2021, we announced a restructuring aligned with our ongoing efforts to improve operating efficiencies. The proposed actions focused on streamlining processes and delivering increased efficiency in functional areas, while improving the productivity of our investments in innovation. As part of the restructuring plan, we closed our R&D sites in Manukau, New Zealand and Cuxhaven, Germany. We have also reduced duplication and optimized structures in U.S. operations, marketing, manufacturing and quality central functions, and administrative areas. The restructuring resulted in the elimination of approximately 330 positions around the world. Activities related to this initiative resulted in favorable adjustments of $1 million and charges of $44 million during the three and nine months ended September 30, 2021, respectively. The favorable adjustments reflect a change in estimate resulting from ongoing negotiations. Initiatives under this program are expected to be substantially completed by the end of 2021.

In September 2020, following the closing of the Bayer Animal Health acquisition, we implemented a restructuring program designed to reduce duplication, drive efficiency and optimize our footprint in key geographies. As part of the restructuring plan, we have eliminated approximately 900 positions across 40 countries, primarily in the commercial and marketing functions, but also in R&D, manufacturing and quality, and back office support functions. During the three and nine months ended September 30, 2021 we recorded favorable adjustments of $1 million and $15 million, respectively, as a change in estimate related to this initiative, which reflects adjustments to severance accruals resulting from favorable negotiations and certain restructured employees filling open positions. Initiatives under this program are expected to be substantially completed by the end of 2021.

The following table summarizes the activity in our reserves established in connection with restructuring activities:
Facility exit costs SeveranceTotal
Balance at December 31, 2019$5 $16 $21 
Charges1 132 133 
Reserve adjustments— (1)(1)
Cash paid(1)(15)(16)
Balance at September 30, 2020$5 $132 $137 
Balance at December 31, 2020$— $130 $130 
Charges— 41 41 
Reserve adjustments— (15)(15)
Cash paid— (95)(95)
Balance at September 30, 2021$— $61 $61 

These reserves are included in other current and noncurrent liabilities on our condensed consolidated balance sheets. Substantially all of the reserves are expected to be paid in the next 15 months primarily due to certain country negotiations and regulations. We believe that the reserves are adequate.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Inventories
 9 Months Ended
Sep. 30, 2021
Inventory Disclosure [Abstract]  
Inventories
Note 6. Inventories

We state all inventories at the lower of cost or net realizable value. We use the last-in, first-out (LIFO) method for a portion of our inventories located in the continental U.S. Other inventories are valued by the first-in, first-out (FIFO) method or the weighted average cost method.

Inventories consisted of the following:
September 30, 2021December 31, 2020
Finished products$595 $772 
Work in process576 625 
Raw materials and supplies255 210 
Total1,426 1,607 
Decrease to LIFO cost(43)(29)
Inventories$1,383 $1,578 
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.21.2
Equity
 9 Months Ended
Sep. 30, 2021
Equity [Abstract]  
Equity
Note 7. Equity

Common Stock Offering

On January 22, 2020, we entered into an underwriting agreement in which we agreed to sell approximately 23 million shares of our common stock at a public offering price of $32.00 per share. In connection with the offering, we granted the underwriters an option to purchase up to an additional 2 million shares, which was exercised in full on January 23, 2020. As a result, we issued and sold a total of approximately 25 million shares of our common stock for $768 million, after issuance costs.

Tangible Equity Unit (TEU) Offering

On January 22, 2020, we also completed our offering of 11 million, 5.00% TEUs. Total proceeds, net of issuance costs, were $528 million. Each TEU, which has a stated amount of $50, is comprised of a prepaid stock purchase contract (prepaid stock) and a senior amortizing note due February 1, 2023. Subsequent to issuance, each TEU may be legally separated into the two components. The prepaid stock is considered a freestanding financial instrument, indexed to Elanco common stock, and meets the conditions for equity classification.

The value allocated to the prepaid stock is reflected net of issuance costs in additional paid-in capital. The value allocated to the senior amortizing notes is reflected in long-term debt on the condensed consolidated balance sheets, with payments expected in the next twelve months reflected in current portion of long-term debt. Issuance costs related to the amortizing notes are reflected as a reduction of the carrying amount and will be amortized through the maturity date using the effective interest rate method.

The proceeds from the issuance were allocated to equity and debt based on the relative fair value of the respective components of each TEU as follows:
Equity ComponentDebt ComponentTotal
Fair value per unit$42.80 $7.20 $50.00 
Gross proceeds$471 $79 $550 
Less: Issuance costs19 3 22 
Net proceeds$452 $76 $528 

The senior amortizing notes have an aggregate principal amount of $79 million and bear interest at 2.75% per year. On each February 1, May 1, August 1, and November 1 until the maturity date, we will pay equal quarterly cash installments of $0.6250 per each amortizing note with an initial principal amount of $7.2007 (except for the first installment payment of $0.6528 per amortizing note paid on May 1, 2020). Each installment constitutes a payment of interest and partial payment of principal, and in the aggregate will be equivalent to 5.00% per year with respect to the $50 stated amount per TEU.

Unless settled early at the holder’s or our election, each prepaid stock purchase contract will automatically settle on February 1, 2023 (the mandatory settlement date) for a number of shares of common stock per contract based on the average of the volume-weighted average trading prices during the 20 consecutive trading day period beginning on, and including the 21st scheduled trading day immediately preceding February 1, 2023 (applicable market value) with reference to the following settlement rates:
Applicable Market ValueCommon Stock Issued
Equal to or greater than $38.40
1.3021 shares (minimum settlement rate)
Less than $38.40, but greater than $32.00
$50 divided by applicable market value
Less than or equal to $32.00
1.5625 (maximum settlement rate)
The prepaid stock purchase contracts are mandatorily convertible into a minimum of 14 million shares or a maximum of 17 million shares of our common stock on the mandatory settlement date (unless redeemed by us or settled earlier at the unit holder's option). The 14 million minimum shares are included in the calculation of basic weighted average shares outstanding. The difference between the minimum and maximum shares represents potentially dilutive securities, which are included in the calculation of diluted weighted average shares outstanding on a pro rata basis to the extent that the average applicable market value is higher than $32.00 but is less than $38.40 during the period.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Debt
 9 Months Ended
Sep. 30, 2021
Debt Disclosure [Abstract]  
Debt
Note 8. Debt

Long-term debt consisted of the following:
September 30, 2021December 31, 2020
Incremental Term Facility$500 $— 
Term Loan B4,129 4,164 
Revolving Credit Facility250 — 
3.912% Senior Notes due 2021
— 500 
4.272% Senior Notes due 2023
750 750 
4.900% Senior Notes due 2028
750 750 
TEU Amortizing Notes40 60 
Other obligations— 1 
Unamortized debt issuance costs(85)(98)
6,334 6,127 
Less current portion of long-term debt61 555 
Total long-term debt$6,273 $5,572 
Farm Credit Agreement

On August 12, 2021, we entered into a new debt financing arrangement with Farm Credit Mid-America, PCA (Farm Credit) for a $500 million credit facility, consisting of a senior secured term loan (Incremental Term Facility) to retire our existing Senior Notes due August 27, 2021. The Incremental Term Facility bears interest at a floating rate of LIBOR plus 175 basis points and is payable in quarterly installments with a final balloon payment due on August 12, 2028. The terms of the Incremental Term Facility, including pledged collateral and financial maintenance covenants, are generally consistent with the terms of our existing term loan B credit facility (Term Loan B) and revolving credit facility.

Bayer Animal Health Related Financing

In connection with the acquisition of Bayer Animal Health, on August 1, 2020, we borrowed $4,275 million under a Term Loan B facility. The Term Loan B bears interest at a floating rate of LIBOR plus 175 basis points and is payable in quarterly installments through August 1, 2027.
Simultaneously, we entered into a revolving credit facility providing up to $750 million (with incremental capacity available if certain conditions are met) and maturing over a five-year term. The revolving credit facility bears interest at LIBOR plus an applicable margin ranging between 1.50% and 2.25% per annum based on our corporate family rating or corporate credit rating. In February 2021, we drew down $150 million on the revolving credit facility for working capital needs. We subsequently repaid $100 million in March 2021 and the remaining $50 million in April 2021. In August 2021, we drew down $350 million on the revolving credit facility to partially fund the acquisition of KindredBio. We subsequently repaid $100 million in September 2021.
These senior secured first lien credit facilities are secured by a significant portion of our assets. They include two financial maintenance covenants which are solely for the benefit of lenders under the revolving credit facility. There are no financial maintenance covenants for the benefit of the Term Loan B facility. The lenders under the Term Loan B facility have no enforcement rights with respect to the financial maintenance covenants for the revolving credit facility.
The first financial maintenance covenant for the revolving credit facility requires us to maintain a net total leverage ratio level (which is not subject to step-downs) as of the end of each quarter. The required level of this covenant is based on closing date pro forma net leverage and pro forma adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) not exceeding 7.71 to 1.00 of our pro forma adjusted EBITDA for the four fiscal quarters ended September 30, 2021.

The second financial maintenance covenant for the revolving credit facility requires us to maintain a ratio of pro forma adjusted EBITDA to cash interest expense of no less than 2.00 to 1.00, tested as of the end of each fiscal quarter. We were in compliance with all covenants under the credit facility as of September 30, 2021.

Senior Notes

In August 2018, we issued $2 billion of senior notes (Senior Notes). The Senior Notes comprised of $500 million of 3.912% Senior Notes due August 27, 2021, which were fully repaid as part of the Farm Credit refinancing, $750 million of 4.272% Senior Notes due August 28, 2023, and $750 million of 4.900% Senior Notes due August 28, 2028. The interest rate payable on each series of Senior Notes is subject to adjustment if Moody's Investor Services, Inc. or Standard & Poor's Financial Services LLC downgrades, or subsequently upgrades, its ratings on the respective series of Senior Notes.
The indenture that governs the Senior Notes contains covenants that limit our, and certain of our subsidiaries' ability, to incur liens or engage in sale-leaseback transactions. The indenture also contains restrictions on our ability to consolidate, merge or sell substantially all of our assets, in addition, to other customary terms. We were in compliance with all such covenants under the indenture governing the Senior Notes as of September 30, 2021.
TEU Amortizing Notes

On January 22, 2020, we issued $550 million in TEUs. We offered 11 million, 5.00% TEUs at the stated amount of $50 per unit, comprised of prepaid stock purchase contracts and a senior amortizing note due February 1, 2023 (the mandatory settlement date). Total cash of $528 million was received, comprised of $452 million of prepaid stock purchase contracts and $76 million of senior amortizing notes, net of issuance costs. During the three and nine months ended September 30, 2021, we paid $7 million and $21 million, respectively, representing partial payment of principal and interest on the TEU amortizing notes. See Note 7: Equity for further information.

Debt Extinguishment

On January 31, 2020, we repaid indebtedness outstanding under our previous term loan facility. We paid $372 million in cash, composed of $371 million of principal and $1 million of accrued interest, resulting in a debt extinguishment loss of $1 million (recognized in interest expense, net of capitalized interest in our condensed consolidated statements of operations for the nine months ended September 30, 2020), primarily related to the write-off of deferred debt issuance costs.

On September 25, 2020, we made a repayment of principal of $100 million on the indebtedness outstanding under our Term Loan B. The repayment was accounted for as a partial debt extinguishment and resulted in a debt extinguishment loss of $2 million (recognized in interest expense, net of capitalized interest in the condensed consolidated statements of operations for the three and nine months ended September 30, 2020), primarily related to the write-off of deferred debt issuance costs.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.21.2
Financial Instruments and Fair Value
 9 Months Ended
Sep. 30, 2021
Fair Value Disclosures [Abstract]  
Financial Instruments and Fair Value
Note 9. Financial Instruments and Fair Value

Financial instruments that are potentially subject to credit risk consist principally of trade receivables. We evaluate the creditworthiness of our customers on a regular basis, monitor economic conditions, and calculate allowances for estimated credit losses on our trade receivables on a quarterly basis using an expected credit loss model. We assess whether collectability is probable at the time of sale and on an ongoing basis. Collateral is generally not required. The risk associated with this concentration is mitigated by our ongoing credit-review procedures.
A large portion of our cash is held by a few major financial institutions. We monitor the exposure with these institutions and do not expect any of these institutions to fail to meet their obligations. All highly liquid investments with a maturity of three months or less from the date of purchase are considered to be cash equivalents. The cost of these investments approximates fair value. We also consider the carrying value of restricted cash balances to be representative of its fair value.

We had investments without readily determinable fair values and equity method investments included in other noncurrent assets on our condensed consolidated balance sheets totaling $21 million and $24 million as of September 30, 2021 and December 31, 2020, respectively. Unrealized net gains and losses on our investments for the three and nine months ended September 30, 2021 and 2020 were immaterial.

The following table summarizes the fair value information at September 30, 2021 and December 31, 2020 for foreign exchange contract assets (liabilities), investments, contingent consideration liabilities, and cash flow hedge assets (liabilities) measured at fair value on a recurring basis in the respective balance sheet line items, as well as long-term debt (including TEU amortizing notes) for which fair value is disclosed on a recurring basis:
  Fair Value Measurements Using 
Financial statement line itemCarrying
Amount		Quoted Prices in Active Markets for Identical Assets
(Level 1)		Significant
Other Observable Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Fair
Value
September 30, 2021
Prepaid expenses and other - foreign exchange contracts not designated as hedging instruments$30 $— $30 $— $30 
Other noncurrent assets - investments15 15 — — 15 
Other current liabilities - foreign exchange contracts not designated as hedging instruments(30)— (30)— (30)
Other current liabilities - contingent consideration(1)— — (1)(1)
Other noncurrent liabilities - forward-starting interest rate contracts designated as cash flow hedges(24)— (24)— (24)
Long-term debt, including current portion(6,419)— (6,551)— (6,551)
December 31, 2020
Prepaid expenses and other - foreign exchange contracts not designated as hedging instruments$36 $— $36 $— $36 
Other noncurrent assets - investments9 9 — — 9 
Other current liabilities - foreign exchange contracts not designated as hedging instruments(36)— (36)— (36)
Other noncurrent liabilities - contingent consideration(1)— — (1)(1)
Other noncurrent liabilities - forward-starting interest rate contracts designated as cash flow hedges(76)— (76)— (76)
Long-term debt, including current portion(6,225)— (6,420)— (6,420)
We determine our Level 2 fair value measurements based on a market approach using quoted market values or significant other observable inputs for identical or comparable assets or liabilities.
Contingent consideration liabilities as of September 30, 2021 and December 31, 2020 related to contingent consideration associated with the acquisitions of Aratana Therapeutics, Inc. (Aratana) and Prevtec Microbia Inc. (Prevtec) during 2019. For Aratana, we will pay up to $12 million in contingent value rights that are dependent on the achievement of a specified milestone by December 31, 2021 as outlined in the merger agreement. For Prevtec, based on the terms of the purchase agreement, we will pay up to $16 million contingent upon the achievement of specific Coliprotec sales milestones by December 31, 2021. The fair value of both contingent consideration liabilities was estimated using the Monte Carlo simulation model and Level 3 inputs including historical revenue, discount rate, asset volatility, and revenue volatility.

Derivative Instruments and Hedging Activities

We are exposed to market risks, such as changes in foreign currency exchange rates and interest rates. To manage the volatility related to these exposures, we have entered into various derivative transactions. We formally assess, designate and document, as a hedge of an underlying exposure, each qualifying derivative instrument that will be accounted for as an accounting hedge at inception. Additionally, we assess, both at inception and at least quarterly thereafter, whether the financial instruments used in the hedging transaction are effective at offsetting changes in either the fair values or cash flows of the underlying exposures.

Derivatives Not Designated as Hedges

We may enter into foreign exchange forward or option contracts to reduce the effect of fluctuating currency exchange rates. These derivative financial instruments primarily offset exposures in the British pound, Canadian dollar, Euro, Japanese yen, Swiss franc (CHF), and Chinese yuan. Foreign currency derivatives used for hedging are put in place using the same or like currencies and duration as the underlying exposures and are recorded at fair value with the gain or loss recognized in other (income) expense, net in the condensed consolidated statements of operations. Forward contracts generally have maturities not exceeding 12 months. At September 30, 2021 and December 31, 2020, we had outstanding foreign exchange contracts with aggregate notional amounts of $1,417 million and $1,391 million, respectively.

The amounts of net gain (loss) on derivative instruments not designated as hedging instruments, recorded in other (income) expense, net are as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Foreign exchange forward contracts (1)
$(2)$(2)$(29)$19 

(1)These amounts were substantially offset in other (income) expense, net by the effect of changing exchange rates on the underlying foreign currency exposures.

Derivatives Designated as Hedges

In October 2018, as a means of mitigating the impact of currency fluctuations on our operations in Switzerland, we entered into a five-year cross-currency fixed interest rate swap with a 750 million CHF notional amount, which was designated as a net investment hedge (NIH) against CHF denominated assets (the fair value of which was estimated based on quoted market values of similar hedges and was classified as Level 2). During the nine months ended September 30, 2020 we fully liquidated our cross currency interest rate swaps for a cash benefit of $35 million (including $2 million in interest). Notwithstanding settlement, gains and losses within accumulated other comprehensive income (loss) will remain in accumulated other comprehensive income (loss) until either the sale or substantial liquidation of the hedged subsidiary.

Gains on the NIH, recognized within interest expense, net of capitalized interest, are as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Cross-currency interest rate swap contracts$— $— $— $6 
Over the life of the derivative, gains or losses due to spot rate fluctuations were recorded in cumulative translation adjustment in other comprehensive income (loss). The amounts of net gains on interest rate swap contracts, recorded, net of tax, in accumulated other comprehensive income (loss), are as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Cross-currency interest rate swap contracts$— $— $— $24 

Separately, in March 2020, as a means of mitigating variability in cash flows associated with the anticipated Term Loan B issuance, we executed forward-starting interest rate swaps with a $4.1 billion notional amount, which are designated as cash flow hedges and have maturity dates ranging between 2022 and 2025. These instruments effectively convert floating-rate debt to fixed-rate debt. The cash flow hedges are recorded at fair value on our condensed consolidated balance sheets, while changes in the fair value of the hedge are recognized in other comprehensive income (loss). Fair value is estimated based on quoted market values of similar hedges and is classified as Level 2. Amounts recorded in accumulated other comprehensive income (loss) are recognized in earnings in interest expense, net of capitalized interest when the hedged transaction affects earnings (i.e., as interest payments are accrued on the Term Loan B).

The amounts of net gains (losses) on cash flow hedges, recorded, net of tax, in accumulated other comprehensive income (loss), are as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Forward-starting interest rate swaps, net of tax benefit of $0, $2, $0 and $20, respectively
$4 $(7)$52 $(67)

There was no tax effect for the three and nine months ended September 30, 2021 after the application of the U.S. valuation allowance. See Note 10: Income Taxes for further discussion. Over the next 12 months we expect to reclassify $26 million from accumulated other comprehensive income (loss) to interest expense, net of capitalized interest due to the amortization of net losses on the interest rate swaps. During the three and nine months ended September 30, 2021, we reclassified $8 million and $22 million, respectively, of net losses into interest expense.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes
 9 Months Ended
Sep. 30, 2021
Income Tax Disclosure [Abstract]  
Income Taxes
Note 10. Income Taxes

Income Tax BenefitThree Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Income tax benefit$(26)$(74)$(71)$(117)
Effective tax rate20.0 %35.4 %15.9 %32.9 %

We were included in Lilly's U.S. tax examinations by the Internal Revenue Service through the full separation date of March 11, 2019. Pursuant to the tax matters agreement we executed with Lilly in connection with the IPO, the potential liabilities or potential refunds attributable to pre-IPO periods in which Elanco was included in a Lilly consolidated or combined tax return remain with Lilly. The U.S. examination of tax years 2016 - 2018 began in the fourth quarter of 2019 and remains ongoing; therefore, the resolution of this audit period will likely extend beyond the next 12 months.

For the three and nine months ended September 30, 2021, we recognized an income tax benefit of $26 million and $71 million, respectively. For the three months ended September 30, 2021, our effective tax rate of 20.0% differs from the statutory income tax rate primarily due to preliminary accounting for the acquisition of KindredBio, which caused a partial release of the U.S. federal valuation allowance, as well as profits being located in jurisdictions with higher statutory tax rates. For the nine months ended September 30, 2021, our effective tax rate of 15.9% differs from the statutory income tax rate primarily because the U.S. federal and state jurisdictions are currently generating losses that are subject to valuation allowances.
For the three and nine months ended September 30, 2020, we recognized an income tax benefit of $74 million and $117 million, respectively. For the three and nine months ended September 30, 2020, our effective tax rate of 35.4% and 32.9%, respectively, differs from the statutory income tax rate primarily due to the release of foreign valuation allowances as a result of gains on divestitures. Additionally, the state tax benefit is a result of U.S. pre-tax losses and the foreign tax benefit is due to losses in jurisdictions with tax rates higher than U.S. statutory rates.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
Note 11. Commitments and Contingencies

Legal Matters

On May 20, 2020, a shareholder class action lawsuit captioned Hunter v. Elanco Animal Health Inc., et al. was filed in the United States District Court for the Southern District of Indiana (the Court) against Elanco, Jeffrey Simmons and Todd Young. On September 3, 2020, the Court appointed a lead plaintiff, and on November 9, 2020, the lead plaintiff filed an amended complaint. The lawsuit alleges, in part, that Elanco and certain of its executives made materially false and/or misleading statements and/or failed to disclose certain facts about Elanco’s supply chain, inventory, revenue and projections. The lawsuit seeks unspecified monetary damages and purports to represent purchasers of Elanco securities between September 30, 2018 and May 6, 2020, and purchasers of Elanco common stock issued in connection with Elanco's acquisition of Aratana. We filed a motion to dismiss on January 13, 2021. The timing of the Court's decision is uncertain. We believe the claims made in the case are meritless, and we intend to vigorously defend our position. The process of resolving these matters is inherently uncertain and may develop over an extended period of time; therefore, at this time, the ultimate resolution cannot be predicted.

On October 16, 2020, a shareholder class action lawsuit captioned Safron Capital Corporation v. Elanco Animal Health Inc., et al. was filed in the Marion Superior Court of Indiana against Elanco, certain executives, and other individuals. On December 23, 2020, the plaintiffs filed an amended complaint adding an additional plaintiff. The lawsuit alleges, in part, that Elanco and certain of its executives made materially false and/or misleading statements and/or failed to disclose certain facts about Elanco’s relationships with third party distributors and revenue attributable to those distributors within the registration statement on Form S-3 dated January 21, 2020 and accompanying prospectus filed in connection with Elanco’s public offering which closed on or about January 27, 2020. The lawsuit seeks unspecified monetary damages and purports to represent purchasers of Elanco common stock or 5.00% TEUs issued in connection with the public offering. This case is currently stayed in deference to Hunter v. Elanco Animal Health Inc.

Claims seeking actual damages, injunctive relief, and/or restitution for allegedly deceptive marketing have been made against Elanco Animal Health Inc. and Bayer HealthCare LLC, along with other Elanco and Bayer entities, arising out of the use of Seresto™, a non-prescription flea and tick collar for cats and dogs. During the nine months ended September 30, 2021, putative class action lawsuits were filed in state and federal courts in the U.S. alleging that the Seresto collars contain pesticides and other ingredients that can cause serious injury and death to cats and/or dogs wearing the product. The cases mention the existence of incident reports involving humans, but no plaintiff has claimed personal harm from the product. One plaintiff filed a petition before the Judicial Panel on Multidistrict Litigation (JPML). The hearing on the JPML petition took place on July 29, 2021, and a decision was reached to consolidate and transfer all pending lawsuits to the federal court in the Northern District of Illinois. We continue to receive information with respect to potential litigation costs, and we will be taking appropriate steps to defend these class action lawsuits.

Further, a U.S. House of Representative subcommittee chair requested that Elanco produce certain documents and information related to the Seresto collar and further made a request to temporarily recall Seresto collars from the market. We are continuing to cooperate with the subcommittee and have produced information pursuant to the request.

Seresto is a pesticide registered with the Environmental Protection Agency (EPA). A non-profit organization submitted a petition to the EPA requesting that the agency take action to cancel Seresto’s pesticide registration and suspend the registration pending cancellation. The EPA is considering this petition and asked for public comment. We submitted a comment to the EPA supporting the safety profile of Seresto. All data and scientific evaluation used during the product registration process and through pharmacovigilance review supports the product’s positive safety profile and efficacy. Therefore, we believe no removal, recall, or cancellation of the pesticide registration is warranted, nor has it been suggested by any regulatory agency. We continue to stand behind the safety profile for Seresto, and it remains available to consumers globally.
We are party to various other legal actions in the normal course of business. In determining whether a pending matter is significant for financial reporting and disclosure purposes, we consider both quantitative and qualitative factors in order to assess materiality. We accrue for liability claims to the extent that it is probable we will incur a loss and we can formulate a reasonable estimate of the costs. As of September 30, 2021 and December 31, 2020, we had no material liabilities established related to litigation as there were no significant claims which were probable and estimable. We are not currently subject to a significant claim other than the lawsuits noted above.

Regulatory Matters
On July 1, 2021, we received a subpoena from the SEC relating to our channel inventory and sales practices prior to mid-2020. We have cooperated in providing documents and information to the SEC and will continue to do so. Management believes that its actions were appropriate.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.21.2
Geographic Information
 9 Months Ended
Sep. 30, 2021
Segment Reporting [Abstract]  
Geographic Information
Note 12. Geographic Information

We operate as a single operating segment engaged in the development, manufacturing, marketing and sales of animal health products worldwide for both farm animals and pets. Consistent with our operational structure, our President and Chief Executive Officer (CEO), as the chief operating decision maker, makes resource allocation and business process decisions globally across our consolidated business. Strategic decisions are managed globally with global functional leaders responsible for determining significant costs/investments and with regional leaders responsible for overseeing the execution of the global strategy. Our global research and development organization is responsible for development of new products. Our manufacturing organization is responsible for the manufacturing and supply of products and for the optimization of our supply chain. Regional leaders are responsible for the distribution and sale of our products and for local direct costs. The business is also supported by global corporate staff functions. Managing and allocating resources at the global corporate level enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, product types, regional commercial organizations and research and development projects in line with our overarching long-term corporate-wide strategic goals, rather than on a product or geographic basis. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, allocating resources, setting incentive compensation targets, as well as forecasting future period financial results.

Our products include Baycox™, Cydectin™, Denagard™, Maxiban™, Optaflexx™, Rumensin™, Tylan™, and other products for livestock and poultry, as well as Advantage™, Advantix™, Advocate™ (collectively referred to as the Advantage Family), Credelio™, Duramune™, Galliprant™, Interceptor™ Plus, Seresto, Trifexis™, and other products for pets.

We have a single customer that accounted for 11% and 12% of revenue for the three months ended September 30, 2021 and 2020, respectively, and 9% and 12% of revenue for the nine months ended September 30, 2021 and 2020, respectively. Product sales with this customer resulted in accounts receivable of $80 million and $87 million as of September 30, 2021 and December 31, 2020, respectively.

We are exposed to the risk of changes in social, political and economic conditions inherent in foreign operations and our results of operations and the value of our foreign assets are affected by fluctuations in foreign currency exchange rates.

Selected geographic area information was as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Revenue
United States$507 $422 $1,621 $970 
International624 468 2,031 1,164 
Revenue$1,131 $890 $3,652 $2,134 
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.21.2
Retirement Benefits
 9 Months Ended
Sep. 30, 2021
Retirement Benefits [Abstract]  
Retirement Benefits
Note 13. Retirement Benefits

The following table summarizes net periodic benefit cost (income) relating to our defined benefit pension plans:
Three Months Ended September 30,
Nine Months Ended September 30,
2021202020212020
Service cost$4 $3 $14 $8 
Interest cost1 — 2 1 
Expected return on plan assets(2)(2)(5)(4)
Amortization of prior service cost(1)(2)(5)(6)
Amortization of net actuarial loss— 1 1 2 
Net curtailments and settlements (Note 5)(9)— (26)— 
Net periodic benefit cost (income)$(7)$— $(19)$1 

The components of net periodic benefit cost other than service cost and net curtailments and settlements are included in other (income) expense, net in our condensed consolidated statements of operations. Net curtailments and settlements are included in asset impairment, restructuring and other special charges, in our condensed consolidated statements of operations.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Loss Per Share
 9 Months Ended
Sep. 30, 2021
Earnings Per Share [Abstract]  
Loss Per Share
Note 14. Loss Per Share

We compute basic loss per share by dividing net loss available to common shareholders by the actual weighted average number of common shares outstanding for the reporting period. Elanco has variable common stock equivalents relating to certain equity awards in stock-based compensation arrangements and the TEU prepaid stock purchase contracts (see Note 7: Equity for further discussion). Diluted earnings per share reflects the potential dilution that could occur if holders of the unvested equity awards and unsettled TEUs converted their holdings into common stock. The weighted average number of potentially dilutive shares outstanding is calculated using the treasury stock method. Potential common shares that would have the effect of increasing diluted earnings per share (or reducing loss per share) are considered to be anti-dilutive and as such, these shares are not included in the calculation of diluted loss per share.

Basic and diluted loss per share are calculated as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Net loss available to common shareholders$(104)$(135)$(375)$(237)
Determination of shares:
Weighted average common shares outstanding487.3 462.4487.1 426.5
Assumed conversion of dilutive common stock equivalents (1)
— — — — 
Diluted weighted average shares outstanding487.3 462.4487.1 426.5
Loss per share (2)
Basic$(0.21)$(0.29)$(0.77)$(0.56)
Diluted$(0.21)$(0.29)$(0.77)$(0.56)
(1)During the three and nine months ended September 30, 2021 and 2020, we reported a net loss. Therefore, dilutive common stock equivalents are not assumed to have been issued since their effect is anti-dilutive. As a result, basic and diluted weighted average shares are the same, causing diluted net loss per share to be equivalent to basic net loss per share. For the three months ended September 30, 2021 and 2020, approximately 1.7 million and 1.6 million, respectively, of potential common shares were excluded from the calculation of diluted earnings per share because their effect was anti-dilutive. For the nine months ended September 30, 2021 and 2020, approximately 1.6 million and 1.9 million, respectively, of potential common shares were excluded from the calculation of diluted earnings per share because their effect was anti-dilutive.
(2)Due to rounding conventions, loss per share may not recalculate precisely based on the amounts presented within this table.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.21.2
Transactions and Agreements with Bayer
 9 Months Ended
Sep. 30, 2021
Related Party Transactions [Abstract]  
Transactions and Agreements with Bayer
Note 15. Transactions and Agreements with Bayer

While Bayer is no longer considered a related party, we have transacted with Bayer during the period after the acquisition of Bayer Animal Health, including the period in which Bayer was considered a principal owner of Elanco. These transactions primarily related to local country asset purchases and various transitional services agreements (TSAs), contract manufacturing arrangements, and certain lease agreements to ensure business continuity after the acquisition.

For regulatory purposes in certain jurisdictions, consideration was required to be paid locally at closing in addition to amounts paid globally for the acquisition. Pursuant to the stock and asset purchase agreement, Bayer has provided a refund for payment amounts duplicated in these regions. The total amount paid to and received from Bayer during the nine months ended September 30, 2021 for these local country asset purchases was approximately $16 million. All local country asset purchases have been completed as of September 30, 2021.
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Basis of Presentation and Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation We have prepared the accompanying unaudited condensed consolidated financial statements in accordance with the United States (U.S.) Securities and Exchange Commission (SEC) requirements for interim reporting. As permitted under those rules, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the U.S. (GAAP) have been condensed or omitted. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our consolidated and combined financial statements and accompanying notes for the year ended December 31, 2020 included in our Annual Report on Form 10-K filed with the SEC on March 1, 2021. In addition, results for interim periods should not be considered indicative of results for any other interim period or for the full year ending December 31, 2021 or any other future period. In our opinion, the financial statements reflect all adjustments (including those that are normal and recurring) that are necessary for fair presentation of the results of operations for the periods shown. In preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from those estimates.
Implementation of New Financial Accounting Pronouncements
The following table provides a brief description of an accounting standard that was effective January 1, 2021 and was adopted on that date:
StandardDescriptionEffect on the financial statements or other significant matters
Accounting Standards Update (ASU) 2019-12, Simplifying the Accounting for Income Taxes
The amendments in this update include simplifications related to accounting for income taxes including removing certain exceptions related to the approach for intraperiod tax allocation and the recognition of deferred tax liabilities for outside basis differences. The standard also clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The adoption of this guidance did not have a material impact on our consolidated financial statements.
The following table provides a brief description of an accounting standard that is applicable to us but has not yet been adopted:
StandardDescriptionEffective DateEffect on the financial statements or other significant matters
ASU 2020-04, Reference rate reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting; ASU 2021-01, Reference Rate Reform (Topic 848): Scope
ASU 2020-04 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. ASU 2021-01 clarifies the scope of Topic 848 so that derivatives affected by the discounting transition are explicitly eligible for certain optional expedients and exceptions.These standards were effective as of March 12, 2020 through December 31, 2022 and adoption is permitted at any time during the period on a prospective basis.We are currently in the process of evaluating the impact of the London Interbank Offered Rate (LIBOR) on our existing contracts and may elect optional expedients in future periods as reference rate reform activities occur. We do not expect that these updates will have a material impact on our consolidated financial statements.
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Implementation of New Financial Accounting Pronouncements (Tables)
 9 Months Ended
Sep. 30, 2021
Accounting Changes and Error Corrections [Abstract]  
Description of Accounting Standards Adopted and Not Yet Adopted
The following table provides a brief description of an accounting standard that was effective January 1, 2021 and was adopted on that date:
StandardDescriptionEffect on the financial statements or other significant matters
Accounting Standards Update (ASU) 2019-12, Simplifying the Accounting for Income Taxes
The amendments in this update include simplifications related to accounting for income taxes including removing certain exceptions related to the approach for intraperiod tax allocation and the recognition of deferred tax liabilities for outside basis differences. The standard also clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The adoption of this guidance did not have a material impact on our consolidated financial statements.
The following table provides a brief description of an accounting standard that is applicable to us but has not yet been adopted:
StandardDescriptionEffective DateEffect on the financial statements or other significant matters
ASU 2020-04, Reference rate reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting; ASU 2021-01, Reference Rate Reform (Topic 848): Scope
ASU 2020-04 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. ASU 2021-01 clarifies the scope of Topic 848 so that derivatives affected by the discounting transition are explicitly eligible for certain optional expedients and exceptions.These standards were effective as of March 12, 2020 through December 31, 2022 and adoption is permitted at any time during the period on a prospective basis.We are currently in the process of evaluating the impact of the London Interbank Offered Rate (LIBOR) on our existing contracts and may elect optional expedients in future periods as reference rate reform activities occur. We do not expect that these updates will have a material impact on our consolidated financial statements.
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue (Tables)
 9 Months Ended
Sep. 30, 2021
Revenue from Contract with Customer [Abstract]  
Summary of Activity in Sales Rebates and Discounts Liability The following table summarizes the activity in our global sales rebates liability:
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Beginning balance$303 $164 $295 $211 
Bayer Animal Health at acquisition— 78 — 78 
Reduction of revenue163 145 516 316 
Payments(150)(108)(495)(326)
Ending balance$316 $279 $316 $279 
Disaggregation of Revenue
In the first quarter of 2021, management revisited how it analyzes revenue, both internally and externally, and determined that disaggregation by major product line provides a more meaningful view of our results. Accordingly, we updated our disaggregated revenue presentation from the previous five categories (i.e., pet health disease prevention, pet health therapeutics, farm animal future protein & health, farm animal ruminants & swine, and contract manufacturing) to the following:
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Pet Health$527 $401 $1,857 $861 
Farm Animal583 473 1,728 1,222 
Contract Manufacturing (1)
21 16 67 51 
Revenue$1,131 $890 $3,652 $2,134 
(1)Represents revenue from arrangements in which we act as a contract manufacturer, including supply agreements associated with divestitures of products related to the acquisition of Bayer Animal Health.
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Acquisitions and Divestitures (Tables)
 9 Months Ended
Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]  
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed The following table summarizes the preliminary amounts recognized for assets acquired and liabilities assumed as of the acquisition date:
Estimated Fair Value at August 27, 2021
Cash and cash equivalents$31 
Other net working capital1 
Property and equipment26 
Intangible assets, primarily acquired in-process research and development352 
Deferred income taxes(22)
Total identifiable net assets388 
Goodwill30 
Settlement of liability related to previous license agreement26 
Total consideration transferred$444 
The following table summarizes the fair value of assets acquired and liabilities assumed as of the acquisition date:

Estimated Fair Value at August 1, 2020
Cash and cash equivalents$169 
Accounts receivable10 
Inventories487 
Prepaid expenses and other current assets60 
Property and equipment315 
Intangible assets:
Acquired in-process research and development 65 
Marketed products3,740 
Assets held for sale138 
Accounts payable and accrued liabilities(237)
Accrued retirement benefits(220)
Other noncurrent assets and liabilities, net (878)
Total identifiable net assets3,649 
Goodwill3,129 
Total consideration transferred$6,778 
Purchase Consideration
Total consideration transferred to Bayer and its subsidiaries for the acquisition is summarized as follows:

Cash consideration (1)
$5,054 
Fair value of Elanco common stock (2)
1,724 
Fair value of total consideration transferred$6,778 
(1)Includes initial cash consideration of $5,170 million less working capital and tax adjustments of $116 million.
(2)Represents the acquisition date fair value of 73 million shares of Elanco common stock at $23.64 per share. Per the terms of the stock and asset purchase agreement, the number of shares was based on approximately $2.3 billion divided by the 20-day volume-weighted average stock price as of the last day of trading before the closing of the acquisition (but subject to a 7.5% symmetrical collar centered on the baseline share number of approximately $2.3 billion divided by an initial share price of $33.60).
Pro Forma Information
The following table presents the estimated unaudited pro forma combined results of Elanco and Bayer Animal Health as if the acquisition of Bayer Animal Health had occurred on January 1, 2020:
Three Months Ended September 30, 2020Nine Months Ended September 30, 2020
Revenue$1,069 $3,308 
Loss before income taxes
(227)(392)
Divestitures Activities
Assets and liabilities considered held for sale in connection with the above divestitures were included in the respective line items on our condensed consolidated balance sheets as follows:
September 30, 2021December 31, 2020
Inventories$38 $2 
Other intangibles, net— 4 
Property and equipment, net55 — 
Deferred tax asset— 1 
Total assets held for sale$93 $7 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.21.2
Asset Impairment, Restructuring and Other Special Charges (Tables)
 9 Months Ended
Sep. 30, 2021
Restructuring and Related Activities [Abstract]  
Total Charges Related to Asset Impairment, Restructuring and Other Special Charges
Components of asset impairment, restructuring and other special charges are as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Restructuring charges:
Severance and other costs (1)
$(2)$130 $26 $131 
Facility exit costs (1)
— — — 1 
Acquisition related charges:
Transaction and integration costs (2)
30 131 141 318 
Non-cash and other items:
Asset impairment (3)
50 — 63 4 
Asset write-down (4)
6 1 275 3 
Gain on sale of fixed assets (5)
— — — (4)
Settlements and other (6)
27 — 13 3 
Total expense$111 $262 $518 $456 
(1)For the nine months ended September 30, 2021, these charges primarily related to a restructuring program announced and initiated in January 2021. These costs were partially offset by the reversal of severance accruals associated with the January 2021 and September 2020 programs during the period. See below for further details.
For the three and nine months ended September 30, 2020, these charges primarily related to a restructuring program announced and initiated in September 2020. See below for further details.
(2)Transaction costs represent external costs directly related to acquiring businesses and primarily include expenditures for banking, legal, accounting and other similar services. Integration costs represent internal and external incremental costs directly related to integrating acquired businesses, including the acquisitions of KindredBio and Bayer Animal Health (e.g., expenditures for consulting, system and process integration, and product transfers), as well as independent company stand-up costs related to the implementation of new systems, programs, and processes.
(3)Asset impairment charges for the three and nine months ended September 30, 2021 related to adjustments to the fair value of IPR&D assets that were subject to product rationalization. The asset impairment charge during the three months ended September 30, 2021 reflects a decision by management to terminate an IPR&D project and fully impair the related asset, which is associated with a farm animal parasiticide. The decision was prompted by unfavorable efficacy results observed during the quarter.
Asset impairment charges for the nine months ended September 30, 2020 related to the impairment of an IPR&D asset resulting from product rationalization and a reassessment of geographic viability.
(4)Asset write-down expenses for the nine months ended September 30, 2021 include the initial adjustments recorded to write down the Shawnee and Speke assets classified as held for sale as of June 30, 2021 to an amount equal to estimated fair value less costs to sell, as well as adjustments to values of assets sold in relation to the Shawnee manufacturing site sold on August 1, 2021 and assets classified as held for sale in relation to the future sale of the Speke manufacturing site during the three months ended September 30, 2021. See Note 4: Acquisitions and Divestitures for further discussion. Other charges for the nine months ended September 30, 2021 include adjustments recorded to write down assets in Belford Roxo, Brazil; Basel, Switzerland; Cuxhaven, Germany; and Manukau, New Zealand that were classified as held and used to their current fair value. These charges were recorded in connection with the January 2021 and September 2020 restructuring programs.
Asset write-down expenses for the three and nine months ended September 30, 2020 resulted from adjustments recorded to write down assets classified as held and used to their current fair value. These charges primarily related to fixed assets in Wusi, China in connection with the announced 2019 program to streamline operations.
(5)Represents a gain on the disposal from the sale of an R&D facility in Prince Edward Island, Canada.
(6)Settlements and other expenses for the three and nine months ended September 30, 2021 include a charge associated with the settlement of a liability for future royalty and milestone payments triggered in connection with our acquisition of KindredBio as discussed further in Note 4: Acquisitions and Divestitures, accounting and advisory fees related to the sale of our manufacturing site in Shawnee, and an $8 million charge related to a litigation settlement for a matter that originated prior to our acquisition of Bayer Animal Health, partially offset by net curtailment and settlement gains from the remeasurement of our pension benefit obligation as a result of workforce reductions in connection with our September 2020 and January 2021 restructuring programs. See Note 13: Retirement Benefits for further information. The amount for the nine months ended September 30, 2021 also includes the gain recorded on the divestiture of an early-stage IPR&D asset acquired as part of the Bayer Animal Health acquisition.
Settlements and other expenses for the three and nine months ended September 30, 2020 relate to a non-recurring litigation settlement for a matter that originated prior to our separation from Lilly.
Summary of Activity in Reserves
The following table summarizes the activity in our reserves established in connection with restructuring activities:
Facility exit costs SeveranceTotal
Balance at December 31, 2019$5 $16 $21 
Charges1 132 133 
Reserve adjustments— (1)(1)
Cash paid(1)(15)(16)
Balance at September 30, 2020$5 $132 $137 
Balance at December 31, 2020$— $130 $130 
Charges— 41 41 
Reserve adjustments— (15)(15)
Cash paid— (95)(95)
Balance at September 30, 2021$— $61 $61 
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Inventories (Tables)
 9 Months Ended
Sep. 30, 2021
Inventory Disclosure [Abstract]  
Schedule of Inventories Inventories consisted of the following:
September 30, 2021December 31, 2020
Finished products$595 $772 
Work in process576 625 
Raw materials and supplies255 210 
Total1,426 1,607 
Decrease to LIFO cost(43)(29)
Inventories$1,383 $1,578 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Equity (Tables)
 9 Months Ended
Sep. 30, 2021
Equity [Abstract]  
Schedule of Stockholders Equity
The proceeds from the issuance were allocated to equity and debt based on the relative fair value of the respective components of each TEU as follows:
Equity ComponentDebt ComponentTotal
Fair value per unit$42.80 $7.20 $50.00 
Gross proceeds$471 $79 $550 
Less: Issuance costs19 3 22 
Net proceeds$452 $76 $528 
Unless settled early at the holder’s or our election, each prepaid stock purchase contract will automatically settle on February 1, 2023 (the mandatory settlement date) for a number of shares of common stock per contract based on the average of the volume-weighted average trading prices during the 20 consecutive trading day period beginning on, and including the 21st scheduled trading day immediately preceding February 1, 2023 (applicable market value) with reference to the following settlement rates:
Applicable Market ValueCommon Stock Issued
Equal to or greater than $38.40
1.3021 shares (minimum settlement rate)
Less than $38.40, but greater than $32.00
$50 divided by applicable market value
Less than or equal to $32.00
1.5625 (maximum settlement rate)
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Debt (Tables)
 9 Months Ended
Sep. 30, 2021
Debt Disclosure [Abstract]  
Schedule of Long-term Debt
Long-term debt consisted of the following:
September 30, 2021December 31, 2020
Incremental Term Facility$500 $— 
Term Loan B4,129 4,164 
Revolving Credit Facility250 — 
3.912% Senior Notes due 2021
— 500 
4.272% Senior Notes due 2023
750 750 
4.900% Senior Notes due 2028
750 750 
TEU Amortizing Notes40 60 
Other obligations— 1 
Unamortized debt issuance costs(85)(98)
6,334 6,127 
Less current portion of long-term debt61 555 
Total long-term debt$6,273 $5,572 
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Financial Instruments and Fair Value (Tables)
 9 Months Ended
Sep. 30, 2021
Fair Value Disclosures [Abstract]  
Summary of Fair Value Information
The following table summarizes the fair value information at September 30, 2021 and December 31, 2020 for foreign exchange contract assets (liabilities), investments, contingent consideration liabilities, and cash flow hedge assets (liabilities) measured at fair value on a recurring basis in the respective balance sheet line items, as well as long-term debt (including TEU amortizing notes) for which fair value is disclosed on a recurring basis:
  Fair Value Measurements Using 
Financial statement line itemCarrying
Amount		Quoted Prices in Active Markets for Identical Assets
(Level 1)		Significant
Other Observable Inputs
(Level 2)		Significant
Unobservable
Inputs
(Level 3)		Fair
Value
September 30, 2021
Prepaid expenses and other - foreign exchange contracts not designated as hedging instruments$30 $— $30 $— $30 
Other noncurrent assets - investments15 15 — — 15 
Other current liabilities - foreign exchange contracts not designated as hedging instruments(30)— (30)— (30)
Other current liabilities - contingent consideration(1)— — (1)(1)
Other noncurrent liabilities - forward-starting interest rate contracts designated as cash flow hedges(24)— (24)— (24)
Long-term debt, including current portion(6,419)— (6,551)— (6,551)
December 31, 2020
Prepaid expenses and other - foreign exchange contracts not designated as hedging instruments$36 $— $36 $— $36 
Other noncurrent assets - investments9 9 — — 9 
Other current liabilities - foreign exchange contracts not designated as hedging instruments(36)— (36)— (36)
Other noncurrent liabilities - contingent consideration(1)— — (1)(1)
Other noncurrent liabilities - forward-starting interest rate contracts designated as cash flow hedges(76)— (76)— (76)
Long-term debt, including current portion(6,225)— (6,420)— (6,420)
Gain (loss), net of tax
The amounts of net gain (loss) on derivative instruments not designated as hedging instruments, recorded in other (income) expense, net are as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Foreign exchange forward contracts (1)
$(2)$(2)$(29)$19 

(1)These amounts were substantially offset in other (income) expense, net by the effect of changing exchange rates on the underlying foreign currency exposures.
Gains on the NIH, recognized within interest expense, net of capitalized interest, are as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Cross-currency interest rate swap contracts$— $— $— $6 
The amounts of net gains on interest rate swap contracts, recorded, net of tax, in accumulated other comprehensive income (loss), are as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Cross-currency interest rate swap contracts$— $— $— $24 
The amounts of net gains (losses) on cash flow hedges, recorded, net of tax, in accumulated other comprehensive income (loss), are as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Forward-starting interest rate swaps, net of tax benefit of $0, $2, $0 and $20, respectively
$4 $(7)$52 $(67)
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes (Tables)
 9 Months Ended
Sep. 30, 2021
Income Tax Disclosure [Abstract]  
Provision for Taxes on Income
Income Tax BenefitThree Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Income tax benefit$(26)$(74)$(71)$(117)
Effective tax rate20.0 %35.4 %15.9 %32.9 %
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Geographic Information (Tables)
 9 Months Ended
Sep. 30, 2021
Segment Reporting [Abstract]  
Revenue by Selected Geographic Area Information
Selected geographic area information was as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Revenue
United States$507 $422 $1,621 $970 
International624 468 2,031 1,164 
Revenue$1,131 $890 $3,652 $2,134 
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Retirement Benefits (Tables)
 9 Months Ended
Sep. 30, 2021
Retirement Benefits [Abstract]  
Schedule of Net Benefit Costs
The following table summarizes net periodic benefit cost (income) relating to our defined benefit pension plans:
Three Months Ended September 30,
Nine Months Ended September 30,
2021202020212020
Service cost$4 $3 $14 $8 
Interest cost1 — 2 1 
Expected return on plan assets(2)(2)(5)(4)
Amortization of prior service cost(1)(2)(5)(6)
Amortization of net actuarial loss— 1 1 2 
Net curtailments and settlements (Note 5)(9)— (26)— 
Net periodic benefit cost (income)$(7)$— $(19)$1 
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.21.2
Loss Per Share (Tables)
 9 Months Ended
Sep. 30, 2021
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted
Basic and diluted loss per share are calculated as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Net loss available to common shareholders$(104)$(135)$(375)$(237)
Determination of shares:
Weighted average common shares outstanding487.3 462.4487.1 426.5
Assumed conversion of dilutive common stock equivalents (1)
— — — — 
Diluted weighted average shares outstanding487.3 462.4487.1 426.5
Loss per share (2)
Basic$(0.21)$(0.29)$(0.77)$(0.56)
Diluted$(0.21)$(0.29)$(0.77)$(0.56)
(1)During the three and nine months ended September 30, 2021 and 2020, we reported a net loss. Therefore, dilutive common stock equivalents are not assumed to have been issued since their effect is anti-dilutive. As a result, basic and diluted weighted average shares are the same, causing diluted net loss per share to be equivalent to basic net loss per share. For the three months ended September 30, 2021 and 2020, approximately 1.7 million and 1.6 million, respectively, of potential common shares were excluded from the calculation of diluted earnings per share because their effect was anti-dilutive. For the nine months ended September 30, 2021 and 2020, approximately 1.6 million and 1.9 million, respectively, of potential common shares were excluded from the calculation of diluted earnings per share because their effect was anti-dilutive.
(2)Due to rounding conventions, loss per share may not recalculate precisely based on the amounts presented within this table.
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue - Narrative (Details)
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Geographic Concentration Risk | Contract With Customer Liability | United States        
Concentration Risk [Line Items]        
Concentration risk (less than 0.1%)     72.00% 74.00%
Product Return Concentration Risk | Net Revenue | Global Customers        
Concentration Risk [Line Items]        
Concentration risk (less than 0.1%) 2.00% 1.00% 1.00% 1.00%
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue - Summary of Activity in Sales Rebates and Discounts Liability (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Change In Contract With Customer, Liability [Roll Forward]        
Beginning balance $ 303.0 $ 164.0 $ 295.0 $ 211.0
Bayer Animal Health at acquisition 0.0 78.0 0.0 78.0
Reduction of revenue 163.0 145.0 516.0 316.0
Payments (150.0) (108.0) (495.0) (326.0)
Ending balance $ 316.0 $ 279.0 $ 316.0 $ 279.0
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue - Disaggregation of Revenue (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Disaggregation of Revenue [Line Items]        
Revenue $ 1,131 $ 890 $ 3,652 $ 2,134
Pet Health        
Disaggregation of Revenue [Line Items]        
Revenue 527 401 1,857 861
Farm Animal        
Disaggregation of Revenue [Line Items]        
Revenue 583 473 1,728 1,222
Contract Manufacturing        
Disaggregation of Revenue [Line Items]        
Revenue $ 21 $ 16 $ 67 $ 51
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.21.2
Acquisitions and Divestitures - Narrative (Details)
$ / shares in Units, $ in Millions
 3 Months Ended 9 Months Ended
Aug. 01, 2021
USD ($)
Aug. 01, 2020
USD ($)
$ / shares
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Aug. 27, 2021
USD ($)
$ / shares
Jun. 30, 2021
USD ($)
employee
Business Acquisition [Line Items]                
Revenue     $ 1,131 $ 890 $ 3,652 $ 2,134    
Inventory fair value step-up amortization         64 33    
Asset impairment     50 0 63 4    
Proceeds from product divestitures         0 435    
Sale of IPR&D         (2) 170    
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations                
Business Acquisition [Line Items]                
Number of employees transferred | employee               600
Asset impairment         271      
Proceeds from product divestitures       435   435    
Sale of IPR&D       156   156    
Divestiture transaction costs       13   13    
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Shawnee                
Business Acquisition [Line Items]                
Proceeds from product divestitures $ 51              
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Rights To The Profender And Drontal | Intangible assets, primarily acquired in-process research and development                
Business Acquisition [Line Items]                
Sale of IPR&D       7        
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Marketed products | Rights To The Profender And Drontal                
Business Acquisition [Line Items]                
Assets held for sale   $ 133            
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Inventories | Rights To The Profender And Drontal                
Business Acquisition [Line Items]                
Assets held for sale   $ 5            
KindredBio                
Business Acquisition [Line Items]                
Common stock price (in dollars per share) | $ / shares             $ 9.25  
Settlement of liability related to previous license agreement             $ 26 $ 26
Transaction costs incurred     4   6      
KindredBio | Intangible assets, primarily acquired in-process research and development                
Business Acquisition [Line Items]                
Intangible assets, primarily acquired in-process research and development             $ 352  
Bayer Animal Business                
Business Acquisition [Line Items]                
Common stock price (in dollars per share) | $ / shares   $ 23.64            
Consideration paid for acquisition   $ 6,778            
Transaction costs incurred       35 3 93    
Revenue     $ 421 $ 196 1,509 $ 196    
Intangible asset adjustment         210      
Property, plant, and equipment, adjustments         32      
Working capital and other adjustment         14      
Goodwill adjustment         $ 207      
Inventories   487            
Inventory fair value step-up amortization   152            
Intangible assets, primarily acquired in-process research and development   65            
Marketed products   $ 3,740            
Weighted average useful life   10 years            
Assets held for sale   $ 138            
Bayer Animal Business | Finished Products                
Business Acquisition [Line Items]                
Inventories   311            
Bayer Animal Business | in Process                
Business Acquisition [Line Items]                
Inventories   81            
Bayer Animal Business | Raw Materials                
Business Acquisition [Line Items]                
Inventories   95            
Bayer Animal Business | Marketed products                
Business Acquisition [Line Items]                
Marketed products   3,740            
Bayer Animal Business | Intangible assets, primarily acquired in-process research and development                
Business Acquisition [Line Items]                
Intangible assets, primarily acquired in-process research and development   $ 65            
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.21.2
Acquisitions and Divestitures - Summary of Amounts Recognized for Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Millions
Sep. 30, 2021
Aug. 27, 2021
Jun. 30, 2021
Dec. 31, 2020
Aug. 01, 2020
Business Acquisition [Line Items]          
Goodwill $ 6,191     $ 6,225  
KindredBio          
Business Acquisition [Line Items]          
Cash and cash equivalents   $ 31      
Other net working capital   1      
Property and equipment   26      
Deferred income taxes   22      
Total identifiable net assets   388      
Goodwill   30      
Settlement of liability related to previous license agreement   26 $ 26    
Total consideration transferred   444      
KindredBio | Intangible assets, primarily acquired in-process research and development          
Business Acquisition [Line Items]          
Intangible assets, primarily acquired in-process research and development   $ 352      
Bayer Animal Business          
Business Acquisition [Line Items]          
Cash and cash equivalents         $ 169
Accounts receivable         10
Inventories         487
Prepaid expenses and other current assets         60
Property and equipment         315
Intangible assets, primarily acquired in-process research and development         65
Marketed products         3,740
Assets held for sale         138
Accounts payable and accrued liabilities         237
Accrued retirement benefits         220
Other noncurrent assets and liabilities, net         878
Total identifiable net assets         3,649
Goodwill         3,129
Total consideration transferred         6,778
Bayer Animal Business | Marketed products          
Business Acquisition [Line Items]          
Marketed products         3,740
Bayer Animal Business | Intangible assets, primarily acquired in-process research and development          
Business Acquisition [Line Items]          
Intangible assets, primarily acquired in-process research and development         $ 65
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.21.2
Acquisitions and Divestitures - Purchase Consideration (Details) - Bayer Animal Business
$ / shares in Units, $ in Thousands, shares in Millions
Aug. 01, 2020
USD ($)
$ / shares
shares
Business Acquisition [Line Items]  
Cash consideration $ 5,054,000
Fair value of Elanco common stock 1,724,000
Fair value of total consideration transferred 6,778,000
Payments to acquire businesses, before working capital adjustment 5,170,000
Working capital adjustments $ 116,000
Shares issued to previous shareholders upon closing (in shares) | shares 73
Common stock price (in dollars per share) | $ / shares $ 23.64
Fair value used in estimate $ 2,300,000
Volume weighted average stock price as of the last day of trading before the closing of the acquisition duration 20 days
Symmetrical collar (as a percent) 7.50%
Volume weighted average price for thirty trading days (usd per share) | $ / shares $ 33.60
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.21.2
Acquisitions and Divestitures - Pro Forma Information (Details) - Bayer Animal Business - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2020
Business Acquisition [Line Items]    
Revenue $ 1,069 $ 3,308
Loss before income taxes $ (227) $ (392)
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.21.2
Acquisitions and Divestitures - Assets and Liabilities Held for Sale (Details) - Worldwide rights to Osurnia and U.S. rights to Capstar - Held for Sale - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Inventories $ 38 $ 2
Other intangibles, net 0 4
Property and equipment, net 55 0
Deferred tax asset 0 1
Total assets held for sale $ 93 $ 7
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.21.2
Asset Impairment, Restructuring and Other Special Charges - Total Charges Related to Asset Impairment, Restructuring and Other Special Charges (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Restructuring charges:        
Severance and other costs $ (2) $ 130 $ 26 $ 131
Facility exit costs 0 0 0 1
Acquisition related charges:        
Transaction and integration costs 30 131 141 318
Non-cash and other items:        
Asset impairment 50 0 63 4
Asset write-down 6 1 275 3
Gain on sale of fixed assets 0 0 0 (4)
Settlements and other 27 0 13 3
Total expense 111 $ 262 518 $ 456
Litigation settlement charges $ 8   $ 8  
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.21.2
Asset Impairment, Restructuring and Other Special Charges - Narrative (Details)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
USD ($)
Sep. 30, 2021
USD ($)
position
country
Sep. 30, 2020
USD ($)
Restructuring Cost and Reserve [Line Items]      
Restructuring adjustments | $ $ 1 $ 15 $ 1
Expected payment term   15 months  
2021 Restructuring Plan      
Restructuring Cost and Reserve [Line Items]      
Expected number of positions eliminated | position   330  
Bayer Animal Business      
Restructuring Cost and Reserve [Line Items]      
Expected number of positions eliminated | position   900  
Restructuring costs | $   $ 44  
Number of countries expected to eliminate positions | country   40  
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.21.2
Asset Impairment, Restructuring and Other Special Charges - Summary of Activity in Reserves (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2021
Sep. 30, 2020
Restructuring Reserve [Roll Forward]      
Balance at beginning of period   $ 130 $ 21
Charges   41 133
Reserve adjustments $ (1) (15) (1)
Cash paid   (95) (16)
Balance at end of period 61 61 137
Facility exit costs      
Restructuring Reserve [Roll Forward]      
Balance at beginning of period   0 5
Charges   0 1
Reserve adjustments   0 0
Cash paid   0 (1)
Balance at end of period 0 0 5
Severance      
Restructuring Reserve [Roll Forward]      
Balance at beginning of period   130 16
Charges   41 132
Reserve adjustments   (15) (1)
Cash paid   (95) (15)
Balance at end of period $ 61 $ 61 $ 132
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.21.2
Inventories (Details) - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Inventory Disclosure [Abstract]    
Finished products $ 595 $ 772
Work in process 576 625
Raw materials and supplies 255 210
Total 1,426 1,607
Decrease to LIFO cost (43) (29)
Inventories $ 1,383 $ 1,578
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.21.2
Equity - Narrative (Details)
$ / shares in Units, shares in Millions
Jan. 23, 2020
USD ($)
shares
Jan. 22, 2020
USD ($)
tradingDay
$ / shares
shares
Sep. 30, 2021
USD ($)
Dec. 31, 2020
USD ($)
Class of Stock [Line Items]        
Number of shares sold in public offering (in shares) | shares 25      
Proceeds after underwriting discounts and commissions $ 768,000,000      
Net proceeds     $ 6,334,000,000 $ 6,127,000,000
Tangible Equity Unit (TEU)        
Class of Stock [Line Items]        
Number of shares sold in public offering (in shares) | shares   11    
Offering price (usd per share) | $ / shares   $ 50    
Proceeds after underwriting discounts and commissions   $ 528,000,000    
Tangible Equity Unit (TEU) | Minimum        
Class of Stock [Line Items]        
Shares issued upon conversion of prepaid stock purchase contracts (in shares) | shares   14    
Average applicable market value necessary to be included in calculation of diluted shares outstanding (usd per share) | $ / shares   $ 32.00    
Tangible Equity Unit (TEU) | Maximum        
Class of Stock [Line Items]        
Shares issued upon conversion of prepaid stock purchase contracts (in shares) | shares   17    
Average applicable market value necessary to be included in calculation of diluted shares outstanding (usd per share) | $ / shares   $ 38.40    
5.00% Tangible Equity Units | Senior Notes        
Class of Stock [Line Items]        
Interest rate on debt component   5.00%    
Number of consecutive trading days | tradingDay   20    
2.75% Senior Amortizing Notes | Senior Notes        
Class of Stock [Line Items]        
Interest rate on debt component   2.75%    
Net proceeds   $ 79,000,000    
Quarterly cash installment per amortizing note   0.6250    
Initial principal amount   7.2007    
First installment payment per amortizing note   $ 0.6528    
Common Stock Offering        
Class of Stock [Line Items]        
Number of shares sold in public offering (in shares) | shares   23    
Offering price (usd per share) | $ / shares   $ 32.00    
Over-Allotment Option        
Class of Stock [Line Items]        
Number of shares sold in public offering (in shares) | shares   2    
Tangible Equity Unit (TEU)        
Class of Stock [Line Items]        
Offering price (usd per share) | $ / shares   $ 50    
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.21.2
Equity - Schedule of Stockholders' Equity (Details) - USD ($)
$ / shares in Units, $ in Millions
 9 Months Ended
Jan. 23, 2020
Jan. 22, 2020
Sep. 30, 2021
Sep. 30, 2020
Class of Stock [Line Items]        
Gross proceeds     $ 0 $ 1,220
Net proceeds $ 768      
Equity Component        
Class of Stock [Line Items]        
Fair value per unit (usd per share)   $ 42.80    
Gross proceeds   $ 471    
Less: Issuance costs   19    
Net proceeds   $ 452    
Debt Component        
Class of Stock [Line Items]        
Fair value per unit (usd per share)   $ 7.20    
Gross proceeds   $ 79    
Less: Issuance costs   3    
Net proceeds   $ 76    
Tangible Equity Unit (TEU)        
Class of Stock [Line Items]        
Fair value per unit (usd per share)   $ 50    
Gross proceeds   $ 550    
Less: Issuance costs   22    
Net proceeds   $ 528    
Tangible Equity Unit (TEU) | Minimum        
Class of Stock [Line Items]        
Applicable Market Value (usd per share)   $ 32.00    
Settlement rate   130.21%    
Tangible Equity Unit (TEU) | Maximum        
Class of Stock [Line Items]        
Applicable Market Value (usd per share)   $ 38.40    
Settlement rate   156.25%    
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.21.2
Debt - Schedule of Long-term Debt (Details) - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Sep. 30, 2020
Jan. 22, 2020
Aug. 31, 2018
Debt Instrument [Line Items]          
Unamortized debt issuance costs $ (85)   $ (98)    
Total debt 6,334 $ 6,127      
Less current portion of long-term debt 61 555      
Total long-term debt 6,273 $ 5,572      
Credit facility | Incremental Term Facility          
Debt Instrument [Line Items]          
Long-term debt, gross 500   0    
Credit facility | Term Loan B          
Debt Instrument [Line Items]          
Long-term debt, gross 4,129   4,164    
Credit facility | Revolving Credit Facility          
Debt Instrument [Line Items]          
Long-term debt, gross $ 250   0    
Senior Notes | 3.912% Senior Notes due 2021          
Debt Instrument [Line Items]          
Interest rate 3.912%       3.912%
Long-term debt, gross $ 0   500    
Senior Notes | 4.272% Senior Notes due 2023          
Debt Instrument [Line Items]          
Interest rate 4.272%       4.272%
Long-term debt, gross $ 750   750    
Senior Notes | 4.900% Senior Notes due 2028          
Debt Instrument [Line Items]          
Interest rate 4.90%        
Long-term debt, gross $ 750   750    
Senior Notes | TEU Amortizing Notes          
Debt Instrument [Line Items]          
Interest rate       5.00%  
Long-term debt, gross 40   60    
Other obligations          
Debt Instrument [Line Items]          
Long-term debt, gross $ 0   $ 1    
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.21.2
Debt - Narrative (Details)
$ / shares in Units, shares in Millions
 1 Months Ended 3 Months Ended 9 Months Ended
Aug. 31, 2021
USD ($)
Aug. 12, 2021
USD ($)
Sep. 25, 2020
USD ($)
Aug. 01, 2020
USD ($)
Jan. 31, 2020
USD ($)
Jan. 23, 2020
USD ($)
shares
Jan. 22, 2020
USD ($)
$ / shares
shares
Apr. 30, 2021
USD ($)
Mar. 31, 2021
USD ($)
Sep. 30, 2021
USD ($)
covenant
Sep. 30, 2021
USD ($)
covenant
Sep. 30, 2020
USD ($)
Aug. 31, 2018
USD ($)
Debt Instrument [Line Items]                          
Net proceeds from revolving credit facility                     $ 250,000,000 $ 0  
Number of shares issued (in shares) | shares           25              
Proceeds after underwriting discounts and commissions           $ 768,000,000              
Tangible Equity Unit (TEU)                          
Debt Instrument [Line Items]                          
Number of shares issued (in shares) | shares             11            
Fair value per unit (usd per share) | $ / shares             $ 50            
Proceeds after underwriting discounts and commissions             $ 528,000,000            
Equity Component                          
Debt Instrument [Line Items]                          
Fair value per unit (usd per share) | $ / shares             $ 42.80            
Proceeds after underwriting discounts and commissions             $ 452,000,000            
Debt Component                          
Debt Instrument [Line Items]                          
Fair value per unit (usd per share) | $ / shares             $ 7.20            
Proceeds after underwriting discounts and commissions             $ 76,000,000            
Senior Notes                          
Debt Instrument [Line Items]                          
Debt instrument, face amount                         $ 2,000,000,000
Senior Notes | 3.912% Senior Notes due 2021                          
Debt Instrument [Line Items]                          
Interest rate                   3.912% 3.912%   3.912%
Debt instrument, face amount                         $ 500,000,000
Senior Notes | 4.272% Senior Notes due 2023                          
Debt Instrument [Line Items]                          
Interest rate                   4.272% 4.272%   4.272%
Debt instrument, face amount                         $ 750,000,000
Senior Notes | 4.900% Senior Notes Due 2028                          
Debt Instrument [Line Items]                          
Interest rate                         4.90%
Debt instrument, face amount                         $ 750,000,000
Senior Notes | TEUs                          
Debt Instrument [Line Items]                          
Interest rate             5.00%            
Debt instrument, face amount             $ 550,000,000            
Partial payment on principal and interest                   $ 7,000,000 $ 21,000,000    
Farm Credit Term Loan Facility | Credit Facility                          
Debt Instrument [Line Items]                          
Net proceeds from revolving credit facility   $ 500,000,000                      
Basis spread on variable rate   1.75%                      
Term Loan B | Credit Facility                          
Debt Instrument [Line Items]                          
Number of financial covenants | covenant                   0 0    
Revolving Credit Facility | Credit Facility                          
Debt Instrument [Line Items]                          
Net proceeds from revolving credit facility $ 350,000,000     $ 150,000,000                  
Credit facility, maximum borrowing capacity       $ 750,000,000                  
Debt maturity term       5 years                  
Repayments of lines of credit $ 100,000,000             $ 50,000,000 $ 100,000,000        
Number of financial covenants | covenant                   2 2    
Required ratio of pro forma net leverage and pro forma adjusted EBITDA                   7.71 7.71    
Required ratio of pro forma adjusted EBITDA to cash interest expense (no less than)                   2.00 2.00    
Revolving Credit Facility | Credit Facility | Minimum | LIBOR                          
Debt Instrument [Line Items]                          
Basis spread on variable rate       1.50%                  
Revolving Credit Facility | Credit Facility | Maximum | LIBOR                          
Debt Instrument [Line Items]                          
Basis spread on variable rate       2.25%                  
Term Loan Facility | Credit Facility                          
Debt Instrument [Line Items]                          
Debt repaid         $ 372,000,000                
Debt repaid, principal         371,000,000                
Debt repaid, interest         1,000,000                
Debt extinguishment loss     $ 2,000,000   $ 1,000,000                
Repayment of principal on indebtedness outstanding     $ 100,000,000                    
Bayer Animal Business | Term Loan B | Credit Facility                          
Debt Instrument [Line Items]                          
Credit facility, maximum borrowing capacity       $ 4,275,000,000                  
Basis spread on variable rate       1.75%                  
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.21.2
Financial Instruments and Fair Value - Narrative (Details)
SFr in Millions
 1 Months Ended 3 Months Ended 9 Months Ended
Oct. 31, 2018
CHF (SFr)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
Mar. 31, 2020
USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Equity method investments   $ 21,000,000   $ 21,000,000   $ 24,000,000  
Expected reclassification from accumulated other comprehensive loss   26,000,000   26,000,000      
Reclassification from AOCI   8,000,000   (22,000,000)      
Cross-currency fixed interest rate swap | Not Designated as Hedging Instrument              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Notional amount (USD, CHF)   1,417,000,000   1,417,000,000   $ 1,391,000,000  
Cross-currency fixed interest rate swap | Designated as Hedging Instrument | Net Investment Hedging              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Notional amount (USD, CHF) | SFr SFr 750            
Term of contract 5 years            
Cash benefit for liquidation         $ 35,000,000    
Interest included in cash benefit         2,000,000    
Forward-starting interest rate contracts designated as cash flow hedges | Designated as Hedging Instrument | Cash Flow Hedging              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Notional amount (USD, CHF)             $ 4,100,000,000
Interest rate swaps, net of tax   0 $ 2,000,000 0 $ 20,000,000    
Aratana              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Maximum aggregate contingent payment   12,000,000   12,000,000      
Prevtec              
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]              
Maximum aggregate contingent payment   $ 16,000,000   $ 16,000,000      
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.21.2
Financial Instruments and Fair Value - Summary of Fair Value Information (Details) - Recurring - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt - senior notes $ 0 $ 0
Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt - senior notes (6,551) (6,420)
Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt - senior notes 0 0
Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt - senior notes (6,419) (6,225)
Fair Value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Long-term debt - senior notes (6,551) (6,420)
Prepaid expenses and other | Quoted Prices in Active Markets for Identical Assets (Level 1) | Foreign exchange contracts not designated as hedging instruments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 0 0
Prepaid expenses and other | Significant Other Observable Inputs (Level 2) | Foreign exchange contracts not designated as hedging instruments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 30 36
Prepaid expenses and other | Significant Unobservable Inputs (Level 3) | Foreign exchange contracts not designated as hedging instruments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 0 0
Prepaid expenses and other | Carrying Amount | Foreign exchange contracts not designated as hedging instruments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 30 36
Prepaid expenses and other | Fair Value | Foreign exchange contracts not designated as hedging instruments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 30 36
Other current liabilities | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration 0  
Other current liabilities | Quoted Prices in Active Markets for Identical Assets (Level 1) | Foreign exchange contracts not designated as hedging instruments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 0 0
Other current liabilities | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration 0  
Other current liabilities | Significant Other Observable Inputs (Level 2) | Foreign exchange contracts not designated as hedging instruments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) (30) (36)
Other current liabilities | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration (1)  
Other current liabilities | Significant Unobservable Inputs (Level 3) | Foreign exchange contracts not designated as hedging instruments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 0 0
Other current liabilities | Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration (1)  
Other current liabilities | Carrying Amount | Foreign exchange contracts not designated as hedging instruments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) (30) (36)
Other current liabilities | Fair Value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration (1)  
Other current liabilities | Fair Value | Foreign exchange contracts not designated as hedging instruments    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) (30) (36)
Other noncurrent liabilities | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration   0
Other noncurrent liabilities | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration   0
Other noncurrent liabilities | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration   (1)
Other noncurrent liabilities | Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration   (1)
Other noncurrent liabilities | Fair Value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration   (1)
Other noncurrent assets | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 15 9
Other noncurrent assets | Quoted Prices in Active Markets for Identical Assets (Level 1) | Forward-starting interest rate contracts designated as cash flow hedges    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 0 0
Other noncurrent assets | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 0 0
Other noncurrent assets | Significant Other Observable Inputs (Level 2) | Forward-starting interest rate contracts designated as cash flow hedges    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) (24) (76)
Other noncurrent assets | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 0 0
Other noncurrent assets | Significant Unobservable Inputs (Level 3) | Forward-starting interest rate contracts designated as cash flow hedges    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 0 0
Other noncurrent assets | Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 15 9
Other noncurrent assets | Carrying Amount | Forward-starting interest rate contracts designated as cash flow hedges    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) (24) (76)
Other noncurrent assets | Fair Value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) 15 9
Other noncurrent assets | Fair Value | Forward-starting interest rate contracts designated as cash flow hedges    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets (liabilities) $ (24) $ (76)
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.21.2
Financial Instruments and Fair Value - Net Gain/Loss on Derivative Instruments (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Cross-currency fixed interest rate swap | Not Designated as Hedging Instrument | Other Operating Income (Expense)        
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]        
Net gain (loss) on derivative instruments $ (2,000,000) $ (2,000,000) $ (29,000,000) $ 19,000,000
Cross-currency fixed interest rate swap | Designated as Hedging Instrument | Net Investment Hedging        
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]        
Gain (loss), net of tax 0 0 0 24,000,000
Cross-currency fixed interest rate swap | Designated as Hedging Instrument | Interest Expense | Net Investment Hedging        
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]        
Amount offsetting interest expense 0 0 0 6,000,000
Forward-starting interest rate contracts designated as cash flow hedges | Designated as Hedging Instrument | Cash Flow Hedging        
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]        
Gain (loss), net of tax 4,000,000 (7,000,000) 52,000,000 (67,000,000)
Interest rate swaps, net of tax $ 0 $ 2,000,000 $ 0 $ 20,000,000
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes - Provision for Taxes on Income (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Income Tax Disclosure [Abstract]        
Income tax benefit $ (26) $ (74) $ (71) $ (117)
Effective tax rate 20.00% 35.40% 15.90% 32.90%
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Income Tax Disclosure [Abstract]        
Income tax benefit $ 26 $ 74 $ 71 $ 117
Effective tax rate 20.00% 35.40% 15.90% 32.90%
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies - Narrative (Details) - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Oct. 16, 2020
Commitments and Contingencies Disclosure [Abstract]      
Percent of TEUs issued involved in lawsuit     5.00%
Liabilities related to litigation $ 0 $ 0  
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.21.2
Geographic Information - Narrative (Details)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
USD ($)
Sep. 30, 2020
Sep. 30, 2021
USD ($)
segment
Sep. 30, 2020
Dec. 31, 2020
USD ($)
Segment Reporting [Abstract]          
Number of operating segments | segment     1    
Concentration Risk [Line Items]          
Accounts receivable $ 924   $ 924   $ 872
Product Sales          
Concentration Risk [Line Items]          
Accounts receivable $ 80   $ 80   $ 87
Customer Concentration Risk | Revenue | Single Customer          
Concentration Risk [Line Items]          
Concentration risk (as a percent) 11.00% 12.00% 9.00% 12.00%  
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.21.2
Geographic Information - Revenue by Selected Geographic Area Information (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]        
Revenue $ 1,131 $ 890 $ 3,652 $ 2,134
United States        
Revenues from External Customers and Long-Lived Assets [Line Items]        
Revenue 507 422 1,621 970
International        
Revenues from External Customers and Long-Lived Assets [Line Items]        
Revenue $ 624 $ 468 $ 2,031 $ 1,164
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.21.2
Retirement Benefits (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]        
Defined Benefit Plan, Type [Extensible Enumeration]     Pension Plan  
Pension Plan        
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]        
Service cost $ 4 $ 3 $ 14 $ 8
Interest cost 1 0 2 1
Expected return on plan assets (2) (2) (5) (4)
Amortization of prior service cost (1) (2) (5) (6)
Amortization of net actuarial loss 0 1 1 2
Net curtailments and settlements (Note 5) (9) 0 (26) 0
Net periodic benefit cost (income) $ (7) $ 0 $ (19) $ 1
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.21.2
Loss Per Share (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Jun. 30, 2021
Mar. 31, 2021
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Sep. 30, 2021
Sep. 30, 2020
Earnings Per Share [Abstract]                
Net loss available to common shareholders $ (104) $ (210) $ (61) $ (135) $ (53) $ (49) $ (375) $ (237)
Weighted average common shares outstanding (in shares) 487.3     462.4     487.1 426.5
Assumed conversion of dilutive common stock equivalents (in shares) 0.0     0.0     0.0 0.0
Diluted weighted average shares outstanding (in shares) 487.3     462.4     487.1 426.5
Basic (usd per share) $ (0.21)     $ (0.29)     $ (0.77) $ (0.56)
Diluted (usd per share) $ (0.21)     $ (0.29)     $ (0.77) $ (0.56)
Antidilutive shares not included in calculating diluted earnings per share (in shares) 1.7     1.6     1.6 1.9
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.21.2
Transactions and Agreements with Bayer - Narrative (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2021
USD ($)
Bayer  
Related Party Transaction [Line Items]  
Asset purchase refund $ 16
XML 74 R9999.htm IDEA: XBRL DOCUMENT v3.21.2
Label Element Value
Accounting Standards Update [Extensible Enumeration] us-gaap_AccountingStandardsUpdateExtensibleList Accounting Standards Update 2016-13 [Member]
EXCEL 75 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

<*-+7-_P!6YV#L$]GMLW7;H/K.,ZJY31$4G BJQXK8"U_,9:D7U/V+[\49OR1V\HOW%G9#?) MH_(_W[Z Z_S32O_&9X]M6A@'1?V+?! : _3L!GBN[+=G\$'7M9;=,];HP?Y&GLFD[KGI#3'BBZ)[Q5L]N<;_)->& S6*ZPK)^6%+->O!-[EVDQ,:J/+M5 MM1>V_LE H]D=0[.K_1YYE?,5S05("9+A7&[D2H*SX\(\QO)-MF1UHQ) MR9+LD,D@#-5Y-.DBF2=O=AL0^,3 M/C2RQ'MT><_EX26IXQTS@V2-J/[R7HH'JG M,5R_7J%?Y9W7G7DBDI[S^%]LJN8G@_$ 3>F,9+%ZX"_7M.Q08/ F/);Y_^BE M;.L,T"23BB>EL?8@86GQE_PH [%FX.(M!FYIX/8U\$H#KZ^!7QKX?0V"TB#H M:Q"6!N&F0;3%("H-H@T#;YO!N#08]W7IJ#0XZFN G15SSJ;)T3:3BNP&VUM- M5G3CWGSC%>&X-^-X13G..1\5Z9OG_@51Y/18\!*2T'P9M-"G?>5:\T]WRSH_9\Q!Y^!"YCHN_/5Z@@]\^M*"<]T#! M;A?*!8SR2!=#Y 8YBK,=Y;*'+P[N0KF"43Z3M(H+@/*I!XKKU5 *UEJPKOM@ MN34LFQ9;46\ZHK40NI].%W.?890[(OIDT9\]^-_P9<*7-"6I:D&[_:5H=_W1 M@'RX[SW:\+@59:0UHQ(.MQ(.-X?U(.&X2:42F9[Z%?KWK6Z ;A1-Y'\ >*^" M]W)X?PO\O2YS%H)/*)U*-!,\T87%DL=+ECZCB:!3IM",3%C,U&L;305XF(.; M]XM%RGH-G2MJAY[E>>^[#G6?)$!>*S2BNES.@4'6C-+.Y\0#_1 MUK'SJ4 /:JZW>Q14'@6@1U]6<20SI3W+TBD5+X(I$\LIDQ.>I4H_3*=HPI-$ MN[M%UC\%C5A%X7@CJC4/P\K#$/3P*TF?V5-,T>7W3#.:3S;HX.OE-RA3HPH\ MVD>FCBOX\3[YOAXW^,:X/9I'E4='H$=7A FT)'%&T2+GVP0SD]/\5^Z(\)M71PVJ@RT<8\>6&L[_)0^OR_?4O'/!1,1K]1 &G2PS\)PG"Y[23=FN@UJM MQ'L12VS5$L-R^2LH+U\1K475=X?C+0&UZYVHQ,O1RRZN8Z^^#;M0XFU50 MW9FUZL_M'3Z=9=[P"+N_H]K=J4Y,4P=#G;<"YWI[B:Z5*1>6J9M4IRJ5"NEU M,&U;1W38%Q%HJT7?:GC_!L-ZYZW\N3WD;Y?4:E:"04=F6=UTX5IP([/\H1MM MR2P/ZKN547.LY%9%T5FC:$5K!5L#^]EB6Q%V(-%N"NS[COL300@ MFKVUU3I,^*I!?LA4ZK?!ZL?%UT7G?8 M!T,'IM-JH@>7ECO2>5W"U>:##CJM?'H=Q201BI$8+HH5@Z80M]$U3 M0[(R;&W2ZK44D&W;0+U'!<).B_VK+Y2?7W+28JNRMTKG:'E MLZO6_:SZ'I35.G\OU:AOQ!@%T+CRK4SZL$Q:^L]VXWUM\]'?"^]6!7VX5+3;73.6 M$CT,]2A<;7$;N06VN_\LH=?WNC;'(=BD[K+551_6Q87/H[5XJ!5<\ KA1S!A.B,F&R1$\O29L''2 !>J5$0+5'8-4V@-7V M@9;3GS0CSSS-+PJRVS@.FOJ*&_I:'-:U-&W/AL^]0.L]M*(=P"+['ETIH6MG M)ANZ C:INVS5/(#5_(%^SYAFP,PKC!O7]:!$^?^1XGJ4RGE5 MA2'Z8T%32=%!RG4$I$1J3M+6D]F@Y:AKLX=0DWKOUD[#X!ELA^E W[EC:2Y* M/]'MS=E?#]!HMA-2L)>MX<#.0 %%5GK# M'OL-0D^*;-KVG4W8W%[P(O"H*+3B&,+BN/;J0[L2;?6B*5Y>!"XJ0RMB88\= MVY47P KX*FP6U+ +:V?V<%F=NT!_F%.=C,EY3G3,9=M!SD4)U7(641?\JY:& ML+M6$T-8PZH2JIC/5CL(>H"R=*J[0J>IF:UXIJ32$[;N56M'FCL='250:+4Q MA+7QC+SJ"NBCGF^T7V>99+E#/]%;5XVAU<1P+YH864V,8 U[9ZT?-0_\?7=5 M[;>'/;*J&,&JN+->=^!MW2X8K7VF:3ZDOB/BF:525TDS#>1HLP$2Q;?)Q0_% M%_F7FT]<*9[DEW/M)!6F@7X^XURM?IB/0:LOQ$__!U!+ P04 " !41V53 M;^0J"Q(% "%%0 &0 'AL+W=O#%5OP&3??5P\*G^HY2BABGF@A$U!\?EF[(A=WM&T- MW(@?@J_USG>PKCQ)^=,^3,/+6L,RXA$/C(5@^/',1SR*+!+R^)6!UO(YK>'N M]RWZQ#F/SCPQS41!%FH1[4#?*QJ/4@F_MZ,S<],C>!>YF8I8:;).1AB?W(;]]\S_[& M;]_WV-=Q'?/%I-O%O*9>P&^!.8(T+ XE MWV=C./FC#&5<':5Q'.7F0[A,/H3+K1]ES(/M^OI0[OPH]TR]@[(7_&9>24T' MVSQ627F]G,(UB["J.,R<_-PJF:Y$LCB%HMIFAAENBPU&;&6[N(9__D1$F.)K M_:^'3ROGTW)\6D?XW/Q*A7F%F)NE#+%0G[DVKKK+\G$#U7%05NZ>AY0TW-^@ M_KR;+%4'WI8,;+T9N.=6.W>K[7?K986RQT,4SB!B6HNY")B3P;F2,6IAD,9I MQ.P(:99<02!C5/6EE5ML7Y'4I0NPF;2]2[=3N@ 5!N[YUBQUY^K; M:%I&MW/ HE?*]G#<&:4^NMV<;M=+=Z1P(<^"5"F>!*\P%R_<)IGA"M,,4"LX MZ#5;P7_P51H8-*]EQ/J?8KRZ^=\^MX%0K<1%J=B ML4QQGA/L-*> HE"J!_V#.)$6Z9:&M/K0V_Y!#9)F_VVY[GE'&L6^H?%!"?!> M\&V.8)BF>8?:CO%$@>SL;\BGR M""T;T-S,#5P(W#*4;J0TDH3NQ[+:/!;&0 M+-+T4OF+JQCD''MD8A0>(TJG]D.TX94SI7TK4R@6\4O6B.DE//&$SX4!/)=! M)%#$0MA.D4XD#\ MZH#GM#53X9DV3!E;/ON5MHV?QF/;;K$YPG,\G\(22XKK:M7HPC"Q5A4*L1 , MTOTC0Z% MX$W_'Y-# 7B;C]DYZ5VLR7&L(\[30DJH7TJNT&F6,-\!K&CW]'.T>UJT>^IO M]_?L1<0I[DP7"\47VVI%(G;:%7L]W/]D1T1Z*/3ET:LRMSA*9H\M3?Y'\[-.W#C57Y::'*R WY^LX=3LS5PMWG80>WG6ES M",W?YG>&5^ZF[,W[$;D8DY+W-^1BLKD1+. W%Y1X(,8NKR'BI#$R=E^7G(5DDQ;8CU]2 M=CRR)4UD5P[XDMCRD![QS,SA'$LZ>RK$=SEC3)$?\RR7YX.94HOWPZ$)AG/*\\'%67GL5ER<%4N5\9S= M"B*7\SD5/S^PK'@Z'[B#YP-?^'2FS('AQ=F"3MD=4U\7MT*_&VYFF? YRR4O M;+S4#JZ^?9_]8GKT^FWLJV:C(_N(3-3L?) ,R80]TF:DO MQ=/O;'U&H9EO7&2R_$N>UK;.@(R74A7S]6#MP9SGJ__TQWHE*@/G$FBBS;PHUZ84[S,:<9NZ5#@/)L_\FN[$CV!WAGK?6^N9Q_/ M:#YE9%SD2NBMMC0+HI=(ZD^I^0XJR8Q-I@89#AM'#!*H[6YB9

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 77 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 78 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 330 357 1 true 87 0 false 11 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.elanco.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 2 false false R3.htm 1002003 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Sheet http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Statements 3 false false R4.htm 1003004 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.elanco.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 4 false false R5.htm 1004005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.elanco.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 5 false false R6.htm 1005006 - Statement - Condensed Consolidated Statements of Equity (Unaudited) Sheet http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited Condensed Consolidated Statements of Equity (Unaudited) Statements 6 false false R7.htm 1006007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies Notes 8 false false R9.htm 2103102 - Disclosure - Implementation of New Financial Accounting Pronouncements Sheet http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncements Implementation of New Financial Accounting Pronouncements Notes 9 false false R10.htm 2105103 - Disclosure - Revenue Sheet http://www.elanco.com/role/Revenue Revenue Notes 10 false false R11.htm 2110104 - Disclosure - Acquisitions and Divestitures Sheet http://www.elanco.com/role/AcquisitionsandDivestitures Acquisitions and Divestitures Notes 11 false false R12.htm 2117105 - Disclosure - Asset Impairment, Restructuring and Other Special Charges Sheet http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialCharges Asset Impairment, Restructuring and Other Special Charges Notes 12 false false R13.htm 2122106 - Disclosure - Inventories Sheet http://www.elanco.com/role/Inventories Inventories Notes 13 false false R14.htm 2125107 - Disclosure - Equity Sheet http://www.elanco.com/role/Equity Equity Notes 14 false false R15.htm 2129108 - Disclosure - Debt Sheet http://www.elanco.com/role/Debt Debt Notes 15 false false R16.htm 2133109 - Disclosure - Financial Instruments and Fair Value Sheet http://www.elanco.com/role/FinancialInstrumentsandFairValue Financial Instruments and Fair Value Notes 16 false false R17.htm 2138110 - Disclosure - Income Taxes Sheet http://www.elanco.com/role/IncomeTaxes Income Taxes Notes 17 false false R18.htm 2142111 - Disclosure - Commitments and Contingencies Sheet http://www.elanco.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 18 false false R19.htm 2144112 - Disclosure - Geographic Information Sheet http://www.elanco.com/role/GeographicInformation Geographic Information Notes 19 false false R20.htm 2148113 - Disclosure - Retirement Benefits Sheet http://www.elanco.com/role/RetirementBenefits Retirement Benefits Notes 20 false false R21.htm 2151114 - Disclosure - Loss Per Share Sheet http://www.elanco.com/role/LossPerShare Loss Per Share Notes 21 false false R22.htm 2154115 - Disclosure - Transactions and Agreements with Bayer Sheet http://www.elanco.com/role/TransactionsandAgreementswithBayer Transactions and Agreements with Bayer Notes 22 false false R23.htm 2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies Basis of Presentation and Summary of Significant Accounting Policies (Policies) Policies http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies 23 false false R24.htm 2304301 - Disclosure - Implementation of New Financial Accounting Pronouncements (Tables) Sheet http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncementsTables Implementation of New Financial Accounting Pronouncements (Tables) Tables http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncements 24 false false R25.htm 2306302 - Disclosure - Revenue (Tables) Sheet http://www.elanco.com/role/RevenueTables Revenue (Tables) Tables http://www.elanco.com/role/Revenue 25 false false R26.htm 2311303 - Disclosure - Acquisitions and Divestitures (Tables) Sheet http://www.elanco.com/role/AcquisitionsandDivestituresTables Acquisitions and Divestitures (Tables) Tables http://www.elanco.com/role/AcquisitionsandDivestitures 26 false false R27.htm 2318304 - Disclosure - Asset Impairment, Restructuring and Other Special Charges (Tables) Sheet http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables Asset Impairment, Restructuring and Other Special Charges (Tables) Tables http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialCharges 27 false false R28.htm 2323305 - Disclosure - Inventories (Tables) Sheet http://www.elanco.com/role/InventoriesTables Inventories (Tables) Tables http://www.elanco.com/role/Inventories 28 false false R29.htm 2326306 - Disclosure - Equity (Tables) Sheet http://www.elanco.com/role/EquityTables Equity (Tables) Tables http://www.elanco.com/role/Equity 29 false false R30.htm 2330307 - Disclosure - Debt (Tables) Sheet http://www.elanco.com/role/DebtTables Debt (Tables) Tables http://www.elanco.com/role/Debt 30 false false R31.htm 2334308 - Disclosure - Financial Instruments and Fair Value (Tables) Sheet http://www.elanco.com/role/FinancialInstrumentsandFairValueTables Financial Instruments and Fair Value (Tables) Tables http://www.elanco.com/role/FinancialInstrumentsandFairValue 31 false false R32.htm 2339309 - Disclosure - Income Taxes (Tables) Sheet http://www.elanco.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.elanco.com/role/IncomeTaxes 32 false false R33.htm 2345310 - Disclosure - Geographic Information (Tables) Sheet http://www.elanco.com/role/GeographicInformationTables Geographic Information (Tables) Tables http://www.elanco.com/role/GeographicInformation 33 false false R34.htm 2349311 - Disclosure - Retirement Benefits (Tables) Sheet http://www.elanco.com/role/RetirementBenefitsTables Retirement Benefits (Tables) Tables http://www.elanco.com/role/RetirementBenefits 34 false false R35.htm 2352312 - Disclosure - Loss Per Share (Tables) Sheet http://www.elanco.com/role/LossPerShareTables Loss Per Share (Tables) Tables http://www.elanco.com/role/LossPerShare 35 false false R36.htm 2407401 - Disclosure - Revenue - Narrative (Details) Sheet http://www.elanco.com/role/RevenueNarrativeDetails Revenue - Narrative (Details) Details 36 false false R37.htm 2408402 - Disclosure - Revenue - Summary of Activity in Sales Rebates and Discounts Liability (Details) Sheet http://www.elanco.com/role/RevenueSummaryofActivityinSalesRebatesandDiscountsLiabilityDetails Revenue - Summary of Activity in Sales Rebates and Discounts Liability (Details) Details 37 false false R38.htm 2409403 - Disclosure - Revenue - Disaggregation of Revenue (Details) Sheet http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails Revenue - Disaggregation of Revenue (Details) Details 38 false false R39.htm 2412404 - Disclosure - Acquisitions and Divestitures - Narrative (Details) Sheet http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails Acquisitions and Divestitures - Narrative (Details) Details 39 false false R40.htm 2413405 - Disclosure - Acquisitions and Divestitures - Summary of Amounts Recognized for Assets Acquired and Liabilities Assumed (Details) Sheet http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails Acquisitions and Divestitures - Summary of Amounts Recognized for Assets Acquired and Liabilities Assumed (Details) Details 40 false false R41.htm 2414406 - Disclosure - Acquisitions and Divestitures - Purchase Consideration (Details) Sheet http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails Acquisitions and Divestitures - Purchase Consideration (Details) Details 41 false false R42.htm 2415407 - Disclosure - Acquisitions and Divestitures - Pro Forma Information (Details) Sheet http://www.elanco.com/role/AcquisitionsandDivestituresProFormaInformationDetails Acquisitions and Divestitures - Pro Forma Information (Details) Details 42 false false R43.htm 2416408 - Disclosure - Acquisitions and Divestitures - Assets and Liabilities Held for Sale (Details) Sheet http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails Acquisitions and Divestitures - Assets and Liabilities Held for Sale (Details) Details 43 false false R44.htm 2419409 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Total Charges Related to Asset Impairment, Restructuring and Other Special Charges (Details) Sheet http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails Asset Impairment, Restructuring and Other Special Charges - Total Charges Related to Asset Impairment, Restructuring and Other Special Charges (Details) Details 44 false false R45.htm 2420410 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Narrative (Details) Sheet http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails Asset Impairment, Restructuring and Other Special Charges - Narrative (Details) Details http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables 45 false false R46.htm 2421411 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Summary of Activity in Reserves (Details) Sheet http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails Asset Impairment, Restructuring and Other Special Charges - Summary of Activity in Reserves (Details) Details 46 false false R47.htm 2424412 - Disclosure - Inventories (Details) Sheet http://www.elanco.com/role/InventoriesDetails Inventories (Details) Details http://www.elanco.com/role/InventoriesTables 47 false false R48.htm 2427413 - Disclosure - Equity - Narrative (Details) Sheet http://www.elanco.com/role/EquityNarrativeDetails Equity - Narrative (Details) Details 48 false false R49.htm 2428414 - Disclosure - Equity - Schedule of Stockholders' Equity (Details) Sheet http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails Equity - Schedule of Stockholders' Equity (Details) Details 49 false false R50.htm 2431415 - Disclosure - Debt - Schedule of Long-term Debt (Details) Sheet http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails Debt - Schedule of Long-term Debt (Details) Details 50 false false R51.htm 2432416 - Disclosure - Debt - Narrative (Details) Sheet http://www.elanco.com/role/DebtNarrativeDetails Debt - Narrative (Details) Details 51 false false R52.htm 2435417 - Disclosure - Financial Instruments and Fair Value - Narrative (Details) Sheet http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails Financial Instruments and Fair Value - Narrative (Details) Details 52 false false R53.htm 2436418 - Disclosure - Financial Instruments and Fair Value - Summary of Fair Value Information (Details) Sheet http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails Financial Instruments and Fair Value - Summary of Fair Value Information (Details) Details 53 false false R54.htm 2437419 - Disclosure - Financial Instruments and Fair Value - Net Gain/Loss on Derivative Instruments (Details) Sheet http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails Financial Instruments and Fair Value - Net Gain/Loss on Derivative Instruments (Details) Details 54 false false R55.htm 2440420 - Disclosure - Income Taxes - Provision for Taxes on Income (Details) Sheet http://www.elanco.com/role/IncomeTaxesProvisionforTaxesonIncomeDetails Income Taxes - Provision for Taxes on Income (Details) Details 55 false false R56.htm 2441421 - Disclosure - Income Taxes - Narrative (Details) Sheet http://www.elanco.com/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 56 false false R57.htm 2443422 - Disclosure - Commitments and Contingencies - Narrative (Details) Sheet http://www.elanco.com/role/CommitmentsandContingenciesNarrativeDetails Commitments and Contingencies - Narrative (Details) Details 57 false false R58.htm 2446423 - Disclosure - Geographic Information - Narrative (Details) Sheet http://www.elanco.com/role/GeographicInformationNarrativeDetails Geographic Information - Narrative (Details) Details 58 false false R59.htm 2447424 - Disclosure - Geographic Information - Revenue by Selected Geographic Area Information (Details) Sheet http://www.elanco.com/role/GeographicInformationRevenuebySelectedGeographicAreaInformationDetails Geographic Information - Revenue by Selected Geographic Area Information (Details) Details 59 false false R60.htm 2450425 - Disclosure - Retirement Benefits (Details) Sheet http://www.elanco.com/role/RetirementBenefitsDetails Retirement Benefits (Details) Details http://www.elanco.com/role/RetirementBenefitsTables 60 false false R61.htm 2453426 - Disclosure - Loss Per Share (Details) Sheet http://www.elanco.com/role/LossPerShareDetails Loss Per Share (Details) Details http://www.elanco.com/role/LossPerShareTables 61 false false R62.htm 2455427 - Disclosure - Transactions and Agreements with Bayer - Narrative (Details) Sheet http://www.elanco.com/role/TransactionsandAgreementswithBayerNarrativeDetails Transactions and Agreements with Bayer - Narrative (Details) Details 62 false false R9999.htm Uncategorized Items - elan-20210930.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - elan-20210930.htm Cover 63 false false All Reports Book All Reports elan-20210930.htm elan-20210930.xsd elan-20210930_cal.xml elan-20210930_def.xml elan-20210930_lab.xml elan-20210930_pre.xml ex311elanco-20210930xceoce.htm ex312elanco-20210930xcfoce.htm ex32elanco-20210930xsectio.htm elan-20210930_g1.jpg http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021 http://fasb.org/srt/2021-01-31 http://xbrl.sec.gov/country/2021 true true JSON 81 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "elan-20210930.htm": { "axisCustom": 0, "axisStandard": 33, "contextCount": 330, "dts": { "calculationLink": { "local": [ "elan-20210930_cal.xml" ] }, "definitionLink": { "local": [ "elan-20210930_def.xml" ] }, "inline": { "local": [ "elan-20210930.htm" ] }, "labelLink": { "local": [ "elan-20210930_lab.xml" ] }, "presentationLink": { "local": [ "elan-20210930_pre.xml" ] }, "schema": { "local": [ "elan-20210930.xsd" ], "remote": [ "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 509, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 3, "http://xbrl.sec.gov/dei/2021": 5, "total": 8 }, "keyCustom": 39, "keyStandard": 318, "memberCustom": 33, "memberStandard": 50, "nsprefix": "elan", "nsuri": "http://www.elanco.com/20210930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.elanco.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105103 - Disclosure - Revenue", "role": "http://www.elanco.com/role/Revenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110104 - Disclosure - Acquisitions and Divestitures", "role": "http://www.elanco.com/role/AcquisitionsandDivestitures", "shortName": "Acquisitions and Divestitures", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117105 - Disclosure - Asset Impairment, Restructuring and Other Special Charges", "role": "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialCharges", "shortName": "Asset Impairment, Restructuring and Other Special Charges", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2122106 - Disclosure - Inventories", "role": "http://www.elanco.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2125107 - Disclosure - Equity", "role": "http://www.elanco.com/role/Equity", "shortName": "Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2129108 - Disclosure - Debt", "role": "http://www.elanco.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2133109 - Disclosure - Financial Instruments and Fair Value", "role": "http://www.elanco.com/role/FinancialInstrumentsandFairValue", "shortName": "Financial Instruments and Fair Value", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2138110 - Disclosure - Income Taxes", "role": "http://www.elanco.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2142111 - Disclosure - Commitments and Contingencies", "role": "http://www.elanco.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2144112 - Disclosure - Geographic Information", "role": "http://www.elanco.com/role/GeographicInformation", "shortName": "Geographic Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i319cd0149cdb41778f6fd9e86cfc44a8_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "role": "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i319cd0149cdb41778f6fd9e86cfc44a8_D20210701-20210930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2148113 - Disclosure - Retirement Benefits", "role": "http://www.elanco.com/role/RetirementBenefits", "shortName": "Retirement Benefits", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2151114 - Disclosure - Loss Per Share", "role": "http://www.elanco.com/role/LossPerShare", "shortName": "Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2154115 - Disclosure - Transactions and Agreements with Bayer", "role": "http://www.elanco.com/role/TransactionsandAgreementswithBayer", "shortName": "Transactions and Agreements with Bayer", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:BasisOfAccounting", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "role": "http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:BasisOfAccounting", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - Implementation of New Financial Accounting Pronouncements (Tables)", "role": "http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncementsTables", "shortName": "Implementation of New Financial Accounting Pronouncements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306302 - Disclosure - Revenue (Tables)", "role": "http://www.elanco.com/role/RevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311303 - Disclosure - Acquisitions and Divestitures (Tables)", "role": "http://www.elanco.com/role/AcquisitionsandDivestituresTables", "shortName": "Acquisitions and Divestitures (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2318304 - Disclosure - Asset Impairment, Restructuring and Other Special Charges (Tables)", "role": "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables", "shortName": "Asset Impairment, Restructuring and Other Special Charges (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2323305 - Disclosure - Inventories (Tables)", "role": "http://www.elanco.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2326306 - Disclosure - Equity (Tables)", "role": "http://www.elanco.com/role/EquityTables", "shortName": "Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i319cd0149cdb41778f6fd9e86cfc44a8_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "role": "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited", "shortName": "Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i319cd0149cdb41778f6fd9e86cfc44a8_D20210701-20210930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2330307 - Disclosure - Debt (Tables)", "role": "http://www.elanco.com/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2334308 - Disclosure - Financial Instruments and Fair Value (Tables)", "role": "http://www.elanco.com/role/FinancialInstrumentsandFairValueTables", "shortName": "Financial Instruments and Fair Value (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2339309 - Disclosure - Income Taxes (Tables)", "role": "http://www.elanco.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2345310 - Disclosure - Geographic Information (Tables)", "role": "http://www.elanco.com/role/GeographicInformationTables", "shortName": "Geographic Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2349311 - Disclosure - Retirement Benefits (Tables)", "role": "http://www.elanco.com/role/RetirementBenefitsTables", "shortName": "Retirement Benefits (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2352312 - Disclosure - Loss Per Share (Tables)", "role": "http://www.elanco.com/role/LossPerShareTables", "shortName": "Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "iaa1cb7c1b993462e85c29773d4e8fa0a_D20210101-20210930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407401 - Disclosure - Revenue - Narrative (Details)", "role": "http://www.elanco.com/role/RevenueNarrativeDetails", "shortName": "Revenue - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "iaa1cb7c1b993462e85c29773d4e8fa0a_D20210101-20210930", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i81b96689427e49d1a9234ee44a4568c7_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - Revenue - Summary of Activity in Sales Rebates and Discounts Liability (Details)", "role": "http://www.elanco.com/role/RevenueSummaryofActivityinSalesRebatesandDiscountsLiabilityDetails", "shortName": "Revenue - Summary of Activity in Sales Rebates and Discounts Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i81b96689427e49d1a9234ee44a4568c7_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i319cd0149cdb41778f6fd9e86cfc44a8_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - Revenue - Disaggregation of Revenue (Details)", "role": "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails", "shortName": "Revenue - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i270e75c3a1b947b4a7a058ed3d049f0b_D20210701-20210930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i319cd0149cdb41778f6fd9e86cfc44a8_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412404 - Disclosure - Acquisitions and Divestitures - Narrative (Details)", "role": "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "shortName": "Acquisitions and Divestitures - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i3db51b873fa44e79abbf90adc6769780_I20210630", "decimals": "0", "lang": "en-US", "name": "elan:DisposalGroupIncludingDiscontinuedOperationNumberOfEmployeesTransferred", "reportCount": 1, "unique": true, "unitRef": "employee", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i1e12f2d736384683a22678bca3958815_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i1e12f2d736384683a22678bca3958815_I20210930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherReceivablesNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i1e12f2d736384683a22678bca3958815_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413405 - Disclosure - Acquisitions and Divestitures - Summary of Amounts Recognized for Assets Acquired and Liabilities Assumed (Details)", "role": "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "shortName": "Acquisitions and Divestitures - Summary of Amounts Recognized for Assets Acquired and Liabilities Assumed (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i52da7902f71f4aab8c43fafd7e4eb376_I20210827", "decimals": "-6", "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "ief61b5a0d0db4e43aef2807e25b8c825_D20200801-20200801", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414406 - Disclosure - Acquisitions and Divestitures - Purchase Consideration (Details)", "role": "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails", "shortName": "Acquisitions and Divestitures - Purchase Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "ief61b5a0d0db4e43aef2807e25b8c825_D20200801-20200801", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i50e98473025148659eb3a3614210003b_D20200701-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415407 - Disclosure - Acquisitions and Divestitures - Pro Forma Information (Details)", "role": "http://www.elanco.com/role/AcquisitionsandDivestituresProFormaInformationDetails", "shortName": "Acquisitions and Divestitures - Pro Forma Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i50e98473025148659eb3a3614210003b_D20200701-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "ie3360e20e528438e867478966a24ed82_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416408 - Disclosure - Acquisitions and Divestitures - Assets and Liabilities Held for Sale (Details)", "role": "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails", "shortName": "Acquisitions and Divestitures - Assets and Liabilities Held for Sale (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "ie3360e20e528438e867478966a24ed82_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i319cd0149cdb41778f6fd9e86cfc44a8_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:SeveranceCosts1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419409 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Total Charges Related to Asset Impairment, Restructuring and Other Special Charges (Details)", "role": "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails", "shortName": "Asset Impairment, Restructuring and Other Special Charges - Total Charges Related to Asset Impairment, Restructuring and Other Special Charges (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i319cd0149cdb41778f6fd9e86cfc44a8_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:SeveranceCosts1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i319cd0149cdb41778f6fd9e86cfc44a8_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserveAccrualAdjustment1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420410 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Narrative (Details)", "role": "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails", "shortName": "Asset Impairment, Restructuring and Other Special Charges - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "lang": "en-US", "name": "elan:RestructuringExpectedPaymentTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i1a2a4d0fae4741b19dcf2486971aad39_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421411 - Disclosure - Asset Impairment, Restructuring and Other Special Charges - Summary of Activity in Reserves (Details)", "role": "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails", "shortName": "Asset Impairment, Restructuring and Other Special Charges - Summary of Activity in Reserves (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i1a2a4d0fae4741b19dcf2486971aad39_I20201231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i1e12f2d736384683a22678bca3958815_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424412 - Disclosure - Inventories (Details)", "role": "http://www.elanco.com/role/InventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i1e12f2d736384683a22678bca3958815_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "ic7b16ab6f26f47cdac5e67dada425799_D20200123-20200123", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427413 - Disclosure - Equity - Narrative (Details)", "role": "http://www.elanco.com/role/EquityNarrativeDetails", "shortName": "Equity - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i225fb06a6a054304bac5913b848b906c_I20200122", "decimals": "-6", "lang": "en-US", "name": "elan:TangibleEquityUnitPrepaidStockPurchaseContractSharesIssuedUponConversion", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428414 - Disclosure - Equity - Schedule of Stockholders' Equity (Details)", "role": "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails", "shortName": "Equity - Schedule of Stockholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "idaac402ea1544d6090f0bb4a0032582f_D20200122-20200122", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i1e12f2d736384683a22678bca3958815_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.elanco.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i1e12f2d736384683a22678bca3958815_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i1e12f2d736384683a22678bca3958815_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431415 - Disclosure - Debt - Schedule of Long-term Debt (Details)", "role": "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "shortName": "Debt - Schedule of Long-term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i1e12f2d736384683a22678bca3958815_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromLinesOfCredit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432416 - Disclosure - Debt - Narrative (Details)", "role": "http://www.elanco.com/role/DebtNarrativeDetails", "shortName": "Debt - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i8ec61b6ae04849a192ecd3da6766071a_I20180831", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i1e12f2d736384683a22678bca3958815_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435417 - Disclosure - Financial Instruments and Fair Value - Narrative (Details)", "role": "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "shortName": "Financial Instruments and Fair Value - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i1a2a4d0fae4741b19dcf2486971aad39_I20201231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "ie38c35dc9f3043deba436d6e7238e67b_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NotesPayableFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436418 - Disclosure - Financial Instruments and Fair Value - Summary of Fair Value Information (Details)", "role": "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails", "shortName": "Financial Instruments and Fair Value - Summary of Fair Value Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "ie38c35dc9f3043deba436d6e7238e67b_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NotesPayableFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OffsettingLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i58a3427968754600a591d46ac7e3372e_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437419 - Disclosure - Financial Instruments and Fair Value - Net Gain/Loss on Derivative Instruments (Details)", "role": "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails", "shortName": "Financial Instruments and Fair Value - Net Gain/Loss on Derivative Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OffsettingLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i58a3427968754600a591d46ac7e3372e_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeGainLossOnDerivativeNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i319cd0149cdb41778f6fd9e86cfc44a8_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2440420 - Disclosure - Income Taxes - Provision for Taxes on Income (Details)", "role": "http://www.elanco.com/role/IncomeTaxesProvisionforTaxesonIncomeDetails", "shortName": "Income Taxes - Provision for Taxes on Income (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R56": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i319cd0149cdb41778f6fd9e86cfc44a8_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2441421 - Disclosure - Income Taxes - Narrative (Details)", "role": "http://www.elanco.com/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R57": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:LegalMattersAndContingenciesTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "ie84b728152df47e3ab917cee8f2873ab_I20201016", "decimals": "INF", "first": true, "lang": "en-US", "name": "elan:LossContingencyPercentOfTEUsIssuedInvolvedInLawsuit", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2443422 - Disclosure - Commitments and Contingencies - Narrative (Details)", "role": "http://www.elanco.com/role/CommitmentsandContingenciesNarrativeDetails", "shortName": "Commitments and Contingencies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:LegalMattersAndContingenciesTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "ie84b728152df47e3ab917cee8f2873ab_I20201016", "decimals": "INF", "first": true, "lang": "en-US", "name": "elan:LossContingencyPercentOfTEUsIssuedInvolvedInLawsuit", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i1e12f2d736384683a22678bca3958815_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2446423 - Disclosure - Geographic Information - Narrative (Details)", "role": "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "shortName": "Geographic Information - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i2f3f274fdaf7425a9dd72eff75bbbcac_I20201231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i319cd0149cdb41778f6fd9e86cfc44a8_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2447424 - Disclosure - Geographic Information - Revenue by Selected Geographic Area Information (Details)", "role": "http://www.elanco.com/role/GeographicInformationRevenuebySelectedGeographicAreaInformationDetails", "shortName": "Geographic Information - Revenue by Selected Geographic Area Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "ib602dd8cc2d149339707f25eef3fbe27_D20210701-20210930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "ib77a982be479474c8810e7b6ea70dd2f_I20191231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed Consolidated Statements of Equity (Unaudited)", "role": "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited", "shortName": "Condensed Consolidated Statements of Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i34568f6c582a42849074f2bcfd7a4e49_D20200101-20200331", "decimals": "-6", "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "ic8ebe05ef224400c962d090fe27d5a79_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2450425 - Disclosure - Retirement Benefits (Details)", "role": "http://www.elanco.com/role/RetirementBenefitsDetails", "shortName": "Retirement Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "ic8ebe05ef224400c962d090fe27d5a79_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i319cd0149cdb41778f6fd9e86cfc44a8_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2453426 - Disclosure - Loss Per Share (Details)", "role": "http://www.elanco.com/role/LossPerShareDetails", "shortName": "Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i319cd0149cdb41778f6fd9e86cfc44a8_D20210701-20210930", "decimals": "-5", "lang": "en-US", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i3d95ce0070f946f1af297997d0ed7dc7_D20210101-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "elan:RelatedPartyTransactionAssetPurchaseRefund", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2455427 - Disclosure - Transactions and Agreements with Bayer - Narrative (Details)", "role": "http://www.elanco.com/role/TransactionsandAgreementswithBayerNarrativeDetails", "shortName": "Transactions and Agreements with Bayer - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i3d95ce0070f946f1af297997d0ed7dc7_D20210101-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "elan:RelatedPartyTransactionAssetPurchaseRefund", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies", "role": "http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - Implementation of New Financial Accounting Pronouncements", "role": "http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncements", "shortName": "Implementation of New Financial Accounting Pronouncements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "elan-20210930.htm", "contextRef": "i45daae75e87a4babab81981a978d8d0e_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9999": { "firstAnchor": null, "groupType": "", "isDefault": "false", "longName": "Uncategorized Items - elan-20210930.htm", "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "shortName": "Uncategorized Items - elan-20210930.htm", "subGroupType": "", "uniqueAnchor": null } }, "segmentCount": 87, "tag": { "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.elanco.com/role/GeographicInformationRevenuebySelectedGeographicAreaInformationDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r723" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r724" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r725" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r725" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r725" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r727" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r725" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r725" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r725" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r725" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r721" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r722" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "elan_A2021RestructuringPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 Restructuring Plan", "label": "2021 Restructuring Plan [Member]", "terseLabel": "2021 Restructuring Plan" } } }, "localname": "A2021RestructuringPlanMember", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_A275SeniorAmortizingNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2.75% Senior Amortizing Notes", "label": "2.75% Senior Amortizing Notes [Member]", "terseLabel": "2.75% Senior Amortizing Notes" } } }, "localname": "A275SeniorAmortizingNotesMember", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_A3.912SeniorNotesDue2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "3.912% Senior Notes Due 2021 [Member]", "label": "3.912% Senior Notes Due 2021 [Member]", "terseLabel": "3.912% Senior Notes due 2021" } } }, "localname": "A3.912SeniorNotesDue2021Member", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "elan_A4.272SeniorNotesDue2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "4.272% Senior Notes Due 2023 [Member]", "label": "4.272% Senior Notes Due 2023 [Member]", "terseLabel": "4.272% Senior Notes due 2023" } } }, "localname": "A4.272SeniorNotesDue2023Member", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "elan_A4.9SeniorNotesDue2028Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "4.9% Senior Notes Due 2028 [Member]", "label": "4.9% Senior Notes Due 2028 [Member]", "terseLabel": "4.900% Senior Notes due 2028" } } }, "localname": "A4.9SeniorNotesDue2028Member", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "elan_A4900SeniorNotesDue2028Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "4.900% Senior Notes Due 2028", "label": "4.900% Senior Notes Due 2028 [Member]", "terseLabel": "4.900% Senior Notes Due 2028" } } }, "localname": "A4900SeniorNotesDue2028Member", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_A500TangibleEquityUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "5.00% Tangible Equity Units", "label": "5.00% Tangible Equity Units [Member]", "netLabel": "TEUs", "terseLabel": "5.00% Tangible Equity Units", "verboseLabel": "TEU Amortizing Notes" } } }, "localname": "A500TangibleEquityUnitsMember", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/CoverPage", "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_AratanaTherapeuticsInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aratana Therapeutics, Inc. [Member]", "label": "Aratana Therapeutics, Inc. [Member]", "verboseLabel": "Aratana" } } }, "localname": "AratanaTherapeuticsInc.Member", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_AssetImpairmentChargesIncludingInventoryWriteDown": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Asset Impairment Charges, Including Inventory Write-Down", "label": "Asset Impairment Charges, Including Inventory Write-Down", "verboseLabel": "Asset impairment and write-down charges" } } }, "localname": "AssetImpairmentChargesIncludingInventoryWriteDown", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "elan_BayerAnimalBusinessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bayer Animal Business", "label": "Bayer Animal Business [Member]", "terseLabel": "Bayer Animal Business" } } }, "localname": "BayerAnimalBusinessMember", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresProFormaInformationDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails", "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_BayerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bayer", "label": "Bayer [Member]", "terseLabel": "Bayer" } } }, "localname": "BayerMember", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/TransactionsandAgreementswithBayerNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableUsedInEstimate": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Used In Estimate", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Used In Estimate", "terseLabel": "Fair value used in estimate" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuableUsedInEstimate", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "elan_BusinessCombinationConsiderationTransferredSymmetricalCollar": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Consideration Transferred, Symmetrical Collar", "label": "Business Combination, Consideration Transferred, Symmetrical Collar", "terseLabel": "Symmetrical collar (as a percent)" } } }, "localname": "BusinessCombinationConsiderationTransferredSymmetricalCollar", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails" ], "xbrltype": "percentItemType" }, "elan_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Consideration Transferred, Working Capital Adjustments", "label": "Business Combination, Consideration Transferred, Working Capital Adjustments", "terseLabel": "Working capital adjustments" } } }, "localname": "BusinessCombinationConsiderationTransferredWorkingCapitalAdjustments", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "elan_BusinessCombinationInventoriesStepUpFairValueAdjustment": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Inventories, Step-Up Fair Value Adjustment", "label": "Business Combination, Inventories, Step-Up Fair Value Adjustment", "terseLabel": "Inventory fair value step-up amortization" } } }, "localname": "BusinessCombinationInventoriesStepUpFairValueAdjustment", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "elan_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentWorkingCapitalAndOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Working Capital and Other", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Working Capital and Other", "terseLabel": "Working capital and other adjustment" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentWorkingCapitalAndOther", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndOtherCurrentAssets": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 7.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable And Other Current Assets", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable And Other Current Assets", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndOtherCurrentAssets", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "elan_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsHeldForSale": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Assets Held For Sale", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Assets Held For Sale", "terseLabel": "Assets held for sale" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsHeldForSale", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "elan_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEmployeeRelatedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 9.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Employee-Related Liabilities, Current", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Employee-Related Liabilities, Current", "terseLabel": "Accrued retirement benefits" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEmployeeRelatedLiabilitiesCurrent", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "elan_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNetWorkingCapital": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 11.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Net Working Capital", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Net Working Capital", "terseLabel": "Other net working capital" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNetWorkingCapital", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "elan_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssetsAndOtherLiabilitiesNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Noncurrent Assets And Other Liabilities, Net", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Noncurrent Assets And Other Liabilities, Net", "terseLabel": "Other noncurrent assets and liabilities, net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssetsAndOtherLiabilitiesNet", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "elan_BusinessCombinationVolumeWeightedAveragePriceFor30TradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Volume Weighted Average Price For 30 Trading Days", "label": "Business Combination, Volume Weighted Average Price For 30 Trading Days", "terseLabel": "Volume weighted average price for thirty trading days (usd per share)" } } }, "localname": "BusinessCombinationVolumeWeightedAveragePriceFor30TradingDays", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails" ], "xbrltype": "perShareItemType" }, "elan_BusinessCombinationVolumeWeightedAverageStockPriceAsOfLastDayOfTradingBeforeClosingAcquisitionDuration": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Volume Weighted Average Stock Price As Of Last Day Of Trading Before Closing Acquisition Duration", "label": "Business Combination, Volume Weighted Average Stock Price As Of Last Day Of Trading Before Closing Acquisition Duration", "terseLabel": "Volume weighted average stock price as of the last day of trading before the closing of the acquisition duration" } } }, "localname": "BusinessCombinationVolumeWeightedAverageStockPriceAsOfLastDayOfTradingBeforeClosingAcquisitionDuration", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails" ], "xbrltype": "durationItemType" }, "elan_ChangeInContractWithCustomerLiabilityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Change In Contract With Customer, Liability [Roll Forward]", "label": "Change In Contract With Customer, Liability [Roll Forward]", "terseLabel": "Change In Contract With Customer, Liability [Roll Forward]" } } }, "localname": "ChangeInContractWithCustomerLiabilityRollForward", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/RevenueSummaryofActivityinSalesRebatesandDiscountsLiabilityDetails" ], "xbrltype": "stringItemType" }, "elan_CommonStockNoParValueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, No Par Value", "label": "Common Stock, No Par Value [Member]", "terseLabel": "Common stock, no par value" } } }, "localname": "CommonStockNoParValueMember", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "elan_CommonStockOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock Offering", "label": "Common Stock Offering [Member]", "terseLabel": "Common Stock Offering" } } }, "localname": "CommonStockOfferingMember", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_ContractManufacturingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract Manufacturing [Member]", "label": "Contract Manufacturing [Member]", "verboseLabel": "Contract Manufacturing" } } }, "localname": "ContractManufacturingMember", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "elan_ContractWithCustomerLiabilityIncreaseFromCashReceipts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Liability, Increase From Cash Receipts", "label": "Contract With Customer, Liability, Increase From Cash Receipts", "negatedTerseLabel": "Payments" } } }, "localname": "ContractWithCustomerLiabilityIncreaseFromCashReceipts", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/RevenueSummaryofActivityinSalesRebatesandDiscountsLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "elan_ContractWithCustomerLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Liability [Member]", "label": "Contract With Customer, Liability [Member]", "terseLabel": "Contract With Customer Liability" } } }, "localname": "ContractWithCustomerLiabilityMember", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_CustomerAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer A [Member]", "label": "Customer A [Member]", "terseLabel": "Single Customer" } } }, "localname": "CustomerAMember", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_DebtInstrumentFirstPeriodicPaymentPerAmortizingNote": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, First Periodic Payment Per Amortizing Note", "label": "Debt Instrument, First Periodic Payment Per Amortizing Note", "terseLabel": "First installment payment per amortizing note" } } }, "localname": "DebtInstrumentFirstPeriodicPaymentPerAmortizingNote", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_DebtInstrumentInitialPrincipalAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Initial Principal Amount", "label": "Debt Instrument, Initial Principal Amount", "terseLabel": "Initial principal amount" } } }, "localname": "DebtInstrumentInitialPrincipalAmount", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_DebtInstrumentNumberOfFinancialCovenants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Number Of Financial Covenants", "label": "Debt Instrument, Number Of Financial Covenants", "terseLabel": "Number of financial covenants" } } }, "localname": "DebtInstrumentNumberOfFinancialCovenants", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "integerItemType" }, "elan_DebtInstrumentPaymentPrincipalAndInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Payment, Principal And Interest", "label": "Debt Instrument, Payment, Principal And Interest", "terseLabel": "Partial payment on principal and interest" } } }, "localname": "DebtInstrumentPaymentPrincipalAndInterest", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_DebtInstrumentPeriodicPaymentPerAmortizingNote": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Periodic Payment Per Amortizing Note", "label": "Debt Instrument, Periodic Payment Per Amortizing Note", "terseLabel": "Quarterly cash installment per amortizing note" } } }, "localname": "DebtInstrumentPeriodicPaymentPerAmortizingNote", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_DerivativeInstrumentsLiquidatedForCashBenefitAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Derivative Instruments, Liquidated For Cash Benefit, Amount", "label": "Derivative Instruments, Liquidated For Cash Benefit, Amount", "terseLabel": "Cash benefit for liquidation" } } }, "localname": "DerivativeInstrumentsLiquidatedForCashBenefitAmount", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_DerivativeInstrumentsLiquidatedForCashBenefitInterestAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Derivative Instruments, Liquidated For Cash Benefit, Interest, Amount", "label": "Derivative Instruments, Liquidated For Cash Benefit, Interest, Amount", "terseLabel": "Interest included in cash benefit" } } }, "localname": "DerivativeInstrumentsLiquidatedForCashBenefitInterestAmount", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_DisposalGroupIncludingDiscontinuedOperationNumberOfEmployeesTransferred": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Number of Employees Transferred", "label": "Disposal Group, Including Discontinued Operation, Number of Employees Transferred", "terseLabel": "Number of employees transferred" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationNumberOfEmployeesTransferred", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "integerItemType" }, "elan_DisposalGroupIncludingDiscontinuedOperationTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Transaction Costs", "label": "Disposal Group, Including Discontinued Operation, Transaction Costs", "terseLabel": "Divestiture transaction costs" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationTransactionCosts", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_FarmAnimalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Farm Animal", "label": "Farm Animal [Member]", "terseLabel": "Farm Animal" } } }, "localname": "FarmAnimalMember", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "elan_FarmCreditTermLoanFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Farm Credit Term Loan Facility", "label": "Farm Credit Term Loan Facility [Member]", "terseLabel": "Farm Credit Term Loan Facility" } } }, "localname": "FarmCreditTermLoanFacilityMember", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_FinishedGoodsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Finished Goods", "label": "Finished Goods [Member]", "terseLabel": "Finished Products" } } }, "localname": "FinishedGoodsMember", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_GlobalCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Global Customers", "label": "Global Customers [Member]", "terseLabel": "Global Customers" } } }, "localname": "GlobalCustomersMember", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_InProcessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "in Process", "label": "in Process [Member]", "terseLabel": "in Process" } } }, "localname": "InProcessMember", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_IncrementalTermFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incremental Term Facility", "label": "Incremental Term Facility [Member]", "terseLabel": "Incremental Term Facility" } } }, "localname": "IncrementalTermFacilityMember", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "elan_KindredBioMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "KindredBio", "label": "KindredBio [Member]", "terseLabel": "KindredBio" } } }, "localname": "KindredBioMember", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "domainItemType" }, "elan_LossContingencyPercentOfTEUsIssuedInvolvedInLawsuit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Percent of TEUs Issued Involved in Lawsuit", "label": "Loss Contingency, Percent of TEUs Issued Involved in Lawsuit", "terseLabel": "Percent of TEUs issued involved in lawsuit" } } }, "localname": "LossContingencyPercentOfTEUsIssuedInvolvedInLawsuit", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "percentItemType" }, "elan_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossNetOfTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Net Of Tax", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Net Of Tax", "terseLabel": "Gain (loss), net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossNetOfTax", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "elan_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossTax": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Tax", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Tax", "terseLabel": "Interest rate swaps, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossTax", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "elan_PaymentsToAcquireBusinessesBeforeWorkingCapitalAdjustment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments to Acquire Businesses, Before Working Capital Adjustment", "label": "Payments to Acquire Businesses, Before Working Capital Adjustment", "terseLabel": "Payments to acquire businesses, before working capital adjustment" } } }, "localname": "PaymentsToAcquireBusinessesBeforeWorkingCapitalAdjustment", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "elan_PetHealthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pet Health", "label": "Pet Health [Member]", "terseLabel": "Pet Health" } } }, "localname": "PetHealthMember", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "elan_PrevtecMicrobiaInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prevtec Microbia, Inc. [Member]", "label": "Prevtec Microbia, Inc. [Member]", "terseLabel": "Prevtec" } } }, "localname": "PrevtecMicrobiaInc.Member", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_ProceedsFromPaymentsToTransactionsWithParent": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From (Payments To) Transactions With Parent", "label": "Proceeds From (Payments To) Transactions With Parent", "terseLabel": "Other net financing transactions with Lilly" } } }, "localname": "ProceedsFromPaymentsToTransactionsWithParent", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "elan_ProductReturnConcentrationRiskMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Product Return Concentration Risk [Member]", "label": "Product Return Concentration Risk [Member]", "terseLabel": "Product Return Concentration Risk" } } }, "localname": "ProductReturnConcentrationRiskMember", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_RelatedPartyTransactionAssetPurchaseRefund": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Related Party Transaction, Asset Purchase Refund", "label": "Related Party Transaction, Asset Purchase Refund", "terseLabel": "Asset purchase refund" } } }, "localname": "RelatedPartyTransactionAssetPurchaseRefund", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/TransactionsandAgreementswithBayerNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_RepaymentsOfLongTermDebtAccruedInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repayments Of Long Term Debt, Accrued Interest", "label": "Repayments Of Long Term Debt, Accrued Interest", "terseLabel": "Debt repaid, interest" } } }, "localname": "RepaymentsOfLongTermDebtAccruedInterest", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "elan_RequiredRatioOfProFormaAdjustedEBITDAToCashInterestExpense": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Required Ratio Of Pro Forma Adjusted EBITDA To Cash Interest Expense", "label": "Required Ratio Of Pro Forma Adjusted EBITDA To Cash Interest Expense", "terseLabel": "Required ratio of pro forma adjusted EBITDA to cash interest expense (no less than)" } } }, "localname": "RequiredRatioOfProFormaAdjustedEBITDAToCashInterestExpense", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "pureItemType" }, "elan_RequiredRatioOfProFormaNetLeverageAndProFormaAdjustedEBITDA": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Required Ratio Of Pro Forma Net Leverage And Pro Forma Adjusted EBITDA", "label": "Required Ratio Of Pro Forma Net Leverage And Pro Forma Adjusted EBITDA", "terseLabel": "Required ratio of pro forma net leverage and pro forma adjusted EBITDA" } } }, "localname": "RequiredRatioOfProFormaNetLeverageAndProFormaAdjustedEBITDA", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "pureItemType" }, "elan_RestructuringAndRelatedCostNumberOfCountriesExpectedToEliminatePositions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restructuring And Related Cost, Number Of Countries Expected to Eliminate Positions", "label": "Restructuring And Related Cost, Number Of Countries Expected to Eliminate Positions", "terseLabel": "Number of countries expected to eliminate positions" } } }, "localname": "RestructuringAndRelatedCostNumberOfCountriesExpectedToEliminatePositions", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" ], "xbrltype": "integerItemType" }, "elan_RestructuringExpectedPaymentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restructuring, Expected Payment Term", "label": "Restructuring, Expected Payment Term", "terseLabel": "Expected payment term" } } }, "localname": "RestructuringExpectedPaymentTerm", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" ], "xbrltype": "durationItemType" }, "elan_RightsToTheProfenderAndDrontalProductFamiliesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rights To The Profender And Drontal Product Families", "label": "Rights To The Profender And Drontal Product Families [Member]", "terseLabel": "Rights To The Profender And Drontal" } } }, "localname": "RightsToTheProfenderAndDrontalProductFamiliesMember", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_ShawneeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shawnee", "label": "Shawnee [Member]", "terseLabel": "Shawnee" } } }, "localname": "ShawneeMember", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_StockholdersEquitySeparationAdjustments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stockholders' Equity, Separation Adjustments", "label": "Stockholders' Equity, Separation Adjustments", "verboseLabel": "Separation activities" } } }, "localname": "StockholdersEquitySeparationAdjustments", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "elan_TangibleEquityUnitAverageApplicableMarketValueTriggeringInclusionInCalculationOfDilutedSharesOutstandingPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible Equity Unit, Average Applicable Market Value Triggering Inclusion In Calculation Of Diluted Shares Outstanding, Per Share", "label": "Tangible Equity Unit, Average Applicable Market Value Triggering Inclusion In Calculation Of Diluted Shares Outstanding, Per Share", "terseLabel": "Average applicable market value necessary to be included in calculation of diluted shares outstanding (usd per share)", "verboseLabel": "Applicable Market Value (usd per share)" } } }, "localname": "TangibleEquityUnitAverageApplicableMarketValueTriggeringInclusionInCalculationOfDilutedSharesOutstandingPerShare", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "elan_TangibleEquityUnitDebtComponentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible Equity Unit, Debt Component", "label": "Tangible Equity Unit, Debt Component [Member]", "terseLabel": "Debt Component" } } }, "localname": "TangibleEquityUnitDebtComponentMember", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "elan_TangibleEquityUnitEquityComponentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible Equity Unit, Equity Component", "label": "Tangible Equity Unit, Equity Component [Member]", "terseLabel": "Equity Component" } } }, "localname": "TangibleEquityUnitEquityComponentMember", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "elan_TangibleEquityUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible Equity Unit", "label": "Tangible Equity Unit [Member]", "terseLabel": "Tangible Equity Unit (TEU)" } } }, "localname": "TangibleEquityUnitMember", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "elan_TangibleEquityUnitPrepaidStockPurchaseContractSharesIssuedUponConversion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible Equity Unit, Prepaid Stock Purchase Contract, Shares Issued Upon Conversion", "label": "Tangible Equity Unit, Prepaid Stock Purchase Contract, Shares Issued Upon Conversion", "terseLabel": "Shares issued upon conversion of prepaid stock purchase contracts (in shares)" } } }, "localname": "TangibleEquityUnitPrepaidStockPurchaseContractSharesIssuedUponConversion", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "elan_TangibleEquityUnitSettlementRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible Equity Unit, Settlement Rate", "label": "Tangible Equity Unit, Settlement Rate", "terseLabel": "Settlement rate" } } }, "localname": "TangibleEquityUnitSettlementRate", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "elan_TangibleEquityUnitsIssuedDuringPeriodValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Tangible Equity Units Issued During Period, Value", "label": "Tangible Equity Units Issued During Period, Value", "terseLabel": "Issuance of tangible equity units, net of issuance costs" } } }, "localname": "TangibleEquityUnitsIssuedDuringPeriodValue", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "elan_TermBLoanFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term B Loan Facility", "label": "Term B Loan Facility [Member]", "terseLabel": "Term Loan B" } } }, "localname": "TermBLoanFacilityMember", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "elan_TermCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term Credit Facility [Member]", "label": "Term Credit Facility [Member]", "netLabel": "Term Loan Facility" } } }, "localname": "TermCreditFacilityMember", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "elan_WorldwideRightsToOsurniaAndUSRightsToCapstarMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Worldwide Rights To Osurnia And U.S. Rights To Capstar", "label": "Worldwide Rights To Osurnia And U.S. Rights To Capstar [Member]", "terseLabel": "Worldwide rights to Osurnia and U.S. rights to Capstar" } } }, "localname": "WorldwideRightsToOsurniaAndUSRightsToCapstarMember", "nsuri": "http://www.elanco.com/20210930", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r2", "r143", "r154", "r160", "r234", "r484", "r485", "r486", "r501", "r502", "r565", "r568", "r571", "r572", "r730" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r2", "r143", "r154", "r160", "r234", "r484", "r485", "r486", "r501", "r502", "r565", "r568", "r571", "r572", "r730" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r2", "r143", "r154", "r160", "r234", "r484", "r485", "r486", "r501", "r502", "r565", "r568", "r571", "r572", "r730" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r219", "r372", "r378", "r692" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r298", "r337", "r471", "r476", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r689", "r693", "r718", "r719" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r298", "r337", "r471", "r476", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r689", "r693", "r718", "r719" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r219", "r372", "r378", "r692" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r214", "r372", "r376", "r640", "r688", "r690" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r214", "r372", "r376", "r640", "r688", "r690" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r298", "r337", "r415", "r471", "r476", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r689", "r693", "r718", "r719" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r298", "r337", "r415", "r471", "r476", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r689", "r693", "r718", "r719" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r215", "r216", "r372", "r377", "r691", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationRevenuebySelectedGeographicAreaInformationDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r215", "r216", "r372", "r377", "r691", "r707", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationRevenuebySelectedGeographicAreaInformationDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Changes and Error Corrections [Abstract]", "terseLabel": "Accounting Changes and Error Corrections [Abstract]" } } }, "localname": "AccountingChangesAndErrorCorrectionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r146", "r147", "r148", "r150", "r225", "r226", "r231", "r232", "r233", "r234", "r237", "r238", "r283", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r488", "r501", "r502", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r570", "r571", "r572", "r573", "r591", "r592", "r593", "r594", "r595", "r596", "r600", "r601", "r616", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r728", "r729", "r730", "r731", "r732" ], "lang": { "en-us": { "role": { "documentation": "Indicates amendment to accounting standards.", "label": "Accounting Standards Update [Extensible Enumeration]", "terseLabel": "Accounting Standards Update [Extensible List]" } } }, "localname": "AccountingStandardsUpdateExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r57", "r628" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r23", "r39", "r221", "r222" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net of allowances of $11 (2021) and $9 (2020)", "verboseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets", "http://www.elanco.com/role/GeographicInformationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r82", "r87", "r94", "r95", "r96", "r538" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Defined Benefit Pension and Retiree Health Benefit Plans" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r55", "r260" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "verboseLabel": "Property and equipment, net of accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "auth_ref": [ "r87", "r94", "r95", "r96", "r97", "r537" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "terseLabel": "Cash Flow Hedge Gain (Loss)" } } }, "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r42", "r85", "r86", "r87", "r677", "r701", "r705" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r84", "r87", "r94", "r95", "r96", "r140", "r141", "r142", "r538", "r696", "r697", "r732" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r80", "r87", "r94", "r95", "r96", "r538", "r604", "r605", "r606", "r607", "r609" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign Currency Translation" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Weighted average useful life" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r40", "r488", "r628" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r140", "r141", "r142", "r484", "r485", "r486", "r571" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedTerseLabel": "Issuance of stock under employee stock plans, net" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r478", "r479", "r489", "r490" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to cash flows from operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r46", "r223", "r239" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "verboseLabel": "Accounts receivable, net of allowances" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r126", "r246", "r254" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r172" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive shares not included in calculating diluted earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/LossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AssetImpairmentChargesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asset Impairment Charges [Abstract]", "terseLabel": "Acquisition related charges:" } } }, "localname": "AssetImpairmentChargesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Assets": { "auth_ref": [ "r134", "r199", "r204", "r210", "r230", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r535", "r540", "r590", "r626", "r628", "r660", "r675" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r24", "r25", "r75", "r134", "r230", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r535", "r540", "r590", "r626", "r628" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current Assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Noncurrent [Abstract]", "terseLabel": "Noncurrent Assets" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r6", "r7", "r14", "r16", "r19", "r264" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Assets", "totalLabel": "Total assets held for sale" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r548", "r552" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccounting": { "auth_ref": [ "r139" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting [Text Block]", "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies" } } }, "localname": "BasisOfAccounting", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r467", "r472" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresProFormaInformationDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r467", "r472", "r520", "r521" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresProFormaInformationDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "auth_ref": [ "r532" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of equity interests issued or issuable to acquire entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "terseLabel": "Shares issued to previous shareholders upon closing (in shares)" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresProFormaInformationDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPreacquisitionContingencyAmountOfSettlement": { "auth_ref": [ "r241", "r524" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount paid or received to resolve the preacquisition contingency.", "label": "Business Acquisition, Preacquisition Contingency, Amount of Settlement", "negatedTerseLabel": "Settlement of liability related to previous license agreement" } } }, "localname": "BusinessAcquisitionPreacquisitionContingencyAmountOfSettlement", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r518", "r519" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "terseLabel": "Pro Forma Information" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business Acquisition, Share Price", "terseLabel": "Common stock price (in dollars per share)" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r518", "r519" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "terseLabel": "Loss before income taxes" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresProFormaInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r518", "r519" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Revenue" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresProFormaInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r517" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "terseLabel": "Transaction costs incurred" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r528", "r529", "r530" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Consideration paid for acquisition", "totalLabel": "Fair value of total consideration transferred" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [ "r528", "r529" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "terseLabel": "Fair value of Elanco common stock" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "auth_ref": [ "r533" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "terseLabel": "Maximum aggregate contingent payment" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationIntegrationRelatedCosts": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails": { "order": 2.0, "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.", "label": "Business Combination, Integration Related Costs", "terseLabel": "Transaction and integration costs" } } }, "localname": "BusinessCombinationIntegrationRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles": { "auth_ref": [ "r526" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to intangibles acquired in connection with a business combination for which the initial accounting was incomplete.", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles", "terseLabel": "Intangible asset adjustment" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment": { "auth_ref": [ "r526" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to property, plant, and equipment acquired in connection with a business combination for which the initial accounting was incomplete.", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Property, Plant, and Equipment", "terseLabel": "Property, plant, and equipment, adjustments" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r523" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r523" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 8.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r523" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Accounts receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r523" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "terseLabel": "Deferred income taxes" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": { "auth_ref": [ "r523" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 10.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets", "terseLabel": "Intangible assets, primarily acquired in-process research and development" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r522", "r523" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Marketed products" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r522", "r523" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventories" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r522", "r523" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Total identifiable net assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r522", "r523" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r523" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Total consideration transferred" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessExitCosts1": { "auth_ref": [ "r126" ], "calculation": { "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails": { "order": 3.0, "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Business Exit Costs", "terseLabel": "Facility exit costs" } } }, "localname": "BusinessExitCosts1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r585", "r586" ], "lang": { "en-us": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying Amount" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r21", "r53", "r128" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets", "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r122", "r128", "r129" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "totalLabel": "Cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r122", "r602" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r545" ], "lang": { "en-us": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedging" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r131", "r134", "r165", "r166", "r167", "r169", "r171", "r181", "r182", "r183", "r230", "r284", "r288", "r289", "r290", "r293", "r294", "r335", "r336", "r340", "r344", "r590", "r726" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CoverPage", "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r67", "r280", "r664", "r681" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r140", "r141", "r571" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "verboseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r38", "r351" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "verboseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r38", "r628" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, no par value, 5,000,000,000 shares authorized, 473,033,625 and 471,921,116 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r90", "r92", "r93", "r103", "r668", "r684" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r187", "r188", "r219", "r587", "r588", "r708" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r187", "r188", "r219", "r587", "r588", "r706", "r708" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r187", "r188", "r219", "r587", "r588", "r706", "r708" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r187", "r188", "r219", "r587", "r588" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk (as a percent)", "verboseLabel": "Concentration risk (less than 0.1%)" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r184", "r187", "r188", "r189", "r587", "r589", "r708" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r187", "r188", "r219", "r587", "r588", "r708" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Summary of Activity in Sales Rebates and Discounts Liability" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r360", "r361", "r373" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/RevenueSummaryofActivityinSalesRebatesandDiscountsLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r360", "r361", "r373" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Sales rebates and discounts" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination": { "auth_ref": [ "r362" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration from customer has been received or is due, from business combination.", "label": "Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination", "terseLabel": "Bayer Animal Health at acquisition" } } }, "localname": "ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/RevenueSummaryofActivityinSalesRebatesandDiscountsLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r374" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Reduction of revenue" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/RevenueSummaryofActivityinSalesRebatesandDiscountsLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r106", "r640" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r105" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Costs, expenses and other" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Costs, expenses and other:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r185", "r219" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r130", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r312", "r319", "r320", "r322", "r331" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r32", "r33", "r34", "r133", "r138", "r295", "r296", "r297", "r298", "r299", "r300", "r302", "r308", "r309", "r310", "r311", "r313", "r314", "r315", "r316", "r317", "r318", "r325", "r326", "r327", "r328", "r614", "r661", "r662", "r674" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r34", "r323", "r662", "r674" ], "calculation": { "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails_1": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "Long-term debt, gross" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days", "terseLabel": "Number of consecutive trading days" } } }, "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r295", "r325", "r326", "r612", "r614", "r615" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Debt instrument, face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r64", "r296" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate", "verboseLabel": "Interest rate on debt component" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r65", "r133", "r138", "r295", "r296", "r297", "r298", "r299", "r300", "r302", "r308", "r309", "r310", "r311", "r313", "r314", "r315", "r316", "r317", "r318", "r325", "r326", "r327", "r328", "r614" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRepurchasedFaceAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of the original debt instrument that was repurchased.", "label": "Debt Instrument, Repurchased Face Amount", "terseLabel": "Repayment of principal on indebtedness outstanding" } } }, "localname": "DebtInstrumentRepurchasedFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r65", "r133", "r138", "r295", "r296", "r297", "r298", "r299", "r300", "r302", "r308", "r309", "r310", "r311", "r313", "r314", "r315", "r316", "r317", "r318", "r321", "r325", "r326", "r327", "r328", "r352", "r355", "r356", "r357", "r611", "r612", "r614", "r615", "r673" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt maturity term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r56", "r308", "r613" ], "calculation": { "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails_1": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedTerseLabel": "Unamortized debt issuance costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r126", "r135", "r499", "r508", "r509", "r510" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Change in deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r492", "r493" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred taxes" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "auth_ref": [ "r392", "r431", "r455", "r461", "r462" ], "calculation": { "http://www.elanco.com/role/RetirementBenefitsDetails": { "order": 5.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "negatedTerseLabel": "Amortization of net actuarial loss" } } }, "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "auth_ref": [ "r392", "r432", "r456", "r461", "r462" ], "calculation": { "http://www.elanco.com/role/RetirementBenefitsDetails": { "order": 6.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "terseLabel": "Amortization of prior service cost" } } }, "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "auth_ref": [ "r392", "r430", "r454", "r461", "r462" ], "calculation": { "http://www.elanco.com/role/RetirementBenefitsDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "negatedTerseLabel": "Expected return on plan assets" } } }, "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r392", "r397", "r429", "r453", "r461", "r462" ], "calculation": { "http://www.elanco.com/role/RetirementBenefitsDetails": { "order": 4.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Interest cost" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r427", "r451", "r461", "r462" ], "calculation": { "http://www.elanco.com/role/RetirementBenefitsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "totalLabel": "Net periodic benefit cost (income)" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1": { "auth_ref": [ "r393", "r434", "r458" ], "calculation": { "http://www.elanco.com/role/RetirementBenefitsDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from settlement and curtailment.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment", "negatedTerseLabel": "Net curtailments and settlements (Note 5)" } } }, "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r395", "r428", "r452", "r461", "r462" ], "calculation": { "http://www.elanco.com/role/RetirementBenefitsDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "terseLabel": "Service cost" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanTypeExtensibleList": { "auth_ref": [ "r388", "r389", "r390", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r441", "r444", "r448", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460" ], "lang": { "en-us": { "role": { "documentation": "Indicates type of defined benefit plan. Includes, but is not limited to, pension plan, other postretirement plan and special and contractual termination benefits payable upon retirement.", "label": "Defined Benefit Plan, Type [Extensible Enumeration]", "terseLabel": "Defined Benefit Plan, Type [Extensible Enumeration]" } } }, "localname": "DefinedBenefitPlanTypeExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": { "auth_ref": [ "r447", "r448", "r449", "r450", "r461" ], "lang": { "en-us": { "role": { "documentation": "Disclosures and provisions pertaining to defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans.", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]", "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]" } } }, "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]", "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]" } } }, "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r126", "r197" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": { "auth_ref": [ "r542" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.", "label": "Derivative Assets (Liabilities), at Fair Value, Net", "terseLabel": "Derivative assets (liabilities)" } } }, "localname": "DerivativeAssetsLiabilitiesAtFairValueNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings": { "auth_ref": [ "r553", "r560" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method.", "label": "Derivative, Excluded Component, Gain (Loss), Recognized in Earnings", "terseLabel": "Amount offsetting interest expense" } } }, "localname": "DerivativeExcludedComponentGainLossRecognizedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r550" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "terseLabel": "Net gain (loss) on derivative instruments" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r78", "r549", "r551", "r554", "r558" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r547", "r549", "r554" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r543", "r544" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Notional amount (USD, CHF)" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTermOfContract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Derivative, Term of Contract", "terseLabel": "Term of contract" } } }, "localname": "DerivativeTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r547" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r372", "r376", "r377", "r378", "r379", "r380", "r381", "r382" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r257", "r259", "r265" ], "lang": { "en-us": { "role": { "documentation": "Disposal group that either has been sold or is classified as held-for-sale. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations [Member]", "terseLabel": "Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations" } } }, "localname": "DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r16", "r257", "r265" ], "lang": { "en-us": { "role": { "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Held-for-sale, Not Discontinued Operations [Member]", "terseLabel": "Held for Sale" } } }, "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Additional Disclosures [Abstract]", "terseLabel": "Non-cash and other items:" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets": { "auth_ref": [ "r6", "r7", "r14", "r264" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails": { "order": 4.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as deferred tax assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Deferred Tax Assets", "terseLabel": "Deferred tax asset" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets": { "auth_ref": [ "r6", "r7", "r14", "r264" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Intangible Assets", "terseLabel": "Other intangibles, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1": { "auth_ref": [ "r6", "r7", "r14", "r264" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as inventory attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Inventory", "terseLabel": "Inventories" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationInventory1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": { "auth_ref": [ "r6", "r7", "r14", "r264" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment", "terseLabel": "Property and equipment, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": { "auth_ref": [ "r126", "r259", "r262" ], "calculation": { "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails": { "order": 7.0, "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal", "negatedLabel": "Settlements and other" } } }, "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown": { "auth_ref": [ "r126", "r259", "r262" ], "calculation": { "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails": { "order": 5.0, "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.", "label": "Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down", "terseLabel": "Asset write-down" } } }, "localname": "DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r467", "r472" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]", "verboseLabel": "Loss per share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r104", "r152", "r153", "r154", "r155", "r156", "r163", "r165", "r169", "r170", "r171", "r175", "r176", "r572", "r573", "r669", "r685" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (usd per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.elanco.com/role/LossPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r104", "r152", "r153", "r154", "r155", "r156", "r165", "r169", "r170", "r171", "r175", "r176", "r572", "r573", "r669", "r685" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (usd per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.elanco.com/role/LossPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r172", "r173", "r174", "r177" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/LossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r602" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r495" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesNarrativeDetails", "http://www.elanco.com/role/IncomeTaxesProvisionforTaxesonIncomeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r62" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Employee compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeSeveranceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Employee Severance [Member]", "terseLabel": "Severance" } } }, "localname": "EmployeeSeveranceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r94", "r95", "r96", "r140", "r141", "r142", "r147", "r157", "r159", "r180", "r234", "r351", "r358", "r484", "r485", "r486", "r501", "r502", "r571", "r603", "r604", "r605", "r606", "r607", "r609", "r696", "r697", "r698", "r732" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r54", "r200", "r229" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Equity method investments" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r310", "r325", "r326", "r584" ], "lang": { "en-us": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Fair Value" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FacilityClosingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan.", "label": "Facility Closing [Member]", "terseLabel": "Facility exit costs" } } }, "localname": "FacilityClosingMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r574", "r575", "r576", "r580" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r574", "r585", "r586" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r310", "r325", "r326", "r416", "r418", "r419", "r420", "r421", "r422", "r423", "r461", "r575", "r629", "r630", "r631" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r310", "r325", "r326", "r574", "r581" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r574", "r575", "r577", "r578", "r582" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [ "r310", "r325", "r326" ], "lang": { "en-us": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r579" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Financial Instruments and Fair Value" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValue" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r310", "r416", "r418", "r423", "r461", "r575", "r629" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r310", "r325", "r326", "r416", "r418", "r423", "r461", "r575", "r630" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Other Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r310", "r325", "r326", "r416", "r418", "r419", "r420", "r421", "r422", "r423", "r461", "r575", "r631" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r574", "r575" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.", "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of Fair Value Information" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r310", "r325", "r326", "r416", "r418", "r419", "r420", "r421", "r422", "r423", "r461", "r629", "r630", "r631" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r579", "r582" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r247", "r250", "r253", "r256", "r641", "r645" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r247", "r252" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r78", "r416", "r556" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Cross-currency fixed interest rate swap", "verboseLabel": "Foreign exchange contracts not designated as hedging instruments" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets": { "auth_ref": [ "r126", "r259", "r262" ], "calculation": { "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails": { "order": 6.0, "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property", "negatedLabel": "Gain on sale of fixed assets" } } }, "localname": "GainLossOnDispositionOfAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfBusiness": { "auth_ref": [ "r126", "r539" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.", "label": "Gain (Loss) on Disposition of Business", "negatedTerseLabel": "Loss (gain) on divestitures", "verboseLabel": "Sale of IPR&D" } } }, "localname": "GainLossOnSaleOfBusiness", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfOtherAssets": { "auth_ref": [ "r126" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of other assets.", "label": "Gain (Loss) on Disposition of Other Assets", "negatedLabel": "Gain on sale of assets" } } }, "localname": "GainLossOnSaleOfOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r126", "r329", "r330" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Debt extinguishment loss" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r186", "r708" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]", "terseLabel": "Geographic Concentration Risk" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r242", "r243", "r628", "r659" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 }, "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "auth_ref": [ "r244", "r516" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Purchase Accounting Adjustments", "terseLabel": "Goodwill adjustment" } } }, "localname": "GoodwillPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r547", "r559" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r547" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r547" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "auth_ref": [ "r126", "r258" ], "calculation": { "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails": { "order": 4.0, "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.", "label": "Impairment of Long-Lived Assets to be Disposed of", "terseLabel": "Asset impairment" } } }, "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "Intangible assets, primarily acquired in-process research and development" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r100", "r199", "r203", "r206", "r209", "r212", "r658", "r665", "r671", "r686" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r467", "r472" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r7", "r8", "r9", "r10", "r11", "r12", "r13", "r15", "r17", "r18", "r19", "r265", "r266" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresAssetsandLiabilitiesHeldforSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r263", "r270" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r136", "r496", "r497", "r498", "r506", "r511", "r513", "r514", "r515" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r137", "r158", "r159", "r198", "r494", "r507", "r512", "r687" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax benefit", "terseLabel": "Income tax benefit", "verboseLabel": "Income tax benefit" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.elanco.com/role/IncomeTaxesNarrativeDetails", "http://www.elanco.com/role/IncomeTaxesProvisionforTaxesonIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapital": { "auth_ref": [ "r125" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.", "label": "Increase (Decrease) in Operating Capital", "negatedTerseLabel": "Changes in operating assets and liabilities, net of acquisitions" } } }, "localname": "IncreaseDecreaseInOperatingCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r249", "r255" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r249", "r255" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r245", "r251" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Other intangibles, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r98", "r196", "r610", "r613", "r670" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 6.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense, net of capitalized interest" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r557" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest Expense" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": { "auth_ref": [ "r561" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.", "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "negatedTerseLabel": "Expected reclassification from accumulated other comprehensive loss" } } }, "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateContractMember": { "auth_ref": [ "r78", "r416", "r555" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.", "label": "Interest Rate Contract [Member]", "terseLabel": "Forward-starting interest rate contracts designated as cash flow hedges" } } }, "localname": "InterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.", "label": "Inventories [Member]", "terseLabel": "Inventories" } } }, "localname": "InventoriesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r70" ], "calculation": { "http://www.elanco.com/role/InventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished products" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryGross": { "auth_ref": [ "r73" ], "calculation": { "http://www.elanco.com/role/InventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Inventory, Gross", "totalLabel": "Total" } } }, "localname": "InventoryGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLIFOReserve": { "auth_ref": [ "r74" ], "calculation": { "http://www.elanco.com/role/InventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.", "label": "Inventory, LIFO Reserve", "negatedTerseLabel": "Decrease to LIFO cost" } } }, "localname": "InventoryLIFOReserve", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r22", "r73", "r628" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.elanco.com/role/InventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets", "http://www.elanco.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsAndSupplies": { "auth_ref": [ "r72" ], "calculation": { "http://www.elanco.com/role/InventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.", "label": "Inventory, Raw Materials and Supplies, Gross", "terseLabel": "Raw materials and supplies" } } }, "localname": "InventoryRawMaterialsAndSupplies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r71" ], "calculation": { "http://www.elanco.com/role/InventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "auth_ref": [ "r281" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.", "label": "Legal Matters and Contingencies [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "LegalMattersAndContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r61", "r134", "r205", "r230", "r284", "r285", "r286", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r536", "r540", "r541", "r590", "r626", "r627" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r45", "r134", "r230", "r590", "r628", "r663", "r679" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r63", "r134", "r230", "r284", "r285", "r286", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r536", "r540", "r541", "r590", "r626", "r627", "r628" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current Liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Noncurrent Liabilities" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r58" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Credit facility, maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Credit Facility", "verboseLabel": "Credit facility" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationReserve": { "auth_ref": [ "r67", "r280" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.", "label": "Estimated Litigation Liability", "terseLabel": "Liabilities related to litigation" } } }, "localname": "LitigationReserve", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.", "label": "Litigation Settlement, Expense", "terseLabel": "Litigation settlement charges" } } }, "localname": "LitigationSettlementExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "LIBOR" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongLivedAssetsHeldForSaleByAssetTypeAxis": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Represents the assets held for sale.", "label": "Long Lived Assets Held-for-sale by Asset Type [Axis]", "terseLabel": "Long Lived Assets Held-for-sale by Asset Type [Axis]" } } }, "localname": "LongLivedAssetsHeldForSaleByAssetTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongLivedAssetsHeldForSaleNameDomain": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "A name of the assets to be disposed.", "label": "Long Lived Assets Held-for-sale, Name [Domain]", "terseLabel": "Long Lived Assets Held-for-sale, Name [Domain]" } } }, "localname": "LongLivedAssetsHeldForSaleNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r34", "r309", "r324", "r325", "r326", "r662", "r676" ], "calculation": { "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Net proceeds", "totalLabel": "Total debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r59" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Less current portion of long-term debt", "verboseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r65" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt", "verboseLabel": "Total long-term debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r65" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r65", "r282" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketingRelatedIntangibleAssetsMember": { "auth_ref": [ "r527" ], "lang": { "en-us": { "role": { "documentation": "Marketing-related asset, including, but not limited to, internet domain name, newspaper mast head, and trademark.", "label": "Marketing-Related Intangible Assets [Member]", "terseLabel": "Marketed products" } } }, "localname": "MarketingRelatedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": { "auth_ref": [ "r20", "r534" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.", "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]", "terseLabel": "Acquisitions and Divestitures" } } }, "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestitures" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r122" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash Provided by Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flows from Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r122" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net Cash Used for Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flows from Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r122", "r123", "r127" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net Cash Provided by Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash Flows from Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r19", "r88", "r91", "r96", "r101", "r127", "r134", "r146", "r152", "r153", "r154", "r155", "r158", "r159", "r168", "r199", "r203", "r206", "r209", "r212", "r230", "r284", "r285", "r286", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r573", "r590", "r666", "r682" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss available to common shareholders" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited", "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited", "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.elanco.com/role/LossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetInvestmentHedgingMember": { "auth_ref": [ "r546" ], "lang": { "en-us": { "role": { "documentation": "Hedges of a net investment in a foreign operation.", "label": "Net Investment Hedging [Member]", "terseLabel": "Net Investment Hedging" } } }, "localname": "NetInvestmentHedgingMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r5", "r144", "r145", "r148", "r149", "r160", "r161", "r162", "r227", "r228", "r235", "r236", "r383", "r384", "r385", "r386", "r487", "r503", "r504", "r505", "r569", "r597", "r598", "r599", "r617", "r642", "r643", "r644", "r700", "r701", "r702", "r703", "r705", "r733" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "terseLabel": "Implementation of New Financial Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Implementation of New Financial Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "Next Largest Country", "verboseLabel": "International" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationRevenuebySelectedGeographicAreaInformationDetails", "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r547" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not Designated as Hedging Instrument" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails", "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonfinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of obligations not classified as financial liabilities. Includes, but is not limited to, accounts payable and accrued liabilities, commitments, obligations, and other liabilities.", "label": "Nonfinancial Liabilities Fair Value Disclosure", "negatedLabel": "Contingent consideration" } } }, "localname": "NonfinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r109" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 7.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedLabel": "Other (income) expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableFairValueDisclosure": { "auth_ref": [ "r60" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of notes payable.", "label": "Notes Payable, Fair Value Disclosure", "negatedTerseLabel": "Long-term debt - senior notes" } } }, "localname": "NotesPayableFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableOtherPayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "Notes Payable, Other Payables [Member]", "terseLabel": "Other obligations" } } }, "localname": "NotesPayableOtherPayablesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OffsettingLiabilitiesTableTextBlock": { "auth_ref": [ "r76", "r77" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative and other financial liabilities that are subject to offsetting, including master netting arrangements.", "label": "Offsetting Liabilities [Table Text Block]", "terseLabel": "Gain (loss), net of tax" } } }, "localname": "OffsettingLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r56" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "verboseLabel": "Other noncurrent assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "auth_ref": [ "r81", "r85" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "terseLabel": "Unrealized gain (loss) on derivatives for cash flow hedges, net of taxes" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r79" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r89", "r92", "r94", "r95", "r97", "r102", "r351", "r603", "r608", "r609", "r667", "r683" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income (loss), net of tax", "totalLabel": "Other comprehensive income (loss), net of taxes" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited", "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "auth_ref": [ "r83", "r85" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "negatedLabel": "Defined benefit pension and retiree health benefit plans, net of taxes" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Other current liabilities" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r26", "r27", "r62", "r628" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r66" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other noncurrent liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other noncurrent assets" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other noncurrent liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).", "label": "Other Operating Activities, Cash Flow Statement", "terseLabel": "Other non-cash operating activities, net" } } }, "localname": "OtherOperatingActivitiesCashFlowStatement", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other operating income (expense).", "label": "Other Operating Income (Expense) [Member]", "terseLabel": "Other Operating Income (Expense)" } } }, "localname": "OtherOperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNetGainLossonDerivativeInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherReceivablesNetCurrent": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.", "label": "Other Receivables, Net, Current", "terseLabel": "Other receivables" } } }, "localname": "OtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]", "terseLabel": "Over-Allotment Option" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": { "auth_ref": [ "r120" ], "calculation": { "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails": { "order": 2.0, "parentTag": "us-gaap_SaleOfStockConsiderationReceivedOnTransaction", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.", "label": "Payment of Financing and Stock Issuance Costs", "terseLabel": "Less: Issuance costs" } } }, "localname": "PaymentOfFinancingAndStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r111", "r114" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other investing activities, net" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r121", "r269" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedTerseLabel": "Cash paid" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForSoftware": { "auth_ref": [ "r113" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.", "label": "Payments for Software", "negatedLabel": "Purchases of software" } } }, "localname": "PaymentsForSoftware", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r119" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r112", "r531" ], "calculation": { "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "verboseLabel": "Cash consideration" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r112" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Cash paid for acquisitions, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r113" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Purchases of intangible assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r113" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Net purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r415", "r417", "r423", "r440", "r442", "r443", "r444", "r445", "r446", "r461", "r463", "r464", "r465", "r477" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "terseLabel": "Retirement Benefits" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefits" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": { "auth_ref": [ "r35", "r390", "r391", "r414", "r461" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.", "label": "Liability, Defined Benefit Plan, Noncurrent", "terseLabel": "Accrued retirement benefits" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionPlansDefinedBenefitMember": { "auth_ref": [ "r388", "r390", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r441", "r444", "r448", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r465", "r466", "r472", "r473", "r474", "r475" ], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.", "label": "Pension Plan [Member]", "terseLabel": "Pension Plan" } } }, "localname": "PensionPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r583" ], "lang": { "en-us": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r37", "r335" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r37", "r628" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, no par value, 1,000,000,000 shares authorized; none issued" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r24", "r51", "r52" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid expenses and other" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueSummaryofFairValueInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates": { "auth_ref": [ "r110" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a business segment or subsidiary or sale of an entity that is related to it but not strictly controlled during the period (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment).", "label": "Proceeds from Divestiture of Businesses and Interests in Affiliates", "terseLabel": "Proceeds from product divestitures" } } }, "localname": "ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromHedgeInvestingActivities": { "auth_ref": [ "r111", "r124" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.", "label": "Proceeds from Hedge, Investing Activities", "terseLabel": "Proceeds from settlement of net investment hedges" } } }, "localname": "ProceedsFromHedgeInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt": { "auth_ref": [ "r116" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).", "label": "Proceeds from Issuance of Senior Long-term Debt", "terseLabel": "Proceeds from issuance of long-term debt" } } }, "localname": "ProceedsFromIssuanceOfSeniorLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r115" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 }, "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails": { "order": 1.0, "parentTag": "us-gaap_SaleOfStockConsiderationReceivedOnTransaction", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from Issuance or Sale of Equity", "terseLabel": "Proceeds from issuance of common stock and tangible equity units", "verboseLabel": "Gross proceeds" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r116", "r133" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Proceeds from Lines of Credit", "terseLabel": "Net proceeds from revolving credit facility" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r117", "r120" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other financing activities, net" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product Sales" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r30", "r31", "r261", "r628", "r672", "r680" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net of accumulated depreciation of $1,050 (2021) and $1,038 (2020)" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PublicUtilitiesInventoryAxis": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Information by type of inventory held.", "label": "Inventory [Axis]", "terseLabel": "Inventory [Axis]" } } }, "localname": "PublicUtilitiesInventoryAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PublicUtilitiesInventoryRawMaterialsMember": { "auth_ref": [ "r47" ], "lang": { "en-us": { "role": { "documentation": "Basic goods that are to be consumed directly or indirectly in the production of finished goods or services.", "label": "Raw Materials [Member]", "terseLabel": "Raw Materials" } } }, "localname": "PublicUtilitiesInventoryRawMaterialsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PublicUtilitiesInventoryTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.", "label": "Inventory [Domain]", "terseLabel": "Inventory [Domain]" } } }, "localname": "PublicUtilitiesInventoryTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r87", "r94", "r95", "r97", "r603", "r607", "r609" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "negatedTerseLabel": "Reclassification from AOCI" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/FinancialInstrumentsandFairValueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r441", "r620", "r621" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/TransactionsandAgreementswithBayerNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/TransactionsandAgreementswithBayerNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r441", "r620", "r623", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r656", "r657" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/TransactionsandAgreementswithBayerNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r618", "r619", "r621", "r624", "r625" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Transactions and Agreements with Bayer" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/TransactionsandAgreementswithBayer" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r118" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "terseLabel": "Debt repaid" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r118", "r133" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Repayments of Lines of Credit", "terseLabel": "Repayments of lines of credit" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r118" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "terseLabel": "Debt repaid, principal" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermLinesOfCredit": { "auth_ref": [ "r118" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Repayments of Long-term Lines of Credit", "negatedTerseLabel": "Repayments of borrowings" } } }, "localname": "RepaymentsOfLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r491", "r639", "r720" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r21", "r29", "r129" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted cash", "verboseLabel": "Restricted cash" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets", "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]", "terseLabel": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The expected number of positions to be eliminated as a result of restructuring activities.", "label": "Restructuring and Related Cost, Expected Number of Positions Eliminated", "terseLabel": "Expected number of positions eliminated" } } }, "localname": "RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r126", "r267", "r274", "r277" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Charges" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [ "r268", "r269", "r277", "r278" ], "lang": { "en-us": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails", "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCosts": { "auth_ref": [ "r126" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Costs", "terseLabel": "Restructuring costs" } } }, "localname": "RestructuringCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring, Impairment, and Other Activities Disclosure [Text Block]", "terseLabel": "Asset Impairment, Restructuring and Other Special Charges" } } }, "localname": "RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialCharges" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringPlanAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by individual restructuring plan.", "label": "Restructuring Plan [Axis]", "terseLabel": "Restructuring Plan [Axis]" } } }, "localname": "RestructuringPlanAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringPlanDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identification of the individual restructuring plans.", "label": "Restructuring Plan [Domain]", "terseLabel": "Restructuring Plan [Domain]" } } }, "localname": "RestructuringPlanDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r269", "r275" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveAccrualAdjustment1": { "auth_ref": [ "r269", "r278" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.", "label": "Restructuring Reserve, Accrual Adjustment", "negatedLabel": "Restructuring adjustments", "terseLabel": "Reserve adjustments" } } }, "localname": "RestructuringReserveAccrualAdjustment1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails", "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Restructuring Reserve [Roll Forward]" } } }, "localname": "RestructuringReserveRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringSettlementAndImpairmentProvisions": { "auth_ref": [ "r107" ], "calculation": { "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of restructuring charges, remediation cost, and asset impairment loss.", "label": "Restructuring, Settlement and Impairment Provisions", "terseLabel": "Asset impairment, restructuring and other special charges", "totalLabel": "Total expense" } } }, "localname": "RestructuringSettlementAndImpairmentProvisions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails", "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringSettlementAndImpairmentProvisionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restructuring, Settlement and Impairment Provisions [Abstract]", "terseLabel": "Restructuring charges:" } } }, "localname": "RestructuringSettlementAndImpairmentProvisionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r41", "r358", "r488", "r628", "r678", "r700", "r705" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r140", "r141", "r142", "r147", "r157", "r159", "r234", "r484", "r485", "r486", "r501", "r502", "r571", "r696", "r698" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r388", "r389", "r390", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r441", "r444", "r448", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r465", "r466", "r467", "r468", "r469", "r470", "r472", "r473", "r474", "r475" ], "lang": { "en-us": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r388", "r389", "r390", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r441", "r444", "r448", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r465", "r466", "r467", "r468", "r469", "r470", "r472", "r473", "r474", "r475" ], "lang": { "en-us": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r194", "r195", "r202", "r207", "r208", "r214", "r215", "r219", "r371", "r372", "r640" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "netLabel": "Revenue", "terseLabel": "Revenue", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.elanco.com/role/GeographicInformationRevenuebySelectedGeographicAreaInformationDetails", "http://www.elanco.com/role/RevenueDisaggregationofRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerMember": { "auth_ref": [ "r187", "r219" ], "lang": { "en-us": { "role": { "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue from Contract with Customer Benchmark [Member]", "terseLabel": "Net Revenue" } } }, "localname": "RevenueFromContractWithCustomerMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r375", "r387" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "terseLabel": "Revenue by Selected Geographic Area Information" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationRevenuebySelectedGeographicAreaInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "calculation": { "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "totalLabel": "Net proceeds", "verboseLabel": "Proceeds after underwriting discounts and commissions" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Number of shares issued (in shares)", "verboseLabel": "Number of shares sold in public offering (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Fair value per unit (usd per share)", "verboseLabel": "Offering price (usd per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r187", "r219" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r520", "r521" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresNarrativeDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresProFormaInformationDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresPurchaseConsiderationDetails", "http://www.elanco.com/role/AcquisitionsandDivestituresSummaryofAmountsRecognizedforAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r520", "r521" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "terseLabel": "Purchase Consideration" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r500" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Provision for Taxes on Income" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r65", "r138", "r325", "r327", "r352", "r355", "r356", "r357", "r611", "r612", "r615", "r673" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long-term Debt" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r7", "r8", "r9", "r10", "r11", "r12", "r13", "r15", "r17", "r18", "r19", "r265", "r266" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Divestitures Activities" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r171" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/LossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r28", "r48", "r49", "r50" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.", "label": "Schedule of Net Benefit Costs [Table Text Block]", "terseLabel": "Schedule of Net Benefit Costs" } } }, "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/RetirementBenefitsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r151", "r154", "r178", "r179" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table Text Block]", "terseLabel": "Description of Accounting Standards Adopted and Not Yet Adopted" } } }, "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/ImplementationofNewFinancialAccountingPronouncementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "verboseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AcquisitionsandDivestituresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r622", "r623" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/TransactionsandAgreementswithBayerNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r268", "r269", "r270", "r271", "r277", "r278", "r279" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesNarrativeDetails", "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r272", "r273", "r276" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Total Charges Related to Asset Impairment, Restructuring and Other Special Charges" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "auth_ref": [ "r269", "r278" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Summary of Activity in Reserves" } } }, "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r99", "r218" ], "lang": { "en-us": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformationRevenuebySelectedGeographicAreaInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r68", "r131", "r181", "r182", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r340", "r344", "r349", "r352", "r353", "r354", "r355", "r356", "r357", "r358" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.", "label": "Schedule of Stockholders Equity [Table Text Block]", "terseLabel": "Schedule of Stockholders Equity" } } }, "localname": "ScheduleOfStockholdersEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r190", "r192", "r193", "r199", "r201", "r206", "r210", "r211", "r212", "r213", "r214", "r218", "r219", "r220" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Geographic Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/GeographicInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r108" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Marketing, selling and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior Notes" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/DebtScheduleofLongtermDebtDetails", "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r126" ], "calculation": { "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails": { "order": 1.0, "parentTag": "us-gaap_RestructuringSettlementAndImpairmentProvisions", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance Costs", "terseLabel": "Severance and other costs" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesTotalChargesRelatedtoAssetImpairmentRestructuringandOtherSpecialChargesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r125" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance at end of period (in shares)", "periodStartLabel": "Balance at beginning of period (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r36", "r37", "r38", "r131", "r134", "r165", "r166", "r167", "r169", "r171", "r181", "r182", "r183", "r230", "r284", "r288", "r289", "r290", "r293", "r294", "r335", "r336", "r340", "r344", "r351", "r590", "r726" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CoverPage", "http://www.elanco.com/role/DebtNarrativeDetails", "http://www.elanco.com/role/EquityNarrativeDetails", "http://www.elanco.com/role/EquityScheduleofStockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r69", "r94", "r95", "r96", "r140", "r141", "r142", "r147", "r157", "r159", "r180", "r234", "r351", "r358", "r484", "r485", "r486", "r501", "r502", "r571", "r603", "r604", "r605", "r606", "r607", "r609", "r696", "r697", "r698", "r732" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r140", "r141", "r142", "r180", "r640" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r37", "r38", "r358" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Issuance of stock to Bayer for acquisition, net of issuance costs (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r37", "r38", "r351", "r358" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of stock under employee stock plans, net (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares (or other type of equity) forfeited during the period.", "label": "Shares Issued, Shares, Share-based Payment Arrangement, Forfeited", "terseLabel": "Issuance of common stock, net of issuance costs (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r69", "r351", "r358" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Issuance of stock to Bayer for acquisition, net of issuance costs" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r37", "r38", "r351", "r358" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock, net of issuance costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r38", "r43", "r44", "r134", "r224", "r230", "r590", "r628" ], "calculation": { "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets", "http://www.elanco.com/role/CondensedConsolidatedStatementsofEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r132", "r336", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r350", "r358", "r359" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/Equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/EquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [ "r268", "r269", "r277", "r278" ], "lang": { "en-us": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/AssetImpairmentRestructuringandOtherSpecialChargesSummaryofActivityinReservesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/DebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r171" ], "calculation": { "http://www.elanco.com/role/LossPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "terseLabel": "Assumed conversion of dilutive common stock equivalents (in shares)" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/LossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r164", "r171" ], "calculation": { "http://www.elanco.com/role/LossPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted weighted average shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.elanco.com/role/LossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r163", "r171" ], "calculation": { "http://www.elanco.com/role/LossPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.elanco.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://www.elanco.com/role/LossPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 11 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3581-108585" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r139": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693" }, "r162": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r177": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e725-108305" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e765-108305" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r220": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r240": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 2.A.6)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=122040515&loc=d3e105049-122735" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2599-110228" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2611-110228" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2443-110228" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r281": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r331": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r359": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r387": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r477": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r515": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=SL65897772-128472" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r534": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=117331979&loc=d3e41228-113958" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(iii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061172-113977" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20,22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r625": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4),(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r721": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r722": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r723": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r724": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r725": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r726": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r727": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "848" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" } }, "version": "2.1" } ZIP 82 0001739104-21-000017-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001739104-21-000017-xbrl.zip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�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�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Ý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�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end